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Preface to “Wound Repair and Regeneration” 
Wounds have been around since time immemorial. Ancient civilisations first described their 
approaches to wound management including herbal remedies, lint, animal grease and honey in 1500 BC. 
Since the 19th century, scientists worldwide have been endeavouring to understand the processes 
involved in wound healing and there have been many important discoveries that have helped to pave the 
way to the wound management that we see today. In the last 20 years in particular, our understanding of 
the molecular and cellular processes that underpin the complexity of wound healing has grown 
exponentially, yet, despite all our best endeavours, there are still limited wound care products on the 
market which can actively stimulate the healing process, and none that lead to the perfect regeneration of 
the skin after injury. Unfortunately, we cannot just sit back and wait another 20 years for new advances to 
occur. Due to our aging populations, the increase in chronic diseases such as diabetes, and the prevalence 
of obesity in our society, we are seeing a spiralling epidemic of wounds affecting the lives and well-being 
of millions of people worldwide.  
The time is therefore right for this book to showcase the “state of the art” research that is being 
undertaken by leading clinicians and academics from all around the world. Our participant authors are at 
the forefront of their studies and are furthering the understanding of molecular processes that are 
involved in wound repair. Using the latest knowledge, they are developing new approaches that are 
leading to improvements in healing in preclinical animal models with the aim that future studies will be 
performed in people that will lead to exciting and innovate wound management developments in the 
future. 
This book brings together a selection of articles that highlight new developments in therapeutic 
approaches for wound repair, including the use of biomaterials to deliver cells and/or drugs to promote 
healing. Cellular responses that underpin angiogenesis, inflammation, proliferation and remodeling, as 
well as advances in cytoskeletal interactions in keratinocytes and fibroblast cell functions, are included. 
Wound remodeling and scar formation including the roles of growth factors, cytokines and stem cells are 
also overviewed. I would very much like to thank all the authors who have generously contributed their 
articles to this book. By disseminating and sharing our research, we ensure that advances in the field can 
be made. It is by connecting the dots, engaging in that lightbulb moment or by having that conversation 
that the next innovation in wound repair will arise. If this book can help get this process started, then we 
will have achieved something worthwhile. 
Allison Cowin 
Professor of Regenerative Medicine 
Future Industries Institute, Mawson Lakes, University of South Australia,  
South Australia 5095, Australia. 
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Abstract: Mice and human patients with impaired vitamin D receptor (VDR) signaling have normal
developmental hair growth but display aberrant post-morphogenic hair cycle progression associated
with alopecia. In addition, VDR–/– mice exhibit impaired cutaneous wound healing. We undertook
experiments to determine whether the stress-inducible regulator of energy homeostasis, DNA
damage-inducible transcript 4 (Ddit4), is involved in these processes. By analyzing hair cycle
activation in vivo, we show that VDR−/− mice at day 14 exhibit increased Ddit4 expression within
follicular stress compartments. At day 29, degenerating VDR−/− follicular keratinocytes, but not
bulge stem cells, continue to exhibit an increase in Ddit4 expression. At day 47, when normal follicles
and epidermis are quiescent and enriched for Ddit4, VDR−/− skin lacks Ddit4 expression. In a skin
wound healing assay, the re-epithelialized epidermis in wildtype (WT) but not VDR−/− animals
harbor a population of Ddit4- and Krt10-positive cells. Our study suggests that VDR regulates Ddit4
expression during epidermal homeostasis and the wound healing process, while elevated Ddit4
represents an early growth-arresting stress response within VDR−/− follicles.
Keywords: wound repair; VDR; mTOR; DDIT4; stress; hair follicle; stem cells
1. Introduction
Besides its known regulation of mineral homeostasis, the vitamin D receptor (VDR) also plays
a functional role within the cutaneous environment. The importance of the cutaneous VDR is
demonstrated in certain human patients with hereditary vitamin D-resistant rickets and mice that
harbor loss-of-function mutations in the VDR and eventually develop hair loss (alopecia totalis [1]),
as well as impaired skin wound repair [2,3]. In utero, the epithelium and underlying mesenchyme
interact to form hair follicles during morphogenesis, which ends during the second week of life in
mice. During the ensuing post-morphogenic hair cycle, the permanent follicular component is retained,
which includes sebaceous glands and the upper outer root sheath that harbors the hair follicle stem
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cell center called the bulge. In contrast, the lower part of the follicle cycles through episodic periods
of growth, regression and quiescence, termed the anagen, catagen and telogen stages respectively.
The telogen-to-anagen transition marks a stage in which stem cells become activated to form a new
hair bulb with concomitant inner root sheath (IRS) and hair shaft differentiation.
The VDR is thought to play a limited role during the early morphogenic period of follicular
development since VDR−/− mice appear grossly normal and generate their first coat of hair [4].
However, VDR−/− mice exhibit compromised post-morphogenic hair cycles and improper anagen
initiation and integrity, in which mutant mice do not grow new hair, and instead the follicles become
epidermal cysts [5–7]. The signaling defects within VDR-deficient hair follicles are localized to
keratinocytes, and not to the mesenchymal component of the follicle [6–8]. Through a series of
recovery transgenesis experiments in mice, studies have shown that the zinc finger DNA binding
domain of the VDR, but not the ligand binding or activation function 2 domains, was critical for the
hair cycle [9–11].
Despite these studies, the biological explanation for hair loss in VDR-deficient mice remains
unclear. The VDR was identified as a major molecular signature within hair bulge label-retaining stem
cells [12], with subsequent studies suggesting that unliganded VDRs are required for the self-renewal,
colony formation and normal lineage specification, as well as function of bulge keratinocyte stem
cells (KSCs; [13]). However other follow-up studies observed no functional defects in VDR-deficient
KSCs [14]. Hair follicle induction and maintenance are controlled by numerous factors such as
fibroblast growth factor, transforming growth factor beta, Hedgehog and Wnt signaling, by controlling
the self-renewal and lineage progression of KSCs and activation of progenitor cells. Studies suggest
that VDR interactions with the lymphoid enhancer-binding factor 1 (lef1) transactivator may be
the mechanism by which the unliganded VDR promotes Wnt signaling [13,15]. Importantly, it was
shown that the VDR interaction with the canonical Wnt target gene, Axin2, was perturbed in both
VDR-null and Lef1-null keratinocytes [16]. Furthermore, the Hedgehog signaling pathway was
found to be disrupted in VDR- and Lef1-null keratinocytes, thus contributing to defective follicular
signaling [16,17].
Besides its role in hair follicle biology, the VDR is expressed ubiquitously in the basal layer
of the interfollicular epidermis [14], and plays a role in epidermal integrity and wound repair.
In the epidermis, the biologically active form of vitamin D, 1,25-dihydroxyvitamin D (1,25D3), is
known to suppress tumor formation, promote innate antimicrobial immunity, suppress epidermal
keratinocyte proliferation and promote differentiation and formation of the permeability barrier
(reviewed in [18]). Epidermal abnormalities are observed in VDR−/− mice at as early as one week of
age, with age-dependent reduction of differentiation markers and lipid content [4,19,20]. Consequently,
the epidermis of VDR−/− mice is generally thicker and more folded, reflecting enhanced epidermal
proliferation [21]. In contrast to VDR−/− mice, mice lacking the enzyme that catalyzes synthesis of
1,25D3 (cytochrome p450 27B1; CYP27B1−/−) have normal hair, but altered epidermal differentiation
signatures, impaired permeability barrier and wound healing responses, suggesting that 1,25D3 is
crucial for epidermal integrity [22,23]. The cutaneous wound healing defects in global VDR−/−
animals have been characterized by scarcity of infiltrating macrophages in the early inflammatory
phase and disrupted vascular invasion of granulation tissue, yet re-epithelialization was reported
to be unaffected [2]. In contrast, epithelial-specific deletion of the VDR in mice results in impaired
re-epithelialization of wounds [3]. Also, in vitro scratch migration assays using VDR−/− primary
keratinocytes showed decreased injury-stimulated migration [14].
Mechanistic/mammalian target of rapamycin (mTOR) is a serine-threonine protein kinase that
is considered to be a “master regulator” of cell growth and survival. It is the major checkpoint for
sensing of cellular nutrients and oxygen and energy levels to orchestrate the cellular responses to any
changes. Upstream inhibitors of mTOR have been characterized, including DNA damage-inducible
transcript 4 (Ddit4), also called REDD1, a mitochondrial protein which is involved in the conservation








Int. J. Mol. Sci. 2016, 17, 1984
UV-induced DNA damage [24], and then during hypoxia, oxidative stress, endoplasmic reticulum
(ER) stress, atrophied glucocorticoid treatment and energy/serum deprivation [25–28]. We have
recently shown that Ddit4/DDIT4 is a direct and conserved transcriptional target of the VDR in human
and mouse bone-forming osteoblasts to promote differentiation [29,30]. In view of the ubiquitous
expression pattern of Ddit4 within the mammalian system, the present study focused on potential
cutaneous interactions between VDR and Ddit4 signaling. Accordingly we hypothesize that in mice:
(1) Ddit4 is functionally regulated by the VDR during the hair cycle and epidermal wound repair, and
(2) given its known role as a stress-inducible factor, Ddit4 may be utilized as an innate surveyor of
VDR-dependent adverse cellular effects. By monitoring the effects on Ddit4 we were able to show that
the VDR and Ddit4 function distinctly at the crossroads between hair follicle cycling and the epidermal
wound repair process.
2. Results
2.1. DDIT4/Ddit4 Is an Acute Phase Effector of Stress Related to Inflammatory and Other Immune Challenges
to Physical or Bacterial Complications
We initially sought a general assessment under which biological stresses regulate DDIT4/Ddit4
gene expression within keratinocytes and other epithelial cell types. To do this, we appraised the
publically available Gene Expression Omnibus (GEO) Profiles repository of curated microarray/next
generation sequencing datasets for individual gene expression profiles (available at: http://www.
ncbi.nlm.nih.gov/geoprofiles). We identified five (cutaneous) experimental DataSet records whereby
DDIT4/Ddit4 was significantly regulated compared to control samples. In a study to explore the space
effects of heavy Fe ion radiation exposure of a rat keratinocyte line, Ddit4 mRNA expression was
decreased, despite the induction of other “DNA repair” genes within the data set [31] and original
discovery of Ddit4 as a major transcript activated by UV irradiation [24] (Figure 1A). In contrast, under
the stress of inflammation (i.e., via overexpression of the NF-κB activator IKKβ) [32] or specific types
of periodontal pathogens [33], Ddit4/DDIT4 transcript was increased within mouse skin and human
gingival epithelial cells, respectively (Figure 1B,C). In another study, human keratinocytes that were
exposed to an enzymatic cell disassociation treatment as a model of epidermal injury [34], resulted in
elevated DDIT4 message (Figure 1D). In a more unperturbed physiological setting, multipotent human
hair follicle stem cells were co-cultured with mesenchymal dermal papilla cells to induce keratinocyte
progenitor differentiation, whereby DDIT4 message levels decreased over time [35].
2.2. VDR Positively Regulates Ddit4 mRNA and Protein Expression in Primary Murine
Epidermal Keratinocytes
To investigate the VDR-Ddit4 relationship within the mouse cutaneous system, we first
determined whether 1,25D3-VDR actions could transcriptionally activate Ddit4 within primary
epidermal keratinocytes harvested and cultured from neonatal pups aged 2–3 days derived from either
wildtype (WT) or VDR−/− mice on a normalized calcium/phosphorous diet. Since keratinocytes
differentiate with calcium, our culture system was established using low-calcium conditions (0.05 mM)
to mimic undifferentiated cells in the basal layer that have the highest concentration and effectiveness
of the VDR [36]. Treatment of WT, but not VDR−/− cells with 1,25D3 (1–100 nM) for 6 h resulted
in a dose-dependent induction of both cyp24a1 (1,25-dihydroxyvitamin D3 24-hydroxylase), a major
transcriptional target and negative feedback regulator of vitamin D, and Ddit4 (Figure 2A). Expression
of Ddit4 mRNA levels in primary keratinocytes was significantly lower in VDR−/− mice, but
transfection of these cells with a murine Vdr transgene resulted in re-expression of Ddit4, and enhanced
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Figure 1. Gene Expression Omnibus (GEO) profile assessment of Ddit4/DDIT4 responses to biological
and stress conditions within epithelial cells. (1.5 column) (A) For all DataSets presented in this figure,
the graphs represent Ddit4/DDIT4 transcript levels. DataSet GDS2637 shows that Ddit4 was not
induced after 56FE ion irradiation within a rat keratinocyte cell line; (B) DataSet GDS3766 shows that
NF-κB activation by IKKβ overexpression in mouse dorsal skin resulted in increased Ddit4 levels;
(C) DataSet GDS3211 reports that periodontal pathogen infection of a human gingival epithelial cell
line with Aggregatibacter actinomycetemcomitans led to DDIT4 induction; (D) DataSet GDS4608 shows
that upon injury of human epidermal cells, DDIT4 transcript levels were increased compared to
uninjured samples; (E) DataSet GDS687 shows that differentiation of keratinocyte stem cells upon
mesenchymal-epithelial interactions resulted in decreased DDIT4 expression over time. All DataSets
can be accessed at: http://www.ncbi.nlm.nih.gov/geoprofiles.
Next we investigated the effects on Ddit4 protein expression within WT and VDR−/− primary
keratinocytes using immunofluorescence staining. In WT cells treated with 1,25D3 (10 nM) for
18 h in growth medium supplemented with FBS with reduced-calcium (0.05 mM), we observed
an increased number of cells with elevated intracellular accumulation of Ddit4 (Figure 2C, upper
middle panel). In addition, these 1,25D3-treated WT keratinocytes appeared to be morphologically
distinct (i.e., enlarged and differentiated) compared to their VDR−/− counterparts. The 1,25D3-treated
VDR-null cells appear to acquire higher length:width ratios, indicative of an undifferentiated motile
state (Figure 2C, lower middle panel). Likewise, after 1,25D3 treatment of VDR-null keratinocytes,
there was a comparable decrease in Ddit4 expression to that of WT cells. As a safeguard for energy
conservation, Ddit4 expression is known to be enhanced under stress conditions such as growth factor
(serum) deprivation [25]. With this in mind, we tested this response in WT keratinocytes and observed
increased Ddit4 protein expression after serum starvation (Figure 2C, upper right panel). Interestingly,
Ddit4 expression was also enhanced in VDR−/− keratinocytes under serum-deprived conditions
(Figure 2C, lower right panel). These results suggest that (1) the Ddit4-mediated energy and growth
factor depletion sensing mechanism has the potential to function independent of cellular VDRs; and
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Figure 2. Regulation of the mechanistic/mammalian target of rapamycin (mTOR) inhibitor and stress
sensor DNA damage-inducible transcript 4 (Ddit4) by liganded vitamin D receptors (VDRs) within
primary keratinocytes (column 1.5). (A) Dose-dependent transcriptional induction of Cyp24a1 and Ddit4
by 1,25-dihydroxyvitamin D (1,25D3, 6 h) in wildtype (WT), but not VDR−/−, primary keratinocytes
derived from neonatal pups; (B) Transient transfection of VDR−/− primary keratinocytes with a
mVDR plasmid restores endogenous Ddit4 transcript levels. Combined treatment further enhanced
Ddit4 mRNA levels (with mVDR transfection and 1,25D3 of 10 nM for 6 h); (C) Immunofluorescence
detection of Ddit4 within primary keratinocytes. WT, but not VDR−/−, primary keratinocytes
exposed to 10 nM 1,25D3 for 18 h resulted in increased intracellular accumulation of Ddit4 (white
arrows). Ddit4 upregulation in response to fetal bovine serum deprivation for 24 h in both WT and
VDR−/− keratinocytes. One-way ANOVA at an α = 0.05 (95% confidence interval) and Tukey’s
multiple comparison post-tests were utilized. Significance is denoted with asterisks: * p < 0.05
(n = 3–4 experiments). RT-qPCR: reverse transcription quantitative polymerase chain reaction.
2.3. Ddit4 Is a Direct Transcriptional Effector of the Liganded VDR within Primary Epidermal Keratinocytes
Transcriptional regulation by 1,25D3 involves occupancy of VDREs on effector genes by
1,25D3-bound or unbound VDRs and numerous other co-regulators. Here, we performed chromatin
immunoprecipitation (ChIP) qPCR assays to assess potential VDRs and general transcriptional element
binding to the Ddit4 promoter within WT neonatal primary keratinocytes. We tiled the proximal
promoter region (i.e., with primers Ddit4-1 and Ddit4-2), which was approximately 500 base pairs
upstream of the Ddit4 transcriptional start site (TSS) on the reverse strand. The distal region was
appraised using primer Ddit4-3, which targeted a DNA region 1.7 kilobases upstream of the TSS.
All sequence positions were based on the primary assembly GRCm38 released by the Genome
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ChIP results show that endogenous VDRs bound strongly to the proximal promoter of Ddit4
under unstimulated conditions (Figure 3(AI)). Upon 1,25D3 stimulation (10 nM, 15 min) there was
increased recruitment of liganded VDRs to the proximal, but not distal, promoter region of Ddit4
as assessed by ChIP-qPCR (Figure 3B). These results suggest that the promoter region of Ddit4 in
keratinocytes includes functional VDRE(s). Although the unliganded VDR bound to the proximal
Ddit4 promoter, this represented a transcriptionally inactive state as RNA polymerase 2 (RNApol2),
a general marker for precursor RNA synthesis, was tethered or poised at the more distal region
(Figure 3(AII)). In contrast, there was accompanying RNApol2 binding activity at the proximal Ddit4
promoter only after 1,25D3 treatment, suggesting direct transcriptional activation of Ddit4 after ligand
stimulation (Figure 3C). For ChIP validation we utilized the murine osteocalcin gene, Bglap, which
has no VDREs in its promoter region, nor is it transcriptionally influenced by addition of 1,25D3 [37].
We also chose the S1 site within intron 3 and 4 of the murine Vdr gene as a potent positive control
for both auto-regulatory VDR and RNApol2 binding, as previously shown in MC3T3-E1 murine
osteoblasts [38]. Interestingly in primary keratinocytes, VDRs but not RNApol2, bound to the S1 site,
suggesting cell type-specific usage of this transcriptional auto-regulatory site. All ChIP-qPCR results
were normalized to a validated non-specific (NS) “naked” control target site . Overall, our findings
support the notion that the liganded VDR directly targets the Ddit4 promoter to induce transcription
within primary epidermal keratinocytes.
Figure 3. Ddit4 transcriptional activity is directly regulated by the VDR within primary epidermal
keratinocytes (1.5 column). (A) Representative chromatin immunoprecipitation (ChIP) gel images of
VDR and RNA polymerase 2 (RNApol2) interactions at the Ddit4 promoter region within WT primary
keratinocytes. Figure 3(AI) shows VDR immunoprecipitation, while Figure 3(AII) shows RNApol2
immunoprecipitation results. Cells were treated with 1,25D3 (10 nM) for 15 min, fixed and then the
chromatin was purified. NS (non-specific), OC (osteocalcin), and VDR-S1 (VDR intron 3 and 4) genomic
sites were used for control purposes. P (proximal), D (distal), VDRE (putative vitamin D response
element); (B) ChIP-Quantitative PCR (qPCR) analysis of VDR immunoprecipitation; (C) ChiP-qPCR
analysis of RNApol2 immunoprecipitation. One-way ANOVA at an α = 0.05 (95% confidence interval)
and Tukey’s multiple comparison post-tests were utilized. Significance is denoted with asterisks:
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2.4. Formation of Ddit4-Positve Stress Compartments in VDR−/− Morphogenic Follicles and Reduced Ddit4
Epidermal Expression
Having shown a direct transcriptional relationship between the VDR and Ddit4 within primary
keratinocytes, we next sought to decipher the potential in vivo role of Ddit4 during activation and
resting stages of the hair follicle cycle and epidermal homeostasis. Hair follicle morphogenesis
initiates during embryogenesis and ceases approximately 2–3 weeks postnatally, whereby the ensuing
post-morphogenic hair cycle marks a new anagen stage (Figure 4A). Using immunostaining, we
monitored Ddit4 protein expression during transitioning hair follicular and epidermal keratinocytes
through morphogenic and post-morphogenic stages within WT and VDR−/− mice maintained on
a rescue diet. Catagen is a transitional apoptosis-mediated involution stage that signals the end of
the active growth of hair. Importantly, the VDR is selectively expressed in hair follicle keratinocytes
during late anagen and catagen stages, which reflects the reduced period of proliferation and elevated
differentiation of follicular cells [39]. At day 14 during the first postnatal early catagen phase, we
observed distinct Ddit4 staining patterns between WT and VDR−/− hair follicles and epidermis
derived from littermates (Figure 4B). Both types of mice showed Ddit4 expression in the inner root
sheath (IRS) of the hair follicle and moderate levels within the interfollicular epidermal regions
(Figure 4B). However, there was slightly higher, atypical Ddit4 expression in VDR−/− follicles.
These punctate regions of increased Ddit4 expression within VDR−/− follicles were observed in
nearly every follicle within superbasal sections at day 14 (Figure 4(BIII–VI)). Given the stress inducible
role of Ddit4, we classified these areas as stress compartments (SC) within VDR-deficient follicles.
These results suggest that VDR-deficient hair follicles that are transitioning between catagen-telogen
exhibit increased cellular stress.
By day 29, initiation of post-morphogenic anagen in the hair follicle is characterized by increased
cell proliferation in the follicular epithelium below the activated bulge. During anagen in WT skin,
Ddit4 expression was substantially reduced within the hair follicle and interfollicular regions compared
to day 14 (Figure 4C), suggesting a reduction of its growth-inhibitory functions. Despite this reduction,
there was more residual Ddit4 within the interfollicular epidermis compared to the follicle. At this
stage, VDR-null hair follicles are degenerated and exhibit an abnormal morphology depicted by
follicular dystrophy, IRS hyperplasia and massive dilation of the junctional canal consistent with
previous work [17]. In contrast to normal hair follicles, VDR-null follicles exhibit increased and
variegated expression of Ddit4 throughout the dystrophic follicular epithelium and interfollicular
regions. There was a statistically significant increase in normalized average fluorescent intensity
(VDR−/−: 538 ± 31 a.u.; WT: 74 ± 11 a.u., n = 8 follicles, p < 0.01) within the bulb region of VDR−/−
hair follicles when compared to WT samples at this stage. We also found that the utricules (u), i.e., the
epidermal portion of abnormal hair follicles, also expressed Ddit4 in the lining epithelium. By day 48,
the hair follicles of normal animals remain in the resting telogen phase and are kept dormant for
another five weeks. The epidermis at this stage also expresses major factors of differentiation [4].
In WT animals, the epidermis and follicular epithelium uniformly expressed increased levels of Ddit4
(Figure 4D), presumably to help maintain a growth-inhibiting, dormant state. Furthermore, dermal
fibroblasts in WT skin also expressed Ddit4. On the other hand, VDR-null mice at day 48 exhibit
epidermal hyperplasia and increased epidermal corneocytes (c), suggesting abnormal shedding of
cornified material. Remarkably, Ddit4 expression was absent within VDR-null skin at telogen. Ddit4
expression was suppressed throughout the epidermis, remaining non-exogenic follicular epithelium
and within the dermis as well. Furthermore, there was increased dermal cellularity in VDR−/− skin,
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Figure 4. Ddit4α-positive stress compartments present in VDR−/− morphogenic hair follicles
(column 2). (A) Chart depicting the morphogenic and post-morphogenic stages of the hair cycle up to
post-natal day 49 (P49); (B) At day 14, hair follicles are within the first postnatal morphogenic early
catagen (regression) phase. In WT (I,II) and VDR−/− (IV,V) animals, Ddit4 is expressed throughout the
inner root sheath (irs), but not in the bulb of the hair follicle (hf). In both genotypes, Ddit4 was expressed
within the interfollicular (if) epidermis. Hair follicles of VDR−/− animals exhibit Ddit4-positive stress
compartments (sc, white arrows) (IV). In the right panel (III,VI), a lower magnification (20×) is
presented where each hair follicle is outlined with a white dotted line. Ddit4 immunostaining is
counter-detected with Alexa® 594 and nuclei stained with DAPI; (C) At day 29, hair follicles are within
the second postnatal anagen (growth) phase. In WT skin, Ddit4 expression was attenuated within
the IF and hair follicle compared to day 14. Asterisks reflect the zoom of the respective hair follicle.
In VDR−/− hair follicles, there was aberrant and increased Ddit4 expression throughout the length of
the follicle (bulb to inner root sheath) compared to WT. There was a similar expression pattern in the
utricles (u) and the interfollicular epidermis; (D) At day 48, WT skin display telogen hair follicles with
quiescent morphology. Ddit4 expression was enhanced and uniform throughout the epidermis (ep)
(white arrow), dermis (dm) and follicular epithelium. In contrast, VDR−/− skin exhibited significant
reduction of Ddit4 throughout the skin. c (corneocytes). For immunostaining, representative slides
are presented. Dotted white lines outline individual hair follicles or the epidermal-dermal junction;
(E) Hair follicle bulge stem cells from 29-day-old animals were fluorescence-activated cell sorting
(FACS) purified and analyzed with RT-qPCR. There was no significant change in Ddit4 message level
between WT and VDR−/− bulge stem cells (n = 4 experiments per genotype).
2.5. The VDR Does Not Regulate Ddit4 within Bulge Keratinocyte Stem Cells
Besides epidermal and follicular keratinocytes, the cutaneous niche consists of many different
cell types, including bulge keratinocyte stem cells (KSCs). It was recently shown that hair follicle
growth and stem cell exhaustion in mice are linked to mTOR dysregulation as a means to maintain
genetic integrity of the stem cell population [40,41]. We therefore hypothesized that the unliganded
VDR maintains proper Ddit4 levels, and hence mTOR function, within KSCs. We compared Ddit4
transcript levels under unliganded conditions within 29-day-old KSCs, a period in which KSCs are
activated (Figure 4C). We isolated living bulge KSC populations from anagen hair follicles of WT and
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Based on these preparations, we observed no difference in Ddit4 message levels between WT and
VDR−/− KSCs. These results suggest no relationship between the VDR and mTOR signaling towards
possible stem cell exhaustion and no effect on the hair loss phenotype, raising the question of primary
defects in progenitor cells instead.
2.6. Impaired Ddit4/Ddit4 and Krt10/Krt10 Expression in the Neo-Epidermis of Wounds from VDR−/− Mice
The cause for delayed onset of cutaneous wound closure in global VDR-null mice is unclear.
Based on this, we studied the association between Ddit4 and VDR during the cutaneous wound
repair process. Mice aged 47 days mice were subjected to 3.5 mm trunk punch biopsies and
tissues were harvested and processed for RT-qPCR, BrdU (5-bromo-2′-deoxyuridine) labeling, and
immunocytochemistry six days after injury. First, we monitored and compared Ddit4 and Krt10
(keratin 10) message levels between WT and VDR−/− animals. Krt10 is an early marker of
differentiating daughter cells in the stratum basale which faces the epidermal surface. We confirmed
the lower Ddit4 message levels within uninjured VDR−/− epidermis, which was accompanied by a
significant reduction in Krt10 mRNA compared to uninjured WT tissue (Figure 5A). Relative to
uninjured skin, there was a significant decrease in both Ddit4 and Krt10 message levels in WT
wounds six days post-injury, representing the early-intermediate phase of the re-epithelialization
process. Compared to WT wounds six days after injury, Ddit4 and Krt10 mRNA levels were further
attenuated in VDR−/− wounds. Histological analysis of wound closure showed larger wound
openings (Figure 5B, red lines) in VDR−/− mice after six days. Interestingly, within VDR−/− injured
skin, in vivo BrdU labeling revealed an increased number of proliferating epidermal and follicular
keratinocytes compared to WT samples at the wound edges, marking a potential reserve of cells
impaired in the re-epithelialization process (Figure 5(BII,IV); representative black box). In both
genotypes, BrdU also labeled damaged hair follicles. Particular to VDR−/− tissue were BrdU-positive
proliferating dermal fibroblasts (red arrows). Next we monitored Ddit4 and Krt10 expression with
immunohistochemistry in the newly restored epidermis six days after injury. We observed moderate
expression of Ddit4 within the newly re-epithelized wound edge in WT animals (Figure 5(BV,VI);
representative red box). In contrast, there was a comparable decrease in Ddit4-positive cells present
within the neo-epidermis in VDR−/− animals (Figure 5(BVII,VIII); representative red box). In WT
neo-epidermis, there were diffuse cells with high Krt10 immuno-reactivity in contrast to VDR−/−
wounds (Figure 5C). Overall, these findings suggest that the loss of Ddit4/Krt10-positive cells in
wounded VDR−/− animals contributes to the impaired re-epithelialization process.
2.7. Ddit4-Deficient Mouse Embryonic Fibroblasts Are Resistant to the Pro-Differentiation Actions of
Vitamin D
Although the initial data suggests a functional association between VDR and Ddit4, the impact of
Ddit4 on vitamin D function is unclear. As Ddit4 is expressed in dermal fibroblasts and dysregulated
in VDR−/− skin (Figure 4D), mouse embryonic fibroblasts (MEFs) derived from Ddit4−/− and WT
animals (kindly provided by Leif W. Ellisen) were tested for any differences in classic vitamin D
anti-proliferative responses. We observed more spindle-shaped cells, characteristic of mitotic cells, in
Ddit4-deficient MEFs even following 50 nM 1,25D3 treatment (Figure 6A, right panels). Measurement
of cell proliferation in WT MEFs showed that even at the lowest concentration range of 1,25D3, cell
proliferation was inhibited compared to the baseline (dotted line) (Figure 6B). At 50 nM 1,25D3, there
was an approximate 10% decrease in cell proliferation in WT samples, but no effect in Ddit4−/−
MEFs. It was only at the highest level (100 nM) of 1,25D3 that Ddit4−/− MEFs exhibited comparable
effects on cell number to WT cells (Figure 6A,B), possibly succumbing to apoptosis [43]. Next, we
performed BrdU-incorporation studies using MEFs treated with 50–75 nM 1,25D3 (Figure 6C,D), and
observed statistically significant decreases in BrdU incorporation within WT, but not Ddit4−/− MEFs.
The fibroblast maturation marker vimentin was also decreased in Ddit4−/− MEFs when compared to
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real-time PCR analysis to monitor Vdr expression and induction of Cyp24a1 (Figure 6(EII–IV)).
Interestingly, Ddit4−/− MEFs expressed more Vdr compared to normal MEFs (Figure 6(EII)). As a
result, there was a concomitant increase in induction of Cyp24a1 in Ddit4−/− MEFs (Figure 6(EIII,IV)).
These results suggest that despite the increase in Vdr and its signaling capacity in MEFs lacking Ddit4,
vitamin D is unable to differentiate these cells due to specific defects in the DDIT4 signaling cascade.
In conclusion, Ddit4-deficient MEFs were resistant to low-to-moderate vitamin D treatments, and Ddit4
is a downstream effector of liganded VDR actions to promote cellular differentiation within fibroblasts.
Figure 5. Reduction of Ddit4 in the re-epithelized wounds of VDR−/− animals (column 1.5).
(A) RT-qPCR analysis of the wound repair process from excised wounds. For uninjured samples,
comparisons were made between genotypes. Six days following injury, sample comparisons were
made between the respective uninjured genotypes. One-way ANOVA at an α = 0.05 (95% confidence
interval) and Tukey’s multiple comparison post-tests were utilized. Significance is denoted with
asterisks: * p < 0.05, ** p < 0.01 (n = 4 samples per genotype and time point); (B) Representative slides
showing 5-bromo-2′-deoxyuridine (BrdU) immunohistochemical (I–IV) and Ddit4 immunofluorescence
(V–VIII) staining of WT and VDR−/− skins six days following injury. Wound closure is depicted by the
horizontal red bars. Black boxed areas in the 4× slides represent the BrdU-labeled magnified regions
(II and IV). Red-boxed areas represent the Ddit4-labeled magnified regions (V–VII). In the BrdU
slides, black arrows depict proliferating epidermal and follicular keratinocytes. Red arrows depict
proliferating dermal fibroblasts. In the Ddit4 panels, the dotted white line marks the re-epithelialized
area. Nuclei are marked in blue with 4′,6-diamidino-2-phenylindole (DAPI), while Ddit4 is labeled in
red. ES: eschar; GR: granulation tissue; EP: epidermis; DM dermis; (C) Krt10 immunostaining within
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Figure 6. Ddit4−/− mouse embryonic fibroblasts are resistant to the pro-differentiation actions of
vitamin D (1 column). (A) Representative images of WT and Ddit4−/− mouse embryonic fibroblasts
(MEFs). MEFs were untreated or treated with a serial dilution of 1,25D3 (0.39–100 nM) for 24 h; (B) Cell
counts performed after 1,25D3 treatment to calculate the proliferation % relative to the untreated
sample. One-way ANOVA at an α = 0.05 (95% confidence interval) and Tukey’s multiple comparison
post-tests were utilized. Significance is denoted with asterisks: * p < 0.05, ** p < 0.01 (n = 3 experiments
per conditions and genotype); (C) Representative BrdU-labeled MEFs shown after 1,25D3 treatment for
12 h. DAPI-positive cells were marked using the Imaris (Bitplane) software to perform quantitative
analysis. Bar = 50 μm; (D) Quantification of BrdU-labeled MEFs after 1,25D3 treatment. Significance
is denoted with asterisks: ** p < 0.01, *** p < 0.001 (n = 3 experiments per conditions and genotype),
ns (not significant); (E) Quantitative PCR analysis of Vimentin in Wt and KO MEFs after 6 h with or
without vitamin D, * p < 0.05 (I). Quantitative PCR analysis of MEFs treated or untreated with low or
high concentrations of 1,25D3 for 6 h (II–IV). Increased expression of Vdr (II) and induction of Cyp24a1
(III,IV) within Ddit4−/− MEFs. (n = 3 preparations of each cell line).
3. Discussion
3.1. Insights into Ddit4-VDR
Perturbation of VDR expression in humans and mice is associated with alopecia. The results
reported here therefore provide novel insights into biological and clinical applications of vitamin D
and skin function. Our data show that the mTOR inhibitor, Ddit4, is a direct transcriptional target of
VDR in epidermal keratinocytes. Regulation of mTOR activity is a major component of “checks and
balances” of energy homeostasis within a cell. Ddit4, a mitochondria-resident protein, represses mTOR
signaling by activating TSC2 (tuberin), a guanosine triphosphate (GTP) hydrolyzing enzyme (GTPase)
activating protein (GAP), which then stimulates the small GTPase Ras homolog enriched in brain
(Rheb) in its GDP-bound form to inactivate mTOR [25]. Dysregulation of mTOR signaling can lead to
a plethora of diseases including cancer and metabolic disorders. Studies have shown that 1,25D3 or
its analogues can suppress tumor cell growth by upregulation of Ddit4 in various cancer cell model
systems [44]. Suppression of mTOR via Ddit4 activation results in attenuation in both cell size and
growth rate, comparable to that observed after nutrient and growth factor deprivation [45]. Conversely,
Ddit4 levels are mitigated under growth-like conditions [27]. The importance of Ddit4 in regulating
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mTOR activity [25]. DDIT4−/− mice are known to be resistant to a diverse set of stress conditions such
as those caused by oxidative stress in the retina, tobacco smoke-induced emphysema, steroid-induced
atrophy in the skin and apoptosis of lung epithelial cells caused by ceramide [46–48]. Mouse Ddit4
resides in a genomic region on chromosome 10 (10: 59316668-74913026), which forms the only syntenic
cluster on human chromosome 10 (10: 53435340-73103214), emphasizing its conservation, genomic and
functional importance. In addition, previous studies found that simultaneous loss of Drosophila scylla
and charybdis, which are homologs of the human DDIT4 and DDIT4-like genes, generated flies that
showed mild overgrowth [49]. In contrast, enhanced expression of Ddit4 can promote apoptotic cell
death or terminal differentiation in certain cell types [50], including VDR-deficient follicular epithelial
cells observed in our studies.
3.2. Hair Follicle Defects in VDR-Deficient Animals
Our data support the notion that abnormalities in Ddit4 signaling disrupt follicular energy
homeostasis to affect follicular integrity in VDR−/− animals. It was previously reported that the
inability of VDR-deficient animals to initiate a new post-morphogenic hair cycle was due to primary
defects within KSCs [13]. Additional findings observed no change in differentiation markers of
VDR-deficient neonatal keratinocytes in culture, concluding that the mutant follicular keratinocytes
during the morphogenic period are normal [5]. In contrast, the findings of this study and others
have shown that there exist defects within the follicular epithelium of VDR−/− mice during the
catagen-to-telogen morphogenic period [17]. In this regard, it has been shown that the failure
of the follicular epidermis to maintain the hair follicle in VDR-deficient animals likely represents
the compromised adhesion and motility capacity of surface cells along the follicle at the onset of
anagen, and not due to functional defects within label-retaining KSCs [14,19]. These defects can
further compromise lineage progression and differentiation status of follicular keratinocytes lacking
a functional VDR. Furthermore, we observed no differences in Ddit4 expression within VDR−/−
KSCs, suggesting that Ddit4-related defects reside either in the hair germ or more in differentiated
progenitor cells. It is well known that mTOR activation propagates metastasis and matrix-stimulated
cell migration, and treatment with mTOR inhibitors such as rapamycin can block cell motility under
numerous experimental conditions (reviewed in [51]). There are also several examples how primary
defects of the strictly regulated morphogenic catagen-telogen transition can lead to failed initiation
of the ensuing anagen hair cycle, much like that observed in VDR−/− animals [52,53]. Overall, our
findings may have uncovered a critical cog—mTOR signaling—in the full understanding of how hair
follicles become impaired and degenerate in VDR−/− animals.
To date, it is unclear if the stress compartments identified in VDR−/− morphogenic follicles are
formed due to systemic and/or local stress stimuli. As a number of sensing cues impinge on the
Ddit4-mTOR signaling pathway, it will require additional efforts to identify the specific cues within
the VDR−/− follicles. It is commonly known that damaged hair follicles endure premature catagen
initiation to inhibit proper hair follicle growth [54], further supporting our findings and suggesting
precocious and prolonged catagen-to-telogen transition in VDR-deficient follicles. This speculation is
supported by a recent study which performed RT-qPCR analysis on plucked VDR−/− hair follicles
during morphogenetic days 13 and 15 [17]. In the study, at day 13 there was a significant increase in
pro-apoptotic CASP3 (caspase 3) transcripts in VDR−/− follicles compared to controls, and at day 15
there was a reported decrease in Shh (sonic hedgehog) message levels. Epithelial Shh is a major
driver of hair follicle morphogenesis, and its decrease in VDR−/− follicles hints at perturbations in
the process. Furthermore, it is unclear if the elevated Ddit4 level in VDR−/− follicles is a harbinger of
apoptosis activation [17], as there is a clear link between persistent Ddit4 activation with programmed
cell death [55]. Lastly, we are unclear whether the Ddit4-positive stress compartments are associated
with clearance of dysfunctional cellular debris, as DDIT4 upregulation and mTOR suppression are
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VDR-null animals does not reflect defects in the VDR-Ddit4 axis within KSCs, rather in the cells that
make up the cycling portion of the hair follicle (Figure 7).
 
Figure 7. Early stress in VDR−/− hair follicles and epidermal regulation of Ddit4 by the VDR
(column 1.5). Schema depicting the major findings. (A) VDR−/− hair follicles (HFs) exhibit DDIT4+
stress compartments, marked in red, during morphogenesis which prolongs the telogen phase;
(B) The VDR regulates Ddit4 expression during epidermal homeostasis and wound healing responses.
By day 48, VDR−/− hair follicles have degenerated resulting in loss of Ddit4expression; (C) Proposed
functional role of Ddit4 and mTOR during epidermal maturation and hair growth. During epidermal
maturation, VDR signaling induces Ddit4 expression to block mTOR cascades. During the initiation
of anagen, Ddit4 levels are suppressed in order to stimulate the mTOR growth-promoting cascade;
(D) Proposed involvement of DDIT4 in regulating the pro-differentiation effects of vitamin D in
embryonic fibroblasts.
3.3. Epidermal Wounding Defects
The defect in VDR−/− hair follicles highlights the dichotomy which exists in the epidermis
(Figure 7). Our data suggests that within uninjured epidermal keratinocytes, both in vitro and in vivo,
the VDR regulates Ddit4 message levels in a concentration and age-dependent manner, respectively.
By day 48 the epidermis normally expresses high levels of differentiation markers, yet animals void of
VDR associate with reduced epidermal differentiation [17,57]. This is consistent with reduced levels of
Ddit4 within skin of VDR−/− mice. This finding is also consistent with increased Shh in the epidermis
of VDR−/− mice [57], which can induce a basal-like phenotype as well as basal cell carcinomas in the
skin. Thus, we speculate that the VDR maintains epidermal homeostasis via direct transcriptional
control of Ddit4 over time.
Skin wounding triggers an acute inflammatory response with the innate immune system
contributing both to protection against invasive organisms and invasion of inflammatory cells into
the wounded area. These cells release a variety of cytokines and growth factors that stimulate the
proliferation and migration of dermal and epidermal cells to close the wound. Mice globally lacking
the VDR or the enzyme CYP27B1 exhibit decreased lipid content of the lamellar bodies leading to a
defective permeability barrier [58], and a defective response of the innate immune system to invading
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VDR−/− mice, which is consistent with most reports [3,14,59]. This is in contrast to one study that
showed no difference in wound closure of VDR−/− animals [2], which may reflect differences in the
age of the animals and/or severity and conditions of the wounds. Regardless, studies investigating
“epithelial-specific” ablation of the VDR resulted in delayed wound closure attributed to impaired
β-catenin signaling within epidermal stem cells [3]. Recently, epithelial-specific ablation of phosphatase
and tensin homolog Pten and tuberous sclerosis 1 Tsc1 (both inhibitors of mTOR) has shown that
mTOR activation can dramatically increase epithelial cell migration and cutaneous wound closure [40].
Although we observed the opposite phenomena, one could argue for global VDR ablation having
systemic effects on the immune system that impedes the subsequent steps of the healing process,
such as re-epithelialization.
Fibroblasts also migrate into the wounded area and proliferate to deposit a provisional
extracellular matrix consisting of reforming granulation tissue. Keratinocytes migrate across the injured
dermis above the provisional matrix and begin to proliferate. By 3–10 days after injury, the wound
is filled with granulation tissue, and fibroblasts are recruited to the wound by growth factors from
macrophages. Fibroblasts then trans-differentiate into myofibroblasts, leading to wound contraction
and immature collagen deposition assisting in wound closure. At this stage, the apical wound
portion is overlaid with a neo-epidermis associated with fibroblasts. At six days after wounding we
observed sporadic Ddit4-postive cells within the re-epithelized wound within the neo-epidermis in WT
animals. The identity of these cells is unclear, and may signify the transitioning (myo)fibroblasts during
the healing process or keratinocytes. At this stage the levels of both Ddit4/Ddit4 and Krt10/Krt10
decreased relative to uninjured tissue representing the development-like regenerative steps of healing.
In contrast, VDR−/− neo-epidermis did not harbor any Ddit4-positive cells, suggesting loss of or
delayed formation and recruitment of this specialized subset of regenerative cells during the healing
process. Importantly, we observed primary ligand resistance to VDR signaling within Ddit4−/− MEFs,
suggesting potential dermal fibroblastic regulation and defects in VDR−/− animals as well.
4. Materials and Methods
4.1. Animal Maintenance
VDR−/− animals (B6.129S4-Vdrtm1Mbd/J) with targeted ablation of the second zinc finger were
purchased from the Jackson Laboratory (JAX: 006133, Bar Harbor, ME, USA). Animal studies were
approved by the institutional animal care and use committee (First Affiliated Hospital of Chongqing
Medical University; SYXK2012-0001, January 2015). Animals were kept in a clean (virus- and
parasite-free) facility under a 12-h light, 12-h dark cycle on a diet enriched with calcium (2%),
phosphorus (1.25%) and lactose (20%) to prevent hyperparathyroidism, rickets and osteomalacia,
but not alopecia [16].
4.2. Mouse Puncture Assay
Male 48-day-old littermate mice (n = 4 mice per time point) were anesthetized and received a
3.5 mm biopsy skin punch on each side of the trunk. Six days after puncture, re-epithelialization was
monitored by harvesting tissue in 10% buffered formalin. Paraffin embedded wounds were processed
for immunohistochemistry. For reverse transcription quantitative PCR (RT-qPCR) analysis, wounds
(n = 4 per genotype and time point) were excised, trimmed and then processed using the RNeasy Plus
Universal Mini Kit (Qiagen, Gaithersburg, MD, USA).
4.3. Chromatin Immunoprecipitation (ChIP)
We performed the ChIP assays using ChIP-IT® Express Chromatin Immunoprecipitation Kits
from Active Motif. Primary keratinocytes were treated for 15 min with 10 nM 1,25D3 (Biomol,
Plymouth Meeting, PA, USA) reconstituted in absolute ethanol. Chromatin was cross-linked
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(SDS) cell lysis buffer. Samples were enzyme-treated to yield fragmented chromatin. Chromatin
samples were incubated with 10 μg ChIP-grade anti-RNA polymerase II (ab26721; Abcam, Boston,
MA, USA) and anti-VDR (sc-1008x; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies.
Quantitative PCR (qPCR) was performed with primers flanking putative vitamin D response
element (VDRE) consensus sequences in the regulatory region of mouse Ddit4 (based on the
GRCm38 mouse assembly; available on: https://www.ncbi.nlm.nih.gov/genome/52). Primers were
designed using Primer3 (bioinfo.ut.ee/primer3-0.4.0/primer3). Ddit4 target: Ddit4-1: (forward)
5-ttcccatccttttgcagttc-3, (reverse) 5-ccactgcccaatttcatctt-3; Ddit4-2: (forward) 5-tcagggtcccagtgtcctac-3,
(reverse) 5-caattcaatggaacccagga-3; and Ddit4-3: (forward) 5-ggtacctttctcccctgctc-3, (reverse)
5-ctctcccctcgccttagc-3. Control primers: OC (osteocalcin): (forward) 5-caggggcagacactgaaaa-3,
(reverse) 5-aggagactgccaggttctga-3; VDR-S1 (VDRE site): (forward) 5-gtagccatccatgtggcttt-3, (reverse)
5-ccagacggaagcctagagaa-3; and non-specific control (calponin) based on [60]. The non-specific control
was used to normalize for DNA content and to calculate the relative enrichment of the regulatory
regions according to the formula of Livak and Schmittgen [61] and presented as fold enrichment.
Samples were run on a 1.5% tris-acetic acid- ethylenediaminetetraacetic acid (TAE) agarose gel
for visualization.
4.4. In Vivo/In Vitro 5-Bromo-2′-deoxyuridine (BrdU) Labeling and Immunocytochemistry
For cell proliferation studies, wounded animals were injected intraperitoneally with
5-bromo-2′-deoxyuridine (BrdU) at 0.25 mg/gram (Roche) three hours prior to the time that the
animals were sacrificed. Wounds were excised, fixed, and processed for immunocytochemical analysis.
Proliferating cells were detected using a BrdU labeling and detection kit (Roche, Indianapolis, IN,
USA) according to the manufacturer′s instructions. For in vitro studies, sterile filtered 10 μM BrdU
was prepared in media. After 12 h of vitamin D treatment, cells were washed with phosphate buffered
saline (PBS), and replaced with the BrdU solution for a 2 h labeling period. Cells were fixed and then
detected as above. Cell counting analysis was performed using the “spot” function on the Imaris
(version 8.4, Bitplane, Concord, MA, USA) software.
4.5. Fluorescence-Activated Cell Sorting of Hair Follicle Stem Cells
Skin from 29-day-old wildtype (WT) and VDR−/− littermates was used to harvest hair follicle
stem cells. The purification of bulge stem cells from mice was performed using established
expression markers α6hi/Cluster of differentiation 34 (CD34+) [12]. The antibodies used were:
Anti-Integrin α6 phycoerythrin (PE) conjugated, ab95703 (Abcam); anti-CD34, ab8158 (Abcam); and
Alexa Fluor® 488 (Thermofisher, Waltham, MA, USA) secondary antibody at ~1 μg antibody per
106 cells. The double-labeled cell suspensions were placed in FACS tubes on ice for sorting on a BD
FACSCalibur™ (BD Biosciences, San Jose, CA, USA). BD Falcon tubes containing 50% chelex-treated
FBS in PBS were used to collect double-labeled KSCs. Using four sets (n = 4 experiments per genotype)
of four 29-day-old postnatal mice, we enriched KSCs for RT-qPCR analysis. KSCs were further collected
in the appropriate RNA stabilization reagent supplied in the RNeasy mini kit (Qiagen).
4.6. Immunofluorescent and Immunohistochemical Labeling of Skin
Skin tissues were obtained from the lower dorsal region. Wounds were excised and fixed in
10% formalin/PBS, processed and embedded vertically in paraffin. Tissues sections were mounted
on microscope slides and processed for immunofluorescence staining with detergent (0.1% triton X).
DDIT4 labeling was detected using an DDIT4 antibody (Abcam, ab106356) at 1:200 dilution followed
by secondary staining with Alexa Fluor® 594 (Thermofisher). Slides were mounted in Vectashield®
mounting medium with DAPI (Vector Laboratory). Immunohistochemistry was performed using
anti-K10 (Abcam, ab9026) at 1:100 dilution with HRP-conjugated secondary antibody and DAB. Slides
were imaged using a FV1000 (Olympus, Center Valley, PA, USA) confocal microscope. Control slides
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For confocal imaging, a series of three-dimensional “z-axis” image projections of follicular axial
depths were obtained in XYZ scan mode set to 1 μm/slice and a sample speed of 12.5 μs/pixel.
All other parameters (e.g., pinhole diameter, gain, laser intensities) were kept constant during imaging.
The fluorescence intensity was never saturated (max. 4096 intensity level) during imaging. The series
of projected “z-axis” images were used to calculate average fluorescent intensity profiles per 594 nm
channel using the freehand analysis tool in the Fluoview software v. 4.1 (Olympus). The proximal
bulb region of Ddit4-stained hair follicles were averaged per image, as well as follicles of negative
controls averaged per image to generate average background fluorescence intensities. Ddit4 levels in
the bulb were relatively compared and background corrected between for eight individual follicles
per genotype.
4.7. Ddit4−/− Mouse Embryonic Fibroblasts (MEFs) and Cell Count Measurement
Ddit4−/− and wild type MEFs were generously provided by Leif W. Ellisen as previously
described [25], and maintained in Dulbecco’s Modified Eagle’s medium (DMEM)/10% fetal bovine
serum, Pen/Strep. Cells were maintained at 37 ◦C in a 95% air/5% CO2 atmosphere. Cells were
plated in 24-well tissue culture plates at 2 × 104 cells per cm2 and then replaced with fresh media and
1,25D3. Cells were trypsinized and counted 24 h later using an automated cell counter (Countess II FL,
Thermofisher). Three sample preparations were made per condition in order to calculate the % of cells
remaining (n = 3).
4.8. mRNA Reverse Transcription Quantitative PCR (RT-qPCR) Analysis
Total RNA was purified using the RNeasy mini kit (Qiagen). cDNA was synthesized from 300 ng
total RNA by SuperScript Reverse Transcriptase III (Invitrogen, Carlsbad, CA, USA) using random
hexamers. RT-qPCR analysis was performed with a Stratagene MX-3005P instrument utilizing TaqMan
system reagents from ABI, and target genes were normalized to ATCB (β-actin) expression. TaqMan®
assays used: (1) Control ATCB, β-actin (VIC®-labeled), assay ID 4352341E; (2) 1,25-dihydroxyvitamin
D3 24-hydroxylase (Cyp24a1, FAM™-labeled), assay ID 4331182; (3) Ddit4 (FAM™-labeled), assay ID
4331182; and (4) Krt10 (FAM™-labeled), assay ID 4331182. All reactions were performed in triplicate
experimental conditions. Data are presented as comparable arbitrary expression units.
4.9. Primary Neonatal Keratinocytes and mVDR Transient Transfection
Primary keratinocytes were harvested from neonatal pups aged 2–3 days using a trypsin floating
method. Briefly, the pups were skinned and then floated on 0.05% trypsin (Sigma, St. Louis, MO, USA)
at low temperature for 12 h. The epidermal sheets were harvested, minced, and then agitated with
a stir bar in a keratinocyte growth medium on ice for 1 h. The medium consisted of: calcium and
magnesium-free Eagle’s Minimal Essential Medium (Gibco, Carlsbad, CA, USA), FBS with reduced
calcium, 2 ng/mL human recombinant epidermal growth factor (EGF) (Novoprotein, Summit, NJ,
USA) supplemented with 1× penicillin–streptomycin (Gibco). Calcium in the serum was removed by
treating FBS with a chelating resin, Chelex®100 (Bio-Rad Laboratories, Hercules, CA, USA). Calcium
concentration was adjusted to 0.05 mM by adding calcium chloride solution. The cell suspension
was then filtered using a 40 micron mesh and were seeded (4 × 104 cells/cm2) in tissue culture
plates pre-coated with type I collagen (Gibco, R-011-K). Cultures were incubated in 8% CO2 and 92%
humidified atmosphere at 34 ◦C, and medium was changed every 2–3 days. The untagged mouse
vitamin D receptor expression vector (pCMV6) was purchased from Origene (BC006716). Transfection
of primary keratinocytes was conducted using the BioT reagent (Biolands) and protocol.
5. Conclusions
In conclusion, we show that Ddit4 marks early stress compartments within VDR−/− hair follicles
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component of growing anagen follicles during the hair cycle. Ddit4 is also a direct transcriptional
target of the VDR within epidermal keratinocytes, highlighting its ligand-dependent genomic role
during vitamin D signaling. VDR regulates Ddit4 during epidermal homeostasis and the wound repair
process, namely the proper differentiation and stratification of the neo-epidermis post injury.
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Abstract: Pseudomonas aeruginosa biofilm maintains and perturbs local host defense, hindering timely
wound healing. Previously, we showed that P. aeruginosa suppressed S100A8/A9 of the murine innate
host defense. We assessed the potential antimicrobial effect of S100A8/A9 on biofilm-infected wounds
in a murine model and P. aeruginosa growth in vitro. Seventy-six mice, inflicted with a full-thickness
burn wound were challenged subcutaneously (s.c.) by 106 colony-forming units (CFUs) of P. aeruginosa
biofilm. Mice were subsequently randomized into two treatment groups, one group receiving
recombinant murine S100A8/A9 and a group of vehicle controls (phosphate-buffered saline, PBS)
all treated with s.c. injections daily for up to five days. Wounds were analyzed for quantitative
bacteriology and contents of key inflammatory markers. Count of blood polymorphonuclear
leukocytes was included. S100A8/A9-treatment ameliorated wound infection, as evaluated by
quantitative bacteriology (p ≤ 0.05). In vitro, growth of P. aeruginosa was inhibited dose-dependently
by S100A8/A9 in concentrations from 5 to 40 μg/mL, as determined by optical density-measurement
(OD-measurement) and quantitative bacteriology. Treatment slightly augmented key inflammatory
cytokine Tumor Necrosis Factor-α (TNF-α), but dampened interferon-γ (IFN-γ) levels and blood
polymorphonuclear count. In conclusion, topical S100A8/A9 displays remarkable novel immune
stimulatory and anti-infective properties in vivo and in vitro. Importantly, treatment by S100A8/A9
provides local infection control. Implications for a role as adjunctive treatment in healing of chronic
biofilm-infected wounds are discussed.
Keywords: biofilm infection; chronic wounds; host defense; Pseudomonas aeruginosa; S100A8/A9
1. Introduction
Infected chronic wounds are an increasing threat to society and can be fatal for diabetic
patients. There is an urgent need for adjunctive therapies taking increasing microbial resistance
into consideration. Innate host mechanisms may hold a key to this progress in the understanding of
wound chronicity.
A rigorous debridement is necessary for optimal treatment of chronic human wounds.
Even though surgical effort has been made in order to optimize the wound bed for healing, failure
of split-skin transplantation is often the case, especially when Pseudomonas aeruginosa biofilm is
present in the wound [1]. P. aeruginosa biofilms reside deeply in the wound bed [2] and have an
undisputable effect on local host response, as increasingly evidencesd in the last decade [3]. Biofilms
are invisible to the naked eye and at present, there is no local marker to guide clinicians. Thus, greater
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understanding of the clinical impact of biofilms on host response is of importance and may lead to the
development of new adjunctive treatment strategies that take sufficient antibiotic therapy as well as
the immunomodulatory effect of biofilm infections into consideration [4].
S100A8 and A9 are the most abundant cytoplasmic proteins of neutrophils and monocytes [5]
and are released upon activation of these phagocytes [6]. They form the physiologically relevant
heterodimeric S100A8/A9, where S100A8 is the active component and S100A9 the regulating
subunit [7]. S100A8/A9 has wide antifungal and antimicrobial potential [8]. We previously reported
reduced S100A8/A9 levels in colonized human chronic wounds [9,10]. Since P. aeruginosa is able to
degrade cytokines [11], S100A8/A9 may likewise be degraded in vivo in anatomically close proximity
to the P. aeruginosa biofilm as part of the evasion of the immune system.
S100A8/A9 may exert its host defense functions locally upon neutrophil death mediated release at
sites of tissue infection, thereby controlling growth of P. aeruginosa [12]. Animal models may shed light
on the complex pathophysiology of chronic wounds and accordingly, possible immunomodulatory
and beneficial effects of S100A8/A9 on wound infection were investigated in the present study using
a representative animal model. The BALB/c strain of mice is susceptible to P. aeruginosa infection and
literature describes a potential anti-infective effect of this protein. Thus, we assessed the impact of
recombinant S100A8/A9 on the course of infection in BALB/c mice as well as the direct inhibitory
effect on S100A8/A9 in vitro.
2. Results
2.1. Quantitative Bacteriology of P. aeruginosa Biofilm-Infected Wounds
In order to determine an anti-infective effect of host response S100A8/A9 on chronic P. aeruginosa
biofilm-infected wounds in vivo, we subjected BALB/c mice to topical intervention by this
recombinant protein.
A significant increase in colony-forming unit (CFU) count from day 1 to day 5 was observed in
the control (phosphate-buffered saline, PBS) group (p < 0.0001). In contrast, no such increase was seen
in the S100A8/A9-treated group. Mean values (log10 CFU/wound) for the treated group compared to
controls was 8.266 ± 0.183 vs. 7.804 ± 0.866 at day 1. At day 2, it was 8.628 ± 0.429 to 8.618 ± 0.328;
day 3, 8.498 ± 0.500 to 8.981 ± 0.437; and day 5, 8.523 ± 1.221 to 9.317 ± 0.316. At the termination of
the experiment on day 5, significantly reduced CFUs were found in the S100A8/A9-treated wounds
compared to the control group (Figure 1, p < 0.05).
Figure 1. Induction of local wound infection control. Log10 colony-forming units (CFUs) of
P. aeruginosa/wound as expression of time in the intervention group (S100A8/A9) and control group
(phosphate-buffered saline, PBS). S100A8/A9-treatment induced infection control. The number of
colony-forming units (CFUs) after 5 days of treatment was significantly reduced as compared to the
non-treated control group (** p < 0.05). Increase in growth over 5 days in the control group only
(* p < 0.0001). Individual values indicate mean of duplicates with overall mean ± standard deviation.
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2.2. Bacterial Growth Inhibition Assay
To verify the anti-infective effect of topical S100A8/A9 on infected wounds, we assessed the direct
interaction of S100A8/9 and planktonic PAO1 (a strain of P. aeruginosa). A growth inhibition assay
was performed to determine whether the reduced bacterial levels in the wounds were due to immune
modulation or direct inhibition of P. aeruginosa growth. The addition of S100A8/A9 reduced bacterial
growth of P. aeruginosa time- and dose-dependently, starting at 2.50 μg/mL at 24 h of incubation
(Figure 2A, optical density (OD) 0.732 versus 0.999 at blank), 5 μg/mL at 6 h (0.481 versus 0.574)
and 10, 20, and 40 μg/mL at 2 h (0.081 versus 0.11). In addition, PAO1 was grown in medium for a
maximum of 24 h at 37 ◦C with or without S100A8/A9. CFU counts the following day confirmed the
result with a lower CFU/mL at 1 h of incubation with 20 and 40 μg/mL. At 6 h, bacterial growth was
inhibited dose-dependently, from 5 to 40 μg/mL (Figure 2B) and a maximal 0.5 log inhibition with












































Figure 2. S100A8/A9 inhibits growth of Pseudomonas aeruginosa. (A) Growth inhibitory effect of
S100A8/A9 on PAO1, shown by OD-curve (read at OD600 at time points indicated). (B) Growth
inhibitory effect of S100A8/A9 on PAO1, shown by bacterial CFU count (1 h, 6 h, 24 h, at concentrations
40, 20, 10, 5, 2.5, or 0 μg/mL). Growth inhibitory effect of S100A8/A9 on PAO1, shown by (A)
OD-curve (read at OD600 at time points indicated) and (B) bacterial count as log10 CFU (1 h, 6 h, 24 h at
concentrations 40, 20, 10, 5, 2.5, or 0 μg/mL).
2.3. The Impact of S100A8/A9-Treatment on Local Wound Inflammatory Markers
We previously described an aggravated Interleukin-1β (IL-1β) response towards P. aeruginosa
biofilm in the chronic wound model using BALB/c mice [13]. As S100A8/A9 is an endogenous peptide,
we speculated that exogenous application would immunomodulate host defense in the wounds.
S100A8/A9 stimulated Tumor Necrosis Factor-α (TNF-α) from day 1 to 5 (p < 0.0261) and 3 to
5 (p < 0.001) (Figure 3A). Interferon-γ (IFN-γ) levels (Figure 3B) were discretely attenuated with a
significant increase from day 1–5, day 2–5, and day 3–5 only in the control group (p < 0.0023, p < 0.0008,
p < 0.0054, respectively). In the S100A8/A9 group, no such increase was seen.
There were no significant immunomodulatory effects of S100A8/A9 on the levels of IL-1β
(Figure 3C), IL-10 (Figure 3D), Keratinocyte-derived Chemokine (KC) (Figure 3E), Granulocyte-Colony
Stimulating Factor (G-CSF) levels (Figure 3F), or IL-17 levels (Figure 3G).
IL-1β, IL-10, KC, and G-CSF levels were all induced by infection (Figures S2–S5). IL-1β levels
were induced in 1 day with treatment or PBS, TNF-α in 5 days with treatment or PBS as compared to
































Figure 3. Modulation of proinflammatory cytokines. (A) Tumor Necrosis Factor-α (TNF-α) levels were
increased in the S100A8/A9 group from day 1 to 5 (p < 0.0261) and day 3 to 5 (p < 0.001). No such
increase was observed in the PBS group; (B) Interferon-γ (IFN-γ) levels were increased in the PBS from
day 1 to 5 (p < 0.0023), 2 to 5 (p < 0.0008), and day 3 to 5 (p < 0.0054). No increase was observed in
the S100A8/A9 group; (C) IL-10. No significant changes were observed in either of the two groups,
but there was a tendency to an attenuated response in the S100A8/A9 group; (D) in the PBS group,
Keratinocyte-derived chemokine (KC) increased from day 1 to 5 (p < 0.0156). In the S100A8/A9 group,
KC increased from day 1 to 5 (p < 0.0139) and day 2 to 5 (p < 0.0017). (E) In both groups, IL-1β
increased from day 1 to 5 (p < 0.0005 in the PBS group and p < 0.0482 in the S100A8/A9 group); (F) In
both groups, Granulocyte-Colony Stimulating Factor (G-CSF) increased with time for all time points
evaluated. (G) In both groups, Il-17 increased with time for all time points evaluated. Modulation of









Int. J. Mol. Sci. 2017, 18, 1359
2.4. Systemic Polymorphonuclear Count
In the S100A8/A9 group, no significant increase in PMN count was observed from 1 to 5 days
of treatment. In contrast, in the control group, an increase in PMN count was seen from 1 to 3 days
after infection (p < 0.03) and from 1 to 5 days of treatment (p < 0.003). Infection induced significantly
higher PMN counts in all groups compared to background mice (no wound, no infection, n = 6, mean
PMNs/mL whole blood ± SD: 2.7 × 105 ± 1.4 × 105). Burn wounding (controls immediately after
wound infliction (n = 3), and at 2 (n = 3) and 4 days (n = 3) post wound infliction) and burn wounded
mice challenged with infection and sacrificed immediately after infection (n = 3) induced higher PMN
count than in background mice (Figure 4). Systemic total white blood cell count at 5 days after infection
was equal between the groups (Figure S6).
Figure 4. S100A8/A9 dampens systemic polymorphonuclear count. Systemic polymorphonuclear
(PMN) count in S100A8/A9 (+) treated group versus PBS (−). Bars are expressed with mean +
standard deviation. No significant increase was seen in the S100A8/A9 group. In contrast, in the
PBS group, an increase in PMN count was seen from day 1 to 3 (p < 0.03) and day 1 to 5 (p < 0.003).
Abbreviations: b: background (n = 6), b0: burned, results obtained immediately after wounding,
b2: burned, two days after wounding, b4: burned, 4 days after wounding; bi: burn and infection, results
obtained immediately after infection. D1, 2, 3, 5: day 1, 2, 3, 5. *, significant increase.
2.5. Digital Planimetry
To assess a clinical impact on wound closure, we analyzed wound area and necrotic areas
by planimetry.
After 5 days of treatment, S100A8/A9 did not affect the total wound area (mean 244.9 mm2 ±
74.11 versus 257.1 ± 60.54 for the control group) or the area of necrosis at day 5 (174.8 mm2 ± 52.38
versus 180.1 ± 34.27 for the control group) (Figures S7 and S8).
2.6. Epidermal Growth Factor Levels
The key growth factor epidermal growth factor (EGF) was quantified as a pseudomarker for
wound closure, with results showing no effect of S100A8/A9 on EGF levels in wounds (Figure S9).
3. Discussion
The aim of the present study was to evaluate an antimicrobial effect in vivo and in vitro of
S100A8/A9 on P. aeruginosa, a clinically important wound pathogen.
Selection of this calcium-binding protein [14] was based on a previous description of reduction of
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Degradation of S100A8/A9 in the proteolytic wound environment could explain this reduction.
However, the protein displays high protease-resistance, suggesting another route [15]. Regardless of
the underlying mechanism behind S100A8/A9 reduction in chronic biofilm-infected wounds, a logical
consequence of previous observations was to perform a study of topical S100A8/A9 treatment with
dose selection of 1 μg/250 μL. Studies performed by Sroussi et al. showed that a single dose of
topically applied ala42 S100A8 (25 μL of a 1 μg/mL solution intradermal +10 μL directly to excisional
murine wounds) reduced bacterial CFU count in mice subject to restraint stress at day 1 and day 5
post wounding. However, the bacteriology was not further described and biofilm presence, in contrast
to the present study, was not considered [16].
The present results show, to our knowledge, a novel inhibitory effect of S100A8/A9 on P. aeruginosa
in a murine model of biofilm-infected wounds as well as in vitro. Growth inhibition by S100A8/A9
has been described by several groups, in multiple species in vitro including Borrelia burgdorferi,
Klebsiella pneumoniae, Escherichia coli [12], Staphylococcus aureus, Candida albicans, and Salmonella
typhimurium [8,17–20]. The addition of zinc in several of the studies reversed the inhibitory effect and
accordingly, S100A8/A9 chelation of zinc and manganese [8] may inhibit growth by nutritional
immunity. Another possibility could be the disruption of biofilm alginate polymerization by
S100A8/A9 bound calcium and a resultant increase in susceptibility of bacteria superficially situated in
the biofilm to phagocytosis by PMNs. Another potential method of action was described by Akerström
et al. [21], who found a lysing effect of S100A8/A9 on the anaerobic bacterium Finegoldia magna
(previously known as Peptostreptococcus magnus) by interacting with the cell membrane.
Regarding the modulation of inflammatory mediators in the wounds, treatment augmented
TNF-α and decreased IFN-γ levels locally. Vogl and colleagues showed that S100A8/A9 amplifies
phagocyte activation during lipopolysaccharide-induced sepsis via activation of TLR-4 upstream of
TNF-α response [7]. The reason for a potential decrease in IFN-γ is not clear. We assessed the wounds
in the early part of inflammation and speculate that at this point IFN-γ acts as an acute inflammatory
marker, related to the wound infliction itself. We have previously shown an improved clinical outcome
of lung disease in Th1-reacting C3H/HeN mice (higher IFN-γ levels) as compared to Th2-reacting
BALB/c mice [22,23]. The adaptive immune response also emerges only at the termination of the
present study. Accordingly, the timing of treatment and improved healing outcome and correlations to
IFN-γ levels need further investigation.
Previously, we found an early aggravating effect of P. aeruginosa biofilm on local IL-1β levels
in BALB/c mice. Treatment by S100A8/A9 in the doses chosen in this study did not counteract
this observation.
In regard to the stability and pharmacodynamics of S100A8/A9, we were unable to find reports
on the durability of exogenously applied S100A8/A9 in vivo, but further experiments could address
this matter. In vitro, S100A8/A9 is extremely protease-resistant [15].
In addition to growth inhibiting properties, S100A8/A9 may also have immunomodulatory
leukocyte effects [24]. In a murine model of P. aeruginosa keratitis, S100A8/A9 treatment promoted
bacterial clearance by increasing production of reactive oxygen species [25]. Interestingly, subunit
S100A9 induces neutrophil phagocytosis of Eschericia coli [26]. Therefore, an increased phagocytosis
caused by appropriate levels of S100A8/A9 might be an additional explanation for the diminished
bacterial count in the present study. A role for S100A8/A9 in the oxidative metabolism and functional
role of neutrophils should be explored further, as this could explain the reduced CFU count in the
S100A8/A9-treated group of mice and may indirectly impact the delayed IL-1β response. Ryckmann
et al. showed that S100A8/A9 in the concentration range 10−12 to 10−10 M acts as a chemotactic factor
for neutrophils in vitro. In the same study, equimolar quantities of S100A8 and A9 (0.1–10 μg/mL),
dissolved in PBS, attracted neutrophils in an in vivo murine air pouch model [27].
In the present study, treatment reduced blood PMN count although this attenuation was not
reflected in the PMN mobilizer G-CSF, nor the two chemo-attractants KC and IL-17. Interestingly,
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control groups while these inflammatory markers increased with time in both groups. We speculate
that the dose of S100A8/A9 chosen was insufficient to cause significant differences. Ongoing studies
will substantiate relevant and safe doses of S100A8/A9 in this model.
A reduction of circulating PMNs could theoretically be beneficial, as chronic wounds are trapped
in the inflammatory state of healing, showing continuous neutrophil extravasation and excessive
host responses regarding TNF-α, but not IL-17, which is part of the adaptive immune system.
IL-17 suppression by S100A8/A9 could imply that this protein delays initiation of the adaptive
immune response. We hypothesize that S100A8/A9 is a marker of activated, phagocytizing leukocytes.
The reduced extracellular levels of this protein, observed in our previous studies, may reflect the
inhibition of neutrophil function and phagocytosis caused by rhamnolipid, produced by P. aeruginosa
biofilms, in the chronically infected wounds, to ensure a fitness advantage and evasion of the immune
system [28,29]. However, further insights on the actual impact of topical S100A8/A9 on PMN
mobilization and physiology should be addressed in vitro.
The intervention did not have any significant impact on wound healing, as determined by
planimetry, or on levels of EGF. This is probably due to the relatively short observation period (up to
10 days after wound infliction or six days post infection).
In conclusion, we have demonstrated that S100A8/A9 mitigates local P. aeruginosa biofilm infection
by modulating local host response and attenuating systemic reaction in the chronic wound murine
model. Accordingly, a clear growth inhibiting effect of recombinant murine S100A8/A9 on P. aeruginosa
was observed in vitro. Apparently, this innate host defense protein possesses the capacity to combat
an established biofilm infection as well as planktonic bacteria. The present study supports a beneficial
role of S100A8/A9 as adjunctive treatment in refractory P. aeruginosa biofilm-infected wounds.
4. Materials and Methods
4.1. Study Design of Animal Experiments
Mice predisposed for chronic P. aeruginosa biofilm infection by infliction of burn wound
full-thickness necrosis were treated daily with S100A8/A9 or vehicle (PBS) for a period of 5 days post
infection. Wounds were assessed by quantitative bacteriology, quantification of key inflammatory
cytokines and growth factors locally, and count of systemically polymorphonuclear (PMN) leukocytes.
Digital photoplanimetry described development of wounds within the 5 day treatment period.
Assessment of epidermal growth factor (EGF) was chosen as a marker for progression in wound closure.
4.2. Animals
In total, 78 female BALB/c mice (Taconic Europe A/S, Lille Skensved, Denmark) were used for
the present study. For comparison of inflammatory reaction to the wound infliction and no consequent
treatment, six sham control and burn wounded, but not infected, mice were included. Three mice were
evaluated at 2 days and three mice at 4 days post wound infliction. An additional three burn wounded
mice were sacrificed immediately after infection for presentation of baseline levels. Two untreated and
unburned mice were kept for background levels.
Animals were acclimatized for at least 1 week in the animal facilities before experimentation and
were allowed free access to chow and water. Animal care was provided by trained personnel.
The study was approved by the Animal Ethics Committee of Denmark (2015-15-0201-00618,
15 July 2017) and all experiments were performed following National and European Union guidelines.
4.3. Establishment of Chronic Wound Infection
First, structural damage to the skin acting as a predisposing factor for settlement of infection was
induced by establishment of third degree burn wounds [13,30]. The area of the thermal lesion was
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Four days post wound infliction, 100 μL of a 107/mL colony forming units (CFU). P. aeruginosa
biofilm solution (106 CFU/wound) was injected subcutaneously (s.c.), centrally, beneath the wound.
The biofilm was prepared as previously described [31]. Treatment was initiated 24 h after biofilm
injection to allow for the settlement of infection. Mice were sacrificed by intraperitoneal injection of
a pentobarbiturate/lidocaine overdose after 1, 2, 3, or 5 days of treatment.
4.4. Immunomodulation of Murine Wounds
Recombinant mouse S100A8/A9 (Cloud Clone, Katy, TX, USA) was reconstituted in sterile-filtered
PBS (0.22 μm) to reach a concentration of 4 μg/mL and 250 μL of the solution (1 μg) was given
s.c. by injection centrally beneath the wounds. Controls received PBS from the same flask used
for reconstitution.
Treatment (+/− S100A8/A9) was given 1, 2, 3, 4, and 5 days after biofilm injection. Fourteen mice
were treated for 1 day, 14 for 2 days, and 16 for 3 days. Eleven mice were given PBS for 5 days (one
mouse died as a result of the burn wound infliction) and 12 mice were given S100A8/A9 for 5 days.
4.5. Collection of Wounds
To minimize tissue disruption, wounds were carefully retrieved (n = 76) with sterile scalpels.
Each wound was placed in 2 mL sterile saline and kept on ice until homogenization for 20 s by
14,000 rpm using a Heidolph Silent Crusher M (Heidolph Instruments, Schwabach, Germany) followed
by centrifugation for 15 min at 5000 rpm. Supernatants were sterile-filtered (0.22 μm) and kept at
−80 ◦C until analysis.
4.6. Quantitative Bacteriology
Serial dilutions of wound homogenates were prepared in saline and aliquots of 0.1 mL were
spread onto modified Conradi-Drigalski medium (State Serum Institute, Copenhagen, Denmark),
selective for Gram-negative rods. CFUs were counted the following day. The actual numbers of CFUs
in the samples were calculated by multiplication with the dilution factor.
4.7. Bacterial Growth Inhibition by S100A8/A9
The growth inhibitory effect of recombinant S100A8/A9 (Cloud-Clone Corps, Katy, TX, USA)
on P. aeruginosa (PAO1, Iglewski) was assessed. Bacteria were grown from an overnight culture to
stationary phase in a liquid culture of Luria-Bertani (LB) medium, and diluted ×100 before assays
to an OD600 of 0.043. One hundred microliters (100 μL) of bacterial suspension was added to
100 μL of recombinant S100A8/A9 heterodimer to reach final concentrations of 40, 20, 10, 5, 2.5,
1.25, and 0 μg/mL and incubated with gentle shaking for 1–24 h at 37 ◦C. OD600 was measured in
duplicates at 0, 2, 4, 6, and 24 h. Bacterial growth and inhibition was assessed by plating 10-fold
serial dilutions of bacterial suspensions on agar plates at 1, 6, and 24 h, which were then incubated at
37 ◦C for 24 h. The actual growth was determined by count of CFU/mL. Data are expressed in log10
CFU/mL as a function of time and concentration.
4.8. Quantification of Inflammatory Cytokines and Growth Factors
Inflammatory markers were quantified in sterile-filtered wound homogenates. Levels of TNF-α,
IFN-γ, IL-10, KC, IL-1β, G-CSF, and IL-17 (Bio-Rad, Hercules, CA, USA) were analyzed by Luminex
Immunoassay (Luminex Corp., Austin, TX, USA). EGF levels were quantified by ELISA (Sigma Aldrich,
Saint Louis, MO, USA), as S100A8/A9 also has stimulatory effects on normal, human keratinocytes [32].
4.9. Systemic Polymorphonuclear Count
Count of systemic PMNs in anticoagulated whole blood was performed immediately after sacrifice
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white blood cells in anticoagulated blood from all mice was determined by use of a FACSCantoTM
flow cytometer (BD Biosciences, San Jose, CA, USA). A 488 nm argon laser and a 530/30 nm band pass
emission filter were used for the recording of hydroxyphenyl fluorescence in FL-1. PI fluorescence was
collected through a 585/42 nm band pass emission filter, recorded in FL-3. Samples were analyzed
at a low flow rate (10 μL/min) and ≥10,000 events were recorded per sample. Cytometer Setup
and Tracking Beads (BD Biosciences, San Jose, CA, USA) was used for calibration of the instrument.
Flow data were processed and analyzed by Diva (BD Biosciences, San Jose, CA, USA).
4.10. Assessment of Wound Closure
All mice were photographed at a fixed distance by camera (CANON, EOS 650D, Kyushu, Japan)
every other day. Mice were anesthetized by halothane during photography. Digital images were
analyzed using photoplanimetry (Image J®, version 1.47, Bethesda, MD, USA). Necrotic area and total
area of each wound were evaluated.
4.11. Statistics
Statistical calculations on continuous data were performed using the statistical programme
GraphPad Prism (version 7.02; GraphPad Software, Inc., San Diego, CA, USA). Quantitative variables
(bacteriology) were compared by student’s unpaired t-test. Cytokine assessment was by two-way
ANOVA (Bonferroni). A level of p ≤ 0.05 was considered statistically significant.
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Abstract: High mobility group box 1 (HMGB1) is tightly connected to the process of tissue
organization upon tissue injury. Here we show that HMGB1 controls epithelium and connective
tissue regeneration both in vivo and in vitro during palatal wound healing. Heterozygous HMGB1
(Hmgb1+/−) mice and Wild-type (WT) mice were subjected to palatal injury. Maxillary tissues were
stained with Mallory Azan or immunostained with anti-HMGB1, anti-proliferating cell nuclear
antigen (PCNA), anti-nuclear factor-κB (NF-κB) p50 and anti-vascular endothelial growth factor
(VEGF) antibodies. Palatal gingival explants were cultured with recombinant HMGB1 (rHMGB1)
co-treated with siRNA targeting receptor for advanced glycation end products (RAGEs) for cell
migration and PCNA expression analysis. Measurement of the wound area showed differences
between Hmgb1+/− and WT mice on Day 3 after wounding. Mallory Azan staining showed densely
packed of collagen fibers in WT mice, whereas in Hmgb1+/− mice weave-like pattern of low density
collagen bundles were present. At three and seven days post-surgery, PCNA, NF-κB p50 and VEGF
positive keratinocytes of WT mice were greater than that of Hmgb1+/− mice. Knockdown of RAGE
prevents the effect of rHMGB1-induced cell migration and PCNA expression in gingival cell cultures.
The data suggest that HMGB1/RAGE axis has crucial roles in palatal wound healing.
Keywords: HMGB1; NF-κB; wound healing; palatal mucosa
1. Introduction
In tissues skin and oral mucosa tissues, wound healing encompasses a number of overlapping
phases, including inflammation, tissue formation and tissue remodeling [1]. The process of wound
repair requires a complex and dynamic interplay of a number of tenant epithelial and mesenchymal
cells with hematopoietic cells to accomplish the three stages of wound healing [2]. In the inflammation
process, the primary phase is characterized by a local activation of innate immune mechanisms
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resulting in an initial influx of neutrophils into the injured tissue followed by macrophages
accumulation. Subsequently, epithelialization proceeds gradually from the wound edges. Finally, tissue
remodeling occurs during maturation of the newly formed tissues, which leads to scar formation [3].
Recently, wound healing analysis in a number of murine knockout models deficient for distinct
inflammatory mediators including tumor necrosis factor (TNF)-α, interleukin (IL)-6, monocyte
chemotactic protein (MCP)-1, and interferon (IFN)-γ have been investigated [4]. Dermal wound
healing is accelerated in TNF-receptor-55 [5] or IFN-γ-deficient mice [6] but is impaired in mice
deficient of IL-6 [7]. Likewise, palatal wound healing is accelerated in Smad3 [8] and interleukin
(IL)-10 [9] deficient mice.
High-mobility group box 1 (HMGB1) is a ubiquitous 25 kDa nuclear DNA-binding protein that,
under typical conditions, is located in the nucleus, where it organizes the basic structural unit of
chromatin, DNA replication, and transcription. HMGB1 also acts in the extracellular environment as a
primary pro-inflammatory cytokine [10]. Upon Prevotella intermedia lipopolysaccharide stimulation,
odontoblast-like cells respond by upregulating receptor for advanced glycation end products
(RAGEs) and producing HMGB1. In addition, HMGB1, a novel cytokine, is known to contribute
to the pathogenesis of various inflammatory diseases [11–13], including periodontal diseases [14].
This suggests that HMGB1 can activate an inflammatory response during infection or injury. On the
contrary, a role for HMGB1 in wound repair has been reported by the results of earlier studies.
HMGB1 promotes neuronal differentiation of embryonic stem cells and neurite outgrowth in the
developing nervous system [15]. Moreover, HMGB1 is a potent chemoattractant and mitogen for blood
vessel-associated stem cells [16]. Limana et al. demonstrated that intracardiac HMGB1 injection in
a mouse model of myocardial infarction induced new myocyte formation and improved infarcted
hearts function [17]. In addition, HMGB1-induced increase of HaCaT keratinocytes proliferation, cell
migration, and wound closure via RAGE and extracellular signal-regulated kinase (ERK) pathway [18].
RAGE is a member of the immunoglobulin superfamily and is expressed on gingival epithelial and
fibroblast cells [19], mononuclear phagocytes, vascular smooth muscle cells, and neurons [20,21].
RAGE interacts with a range of ligands, including advanced glycation end products (AGEs), HMGB1,
and S100/calgranulins [22,23]. Ligand binding results in RAGE-dependent sustained nuclear
factor-kappa B (NF-κB) activation [24] as well as in wound healing promotion [25]. These reports
indicate that HMGB1 is a multifunctional cytokine involved in inflammatory responses and tissue
repair. Despite this, whether and how HMGB1 contributes to protective and/or pathological responses
of palatal wound healing in vivo is unclear. In this study, we provide evidence that the loss of Hmgb1
gene in HMGB1-heterozygous (Hmgb1+/−) mice results in delayed palatal wound closure. In addition,
RAGE silencing reduces closure of an in vitro scratch wound gingival cell migration and proliferating
cell nuclear antigen (PCNA) expression. Our results, show for the first time, that HMGB1/RAGE
axis has crucial roles in palatal wound healing, by regulating collagen accumulation, cell proliferation
and cell migration. Taken together, these results bring scientific support to the possible application of
HMGB1 in regenerative medicine.
2. Results
2.1. Identification and Targeted Disruption of the Mouse Gene
DNA extraction from mouse tail and genotyping PCR separated by agarose gel electrophoresis
has been performed in Hmgb1+/− and Wild-type (WT) mice (Figure 1A). PCR with the HMGB1 primer
pair, for the mouse genome identifies WT mice, in which the product is detected at about 500 bp band
(Figure 1A, lanes 1–4). On the other hand, PCR with the primer complementary to the gene identifies
Hmgb1+/− mice, shows a bright band at about 500 bp (amplification control) and another at about
300 bp (Figure 1A, lanes 1–3). The target allele of PCR product is 495 bp for WT mice and 336 bp for
Hmgb1+/− mice. Our data replicated previous findings that Hmgb1+/− mice contained approximately
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immunohistochemistry of HMGB1 protein within the unwounded site (Day 0) and experimental
wound (Day 7) of hard palate mucosa in mice. By using a specific anti-HMGB1 polyclonal rabbit
antibody (Ab) that does not detect HMGB2 and HMGB3 [27], we found that at seven days post-surgery,
tissues from the WT mice presented higher expression of HMGB1 in the periphery of the nucleus
together with some translocation from the nucleus to the cytoplasm of basal epithelial cells and cells of
connective tissue compared with that in unwounded site (Figure 1B). Interestingly, marked differences
in the intensity and localization of HMGB1 staining in unwounded and wounded sites were observed
between Hmgb1+/− and WT mice. Very faint staining of HMGB1 in Hmgb1+/− mice tissue was shown
and the pattern of HMGB1 expression was mainly intranucleus in basal keratinocytes. These results





Figure 1. RT-PCR transcripts of mouse tail and immunohistochemistry determination of palatal section
for Hmgb1+/− and WT mice. (A) PCR products were separated in ethidium-bromide-stained agarose
gels with DNA molecular weight marker (M, 100 bp ladder). PCR with the primer complementary to
the gene identifies Hmgb1+/− mice, shows two bands, a bright band at 500 bp (upper) and another at
about 300 bp (lower). The predicted size of HMGB1 in WT and Hmgb1+/− mice was 495 and 336 bp,
respectively. Arrow indicates target allele of Hmgb1+/− mice and (B) Immunohistochemical analysis
of HMGB1 in palatal section of unwounded (Day 0) and wounded site (Day 7). Arrowheads indicate
HMGB1 positive staining in the cytosol. Original magnifications: left panels 400×, right panels 800×.
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2.2. Wound Closure Is Attenuated in Hmgb1+/− Mice
Macroscopic wound closure was attenuated in Hmgb1+/− mice compared with WT animals.
At three days post-surgery, it was observed that mucosal closure was not completed in the Hmgb1+/−
mice (Figure 2A). The wound of WT mice appeared epithelialized, whereas the mutant wounds showed
partial epithelialization. At seven days post-surgery, wound healing was more favorable in incision
areas in the WT group than that of Hmgb1+/− group. Measurement of the wound area on digital images
showed that the differences between Hmgb1+/− (55.8% ± 1.48% of Day 0) and WT mice (25.6% ± 0.7%
of Day 0) were statistically significant on Day 3 after wounding (p < 0.001, Figure 2B). Wound area
assessment demonstrated significantly larger wounds in Hmgb1+/− mice compared to WT controls at
Day 3 (1.2 ± 0.06 mm2 vs. 0.7 ± 0.04 mm2; p < 0.05) after wounding, whereas there was no statistically
significant difference (p > 0.05) in the wound area between both groups at Day 7 (Figure 2C). The wound
areas on Days 0, 3, and 7 were measured by three examiners. Pearson’s correlation coefficient (r) was
used to show the correlation between the examiners (Figure S1). In WT mice, we found a statistically
significant correlation between examiner 1 and examiner 2 (r = 0.9992, p < 0.001); examiner 1 and
examiner 3 (r = 0.9992, p < 0.001); and examiner 2 and examiner 3 (r = 0.9998, p < 0.001). Likewise, we
demonstrated a statistically significant correlation between examiner 1 and examiner 2 (r = 0.9909,
p < 0.05); examiner 1 and examiner 3 (r = 0.9902, p < 0.01); and examiner 2 and examiner 3 (r = 0.9906,
p < 0.01) in Hmgb1+/− mice. According to the macroscopic results, we concluded that Hmgb1+/− mice





Figure 2. Wound closure is attenuated in Hmgb1+/− mice vs. WT mice. (A) Macroscopic appearance of
wounds of Hmgb1+/− and WT mice at indicated time points after injury. Arrows indicate the wound
bed or scar margins. Scale bars: 1.0 mm; (B) At the time points indicated, the wound area was analyzed
and expressed as the percentage of the initial wound areas; (C) The reduction in wound area in WT
and Hmgb1+/− mice in mm2. Data are expressed as mean ± SD, n = 5 wounds for each time point and
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2.3. Reduction of Collagen Fibers and Delayed Re-Epithelialization in HMGB1+/− Wound
Collagen components are a major part of oral mucosa development [28]. The macroscopic findings
of wound closure were confirmed by histological assessment. At three days post-surgery, delayed
wound healing was determined in the Hmgb1+/− group compared to the WT group. Mallory Azan
staining of Day 3 wound showed well-organized, parallel, densely packed and thick bundles of collagen
fibers in WT mice, whereas in Hmgb1+/− mice weave-like pattern of low density collagen bundles
were present (Figure 3A). At seven days post-surgery, the collagen fibers were prominently mature
and re-epithelialization was observed in wound regions of both groups. A corresponding hematoxylin
and eosin (H & E)-stained wound section is shown in Figure 3B for comparison. In the Hmgb1+/−
group, subepithelial healing was evidenced but was not completed and, in connective tissue region,
mononuclear cell infiltration was present at three days post-surgery. More prominent infiltration of
mononuclear cell infiltration was present in WT mice than in Hmgb1+/− mice. At Day 7, the wound
healing properties were not different in Hmgb1+/− and WT mice. Collectively, these findings show
significant delays in wound healing parameters, including epithelialization and decreased collagen
formation in Hmgb1+/− mice.
A
B
Figure 3. Reduction of collagen fibers and delayed re-epithelialization in Hmgb1+/− wound on Day 3
after wound surgery. (A) Sections were stained with Mallory’s azan. Representative palatal wound
sections show the collagen bundles of WT and Hmgb1+/− mice. Note that blue indicates collagen
bundle stained by Mallory’s azan stain. Arrows indicate weave-like pattern of collagen bundles in
Hmgb1+/− mice. Original magnifications: left panels 200×, right panels 400×; (B) Sections were stained
with hematoxylin and eosin. E, epithelium; C, collagen bundle; P, palatal bone. n = 5 wounds for each
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2.4. Immunohistochemistry Determination of Proliferating Cells at Palatal Wounds in WT and Hmgb1+/− Mice
To identify the mechanism underlying the attenuated palatal wound closure in Hmgb1+/− mice,
we assessed cell proliferation in the repaired tissue by immunohistochemistry, using PCNA Ab. PCNA
is expressed in both basal and suprabasal cell layers (Figure 4A). At three days post-surgery, the
numbers of PCNA-positive keratinocytes in WT mice wound site (168 ± 18) were significantly greater
than Hmgb1+/− mice (70 ± 8.7) (Figure 4B, p < 0.001). At seven days post-surgery, PCNA-positive
keratinocytes numbers are reduced in both groups. The values were significantly higher (p < 0.001) in
WT mice (106.5 ± 10.4) than Hmgb1+/− mice (55 ± 9.7). From the above results, we conclude that the





Figure 4. Distribution of proliferating cells at palatal wounds in WT and Hmgb1+/− mice. (A) Analysis
of cell proliferation by immunohistochemistry stained with the anti-PCNA Ab in the palatal wounds
on Day 3 and Day 7 post surgery. Scale bars = 100 μm; (B) The number of PCNA-positive cells per field
in palatal wound. Data are expressed as the mean ± SD. (n = 5–8 for each group). * p < 0.001 vs. the
WT group.
2.5. Localization of NF-κB p50 Isoform at Palatal Wounds in WT and Hmgb1+/− Mice
Blocking HMGB1 can decrease the degree of radiation-induced pulmonary damage, and its
mechanism may be related to the promotion of NF-κB p50 activation and its downstream molecular
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tissue block (Figure 5A). At three days post-surgery, NF-κB p50-immunopositive cells in WT mice
wound site (75.6 ± 7.8) were significantly greater (p < 0.05) than Hmgb1+/− mice (35.1 ± 4.9). At seven
days post-surgery, NF-κB p50-positive cell numbers are reduced in both groups. The values were
significantly higher (p < 0.05) in WT mice (45.1 ± 10.5) than Hmgb1+/− mice (25.1 ± 2.9) (Figure 5B).
These results indicated that pro-inflammatory signaling pathway, NF-κB was significantly lower in the
Hmgb1+/− mice compared with WT mice. No tissues in samples from WT and Hmgb1+/− group were
stained with isotype-matched control IgG (Figure S2).
A
B
Figure 5. Localization of NF-κB p50 isoform at palatal wounds in WT and Hmgb1+/− mice.
(A) By immunohistochemistry, slides were stained with the anti-NF-κB p50 Ab in the palatal wounds
on Day 3 and Day 7 post surgery. Nuclei were counterstained with Mayer’s hematoxylin. Arrowheads
indicate NF-κB p50-positive stained nuclei of epithelial cells. Arrows indicate faint immunostaining of
NF-κB p50 in Hmgb1+/− mice; (B) The number of NF-κB p50-positive cells per field in palatal wound.
Data are expressed as the mean ± SD. Error bars indicate standard deviation (n = 5 for each group).
* p < 0.05 vs. the WT group.
2.6. Determination of VEGF Expression and Localization in Palatal Wounds of WT and Hmgb1+/− Mice
The expression of VEGF within the area of granulation tissue was used as read-out for
neovascular processes [30]. Real time PCR analysis demonstrated the ratio of VEGF normalized
to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript content in palatal wound site
of Hmgb1+/− and WT mice (Figure 6A). At three days post-surgery, VEGF mRNA in WT mice wound
site (1.4 ± 0.07) were significantly greater (p < 0.001) than Hmgb1+/− mice (0.5 ± 0.1). There was no
statistically significant difference of VEGF values between three days and seven days post-surgery in
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WT mice (1.3 ± 0.3) than Hmgb1+/− mice (0.37 ± 0.05). Next, we examined by immunohistochemistry
the presence of VEGF protein within the wound site at three and seven days after surgery. At three
days post-surgery, VEGF was detected in the oral epithelia above the basal layer (Figure 6B) to the
spindle cell layers with rising density in the wound site of WT mice. In Hmgb1+/− group, on the
other hand, specific labeling was faint or negative, indicating that VEGF is poorly expressed in these
cells. There was also scattered VEGF in capillary endothelial cells, infiltrating inflammatory cells, and
fibroblast-like cells in the connective tissue of all WT mice and Hmgb1+/− mice wound sites. At seven
days post-surgery, VEGF was detected in the whole layer of oral epithelia; whereas in the Hmgb1+/−
group, VEGF is absent in these cells. No tissues in samples from WT and Hmgb1+/− group were stained
with isotype-matched control IgG (Figure S2). Collectively, these results demonstrate that HMGB1




Figure 6. Determination of VEGF mRNA expression and VEGF protein immunolocalization in the
palatal wounds of WT and Hmgb1+/− mice. (A) Expression of VEGF mRNA in palatal wounds on
Day 3 and Day 7 post surgery was quantified by real time PCR analysis and reported by normalized
to GAPDH. Data are expressed as the mean ± SD of at least three independent determinations.
* p < 0.001 vs. the WT group; (B) Analysis of angiogenic response by immunohistochemistry stained
with the anti-VEGF Ab. Original magnifications: left panels 400×, right panels 800×. Experiments
were performed in triplicate.
2.7. Efficiency of RAGE Gene Knockdown
The silencing of RAGE gene expression was carried out following the transfection of
RAGE-specific siRNA in gingival epithelial cells (Figure 7A). Western blot analysis showed that
both 150 and 300 nM of RAGE siRNA significantly decreased the expression of RAGE protein by
50% and 70%, respectively, without affecting house-keeping gene (β-actin) expression or any toxicities
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A B
 
Figure 7. Efficiency of RAGE gene knockdown in gingival epithelial cells. (A) A representative
Western blot using antibodies against RAGE and β-actin is shown. The results showed decreased
expression of RAGE protein in the siRNA group compared to the control siRNA and blank control
groups. The intensity of the protein bands in Western blotting was quantified by densitometry and
normalized to β-actin. Three independent measurements were performed. Data are expressed as
mean ± SD. * p < 0.001 vs. the control group; (B) Cytotoxicity of the siRNA complexes was assessed by
MTT assay. There was no evidence of cell toxicity found in the RAGE siRNA transfected cells. Data are
expressed as the mean ± SD. Error bars indicate SD of at least three independent determinations.
2.8. RAGE Silencing Reduces Closure of an In Vitro Scratch Wound and PCNA Expression
A cell monolayer scratch assay is used to evaluate keratinocyte proliferation and migration during
re-epithelialization [31]. To assess whether delayed in the wound healing at the wound sites of the
Hmgb1+/− mice is accompanied by retarded re-epithelialization mechanism, gingival epithelial cells
were subjected to wound-healing (scratch) assay, in which the ability of cells to migrate and cover the
cell-free space is monitored. Effects of recombinant HMGB1 (rHMGB1) on the cell migration were
studied. Cells were either exposed to rHMGB1 at the concentration of 50 and 100 ng/mL or pretreated
with RAGE siRNA. As shown in Figure 8A,B, untreated cells tend to close the wound by about 8%
within 48 h. Interestingly, treatment with 100 ng/mL rHMGB1 enhanced cell migration by 32% and
100% at 24 and 48 h, respectively. Previous study reported that HMGB1 binds RAGE and promotes
NF-κB activation [32]. In the present study, transfection of gingival epithelial cells with RAGE siRNA
suppressed rHMGB1-induced cell migration by ~85% compared with cells treated with 100 ng/mL
rHMGB1 for 48 h (Figure 8B). PCNA is considered to be a marker of cell proliferation [33]. In our study,
immunohistochemical staining for PCNA in the wound section revealed that PCNA expression was
significantly lower in the Hmgb1+/− mice compared with WT mice. We therefore sought to determine
whether retarded in the wound healing of Hmgb1+/− mice is related to cell proliferation mechanism.
Cells were treated with rHMGB1 at the concentration 100 ng/mL or pretreated with 300 nM RAGE
siRNA (Figure 8C). Transcript levels of PCNA were significantly higher in the rHMGB1-treated cell
than in the control group (p < 0.001). Knockdown of RAGE prevents the effect of HMGB1-induced
PCNA expression in gingival epithelial cells by ~70% compared with cells treated with rHMGB1.
No effects were observed on control siRNA-treated cells. These results thus suggested that knockdown
of RAGE prevents the effect of HMGB1-induced cell migration and cell proliferation in gingival













Figure 8. RAGE silencing reduces closure of an in vitro scratch wound, gingival epithelial cell migration
and PCNA expression. (A) Representative photomicrographs of a cell migration assay. Cells were
pretreated with 300 nM siRNA against RAGE and stimulated with rHMGB1 at different concentrations
in culture media containing 2% FBS for the cell migration assay with 20× magnification. Treatment
with rHMGB1 (100 ng/mL) increases the ability of cells to migrate into the empty area and to repair
the wound at all-time points (24 and 48 h) examined. Yellow arrows indicate migration into the cell
free-space; (B) The ability of cells to migrate and cover the empty space was determined as a wound
repair by percent of 0 h (T0). Data are mean ± SD of 3–5 independent experiments. * p < 0.001 vs. the
control siRNA and blank control groups; (C) Expression of PCNA mRNA in the cells after addition of
300 nM RAGE siRNA or control siRNA and stimulation by 100 ng/mL rHMGB1 was quantified by real
time PCR analysis and reported by normalized to GAPDH. Data are expressed as the mean ± SD of
three independent determinations. * p < 0.001 vs. the rHMGB1 group.
3. Discussion
The present study is, as far as we know, the first in which the regulatory role of HMGB1 and its
potential involved signal pathways in palatal wound healing has been examined. We show that wound
healing is attenuated in Hmgb1+/− mice compared with WT mice. In vitro studies demonstrate cell
mobility and cell proliferation in gingival epithelial cells after rHMGB1 stimulation. HMGB1 protein
is a multifunctional cytokine involved in tissue inflammation and regeneration. Recent studies have
documented an important role of HMGB1 in mediating tissue repair [15–17]. Straino et al. has shown
that HMGB1 administration promotes wound healing in diabetic mice [26]. Furthermore, HMGB1
had a chemotactic effect on skin fibroblasts and keratinoyctes during wound healing process [18].
Additionally, HMGB1 was able to significantly induce proliferation of human gingival fibroblast and
induce cell migration [27]. With these outcomes, it is interesting that HMGB1 may be important for
wound healing and promote evidences which support our study.
Although the distribution of HMGB1 in relation to wound healing has been observed in human
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of Hmgb1 gene in vivo have not been previously performed. In our study, we found that HMGB1
expression in unwounded and wounded site of Hmgb1+/− mice is very low compared to WT mice.
In addition, a delayed epithelialization contributed to the attenuation of Hmgb1+/− mice wound
closure and was significantly difference from WT mice at three days post-surgery. These results imply
that HMGB1 is responsible for palatal wound repair. HMGB1 is translocalized and released after
inflammatory stimuli [29,30] and is mobilized from gingival epithelial cells in response to periodontal
inflammation [31]. Our findings demonstrate that at seven days after surgery, tissues from the WT
mice presented HMGB1 protein translocation from the nucleus to the cytoplasm of basal epithelial cells
and cells of connective tissue, which is in accordance with results obtained in other cell types [29–31].
Palatal wound healing involves a complex, well-orchestrated series of events like hemostasis,
inflammatory response and collagen synthesis. A previous study has demonstrated that treatment
with 100 ng/mL has a chemotactic effect on fibroblasts and keratinocytes. Following a single dose of
200 and 400 ng HMGB1, wound closure was accelerated in diabetes mice compared to wounds treated
either with saline or 800 ng of this protein [26]. In our in vitro study, rHMGB1 at a concentration of
100 ng/mL induces gingival epithelial cells migration and PCNA mRNA overexpression. Accordingly,
it is likely that HMGB1 promotes palatal wound healing by accelerating the re-epithelialization and
proliferation of gingival epithelial cells, may occur in vivo. Nevertheless, another study showed that
treatment with 100 ng/mL of HMGB1 protein impairs fibroblast collagen synthesis in rats undergoing
full-thickness incisional wound. Reduction of HMGB1 levels in the wound using ethyl pyruvate
leads to significant increases in reparative collagen deposition [32]. The difference in the results of
these studies may be associated with the variations in fibroblast subpopulations and the proliferative
potential of the cells in the lesion.
VEGF appears to play a crucial role in the proliferative phase of wound healing, promote
migration, differentiation and tube formation of endothelial cells which are key elements in early
stages of angiogenesis [33]. Our study demonstrated new vessels appear as early as three days after
wounding and staining for VEGF was most prominent in keratinocytes at seven days post-surgery,
consistent with VEGF expression results of previous reports [34–36]. HMGB1 administration restored
the blood flow recovery in the ischemic muscle of diabetic mice is associated with the increased
expression of VEGF [37]. In our study, we show that decreased VEGF expression in keratinocytes is
associated with impaired wound healing in the Hmgb1+/− mice. One explanation for this result is
that about three to ten days after the wound occurs, macrophages are abundant in the wound tissue
and new blood vessels are formed [38]. Activated macrophages and monocytes secrete HMGB1 [39]
and this HMGB1 may in turn induce VEGF expression in keratinocytes. However, wound healing is a
complex organized process including a variety of cell types (keratinocytes, endothelial cells, fibroblasts,
inflammatory cells and epidermal cells) and angiogenesis inducers other than VEGF. Thus, despite an
impairment of wound healing in Hmgb1+/− mice in this study, further studies are required to rule out
crucial biological processes involved in the early and late phase of wound repair in this model.
A cell monolayer scratch assay is used to assess re-epithelialization [40]. In the present study,
we demonstrated a large induction of cell migration in gingival epithelial cells by rHMGB1 during
wound scratch assay after 24–48 h. This finding is consistent with previous report that HMGB1 is a
potent cell migration and proliferation promoting agent [41]. Nevertheless, HMGB1-induced increase
in human gingival and periodontal ligament fibroblast migration after 16 h stimulation in the transwell
chamber assay [27]. It is possible that the difference in the speed of cell migration in our experiment
compared to the previous study may depend in part on particular cell type and assay protocol.
HMGB1 binding to RAGE triggers transcription factor NF-κB [42]. Knockdown of HMGB1 or
RAGE inhibited NF-κB p50 and p65 expression [43]. Our study demonstrated that NF-κB p50-positive
epithelial cells of WT mice were significantly higher than in Hmgb1+/− mice. This data correlated
with previous studies in which reduction in HMGB1-RAGE [43] or Toll-like receptor [44] axis reduced
NF-κB activation and could not promote cellular proliferation. To elucidate the molecular mechanisms
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and PCNA transcription in gingival epithelial cells-treated with rHMGB1 in the presence or absence of
RAGE siRNA. The result of our study demonstrates that HMGB1 signaling promotes wound healing of
palatal mucosa via RAGE-dependent. It is noteworthy that intraoral wound healing process involves
interaction of other signal molecules such as Smad3 [8] and transforming growth factor beta 1 [45].
Hence, the HMGB1 mouse model in our study may partly explain one of the biological factors that
regulate palatal tissue repair and support the view that the local inflammatory response can promote
wound closure. At the molecular level, these observations may be explained, at least in part, by the
capacity of HMGB1 molecules in keratinocytes on palatal wound repair. As such, further analysis of
specific effects of this protein may lead to novel therapies for improved wound healing properties.
Attempts have been made to repair and restore destroyed periodontal tissues, including the use
of particular bioactive substances or surgical bone grafts [20,34]. Nowadays, conventional therapies
are poorly effective on complex chronic ulcers and tissue lesions occurring in specific diseases, like
diabetes. Topical application of HMGB1 to the wounds of streptozotocin-induced diabetic models
in mice, enhanced arteriole density, granulation tissue formation, and accelerated wound healing
in mice skin [26]. HMGB1-induced human gingival fibroblasts [27] and gingival epithelial cells
proliferation and migration. These data suggest that HMGB1 may have potential beneficial effects on
tissue remodeling and repair. Therefore, there is a great interest for a new generation of topical chronic
wound treatments containing low levels of HMGB1 to accelerate intraoral wound healing and reduce
wound-related complications.
4. Materials and Methods
4.1. Reagents
VEGF and HMGB1 Ab were obtained from Abcam (Cambridge, MA, USA). NF-κB p50 and PCNA
Ab were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Unless otherwise stated,
all other reagents were supplied by Sigma-Aldrich Inc. (St. Louis, MO, USA).
4.2. Mice
All animal experiments were performed according to protocols approved by the institutional
guidelines at Kagoshima University Graduate School of Medical and Dental Science. (Ethic approval
number: H26/078, Approval date: 24 October 2014) Generation of Hmgb1 heterozygotes (Hmgb1+/−)
mice on a pure BALB/c (Wild-type, WT) genetic background used in the present study were described
before [46]. All mice were maintained and bred under standard pathogen-free conditions. Northern
blot analysis of total RNA extracted from Hmgb1+/− mice newborn liver using cDNA-encoding
HMGB1 demonstrated approximately one-half the level of HMGB1 mRNA and protein compared
with WT mice [46].
4.3. Polymerase Chain Reaction (PCR) Genotyping Assay
For genotyping PCR analysis, 3 mm sections of tail tip were dissolved in 0.1 mL of 50 mM
Tris (pH 8.0), 100 mM EDTA, 0.5% SDS, and 0.5 mg/mL proteinase K solution at 55 ◦C for 2 to 6 h
with vigorous shaking. DNA was prepared using DNeasy Blood Tissue Kit (Qiagen, Redwood City,
CA, USA) and subjected to reverse transcription (RT)-PCR. We routinely genotyped newborn mice
RT-PCR analysis of tail DNA (100 ng) using a commercial RT-PCR kit (Takara Biomedicals, Shiga,
Japan), and the reaction was performed following the manufacturer’s instructions. The resulting
cDNA mixture was amplified with Taq polymerase, and the following specific primers (Sigma,
St. Louis, MO, USA) were used: WT allele, 5′-GCAGGCTTCGTTGTTTTCATACAG-3′ and
5′-TCAAAGAGTAATACTGCCACCTTC-3′, which generate a 495-bp fragment. The mutant
Hmgb1 allele was detected by using primer complementary to the neomycin resistance gene,
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336-bp fragment [11]. Amplification conditions were 1 cycle of 95 ◦C for 5 min, 35 cycles of 95 ◦C for
45 s, 60 ◦C for 30 s, 72 ◦C for 30 s with primer extension time at 72 ◦C for 5 min.
4.4. Palatal Wound Healing Model and Histological Analysis
The criteria used for assessing wound healing included; the epithelialization (as assessed by
macroscopic evaluation for wound closure) [47], the degree of inflammation in the tissues [22] and
collagen formation, which is responsible for tissue repair [48]. The macroscopic finding of continuous
wound closure was confirmed by histology (H & E stain) and Mallory Azan. We determined the
expression of cell proliferation (PCNA) and angiogenesis (VEGF) in wound tissue of the mice studied
by immunohistochemistry. Eight- to fifteen-week-old mice were used in this study (5–7 mice per
group). All animals were anaesthetized with isoflurane. A full-thickness incision wound, 1.0-mm
width and 2.0-mm length, was made in the mucoperiosteum of the hard palate under sterile condition
based on previous study with a slight modification [49]. After the incision was made, animals
were sacrificed on Days 0, 3 and 7. No medication was used throughout the experiment. At the
time points indicated, the wound kinetics were determined by using image-processing software
(ImageJ, US National Institutes of Health, Bethesda, MD, USA) to measure the wound area; wound
area was demonstrated as a percentage of the initial wound area. The wound closure was considered
complete when the entire surface area was covered with tissue. The measurements were performed
by three different examiners and blinded to each other. Pearson’s correlation coefficient was used to
represent inter-examiner reliability.
To assess the wound healing process by microscopic examination, maxillary tissues after
wounding were harvested. Tissues were fixed in 4% freshly made paraformaldehyde in 100 mM
sodium phosphate buffer (pH 7.0) overnight at 4 ◦C. The samples were then decalcified with 19%
EDTA in 100 mM PBS for 3 weeks, dehydrated, and embedded in paraffin. Serial sections, 4 μm
thick, were cut in the frontal plane through the midpoints of the bilateral second molars. Slides were
stained with H&E or Mallory Azan, and evaluated for the histological changes under light microscope
(Jenamed II, Carl Zeiss, Gottingen, Germany).
4.5. Immunohistochemistry
Paraffin-embedded sections were deparaffinized in xylene and rehydrated through a series of
decreasing concentrations of ethanol. Staining was carried out using indirect immunoperoxidase
diaminobenzidine (DAB). Endogenous peroxidase was blocked by 0.3% H2O2 for 5 min. Sections were
incubated for 1 h at room temperature with polyclonal anti-PCNA (1:200), NF-κB p50 (1:500), HMGB1
(1:200) and VEGF Ab (1:200) in Ab diluent with background reducing components (DakoCytomation,
Carpinteria, CA, USA). As a negative control, the IgG isotype control was employed at the same time
and concentration as the test antibodies. After rinsing with PBS, sections were finally developed
with a DAKO LSAB+ System, horseradish peroxidase (HRP) (DakoCytomation; KO679), and
immunostaining was visualized with substrate solution (DAB). Counterstaining was performed
with Mayer’s hematoxylin. Immunostaining of PCNA and NF-κB p50 were localized in the nucleus of
epithelial cells. VEGF staining was noticed in the cytoplasm. The number of PCNA and NF-κB p50
immunopositive cells from six slides in experimental and control samples were selected randomly and
evaluated by two blinded observers and scored.
4.6. Quantitative Real-Time PCR Analysis of VEGF Expression in the Wound Tissues
Total RNA was extracted from palatal wound tissues of WT mice or Hmgb1+/− mice using TRIzol
Reagent (Invitrogen, Carlsbad, CA, USA). Total RNA samples (2 μg) were reverse transcribed using a
First Strand complementary DNA synthesis kit for RT-PCR (Roche, Indianapolis, IN, USA). cDNA
was augmented by real-time RT-PCR (Ct value 20–30 s cycles) using a 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). The primers for gene amplification were as follows: VEGF
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(accession number MN_00441242); GAPDH sense, 5’-TGTGTCCGTCGTGGATCTGA-3’; GAPDH
antisense, 5’-CCTGCTTCACCACCTTCTTGAT-3’ (accession number NM_008084.3). The PCR
conditions were 95 ◦C for 2 min followed by 40 cycles of 95 ◦C for 15 s, annealing at 58 ◦C for
30 s, and extension at 72 ◦C for 15 s. All reactions were run in triplicate. VEGF expression was defined
on the basis of the threshold cycle (Ct value) and normalized to the GAPDH expression.
4.7. Primary Cell Cultures
Palatal gingival explants were prepared for the cell culture according to our previous study [50]
with some modification. Briefly, the gingival tissues were surgically removed from the animal, placed
in tissue culture plates and soaked in Dulbecco’s-modified Eagle Medium (DMEM; Sigma-Aldrich,
St. Louis, MO, USA) containing 10% fetal bovine serum (FBS). After 2 weeks, gingival epithelial cells
were harvested from the culture medium and further incubated in Keratinocyte-Serum Free Medium
(Life Technologies, Rockville, MD, USA) supplemented with epidermal growth factor (5 ng/mL) and
bovine pituitary extract (30–50 μg/mL). The cells of passages 4–6 were used for experiments. All cells
were cultured in serum-free Opti-MEM-I medium (Gibco, Grand Island, NY, USA) for at least 15 h
before treatment to eliminate the possible side effect of growth factors.
4.8. Silencing of RAGE Gene Expression and Western Blot Detection for RAGE Protein Expression
RNA silencing was performed with siRNA targeting RAGE mRNA or control siRNA (Santa
Cruz, catalog: sc-36375) prepared according to the method described in our previous study [29].
Cells were transfected with siRNA duplexes suspended in lipofectamine reagent (Life Technologies)
following the manufacturer’s protocol. Briefly, cells were cultured in 6-well plates until 60% confluence.
Cells were washed with serum-free Opti-MEM I Reduced Serum Medium (Gibco, Grand Island, NY,
USA). RAGE siRNA and negative control siRNA were gently premixed with lipofectamine reagent
in Opti-MEM medium for 20 min at RT. The siRNA (final concentration 150–300 nM)/lipofectamine
reagent complex was overlaid onto the washed cells for an additional 24 h at 37 ◦C in 5% CO2.
The efficacy of gene silencing was evaluated using Western blot analysis. Protein concentrations
were determined by Bradford protein assay using bovine serum albumin as standard (Bio-Rad,
Hercules, CA, USA). Samples were mixed with 2× electrophoresis sample buffer solution with
bromophenol blue (Santa Cruz Biotechnology) before being subjected to 12% SDS-polyacrylamide
gel electrophoresis (PAGE) and transferred onto nitrocellulose membranes (Schleicher & Schuell,
Dassel, Germany). Samples containing 10 or 15μg of total protein were used. To prevent nonspecific
binding, the membrane was blocked with a solution containing 5% (w/v) nonfat dry milk with 1%
(v/v) Tween 20 in PBS for 1 h at RT. Rabbit anti-RAGE primary Ab was incubated for overnight at
4 ◦C. Then the membranes were washed and incubated with HRP-conjugated anti-rabbit polyclonal
IgG (MP Biomedicals Inc., Solon, OH, USA) at RT for 1 h. Labeled bands were visualized using an
enhanced chemiluminescence system (GE Healthcare Bio-Science, Pittsburgh, PA, USA) and exposed
to high-performance chemiluminescence film (GE Healthcare). The intensity of the protein bands in
Western blotting was quantified using National Institutes of Health Image 1.63 software.
4.9. Cell Viability Test
Cell viability was monitored after incubation with siRNA for 48 h by MTT
(3-[4,5]-2,5-diphenyltetrazolium bromide) assay. Briefly, cells were harvested and incubated
with MTT (0.5 mg/mL; final concentration) for 3 h. Formazan crystal was solubilized by adding
dimethyl sulfoxide for 16 h. Dehydrogenase activity was expressed as absorbance at 570 and 630 nm.
4.10. In Vitro Scratch Assay
Cells were scratched with a sterile P200 pipette tip according to a method previously described [51].
After repeated washes to remove the resulting debris, cells were either exposed to rHMGB1 at the
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siRNA were used as a negative control. The wound closure in scratch assay was monitored by phase
microscopy capturing images of the same field with a 20× objective at different times, as specified.
Migration of cells into the cell-free space was determined by the digital image processing software
“Image J” developed by NIH. In some experiments, the cells were harvested for RNA extraction.
4.11. Quantitative Real-Time PCR Analysis of PCNA Expression in the Gingival Epithelial Cells
After the induction of the cell damage for 48 h with or without 300 nM of RAGE siRNA, cells were
collected and lysed with TRIzol Reagent according to the manufacturer’s instruction and performed
with nearly the same protocol with VEGF mRNA expression analysis. The selected specific primer
was purchased from Biomol International (Plymouth Meeting, PA, USA). The PCR conditions were
95 ◦C for 30 s, followed by 1 min annealing at 58 ◦C and then followed by 1 min extension at 72 ◦C for
a total of 45 cycles.
4.12. Statistical Analysis
Experimental values are given as mean ± S.D. Statistical significances between different groups
were assessed by one-way analysis of variance (ANOVA) test or Student’s paired t-test. The correlations
among three examiners and the wound area measurement were calculated using Pearson’s correlation
coefficient. All calculations were performed employing Sigma Stat for Windows, version 3.5
(Systat Software, Inc., Chicago, IL, USA). p values < 0.05 were considered statistically significant.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/11/1961/s1.
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Abstract: Angiogenesis is involved in the inflammation and proliferation stages of wound healing,
to bring inflammatory cells to the wound and provide a microvascular network to maintain new tissue
formation. An excess of inflammation, however, leads to prolonged wound healing and scar formation,
often resulting in unfavourable outcomes such as amputation. CC-chemokines play key roles in
the promotion of inflammation and inflammatory-driven angiogenesis. Therefore, inhibition of the
CC-chemokine class may improve wound healing. We aimed to determine if the broad-spectrum
CC-chemokine inhibitor “35K” could accelerate wound healing in vivo in mice. In a murine wound
healing model, 35K protein or phosphate buffered saline (PBS, control) were added topically daily
to wounds. Cohorts of mice were assessed in the early stages (four days post-wounding) and
in the later stages of wound repair (10 and 21 days post-wounding). Topical application of the
35K protein inhibited CC-chemokine expression (CCL5, CCL2) in wounds and caused enhanced
blood flow recovery and wound closure in early-mid stage wounds. In addition, 35K promoted
neovascularisation in the early stages of wound repair. Furthermore, 35K treated wounds had
significantly lower expression of the p65 subunit of NF-κB, a key inflammatory transcription factor,
and augmented wound expression of the pro-angiogenic and pro-repair cytokine TGF-β. These
findings show that broad-spectrum CC-chemokine inhibition may be beneficial for the promotion of
wound healing.
Keywords: chemokine; angiogenesis; wound; healing; inflammation
1. Introduction
Wound healing is a complex multistep process comprised of three overlapping but distinct phases:
inflammation, proliferation and remodelling. It begins with the inflammation phase, where neutrophils
and macrophages are recruited to the wound site to remove cell debris and phagocytose infectious
pathogens. This is followed by the proliferation stage, where re-epithelialization and the formation
of granulation tissue begin to close the wound. Angiogenesis, the formation of new blood vessels,
is important during both the inflammation and proliferation phases, forming angiogenic capillary
sprouts that allow for recruitment of inflammatory cells to the wound for debris removal, invasion of
the fibrin/fibronectin-rich wound clot, and reorganization of a microvascular network to maintain the
new granulation tissue being formed [1]. Finally, during the remodelling phase, fibroblasts reorganize
the collagen matrix, forming a closed wound [2]. All three phases must occur in the proper sequence
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and time frame in order for a wound to heal successfully. Excessive macrophage accumulation during
the inflammation and proliferation stages may prolong the inflammatory response leading to delayed
wound healing and scar formation at the injury site. Macrophage phenotype has also been reported
to change throughout the wound healing process, alternating between inflammatory M1 and repair
M2 phenotypes [3]. The regulation of these phenotypes has been shown to affect wound functionality
and the extent of scar tissue [4]. Wounds that exhibit impaired healing frequently enter a state of
pathological inflammation, with most chronic wounds developing into ulcers. The incidence of chronic
wounds is associated with ischemia, diabetes mellitus, venous stasis disease or pressure [5]. Chronic,
non-healing wounds greatly impact a person’s quality of life and, when left untreated, sometimes lead
to amputation, resulting in an enormous health care burden [6,7]. While current therapies provide some
relief, there is a need for the continued development of novel therapies that address the debilitating
effects of impaired wound healing.
CC-chemokines are small inflammatory cytokines that have been shown to play a key role in the
induction of inflammation and inflammation-mediated angiogenesis. In the wound healing process,
macrophage infiltration is highly regulated by CC-chemokine gradients released by hyper-proliferating
keratinocytes, fibroblasts and other macrophages [8,9]. In human wounds, a host of CC-chemokines
including CCL1, CCL2, CCL3, CCL4, CCL5 and CCL7 are expressed during the first week after injury
and high levels of CCL2 have been found in human burns [10,11]. Additionally, studies in excisional
wounds have found localized expression of CCL2 and CCL3 in the epidermis, while CCL3 is expressed
in follicular epithelium and sebaceous glands [12]. CC-chemokines regulate key angiogenic processes
such as the recruitment of inflammatory cells to the wound, to provide support for proliferating and
migrating cells [13], and the formation of granulation tissue [9]. Furthermore, incubation with the
recombinant CC-chemokines CCL2 and CCL5 stimulate angiogenic functions such as endothelial
cell tubulogenesis and migration [14–18]. Therefore, manipulation of the CC-chemokine family
may modulate key wound healing processes to confer benefits. To date, studies have inhibited a
single CC-chemokine and shown modest or no effect on wound healing. CCL2 knockout mice have
delayed re-epithelialization and reduced angiogenesis in the early stages of wound repair, whilst
the CCL3 knockout mice have normal wound healing [19]. Similarly, CCR1 knockout models have
no alteration in wound healing [20]. Inhibition of a single CC-chemokine, however, may not be
as effective in modulating wound healing due to redundancies in CC-chemokine signalling [21,22].
A broad-spectrum CC-chemokine inhibition approach may therefore have increased efficacy.
The broad-spectrum CC-chemokine inhibitor “35K” is a 35 kDa soluble protein produced by
the Vaccinia virus that uniquely inhibits only the CC-chemokine class [23]. It recognizes and binds
to common structural features shared by most CC-chemokines, preventing binding to their cognate
receptors [24]. Broad-spectrum CC-chemokine inhibition using 35K inhibits a host of inflammatory
diseases including atherosclerosis, acute peritonitis, hepatitis and liver fibrosis [25–28]. Given the
inhibitory effects of 35K on inflammatory-mediated diseases and the role of CC-chemokines in
angiogenesis, we sought to elucidate the effect of broad-spectrum CC-chemokine inhibition on wound
healing. We found that topical application of 35K enhanced wound closure, blood flow perfusion and
neovascularisation at the early-mid stages of wound healing. Augmentation of wound angiogenesis
by 35K was mediated via an increase in the pro-angiogenic and pro-repair cytokine TGF-β. In addition,
35K treatment inhibited wound levels of inflammatory transcription factor NF-κB and reduced collagen
deposition at the late stages of wound healing in the 35K-treated wounds, suggesting a reduction in
scar formation. Taken together, these findings show that broad-spectrum inhibition of CC-chemokines
may be beneficial for the promotion of wound healing by suppressing inflammation and promoting
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2. Results
2.1. Topical 35K Increases Wound Blood Perfusion and the Rate of Wound Closure in Early-Mid Stage
Wound Repair
Topical treatment of wounds with 35K protein caused significantly faster wound closure
throughout the early to mid-stages of wound healing at Day 7 (42%, p < 0.05) and Day 8 (33%, p < 0.05)
compared to PBS treated wounds (Figure 1a). Using Laser Doppler imaging, it was revealed that 35K
protein augmented wound blood perfusion (Figure 1b). The Laser Doppler Index (LDI), used as a
marker of wound angiogenesis and determined as the ratio of 35K:PBS wounds, was significantly
elevated in the 35K treated wounds in the early stages following wounding (Day 3, 4), compared to
PBS control wounds (values above 100% indicate increased wound blood perfusion with 35K treatment
relative to PBS control). In the later stages of the wound healing process, at seven days post-wounding,
blood perfusion started to decline in wounds treated with 35K, compared to the PBS treated control
wounds. After Day 7, blood perfusion fluctuated along the baseline and very little blood perfusion
was detected. There were no significant increases or decreases to the end point.
Figure 1. Topical 35K increases the rate of wound closure and wound blood perfusion in early-mid
stage wound repair. Two full thickness wounds were created on C57Bl/6J mice (n = 7–12). Mice received
daily topical application of 35K protein (200 nM) or PBS (vehicle). (a) representative images of the
wounds and wound blood perfusion using Laser Doppler imaging (high (red) to low (blue) blood flow);
(b) wound area was calculated from the average of three daily diameter measurements along the x-, y-
and z-axes. Wound closure is expressed as a percentage of initial wound area at Day 0. Black circles
are PBS treated wounds; grey triangles are 35K treated wounds; and (c) the 35K:PBS wound blood
flow perfusion ratio was determined using Laser Doppler imaging (LDI). Data is represented as
mean ± SEM. Points above the dotted line represent an improvement with 35K treatment. Statistical
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2.2. Inhibition of CC-Chemokines by 35K Increases Neovessel Formation in Early Stage Wounds but Decreases
Neovessels in Late Stage Wounds
To investigate wound angiogenesis, neovessels and arterioles were assessed. In the early stages
of wound healing (Day 4), there was an increase in the presence of wound neovessels in the 35K
treated wounds as determined by CD31+ staining (182%, p < 0.05, Figure 2a). However, at Day 10
post-wounding, there were significantly fewer wound neovessels (39% decrease, p < 0.05) following
35K treatment. At Day 21, there were no differences in neovessels between 35K and PBS treated
wounds. A similar biphasic pattern was also seen with the arterioles (α-actin+ staining), although,
at Day 4, the trend for an increase in arterioles did not reach significance, but there was a significant
48% decrease in arterioles (p < 0.05) in the 35K treated wounds at Day 10 post-wounding (Figure 2b).
No CD31+ and α-actin+ staining is detected in IgG controls (Figure S1).
 
Figure 2. Inhibition of CC-chemokines by 35K increases neovessel formation in the early stages
of wound repair but decreases neovessels in later stages. Immunocytochemistry was used to
detect the presence of neovessels and arterioles. Photomicrographs represent wounds stained for
(a) CD31+ neovessels (stained brown, noted by black arrows) and (b) α-SMC+ arterioles (stained pink,
noted by black arrows). Three tiled images were taken per wound (n = 7–12/treatment). Scale bars
represent 50 μm. Data is represented as mean ± SEM. Statistical analysis was performed by an unpaired
two-tailed t-test. * p < 0.05 compared to PBS treated wounds.
2.3. Inhibition of CC-Chemokines by 35K Modulates Pro-Angiogenic Markers TGF-β and Vascular Endothelial
Growth Factor (VEGF) in Early and Late Stage Wounds
The expression of key angiogenic markers TGF-β and vascular endothelial growth factor (VEGF),
known to be involved in wound healing, were measured next. Interestingly, TGF-β expression was
significantly higher in 35K-treated wounds in the early stages of wound repair (Day 4 post-wounding,
88%, p < 0.05, Figure 3a). However, in the later stages post-wounding (Day 10), the expression of
TGF-β had normalised back to control levels. There were no differences in VEGF protein levels at
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groups had significantly lower levels of VEGF protein, compared to wounds at Day 10 (p < 0.01).
The protein levels of fibroblast growth factor-2 (FGF-2), were also measured, but no differences were
detected (Figure S2a). Neither were there changes in wound protein levels of HIF-1α, a regulator of
VEGF (Figure S2b).
Figure 3. Modulation of pro-angiogenic markers following inhibition of CC-chemokines by 35K in
early and late stage wounds. RNA and protein were isolated from PBS and 35K treated wounds at
both the early (Day 4) and late (Day 10) time points (n = 12/time point); (a) real-time PCR was used to
measure mRNA levels of TGF-β; (b) vascular endothelial growth factor (VEGF) protein levels were
detected by ELISA. Data is represented as mean ± SEM. Statistical analysis was performed by an
unpaired two-tailed t-test. ## p < 0.01, ### p < 0.001 compared to respective treatment group wounds at
Day 4. * p < 0.05 compared to PBS treated wounds.
2.4. Inhibition of CC-Chemokines by 35K Reduces Inflammation but Has No Effect on Wound
Macrophage Content
Broad-spectrum CC-chemokine inhibition suppressed the mRNA levels of p65, the active subunit
of NF-κB, with 34% and 62% decreases seen in Day 4 and 10 in 35K treated wounds respectively,
compared to PBS treated wounds (all p < 0.05, Figure 4a). A similar trend was observed for mRNA
levels of the macrophage marker CD68, which were also lower in the 35K treated wounds but did
not reach significance (Day 4: 39% ns; Day 10: 30% ns, Figure 4b). Despite this, histological analysis
of macrophages in wound sections did not find a difference in CD68+ cells in 35K and PBS treated
wounds at Day 4, 10, and 21 post-wounding (Figure 4c). Analysis of wound macrophage phenotype
revealed that there were no significant changes in the mRNA levels of M2 macrophage marker CD206
in the 35K treated wounds (Figure S3a). Interestingly, M1 macrophage markers CD80 and CD86 were
unchanged at Day 4 but elevated in Day 10 35K treated wounds (278% and 342% respectively, p < 0.01,
Figure S3b,c). No CD68+ staining is detected in IgG control (Figure S1).
2.5. Inhibition of CC-Chemokines by 35K Decreases Collagen Formation in Late Stage Wounds
Milligan’s trichrome staining was used to detect the collagen content in the wounds as a marker
of tissue remodelling. While no differences in collagen deposition were observed at Day 4 and 21
between 35K and PBS wounds, a 25% decrease (p < 0.05) in collagen content was seen in the 35K
treated wounds at Day 10 (Figure 5a). The picrosirius red stain was imaged under polarized light to
differentiate between type III and type I collagen. There was 10–100 times more type I collagen to type
III collagen (across Day 4–21), but there were no significant differences between 35K and PBS treated
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Figure 4. Inhibition of CC-chemokines by 35K reduces inflammation but has no effect on wound
macrophage content. Total RNA was isolated from PBS and 35K treated wounds at both the early (Day 4)
and late (Day 10) time points (n = 12/time point). Real-time PCR was used to measure mRNA levels
of (a) p65, the active subunit of the key inflammatory transcription factor NF-κB and (b) macrophage
marker CD68; (c) immuno-histochemistry was used to detect the presence of wound macrophages.
Photomicrographs represent wound sections stained for CD68+ macrophages (stained brown, noted by
black arrows). Three tiled images were taken per wound (n = 7–12/treatment). Scale bars represent
50 μm. Data is represented as mean ± SEM. Statistical analysis was performed by an unpaired
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Figure 5. Inhibition of CC-chemokines by 35K decreases collagen formation in Day 10 wounds.
Masson’s trichrome staining was used to detect the collagen content in the wounds. (a) green staining
in wound sections is collagen, purple staining are nuclei; (b) to differentiate collagen type, wound
sections were stained red with picrosirius and imaged under polarized light. Green represents Type III
collagen, yellow to red represents Type I collagen. Three tiled images were taken per wound (n = 12 or
7/treatment). Scale bars represent 50 μm. Data is represented as mean ± SEM. Statistical analysis was
performed by an unpaired two-tailed t-test. * p < 0.05 compared to PBS treated wounds.
2.6. Topical 35K Suppresses CC-Chemokine Expression in the Wounds
The effect of 35K on wound CC-chemokine protein and gene expression was measured. There
was a significant decrease in CCL5 protein levels in 35K treated wounds at both the Day 4 (36%,
p < 0.05) and Day 10 (66%, p < 0.05) time points (Figure 6a). There were also similar decreases in CCL5
mRNA levels in wounds treated with 35K (Day 4: 32%, ns and Day 10: 62%, p < 0.05, Figure 6b). CCL2
protein levels were lower in wounds at the Day 4 time point (41%, p < 0.05, Figure 6c), but the trend
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consistent for wound CCL2 mRNA levels in which 35K treatment decreased CCL2 wound mRNA at
the Day 4 time point (36%, p < 0.05, Figure 6d), with no significant decrease in Day 10 wounds.
Figure 6. Topical 35K suppresses CC-chemokines in wound tissues. Protein and RNA were
isolated from PBS and 35K treated wounds at both the early (Day 4) and late (Day 10) time points
(n = 12/time point). ELISAs and real-time PCR was used to measure protein and mRNA levels of (a,b)
CCL5 and (c,d) CCL2. Data is represented as mean ± SEM. Statistical analysis was performed by an
unpaired two-tailed t-test. * p < 0.05, ** p < 0.01 compared to PBS treated wounds.
3. Discussion
The stages of the wound healing process encompass the most complex biological processes that
occur in human life. An imbalance can greatly affect the outcome of wound repair, with impaired
wound healing often leading to severe unfavourable outcomes such as amputation. This highlights the
need to develop novel agents that promote wound recovery. CC-chemokines have been shown to play
a key role in the promotion of inflammation and inflammatory-induced angiogenesis, two important
processes involved in wound healing. To date, only single CC-chemokine intervention studies have
been done, with minimal to no benefit, suggesting that a broad-spectrum inhibition approach may
have improved efficacy. In this study, we report that topical application of the broad-spectrum
CC-chemokine inhibitor “35K” decreased wound CCL5 and CCL2 protein levels, leading to enhanced
wound healing and wound neovascularisation during the early stages of wound healing. Histological
analysis of wounds showed that 35K treatment significantly increased neovessels in the early stages of
wound healing, when angiogenesis is most important. Mechanistically, we found that the classical
VEGF-mediated angiogenic pathway was not responsible for the augmentation of angiogenesis by
35K, but, instead, 35K elevated the pro-angiogenic and pro-repair cytokine TGF-β. Furthermore,
35K treated wounds had significantly lower mRNA levels of p65, the active subunit of the inflammatory
transcription factor NF-κB. In addition, 35K treated wounds at Day 10 had lower collagen content,
suggesting a reduction in scar formation. Taken together, these findings suggest that broad-spectrum
inhibition of CC-chemokines may be an alternate therapeutic approach to improve wound healing by
simultaneously suppressing inflammation while augmenting neovascularisation at the critical early
stages of wound repair.
Macroscopic wound measurements revealed that wound closure was faster in 35K treated wounds
compared to PBS treated control wounds. This was supported by the increased blood flow perfusion
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perfusion is critical to support the wound healing process to supply the wound with nutrients and
growth factors, and accelerate debris removal [2,29]. Increased blood flow perfusion also allows for
increased oxygenation to help maintain the newly forming wound tissue [30]. This early boost in
perfusion may support the increased closure seen at Day 7 and 8. By Day 7, wound blood perfusion
then started to decline in the 35K treated wounds. At this stage, remodelling is commencing, and, whilst
neovessels are still present, the impetus for new wound neovessels has started to decline, supporting
the decrease in wound blood perfusion at this stage. After Day 7 post-wounding, there is very little
detectable blood perfusion using the Laser Doppler for both treatments. Consistent with our blood
perfusion measurements, the current study also found that topical application of 35K increased the
presence of wound neovessels at Day 4, and, at Day 10, neovessels and arterioles were reduced in the
35K treated wounds. At this late stage, the wound has nearly healed, re-epithelialization is complete,
inflammation has ceased, a scar has formed and collagen remodelling from type III to type I collagen
begins [31]. Importantly, as the wound healing process is near-completion, angiogenesis may decline
to allow for continued remodelling [9,32]. The lower number of neovessels and arterioles seen at
Day 10 suggest that these wounds have healed quicker and have now entered the remodelling phase.
However, at Day 21, the wounds are further in the remodelling phase, bringing stability to neovessel
content. The reduction in collagen content of the 35K treated wounds at Day 10 may further lead to
reduced scar formation, as scars are mainly comprised of collagen [33]. At Day 21, the collagen content
returns to a stable level, when compared to PBS wounds. This suggests that whilst the wounds may
have less scar the stability of the skin is not compromised. Interestingly, at Day 4 there is 10 times more
type I collagen than type III, and, when the wound is completely healed and undergoing remodelling,
there is an increase of 50 times in type I collagen in wounds. These findings are consistent with
previous studies where reduced fibrosis was detected in the kidneys and lungs of mice following
inhibition of the chemokine receptors CCR1 or CCR5 [34–36].
Angiogenic mediators such as VEGF and FGF-2 are released by various cell types including
endothelial cells, fibroblasts, keratinocytes and macrophages. VEGF is primarily produced by
endothelial cells, whilst FGF-2 is produced by fibroblasts. Interestingly, 35K had no effect on these key
angiogenic mediators involved in wound healing. Furthermore, we found no change in wound HIF-1α
expression, which regulates VEGF and is triggered in response to tissue ischemia. This suggests
that there was sufficient blood perfusion and oxygenation to the wounds. VEGF is involved in
angiogenesis and synthesis of collagen in the wound [8,37]. It is produced by wound fibroblasts,
keratinocytes and macrophages [8,32,38]. VEGF levels remained unchanged in 35K treated wounds,
suggesting that VEGF is not involved in the augmentation of wound healing and wound angiogenesis
by 35K. An alternative suggestion is that VEGF expression increased very early post-wounding
with 35K, which was missed at the Day 4 time point. Studies have shown increases in VEGF just
24 h post-wounding [39], which then return to baseline once angiogenesis is underway. There was,
however, an increase in wound neovessels with 35K treatment at the Day 4 time point, despite
no changes in VEGF or HIF-1α. Interestingly, both VEGF and HIF-1α are induced by NF-κB in
inflammatory pathological angiogenesis. This study found that 35K significantly inhibited p65
(active NF-κB subunit) mRNA levels. This reduction in NF-κB may be part of the reason for the
lack of change in VEGF and HIF-1α and suggests that 35K was preventing pathological excessive
wound angiogenesis. Furthermore, the reduction in wound CC-chemokine levels by 35K would
also contribute to the suppression of pathological angiogenesis that can compromise wound repair
if it persists in the later stages of healing. The increase in angiogenesis seen during early wound
healing, where it is critical, is likely to be the result of increased TGF-β expression in the Day 4 35K
treated wounds. TGF-β increases key angiogenic functions including endothelial cell proliferation
and migration [40,41] TGF-β also has a number of roles in the wound repair process including
fibroblast proliferation, collagen formation and remodelling of the extracellular matrix [42] and the
initiation in the formation of granulation tissue [43]. TGF-β stimulates contraction of fibroblasts [44]
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together, our results demonstrate that 35K does not augment wound angiogenesis via the classical
HIF-1α/VEGF angiogenic pathway but rather through the induction of TGF-β, and may in fact
suppress excessive pathological angiogenesis in the mid-late stages of wound repair via inhibition of
NF-κB and CC-chemokine levels.
Despite the reduction in NF-κB by 35K, there were no changes in the number of wound
macrophages as may have been expected. Macrophages can be roughly divided into pro- and
anti-inflammatory phenotypes (M1 and M2) and both are involved in different stages of wound
healing [46]. Our results indicate an increase in the M2 macrophage phenotype during the early
wound healing stage (TGF-β, CD206), which is known to be associated with improved wound repair,
sufficient formation of granulation tissue and new vascular networks [46]. Interestingly, there was a
surprising increase in M1 macrophage markers at Day 10 (CD80, CD86), which is inconsistent with the
reduction in NF-κB at this time point. However, previous studies have shown that the presence of M1
macrophages at this late-stage does not affect the wound healing process [4].
There was a decrease in CCL5 and CCL2 protein in the tissues of wounds treated with the
CC-chemokine inhibitor 35K. This would typically be associated with a decrease in macrophages;
however, no significant reductions in macrophages were observed. A previous study reported
that despite dominant expression of CCL2 in dermal mouse wounds, a relatively low CCL2 level
correlated with optimal monocyte accumulation [12], indicating that a reduction, but not complete
ablation of CCL2, may not affect macrophage recruitment in the early stages of wound healing.
However, at the later stage (i.e., Day 10), the wound is preparing to enter the remodelling phase
in which macrophages undergo apoptosis and chemokines and angiogenesis are subsequently
reduced. Additionally, chemokines from other classes and other cytokines that are not affected by
35K (for example CX3CL1, IL-1, IFN-γ) are released from the wound site and may have assisted in
maintaining macrophage infiltration [47], even with lower CCL2 and CCL5 levels. This may explain
the consistent macrophage levels seen in our study despite the reduction in CC-chemokine levels.
4. Materials and Methods
4.1. Generation and Isolation of 35K Protein
A recombinant adenovirus overexpressing 35K (Ad35K) was generated as described previously [48].
To isolate 35K protein, 20 large flasks of Ad293 cells (293AD cell line, AD-100, Cell Biolabs Inc., San Diego,
CA USA) were infected with 5 × 1011 Ad35K virus particles. After 24–48 h, cells were microscopically
examined for evidence of complete cytopathic effect (CPE). 35K protein was isolated from Ad35K
viral media using anti-HA tagged agarose-conjugated beads (A2095, Sigma-Aldrich, St. Louis, MO,
USA). The media was run through a column packed with anti-HA agarose beads to bind 35K protein,
which was then eluted from the column with 3 M sodium thiocyanate into 1 M Trizma Base (pH 8).
Isolated 35K protein was dialyzed into sterile PBS and then filtered through 0.45 μm low protein binding
syringe filter (Pall Corporation, Port Washington, NY, USA). The concentration of 35K protein was
determined by measuring absorbance at 280 nm and aliquoted to 200 nM before freezing at −80 ◦C.
4.2. Murine Wound Healing Model
All experimental procedures and protocols were conducted with approval from the Sydney Local
Health District Animal Welfare Committee (#2013/027A), and conformed to the Guide for the Care
and Use of Laboratory Animals (United States National Institute of Health, Bethesda, MD, USA).
To explore the effect of broad-spectrum CC-chemokine inhibition on wound healing, a murine model
that closely mimics the human wound healing process was used [49]. Briefly, C57Bl6/J wildtype
mice were anesthetized by inhalation of methoxyflurane. Then, a 6 mm biopsy punch was used to
outline two circular full-thickness excisions, 5 mm in diameter, that include the panniculus carnosus
created on the dorsum, one on each side of the midline of the mouse. A 0.5 mm thick silicone
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interrupted sutures. For each mouse, one wound received purified 35K protein (200 nM in 50 μL PBS)
and the other endotoxin-free PBS (50 μL, vehicle control), topically applied daily beginning on the
day of wounding (Day 0). A transparent occlusive dressing (Opsite™ Flexifix™, Smith & Nephew,
London, UK) was then applied. Mice were given carprofen (5 mg/kg) daily 3 days post-surgery to
alleviate any pain. Digital images were taken and micro-callipers were used to measure wound area
daily along the x-, y- and z-axes. Blood perfusion in wound areas was determined using Laser Doppler
Perfusion Imaging (moorLDI2-IR, Moor Instruments, Devon, UK). For this study, two cohorts were
taken at 4 (n = 12), 10 (n = 12), or 21 (n = 7) days after wounding. Both PBS and 35K treated wounds
were collected for histological, protein and gene analysis.
4.3. Immunohistochemistry
Wound tissues were fixed in 4% (v/v) paraformaldehyde overnight, and then embedded in
paraffin. Furthermore, 5 μm wound sections were taken from the midpoint. Wounds were assessed for
neovessels by detection with rabbit polyclonal anti-CD31 antibody (1:100, ab28364, Abcam, Cambridge,
UK), arterioles by detection with mouse monoclonal smooth muscle α-actin antibody (1:100, A5691,
Sigma-Aldrich) and for macrophages by detection with mouse monoclonal anti-CD68 antibody
(1:100, ab31630, Abcam) staining. Secondary antibodies were pre-diluted horseradish peroxidase
(HRP) secondary antibody α-rabbit (K4011, Dako) or pre-diluted HRP secondary antibody α-mouse
(K4007, Dako, Glostrup, Denmark) for CD31 and CD68, respectively. The staining was visualized using
3,3′-Diaminobenzidine (DAB) (Dako) for CD31 and CD68 or Vector Red alkaline phosphatase substrate
(SK-5100, Vector Laboratories, Burlingame, CA, USA) for smooth muscle α-actin. Appropriate IgG
controls were used for all antibodies. Collagen was measured following Milligan’s trichrome staining.
Picrosirius red staining, imaged under polarized light, was used to differentiate type I and type
III collagen. For all histological quantification, three sections were imaged at 10× magnification,
the images were tiled and “stitched” to obtain the entire wound cross section for each treatment
group per mouse (n = 7–12) and assessed using Image-Pro® Premier 9.0 software (Media Cybernetics,
Rockville, MD, USA).
4.4. Protein Expression
Wound tissues were homogenized in lysis buffer (80 mM Tris HCl, 10 mM NaCl, 50 mM NaF,
5 mM Na4P2O7, 15 mM Triton-X 100). Wound tissue lysates (50 μg) were subjected to Western
immunoblotting and probed for HIF-1α (1:1000, NB100-105, Novus Biologicals, Littleton, CO, USA) α
Tubulin (1:5000, AB40742, Abcam) was used to confirm even protein loading. Commercially available
ELISA kits (Quantikine, RnD Systems, Minneapolis, MN, USA) were used to determine protein levels
of VEGF, CCL2 (MCP-1) and CCL5 (RANTES) in 100 μg of wound tissue lysates, while FGF-2 protein
levels were measured in 50 μg of wound tissue lysates.
4.5. Gene Expression
Total RNA was isolated from wound samples using TRI reagent (Sigma-Aldrich). Furthermore,
300 ng total RNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA) before amplification using the iQ SYBR Supermix (Bio-Rad) in a Bio-Rad Cfx384 thermocycler.
The following mouse primers were used to probe for HIF-1α (F 5′-TCCCTTGCTCTTTGTGGTTGGGT-3′,
R 5′-AACGTAAGCGCTGACCCAGG-3′), VEGF (F 5′-GAGTACCCCGACGAGATAGAGT-3′, R 5′-GGT
GAGGTTTGATCCGCATGA-3′), p65 (F 5′-AGTATCCATAGCTTCCAGAACC-3′, R 5′-ACTGCATTCAA
GTCATAGTCC-3′), CD68 (F 5′-GGGGCTCTTGGGAACTACAC-3′, R 5′-GTACCGTCACAACCTC
CCTG-3′), TGF-β (F 5′-GGATACCAACTATTGCTTCAGCTCC-3′, R 5′-AGGCTCCAAATATAGGGG
CAGGGTC-3′), CD206 (F 5′-CAGGTGTGGGCTCAGGTAGT-3′, R 5′-TGTGGTGAGCTGAAAGGT
GA-3′), CD80 (F 5′-ACCCCCAACATAACTGAGTCT-3′, R 5′-TTCCAACCAAGAGAAGCGAGG-3′),
CD86 (F 5′-CAGCTCACTCAGGCTTATGTTT-3′, R 5′-TGTTTCCGTGGAGACGCAAG-3′), CCL2
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AGTGCTCCAATCTTGCA-3′, R 5′-CTTCTCTGGGTTGGCACACA-3′) and 36B4 (F 5′-CAACGCAGCA
TTTATAACCC-3′, R 5′-CCCATTGATGATGGAGTGTGG-3′). Relative changes in gene expression were
normalized using the ΔΔCt method to 36B4 as the housekeeping gene.
4.6. Statistics
All results are expressed as mean ± SEM. All data were compared using an unpaired two-tailed
t-test. Significance was set at a value of p < 0.05.
5. Conclusions
In conclusion, our findings show that broad-spectrum CC-chemokine inhibition via topical
application of 35K enhanced wound closure through the early promotion of neovascularisation.
Furthermore, inhibiting the CC-chemokine class resulted in a reduced inflammatory state as indicated
by reduced NF-κB. Mechanistically, 35K augmented wound angiogenesis via the induction of the
pro-angiogenic cytokine TGF-β, rather than the HIF-1α/VEGF angiogenic pathway. Taken together,
our findings (summarized in Figure 7) demonstrate that broad-spectrum CC-chemokine inhibition
may improve wound healing by suppressing the inflammatory state of the wound while augmenting
wound angiogenesis and suppressing scar formation.
 
Figure 7. Summary of proposed 35K action in wound healing. Broad-spectrum CC-chemokine
inhibition by 35K has a significant impact on key mechanisms involved in wound healing. In addition,
35K enhances wound closure through the early promotion of neovascularisation via the induction of
TGF-β, rather than the HIF-1α/VEGF angiogenic pathway. 35K treatment reduces inflammation via
inhibition of NF-κB, which may help to stave off pathological angiogenesis in the later stages of wound
repair, along with the reductions in CCL5 and CCL2 but with no change in macrophages. Finally, 35K
suppresses collagen deposition at the late stage of wound healing, but not early, indicative of reduced
scar formation.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/1/155/s1.
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Abstract: Postoperative intra-abdominal adhesion is a very common complication after abdominal
surgery. One clinical problem that remains to be solved is to identify an ideal strategy to prevent
abdominal adhesions. Keratinocyte growth factor (KGF) has been proven to improve the proliferation
of mesothelial cells, which may enhance fibrinolytic activity to suppress postoperative adhesions.
This study investigated whether the combined administration of KGF and a sodium hyaluronate
(HA) gel can prevent intra-abdominal adhesions by improving the orderly repair of the peritoneal
mesothelial cells. The possible prevention mechanism was also explored. The cecum wall and its
opposite parietal peritoneum were abraded after laparotomy to induce intra-abdominal adhesion
formation. Animals were randomly allocated to receive topical application of HA, KGF, KGF + HA,
or normal saline (Control). On postoperative day 7, the adhesion score was assessed with a visual
scoring system. Masson’s trichrome staining, picrosirius red staining and hydroxyproline assays
were used to assess the magnitude of adhesion and tissue fibrosis. Cytokeratin, a marker of the
mesothelial cells, was detected by immunohistochemistry. The levels of tissue plasminogen activator
(tPA), interleukin-6 (IL-6), and transforming growth factor β1 (TGF-β1) in the abdominal fluid were
determined using enzyme-linked immunosorbent assays (ELISAs). Western blotting was performed
to examine the expression of the TGF-β1, fibrinogen and α-smooth muscle actin (α-SMA) proteins
in the rat peritoneal adhesion tissue. The combined administration of KGF and HA significantly
reduced intra-abdominal adhesion formation and fibrin deposition and improved the orderly repair
of the peritoneal mesothelial cells in the rat model. Furthermore, the combined administration of
KGF and HA significantly increased the tPA levels but reduced the levels of IL-6, tumor necrosis
factor α (TNF-α) and TGF-β1 in the abdominal fluid. The expression levels of TGF-β1, fibrinogen and
α-SMA protein and mRNA in the rat peritoneum or adhesion tissues were also down-regulated
following the combined administration of KGF and HA. The combined administration of KGF and
HA can significantly prevent postoperative intra-abdominal adhesion formation by maintaining the
separation of the injured peritoneum and promoting mesothelial cell regeneration. The potential
mechanism may be associated with rapid mesothelial cell repair in the injured peritoneum. This study
suggests that combined administration of KGF and HA may be a promising pharmacotherapeutic
strategy for preventing abdominal adhesions, which is worth further study, and has potential value
in clinical applications.
Keywords: peritoneum; mesothelial cells; regeneration; postoperative adhesions; keratinocyte
growth factor
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1. Introduction
Postoperative intra-abdominal adhesions are a very common complication of abdominal surgery
that may occur in 90% to 95% of patients undergoing abdominal surgery [1–3]. These unavoidable
postoperative adhesions can cause a series of clinical problems, such as intestinal obstruction,
postoperative abdominal and pelvic pain, female infertility, and difficult access in a subsequent
surgery [4,5]. Ten percent of patients with intestinal obstructions caused by intra-abdominal adhesions
must undergo adhesiolysis, for which the mortality rate is between 5% and 20%. The recurrent rate is
very high after surgical treatment of adhesive intestinal obstructions. Without effective prevention
of adhesions, the recurrence rate is 12% within 41 months after surgery; the recurrent risk is still
considerable even 20 years after surgery. Studies of postoperative intra-abdominal adhesions have
been ongoing since the emergence of surgery [6], but an effective medication that has a reliable effect
and fewer side effects has not been identified. Clinically, many medications and approaches have been
tested; however, the results have been inconclusive. Thus, a current clinical problem that remains to be
solved is to identify an ideal strategy that prevents intra-abdominal adhesions [7].
Intra-abdominal adhesion formation results from fibrin exudation and deposition caused by
a series of inflammatory processes in the injured peritoneum; furthermore, a decreased ability to
dissolve fibrin at the injured sites can also lead to adhesion formation [8]. Peritoneal injury can induce
the production of a fibrinogen-rich serous exudate, which activates the coagulation system and converts
fibrinogen into fibrin to form deposits. Fibrin deposits can degrade into fibrin degradation products,
and then, the injured peritoneum can be repaired by mesothelial cell regeneration. The degeneration of
fibrosis is mainly completed by the peritoneal fibrinolytic system. Tissue plasminogen activator (tPA)
and plasminogen activator inhibitor type 1 (PAI-1) of mesothelial cells, the main components of the
peritoneal fibrinolytic system, play key roles in adhesion formation and development. Fibrin deposition
can persist and form permanent fibrous adhesions when fibrinolytic activity is decreased due to poor
mesothelial cell regeneration.
To this end, mesothelial injury is considered to be one of the causes of peritoneal adhesion
formation [9]. The integrity of the peritoneal mesothelial cell layer is closely associated with fibrinolytic
activity. Moreover, the loss of or poor proliferation and migration of mesothelial cells is another
factor that promotes adhesion formation [10]. Peritoneal mesothelial cells not only form the smooth
surface of the peritoneum but also exhibit fibrinolytic activity. Mesothelial cells are considered as the
primary source of tPA in the serous cavity; their fibrinolytic activity in serous cavities plays a decisive
role in local fibrin deposition and removal [10]. Normally, the balance between fibrin formation
and dissolution of peritoneal mesothelial cells is maintained. However, when some pathological
factors, such as peritoneal inflammation, mechanical damage, tissue ischemia, and foreign body
implantation, are present, the mesothelial cells can be injured, reducing their fibrinolytic capacity.
An imbalance between fibrin exudation and fibrinolysis can subsequently lead to tissue organization
and adhesion formation.
The target of keratinocyte growth factor (KGF) is epithelial cells (including mesothelial cells).
KGF can promote epithelial cell proliferation and growth and increase the rate of epithelialization [11,12].
KGF has rarely been reported to prevent intra-abdominal adhesions by promoting mesothelial cell
regeneration. KGF has been shown to improve mesothelial cell proliferation, which may enhance
fibrinolytic activity to potentially suppress postoperative adhesions [13]. This study investigated whether
the combined administration of KGF and sodium hyaluronate (HA) can prevent intra-abdominal
adhesions in rats by promoting the orderly repair of the injured peritoneal mesothelial cell layer.
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2. Results
2.1. The Combined Administration of Keratinocyte Growth Factor (KGF) and Sodium Hyaluronate (HA)
Significantly Reduced the Abdominal Adhesion Score in the Rat Model Using the Visual Scoring System
Animal death was not observed, and all animals completed the entire experimental protocol.
No wound disruption, wound infection or intra-abdominal infections were observed in any of
the groups. The magnitude of abdominal adhesions between groups was different (Figure 1).
Adhesion formation was rarely observed in the sham laparotomy group, and the surface of the
parietal peritoneum was smooth. Sheet-like adhesions were observed in the control group, which were
difficult to separate. In the HA group, the jelly-like HA gel on the animal’s cecal surface was completely
absorbed, and the partially injured visceral surface was repaired. Strip-like adhesions were observed
between the parietal peritoneum and cecum wound bed or between the omentums. The magnitude of
adhesion information was milder than the control group. The magnitude of adhesion formation in the
KGF group was similar to the HA group. In the animals of the KGF and HA groups, there was a low
magnitude of adhesion formation, which appeared loose and had a thin thread-like morphology.
Figure 1. The combined administration of keratinocyte growth factor (KGF) and sodium hyaluronate
(HA) prevented postoperative abdominal adhesion formation in rats. Representative images showing
the intra-abdominal adhesions (black triangle) or the injured areas on the opposite parietal peritoneum
on postoperative day 8 in each group of rats. (A) A large area of dense adhesions formed and the
adhesions were difficult to separate in the control group; (B) Moderate adhesions were less severe in
the HA group of rats than in the control group; (C) The relatively significant adhesions in the KGF
group of rats were similar to those in the HA group in magnitude; (D) Very mild adhesions in some
rats in the KGF plus HA group; (E) No adhesions were observed in the sham group. The surfaces of
the parietal peritoneum and cecum were smooth.
Figure 2. Comparison of intra-abdominal adhesion score in each group (n = 8). HA or KGF has
a non-obvious trend to reduce adhesions in the rats. The magnitude of adhesion was significantly
decreased in the KGF plus HA group. (A) Intra-abdominal adhesion score based on Nair’s classification
(* p < 0.05, compared with the control group); (B) Intra-abdominal adhesion score based on Leach’s
classification (* p < 0.05 compared with the control group); (C) Comparison of the non-adhesion rate
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The magnitude of intra-abdominal adhesions was scored according to Nair’s classification,
and there was a significant difference among the five groups of rats (p < 0.05) (Figure 2A).
Compared to the control group, HA or KGF reduced the postoperative adhesions in the rats respectively.
The differences were not significant. In contrast, the magnitude of intra-abdominal adhesion formation
was significantly decreased in the KGF plus HA group of rats (p < 0.05). In addition, the adhesion
score was the lowest in the KGF plus HA group when using the scale described by Leach et al.
(Figure 2B). The proportion of rats without abdominal adhesions in all groups was analyzed; we found
that the rate of animals without adhesion formation was 75% in the KGF plus HA group and was
significantly increased compared to the HA and KGF groups. The above-reported results indicated that
the combined administration of KGF and HA can significantly prevent postoperative intra-abdominal
adhesion formation in rats.
2.2. The Combined Administration of KGF and HA Decreased Collagen Deposition in the Injured Peritoneum of
the Rat Model
Collagen fibers are stained blue by Masson’s trichrome staining (Figure 3). The structure of the
collagen fibers was intact, and collagen fiber proliferation was not observed in the sham operation
group, whereas collagen fibers were stained dark blue in the control group, representing obvious
hyperplasia. In the HA and KGF groups, collagen fibers were stained different shades of blue,
which was somewhat lighter than the staining in the control group. More importantly, the area
size and density of collagen fibers were not only significantly reduced in the KGF plus HA group
compared with the control group but also significantly reduced compared with the HA and KGF
groups. In addition, we examined the thickness of the abdominal adhesions between the injured rat
peritoneum using picrosirius red staining of collagen fibers (Figure 4A). Compared with the HA and
KGF groups, the collagen fibers in the rat adhesion tissue appear more loose, and the thickness of the
abdominal adhesions was significantly decreased in the KGF plus HA group (p < 0.05) (Figure 4B).
Furthermore, the combined administration significantly reduced the hydroxyproline content of the
adhesion tissue in the animals of the KGF plus HA group (p < 0.05) (Figure 4C). Thus, our data
suggested that the combined administration of KGF plus HA could decrease collagen deposition
during adhesion formation in the rat model.
Figure 3. Masson’s trichrome-stained images showing the intra-abdominal adhesions (black
triangle) or injured areas on the opposite parietal peritoneum (white triangle) in each group of rats.
(100× magnification pictures in upper plate, 200× magnification pictures in below plate; the black
scale bar represents 100 μm). (A1,2) Image showing the compact structure and significant hyperplasia
of the collagen fibers (dark blue staining) in the control group; (B1,2) Image showing the collagen fibers
(dark to light blue staining) in the HA group, in which the staining is somewhat lighter than the control
group; (C1,2) The abundance of collagen fiber hyperplasia in the KGF group was similar to the HA
group; (D1,2) The collagen fiber was significantly impoverished in the KGF plus HA group; (E1,2) The
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Figure 4. The magnitude of fibrosis in the intra-abdominal adhesions or the injured areas on the
opposite parietal peritoneum in each group of rats (n = 8). (A–E) Representative images of picrosirius
red staining (100×; insets, 200×) in each group. The adhesive tissues are located between the black
brackets. The black scale bar represents 100 μm; (F) The thickness of the collagen deposits in the
adhesive tissue of each group of rats (* p < 0.05 compared with the control group); (G) Hydroxyproline
content in the adhesion tissues of each group of rats (* p < 0.05 compared with the control group).
2.3. The Combined Administration of KGF and HA Can Reduce Inflammatory Infiltration in the Injured
Rat Peritoneum
We utilized the hematoxylin and eosin (HE) staining technique to compare the magnitude of
inflammatory cell infiltration in the peritoneum (Figure 5A–E). The criteria for the inflammation score
were listed in Table S3. In the control group, the accumulation of a number of inflammatory cells and
some small abscesses were noted in the peritoneal tissue. The same inflammatory cells were also noted
in the HA and KGF groups; however, the magnitude of the accumulation was less severe than that in
the control group. Only a few scattered inflammatory cells were noted in the KGF plus HA group,
indicating a significant decrease in inflammatory cell accumulation compared to that in the HA or KGF
group. The inflammation scores were significantly different among the five groups of rats (Figure 5F),
in which the highest score was observed in the control group. The score in the KGF plus HA group
was not only significantly reduced compared with the control group (p < 0.05) but also significantly
reduced compared with the HA and KGF groups (p < 0.05). Thus, the results have shown that the
combined administration of KGF and HA significantly inhibited the accumulation of inflammatory








Int. J. Mol. Sci. 2016, 17, 1611
Figure 5. Inflammatory infiltration in the intra-abdominal adhesions or the injured areas on the
opposite parietal peritoneum in each group of rats (n = 8). (A1,2–E1,2) Representative images of HE
staining in the intra-abdominal adhesions or the injured areas on the opposite parietal peritoneum in
each group of rats (100× magnification pictures in upper plate, 200× magnification pictures in below
plate; the black scale bar represents 100 μm); (F) Inflammatory infiltration score for the adhesive tissue
in each group of rats (* p < 0.05 compared with the control group).
2.4. The Combined Administration of KGF and HA Promotes Mesothelial Cell Repair on the Injured
Peritoneal Surface
Immunohistochemical staining for cytokeratin (CK), a marker of mesothelial cells, was used to
assess the continuity of the mesothelial cell layer of the injured rat peritoneum (Figure 6). The shape of
representative mesothelial cells resembles cobblestones, and the cytokeratin staining is positive [14].
Our studies have observed the presence of a continuous and intact cell layer on the surface of
the parietal and visceral peritoneum in the sham group. In contrast, mesothelial cells were not
present on the surface of the injured parietal and visceral peritoneum in the control group. Similarly,
mesothelial cell repair was not evident in the HA group. Mesothelial cell regeneration was noted in the
KGF or KGF plus HA group, but, more importantly, a well-repaired mesothelial cell layer was noted
in the KGF plus HA group, and its continuity was similar to the sham group. Therefore, the combined
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Figure 6. Immunohistochemical staining of cytokeratin in the intra-abdominal adhesions or the
injured areas on the opposite parietal peritoneum in each group of rats (100× magnification pictures
in upper plate, 200× magnification pictures in below plate; the black scale bar represents 100 μm).
(A1,2) In the control group, the brown thin continuous line was completely interrupted; the interrupted
brown line indicated the injured mesothelial cell layer; (B1,2, C1,2) The mesothelial cell layer (brown
thin continuous line) was interrupted in the KGF and HA groups; (D1,2) In the KGF plus HA group,
continuous brown lines were observed, indicating that the peritoneal mesothelial cell layer was
completely repaired by regeneration; (E1,2) In the sham operation group, the parietal peritoneum
and visceral peritoneum of the intestine surface were stained brown. A brown thin continuous
line was formed, indicating that the peritoneal mesothelial cell layer was intact. Arrow: peritoneal
mesothelial cell.
2.5. The Combined Administration of KGF and HA Inhibited the Severity of the Fibrous Changes in the Injured
Peritoneum and/or Adhesion Tissue in the Rat Model
Using immunohistochemical staining for α-smooth muscle actin (α-SMA), an activated fibroblast
marker, the degree of fibrous changes in the injured rat peritoneum and/or adhesion tissue was
examined (Figure 7A–E). In the sham laparotomy group, the peritoneum was intact, and no positive
staining was observed. In the control group, a large amount of fusiform fibroblasts with positive
brown staining were observed in the thick adhesive tissue. In the HA and KGF groups, the number of
fibroblasts with positive α-SMA expression was slightly less than the number in the control group.
However, in the KGF plus HA group, the degree of fibrous changes in the injured peritoneum and/or
adhesion tissue was significantly reduced. Immunohistochemical staining for collagen I deposition
(Figure 7F–J), a marker of fibrosis, showed that the amount of collagen I deposition on a scale from
high to low was the control group, the HA group, the KGF group, the KGF plus HA group and the
sham operation group. Thus, the results showed that the combined administration of KGF and HA
could effectively inhibit fibrosis of the injured or adhesive peritoneum in a rat model.
2.6. The Combined Administration of KGF and HA Suppressed the Abdominal Fluid Levels of Tissue
Plasminogen Activator (tPA) and the Pro-Inflammatory Cytokines Transforming Growth Factor β1 (TGF-β1)
and Interleukin 1β (IL-1β) in the Rat Model
On postoperative day 7, the abdominal fluid levels of tPA, TGF-β1 and IL-1β were measured by
ELISAs (Figure 8). The results revealed that the tPA levels in the abdominal fluid were significantly
reduced in the control group compared with the sham operation group, but the levels of the
pro-inflammatory cytokines TGF-β1 and IL-1β were significantly increased compared with the sham
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local fibrinolytic activity and significant inflammatory responses. Moreover, the KGF plus HA
intervention could significantly inhibit the decrease in the tPA levels and the increase in the TGF-β1
and IL-1β levels (p < 0.05). This inhibitory effect was not significantly different in the HA group and
the KGF group (p > 0.05). These results suggested that the combined administration inhibited the
down-regulation of fibrinolytic activity and the significant release of inflammatory factors induced by
the injured peritoneum during adhesion formation.
Figure 7. Immunohistochemical staining of α-smooth muscle actin (α-SMA), vimentin and collagen
I in the intra-abdominal adhesions or the injured areas on the opposite parietal peritoneum in each
group of rats (200×; insets, 400×). The black scale bar represents 100 μm. (A–E) α-SMA staining;
(F–J) Collagen I staining.
Figure 8. Abdominal fluid levels of tissue plasminogen activator (tPA) (A); transforming growth factor
β1 (TGF-β1) (B); and interleukin 1β (IL-1β) (C) in each group (n = 8) (* p < 0.05 compared with the
control group).
2.7. The Combined KGF and HA Treatment Inhibited Src Phosphorylation and Expression of TGF-β1,
Fibrinogen, and α-Smooth Muscle Actin (α-SMA) in the Injured Peritoneum and/or Adhesion Tissue in
the Rat Model
The Western blot analysis showed that Src phosphorylation was significantly increased on
postoperative day 7 in the KGF group and KGF plus HA group, suggesting that KGF can promote
Src phosphorylation and activation (Figure 9). In addition, TGF-β1 expression in the abdominal
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group. Compared with the control group, the HA and KGF groups did not show apparent TGF-β1
down-regulation. However, in the KGF plus HA group, expression of the TGF-β1 protein in the injured
peritoneum and/or adhesion tissue was significantly decreased compared with that in the control,
HA, and KGF groups (Figure 9). Moreover, we examined the expression of the fibrinogen and α-SMA
proteins. With a similar pattern as the TGF-β1 levels in the groups, the expression levels of fibrinogen
and α-SMA protein were reduced by the combined administration of KGF plus HA in the injured
peritoneum and/or adhesion tissue (Figure 9).
Figure 9. Expression of phosphorylated Src, Src, TGF-βl, fibrinogen and α-SMA protein in the
intra-abdominal adhesions or the injured areas on the opposite parietal peritoneum by Western blotting.
The expression levels of TGF-β1, fibrinogen and α-SMA mRNA in the injured peritoneum and/or
adhesion tissue on postoperative day 8 were determined using the real-time RT-PCR technique
(Figure 10). We found that the expression levels of TGF-β1, fibrinogen and α-SMA mRNA in the
injured peritoneum and/or adhesion tissue were the lowest in the KGF plus HA group (p < 0.05).
The mRNA expression levels were consistent with the protein expression levels shown in the Western
blot analysis.
Figure 10. Expression of TGF-βl (A); fibrinogen (B) and α-SMA (C) mRNA in the intra-abdominal
adhesions or the injured areas on the opposite parietal peritoneum by real-time RT-PCR (n = 8).
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3. Discussion
The results of this study have shown that, compared to the administration of either KGF or HA
alone, the combined administration of KGF and HA can more effectively prevent intra-abdominal
adhesion formation in a rat model. This good preventative effect may be associated with the synergistic
effect of the two agents, which can promote the repair of the mesothelial cell layer. Therefore, this study
showed that the combined administration of KGF plus HA is a promising initial strategy for the
prevention of intra-abdominal adhesions. It is worth continuing the study of its mechanism and
translating the results into clinical practice.
At present, the following pharmacological preventive strategies against postoperative
intra-abdominal adhesions should be considered [15–17]: (1) minimizing the initial inflammatory
reaction and exudate; (2) inhibiting agglutination of the exudate; (3) promoting fibrinolysis; (4) using
a physical barrier that can isolate the injured surface coated with fibrin; and (5) inhibiting fibroblast
proliferation. Unfortunately, most of the regimens that have been used to prevent adhesion formation
have limited effectiveness and considerable side effects [18]. It has been reported that intra-abdominal
perfusion of crystalloid solutions and dextran injections are ineffective at preventing adhesions;
moreover, the use of anti-inflammatory drugs has increased the risk of gastrointestinal anastomotic
leakage. Currently, the most widely accepted method for the prevention of intra-abdominal adhesions
is to place a medication barrier or gel between the injured peritoneal surfaces for at least 5 to 7 days.
Some animal and clinical trials have shown that HA, chitosan and polyethylene glycol/polylactic acid
films can indeed reduce adhesions [1–3], but others reported that the effectiveness of these medications
is not significant [19]. The reason that the above-mentioned medications are not ideally effective in
adhesion prevention may be because researchers have overlooked the function of mesothelial cells on
the surface of the peritoneum.
Mesothelial cells are specialized epithelial cells that line the internal organs and body wall in
the peritoneal, pleural, and pericardial cavities [20,21]. The surface of the serous peritoneum is an
intact mesothelial cell layer. Intra-abdominal adhesions form between the injured surfaces of the
two mesothelial cell layers [22]. Surgical injury may cause local tissue ischemia and hypoxia in the
peritoneum [23], which trigger the inflammatory responses involving polymorphonuclear leukocytes,
macrophages, fibroblasts and neovascularization and result in fibrin deposition for the initial adhesion
formation [24,25]. Thereafter, the activation of the fibrinolytic system can degrade the fibrin deposits in
the abdominal cavity. If fibrinolytic activation did not occur, fibroblasts would produce large amounts
of collagen to form adhesions in 5 to 6 days after the injury of peritoneal mesothelial cell layer. Then,
the mesothelial cells would completely cover the injured surface and adhesion area by proliferating to
form fibrous adhesions, leading to permanent adhesion formation [26].
Mature adhesions can be effectively prevented if the intended techniques are used to enhance
the regeneration ability of mesothelial cells and to rebuild the intact mesothelial cell layer in early
intra-abdominal adhesions [27]. However, strategies to protect mesothelial cell regeneration are
rarely reported, even though there have been a number of approaches described for the prevention of
intra-abdominal adhesions. Bertram et al. [28] reported that intraperitoneal transplantation of isologous
mesothelial cells resulted in a significant reduction of adhesion formation. Guo and colleagues [29]
showed that high expression of sphingosine kinase (SPK1) can enhance both the proliferation and
migration of mesothelial cells to accentuate the repair of mesothelial cells; SPK1 can also induce the
cells to secrete plasminogen activator to enhance the peritoneal fibrinolytic capacity and ultimately
prevent adhesion formation. These results suggest that the rapid enhancement of mesothelial cell
regeneration is a possible strategy to prevent adhesion formation.
KGF is a single-chain polypeptide that was first isolated from the culture medium of human
embryonic lung fibroblasts by Finch and Rubin in 1989 [30]. Its molecular weight is 26 to 28 kDa.
The gene sequence analysis indicates that KGF is a member of the fibroblast growth factor (FGF)
family and thus is known as FGF-7. KGF targets epithelial cells (including mesothelial cells) and
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KGF can prevent and repair epithelium injuries of the skin, cornea, bladder, lungs, intestines, and liver
through multiple approaches and multiple levels [32]. Lopes et al. [13] employed KGF to prevent
swine pericardial adhesions in their study and suggested that the use of growth factors targeting
mesothelial cell proliferation or regeneration can reduce the severity of adhesions. However, it has not
been reported that KGF can prevent peritoneal adhesions. This study assessed the effect of KGF on
adhesion formation in rats. The results have shown that KGF indeed reduced the severity of peritoneal
adhesions and that the administration of KGF alone had approximately the same effect as the HA gel.
KGF function depends on the phosphorylation of the tyrosine kinase Src. Src can be phosphorylated
by the KGF receptor (KGFR) after KGF binds KGFR [33] and thus exert its biological effects on
downstream targets. In our study, we evaluated Src phosphorylation levels after the administration of
KGF. We found that the levels of the phosphorylated Src protein were up-regulated in the peritoneal
tissue after the administration of KGF to rats. This result suggests that KGF indeed plays a role in the
local repair of the injured peritoneum.
KGFR is only distributed in epithelial cells (including mesothelial cells), and thus, KGF has no
effect on fibroblasts and endothelial cells [11]. Therefore, the use of KGF can reduce adhesions without
stimulating fibroblast proliferation and activation and thus can avoid aggravating adhesion fibrosis.
Our experimental results showed that the degrees of collagen deposition and fibrosis in the adhesive
tissue were reduced in the rats of the KGF intervention group compared with the control group.
Although KGF reduced the peritoneal adhesions, its effect was similar to the effect of the HA
gel in clinical practice. The proportion of rats without adhesion formation did not reach 50% of the
total number of rats. This result indicated that a considerable number of rats did not obtain a benefit
from the KGF intervention. The possible reason is that the timing and speed of mesothelial cell repair
is crucial for peritoneal adhesion prevention. Typically, mesothelial cell repair begins at 1 or 2 days
and is completed in approximately 8–10 days after peritoneal injury [34] because peritoneal injury
causes a large amount of fibrin deposition in the injured sites during this period. If the regenerated
mesothelial cells cover the surface of the fibers and collagen, they can instead promote adhesion
maturation and lead to permanent adhesion formation. Therefore, we suspect that the inhibition of
fibrin deposition on the injured peritoneal surface during KGF-promoted mesothelial cell repair can
greatly increase the effect on adhesion prevention.
HA gels are a commonly used barrier-like material for the clinical prevention of postoperative
abdominal adhesions [1]. Hyaluronic acid is an acidic mucopolysaccharide. It is a normal
glycosaminoglycan that is distributed in the extracellular matrix of the connective tissue in the
human body. At physiological concentrations, hyaluronic acid molecules are entangled and form
a disordered network of fibers that comprise its unique three-dimensional structure. It is difficult for
some macromolecules, such as fibrinogen, collagen and proteoglycan, to enter this network structure.
Hyaluronic acid enters the abdominal cavity in a colloidal state to form a jelly-like substance and
covers the surface of the injured peritoneum to avoid the direct and effective contact between the
surfaces. HA is a form of the sodium salt of hyaluronic acid, a naturally degraded and absorbable
biomedical material [35]. Furthermore, HA can reduce the exudation of inflammatory cells, reduce the
deposition of collagen at injured sites, and promote the physiological repair of injured tissue [36].
HA definitely plays a beneficial role in isolating the injured surface. This study showed that the barrier
effect of HA also mildly or moderately reduced the magnitude of abdominal adhesions.
In theory, better prevention of adhesion formation can be achieved if a barrier material is used
to maintain the separation between the parietal and visceral peritoneum before KGF accentuates
the restoration of the integrity of the mesothelial cell layer of the peritoneum. The mechanisms
by which KGF and HA prevent adhesions are different. Thus, we speculated that, theoretically,
the combined administration of the two agents may be more efficacious in preventing adhesions.
Our study also showed that the combined administration of KGF and HA can achieve better results
in terms of adhesion severity and reducing the inflammatory cytokine levels compared to each








Int. J. Mol. Sci. 2016, 17, 1611
of inflammatory infiltration and collagen deposition at the injured peritoneal adhesions in rats.
The combined administration can take advantage of the synergistic effects to achieve better results in
the prevention of peritoneal adhesions (Figure 11).
Figure 11. Mechanism by which the combined administration of KGF and HA prevents intra-abdominal
adhesions. The HA gel can maintain the separation of the parietal and visceral peritoneum;
KGF accentuates the regeneration and repair of the peritoneal mesothelial cell layer and thus the
orderly repair of the integrity of the injured peritoneal mesothelial cell layer.
There are some limitations and concerns with this study. KGF should be used with caution
to prevent postoperative abdominal adhesions in the setting of abdominal tumor surgery because
experimental studies suggested that KGF, a growth factor, may have the potential to promote tumor
growth [36] or increase tumor resistance to chemotherapy [37]. Oelmann et al. [38] have proven
that under the effects of recombinant KGF (r-KGF), the majority of tumor cell lines did not exhibit
meaningful proliferation in vitro among 35 cancer cell lines of epithelial origin and 22 lymphoma and
leukemia cell lines. Only five cancer cell lines (two lung cancer, one gastric cancer, one colon cancer
and one breast cancer) exhibited statistically significant proliferation in a dose-dependent manner.
Although KGF has been used at non-tumor sites to treat disease [39], people are still concerned about
whether its use will cause tumor growth. Another issue of this present study regarded the lasting
effective period of KGF in the body. KGF has poor stability and a short biological half-life; the biological
activity of KGF is highly susceptible to environmental changes. Mesothelial cells require 8 days to
repair the injured surface; however, the activity of intraperitoneally administered KGF cannot last for
a long time due to the impact of a variety of biological enzymes. Thus, further improvements in the
KGF dosage form are needed to maintain stable pharmacological effects on the body.
In summary, the present study has shown that the combined administration of KGF and HA can
effectively prevent postoperative intra-abdominal adhesion formation in a rat model by maintaining
the separation of the injured peritoneum and promoting mesothelial cell regeneration. The combined
administration of KGF and HA has shown considerable advantages from the aspects of the inhibition
of collagen deposition, tissue fibrosis, and inflammation. This study suggests that the combined
administration of KGF and HA is a promising pharmacotherapeutic strategy in intra-abdominal
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4. Materials and Methods
4.1. Agents
The r-KGF was purchased from Prospec (Rehovot, Israel; CAT#: cyt-219) in a highly purified state
(95%). Stock solutions were made after an initial dilution with sterile phosphate-buffered saline and
stored at −20 ◦C at a 1000 ng/mL concentration. At the time of use, the stock solutions were thawed
and diluted in sterile water. The sample for the KGF group consisted of a 15 mL solution containing
25 ng/mL r-KGF. The medical HA gel (10 mg/mL) was produced by Hangzhou Singclean Medical
Products Co., Ltd., China. KGF at a 1000 ng/mL concentration was thawed and dissolved in the sterile
hyaluronate gel. The final sample of KGF + HA gel contains 25 ng/mL r-KGF.
4.2. Surgical Procedures
Male Sprague-Dawley rats weighing 200 to 250 g were purchased from the Experimental Animal
Center of Xi'an Jiaotong University. These animals were housed at room temperature (22 ± 2 ◦C),
with free access to water and standard rat chow. All animal experiment protocols were approved
by Xi'an Jiaotong University Experimental Animal Ethics Committee (No. 2015-156, 6 March 2015).
The animals were anesthetized through the inhalation of methoxyflurane. The abdominal skin was
prepared and disinfected with the povidone-iodine prior to the procedure. As previously described in
the literature [40], a 2- to 3-cm-long lower abdominal midline incision was used to access the abdominal
cavity. The pouch-like cecum was located in the right iliac fossa. The cecum wall and its opposite
parietal peritoneum were abraded with sterile gauze until spot bleeding was observed. The abraded
area was approximately 2–3 cm2 and was exposed to air for approximately 5 min. The bowels were
arranged to ensure that the abraded cecum wall was opposite the abraded peritoneum. In the group
with a sham operation, the abrasion and exposure was not performed. In the Control, HA, KGF or
KGF + HA groups, a 1 mL normal saline, HA gel, r-KGF or HA gel containing r-KGF was applied to
the abraded peritoneum and its surrounding areas, respectively. Interrupted 3-0 Vicryl sutures were
used to close the peritoneum, the abdominal muscles, and the skin in 2 layers.
4.3. Adhesion Grade and Assessment
On day 8 after surgery, all rats were anesthetized, and an inverted “U” shape incision was used
to open the abdomen. The magnitude of the intra-abdominal adhesions was assessed according
to the adhesion grade criteria reported by Nair et al. [41] (Table S1) or Leach et al. [42] (Table S2).
The investigators who assessed the adhesion grade were independent researchers and were blinded to
the protocol. The rats were sacrificed after the assessment, and the specimens were collected for the
subsequent studies.
4.4. Hematoxylin and Eosin (HE) Staining and Microscopic Histological Grading of Inflammation
The injured peritoneum and adhesion tissues were excised. Specimen fixation and section
preparation were carried out. Then, HE staining was performed. The tissues were evaluated under
a microscope in regards to the severity of inflammatory cell reaction by using the classification
described by Mahdy et al. [43]. The standard was as follows: degree of inflammation (grade 0: absent
or normal in number; grade 1: mild increase giant cells, occasional scattered lymphocytes and plasma
cells; grade 2: moderate infiltration, giant cells with increased numbers of admixed lymphocytes,
plasma cells, eosinophils, neutrophils; grade 3: massive infiltration, many admixed inflammatory cells,
microabscesses present).
4.5. Picrosirius Red Staining for Collagen
Picrosirius red staining for collagen was achieved using 0.1% picrosirius red (Direct Red 80;
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of the positively stained area in eight randomly selected fields was evaluated using ImagePro Plus
5.0 software (Leica Qwin. Plus, Leica Microsystem Imaging Solutions Ltd., Cambridge, UK), and the
average of the eight values was taken as the collagen content in the adhesions.
4.6. Immunohistochemistry
Immunohistochemical staining was performed using the SABC kit (Maxim, Fuzhou, China),
according to the manufacturer’s instructions. The tissue sections were incubated with primary
antibodies for cytokeratin AE1/AE3 (1:400 dilution), alpha smooth muscle actin (α-SMA)
(1:500 dilution), and collagen I (1:300 dilution) overnight at 4 ◦C and incubated with the appropriate
biotinylated secondary antibody for 30 min at room temperature, followed by a 30 min incubation
with streptavidin peroxidase (Dako LSAB + HRP kit). After rinsing, the results were visualized using
Diaminobenzidine tetrahydrochloride (DAB), and the slides were counterstained with hematoxylin.
4.7. Western Blot
Total proteins were extracted from the tissues using RIPA lysis buffer as previously described [44].
Cell lysates were resolved on 10% sodium dodecyl sulfate polyacrylamide gels and transferred to PVDF
membranes. The membranes were blocked with 5% skim milk and incubated with primary antibodies
overnight at 4 ◦C, which included an anti-phospho Src antibody (ab185617, Abcam, Cambridge,
UK, 1:1000 dilution), anti-Src antibody (ab47405, Abcam, 1:600 dilution), anti-TGF-β1 antibody
(sc-146, Santa Cruz Biotechnology, Dallas, TX, USA, 1:400 dilution), anti-fibrinogen antibody (sc-18029,
Santa Cruz Biotechnology, 1:800 dilution), anti-α-SMA antibody (sc-53015, Santa Cruz Biotechnology,
1:800 dilution), and anti-β-actin antibody (sc-47778, Santa Cruz Biotechnology, 1:1000 dilution).
The membranes were washed and incubated with the secondary antibodies for 2 h at room temperature.
Protein expression was detected using a chemiluminescence system (Millipore, Billerica, MA, USA)
according to the manufacturer’s specifications.
4.8. Real-Time RT-PCR
Real-time RT-PCR was performed to determine the messenger RNA (mRNA) levels of TGF-β1,
fibrinogen, α-SMA and GAPDH. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA), and reverse transcription was performed using a PrimeScript RT reagent Kit (TaKaRa,
Dalian, China). The real-time experiments were conducted on an iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad, Hercules, CA, USA) using a SYBR Green Real-time PCR Master Mix
(TaKaRa). The PCR reactions consisted of 5 s at 94 ◦C followed by 40 cycles at 94 ◦C for 30 s, 60 ◦C
for 30 s, and 72 ◦C for 30 s. The PCR primer sequences are listed in Table S4. The comparative C(T)
method was used to quantitate the expression of each target gene using GAPDH as the normalization
control [45].
4.9. ELISA Quantification of Abdominal Fluid Levels of IL-6, Tumor Necrosis Factor α (TNF-α), TGF-β1
Abdominal fluid samples were collected from the abdomens of the animals and centrifuged at
3000 rpm for 30 min. The supernatant was stored at −20 ◦C. The concentrations of IL-6, tumor necrosis
factor α (TNF-α), and TGF-β1 were measured using ELISA kits (R & D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
4.10. Hydroxyproline Determination
Hydroxyproline content was determined using a Hydroxyproline Assay Kit (Sigma-Aldrich)
according to the manufacturer’s instructions. The tissue hydroxyproline levels, which were used
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4.11. Statistical Analyses
Categorical variables are listed as medians (minimum to maximum), and continuous variables
are listed as averages and standard deviations. The categorical variables were evaluated by the
Kruskal-Wallis H variance analysis for independent samples and the post hoc Mann-Whitney U test for
multiple matches. Continuous variables were analyzed using one-way analysis of variance followed
by the least significant different (LSD) test. The SPSS 15.0 software package (SPSS, Chicago, IL, USA)
was used for data analysis. p < 0.05 was considered significant.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/10/1611/s1.
References [41,42] are cited in the supplementary materials.
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Abstract: Early wound healing after periodontal surgery with or without enamel matrix
derivative/biphasic calcium phosphate (EMD/BCP) was characterized in terms of soft tissue closure,
changes of microcirculation, and expression of pro- and anti-inflammatory cytokines in gingival
crevicular fluid/wound fluid (GCF/WF). Periodontal surgery was carried out in 30 patients (18 patients:
application of EMD/BCP for regeneration of bony defects; 12 patients: surgical crown lengthening
(SCL)). Healthy sites were observed as untreated controls. GCF/WF samples were collected during
two post-surgical weeks. Flap microcirculation was measured using laser Doppler flowmetry (LDF).
Soft tissue healing was evaluated after two weeks. GCF/WF levels of interleukin 1β (IL-1β),
tumour necrosis factor (TNF-α), IL-6, and IL-10 were determined using a multiplex immunoassay.
Surgery caused similar reductions of flap microcirculation followed by recovery within two weeks in
both EMD/BCP and SCL groups. GCF/WF and pro-inflammatory cytokine levels were immediately
increased after surgery, and returned only partially to baseline levels within the two-week observation
period. Levels of IL-10 were temporarily reduced in all surgical sites. Flap dehiscence caused
prolonged elevated levels of GCF/WF, IL-1β, and TNF-α. These findings show that periodontal
surgery triggers an immediate inflammatory reaction corresponding to the early inflammatory phase
of wound healing, and these inflammation measures are temporary in case of maintained closure of
the flap. However, flap dehiscence causes prolonged inflammatory exudation from the periodontal
wound. If the biological pre-conditions for periodontal wound healing are considered important for
the clinical outcome, care should be taken to maintain primary closure of the flap.
Keywords: periodontal surgery; periodontal regeneration; surgical crown lengthening;
wound healing; cytokines
1. Introduction
Periodontal surgery is routinely performed in order to remove microbial deposits from root
surfaces and for corrective measures such as pocket elimination, removal of roots, or contouring of
bony defects. Further, periodontal surgery allows placing of biomaterials or grafts for regeneration of
lost periodontal structures [1]. Surgical lengthening of the clinical crown in order to increase retention
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of prospective restorations or to avoid subgingival restoration margins is another common periodontal
surgical procedure [2].
Irrespective of the intention and the modalities of surgery, periodontal wound healing always begins
with a blood clot in the space maintained by the closed flap after suturing [3]. In the early inflammation
phase of wound healing, inflammatory cells are attracted by platelet and complement derived
mediators and aggregate around the blood clot. While polymorphnuclear neutrophil granulocytes
(PMN) dominate initially, monocytes and macrophages emerge within the first days [4]. The blood
clot also provides a provisional matrix for cells originating from the surrounding tissues (i.e., gingiva,
periodontal ligament (PDL), cementum, and alveolar bone) [5]. Thus, gingival fibroblasts, endothelial
cells, osteoblasts, and special fibroblast populations originating from the PDL proliferate into the
wound area. Wound healing progresses consequently through several phases from inflammation to
cell proliferation and matrix formation and repair; then, these stages are followed by remodelling
and maturation [4]. Reparative healing with formation of a long junctional epithelium and only little
reorganization of connective tissue attachment is the expected outcome in periodontal wound healing
without regenerative measures [6,7].
Clinical and human histological data show the efficacy of enamel matrix derivative (EMD) for
inducement of periodontal regeneration [8–10]. These effects are mainly attributed to the proven
stimulatory effects of EMD on PDL fibroblasts, cementoblasts, and osteoblasts [11–13], as well as
to inhibitory effects on the competing epithelial cells [14]. However, other mechanisms may also
contribute to the beneficial effects of EMD. Since a high microbial load negatively affects “gain” of
clinical attachment after periodontal surgery [15], antibacterial effects of the EMD preparation may add
to the stimulation of regeneration [16,17]. As wound healing is regulated by endogenous substances
such as pro- and anti-inflammatory cytokines, the resolution of inflammation appears important for the
outcome of wound healing [18]. For example, tissue destruction due to high levels of pro-inflammatory
mediators like interleukin 1β (IL-1β), IL-6, and tumour necrosis factor (TNF-α) are reversed
by the anti-inflammatory cytokine IL-10 [19]. Suppression of various pro-inflammatory cytokines
and anti-inflammatory modulation of macrophages have been confirmed for EMD in vitro [20,21].
Direct influences have been shown on T helper lymphocyte migration, CD25 activation, and apoptosis in
a three-dimensional collagen matrix migration model [22]. Correspondingly, these immunomodulatory
effects of EMD may promote favourable conditions for periodontal wound healing.
Regardless of with or without application of bioactive substances, the course of early healing
after periodontal surgery is scarcely investigated in humans, although the first post-surgical weeks
are considered important [23]. The aim of this descriptive study was to characterize early wound
healing after periodontal surgery with or without application of EMD combined with granular biphasic
calcium phosphate (BCP) in terms of soft tissue closure, changes of microcirculation, and expression of
pro- and anti-inflammatory cytokines.
2. Results
2.1. Patients
Thirty patients were recruited, treated, and analysed (EMD/BCP group: 18 patients; SCL group:
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Table 1. Demographic and clinical patient characteristics at baseline. EMD/BCP: enamel matrix
derivative/biphasic calcium phosphate; SCL: surgical crown lengthening. IQ: inter-quartiles. n.d.:
Not Detected.
Patient Data EMD/BCP 18 Patients SCL 12 Patients p
Age (years, median, IQ) 58 (47, 71) 51 (48, 58) >0.05
Gender (male/female) 9/9 7/5 >0.05
Cigarette smokers (yes/no) 3/15 1/11 >0.05
Probing depth (mm, median, IQ) Min/max 7 (6.3, 9) 6, 11 n.d. -
median tooth mobility (0–III) Min/max 0 (0, 1) 0, 2 0 >0.05
Radiographic defect depth (mm, median, IQ) Min/max 6 (5, 7) 3, 9 0 <0.001
2.2. Microcirculation
In each group, untreated control sites did not show any significant changes of perfusion
throughout all 14 days of observation. Directly after surgery (D0b), both EMD/BCP and SCL groups
showed significantly reduced microcirculation values at the papillary base compared to baseline at
D0a (Figure 1A). Although perfusion increased significantly from termination of surgery (D0b) to D1
in both surgery groups, microcirculation was significantly lower than at untreated control sites not
only after surgery (D0b), but also at D1. The ongoing significant recovery until 14 days after surgery




































































































































































































































































































Figure 1. (A) LDF measurements of microcirculation; (B) Measurements of GCF/WF volume;
(C) Concentration of IL-1β in GCF/WF samples; and (D) Total amount of IL-1β in GCF/WF
samples. EMD/BCP (enamel matrix derivative/biphasic calcium phosphate): red, SCL (surgical
crown lengthening): blue, Ctrl (control): white; LDF: laser Doppler flowmetry; GCF/WF: gingival
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2.3. GCF/WF
The results for analyses of GCF/WF samples and their changes are shown in Figure 1B. At baseline
(D0a), GCF sample volume was significantly greater in EMD/BCP sites, when compared to SCL and
control sites. One and three days after surgery (D1, D3), both surgical groups showed significantly higher
sample volumes than found in control sites. In addition, WF sample volume at D1 was significantly
greater in EMD/BCP sites than in SCL sites. Further, EMD/BCP sites showed higher volumes of WF at
days three and seven (D3, D7), when compared to control sites.
2.4. Cytokine Levels at EMD/BCP, SCL, and Control Sites
All three groups showed similar concentrations of IL-1β at baseline (Figure 1C). One day after
surgery (D1), IL-1β concentrations were similarly elevated over healthy control sites in both surgical
groups (EMD/BCP: 7.5-fold, SCL: 6-fold; p < 0.05). In both EMD/BCP and SCL sites, the concentrations
of IL-1β decreased significantly again until the end of the observation period (from D3 to D7).
At baseline (D0a), all three groups showed similar amounts of IL-1β/sample (Figure 1D). At day
one (D1) and at day three (D3), the amounts of IL-1β were significantly enhanced in EMD/BCP and SCL
samples, when compared to control samples (39-fold and 19-fold, respectively, p < 0.001). The amount
of IL-1β/sample decreased significantly for both surgical groups from D1 to D14. However, IL-1β
levels detected in EMD/BCP sites after 14 days (D14) were still significantly elevated, when compared
to both other groups (6-fold and 12-fold, respectively, p < 0.05).
At baseline (D0a), control sites showed a significantly higher concentration of TNF-α than







































































































































































































































































































































































Figure 2. (A) Concentration of TNF-α in GCF/WF samples; (B) Total amount of TNF-α in GCF/WF
samples; (C) Concentration of IL-6 in GCF/WF samples; (D) Total amount of IL-6 in GCF/WF samples;
(E) Concentration of IL-10 in GCF/WF samples. EMD/BCP (enamel matrix derivative/biphasic
calcium phosphate): red, SCL (surgical crown lengthening): blue, Ctrl (control): white; GCF/WF:
gingival crevicular fluid/wound fluid; TNF-α: Tumour necrosis factor α; IL-6: Interleukin 6; IL-10:
Interleukin 10; *: p < 0.05; **: p < 0.01, ***: p < 0.001.
All three groups showed similar amounts of TNF-α/sample prior to surgery at D0a (Figure 2B).
After one and three days (D1, D3), the amount of TNF-α had significantly increased in both surgical
groups and exceeded the levels found in control sites significantly. In the EMD/BCP group, the
amount of TNF-α/sample remained high, and a significantly greater amount of TNF-α was found
in EMD/BCP sites after 14 days (D14) in comparison to both SCL and healthy sites (2- and 2.5-fold,
respectively, p < 0.05).
Prior to surgery (D0a), the concentration of IL-6 in EMD/BCP sites was significantly lower than in
control sites (Figure 2C). In both surgical groups, the concentration of IL-6 increased significantly after
surgery, and decreased again from D1 to D7. Accordingly, the EMD/BCP and SCL groups showed
significantly higher IL-6 concentrations than controls at D1, D3, and D7.
The amounts of IL-6/sample were similar in all groups at baseline (D0a) (Figure 2D). At D1, the
amounts of IL-6 were significantly increased by a factor of 39 for EMD/BCP and 22 for SCL, respectively
(p < 0.001), and decreased significantly again over the course of 14 days (D3 to D14, p < 0.05).
However, when compared to controls, both surgical groups showed significantly higher amounts
of IL-6 continuously from D1 to D14 (p < 0.05).
The concentration of IL-10 decreased similarly and significantly between D0a and D1 in both
EMD/BCP and SCL groups; accordingly, significantly reduced concentrations of IL-10 were found in
both surgical groups at D1, D3, and at D7, when compared to healthy sites (0.25- to 0.4-fold in both
surgery groups, p < 0.05; Figure 2E).
The amount of IL-10/sample did not change significantly over time within all groups, and
significant differences among the groups were not detected (data not shown).
2.5. Soft Tissue Healing
Two weeks after surgery (D14), the SCL group presented significantly better EHI values compared
to the EMD/BCP group (p = 0.032, Table 2, Figure 3). While 13 EMD/BCP sites presented inter-proximal
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Table 2. Contingency table for wound healing in both groups, evaluated using the Early Healing
Index (EHI). Significant difference favouring the SCL group (p = 0.032, Pearson’s Chi2 test). EMD/BCP:
enamel matrix derivative/biphasic calcium phosphate; SCL: surgical crown lengthening.
EHI 1 2 3 4 5
EMD/BCP 2 (11%) 2 (11%) 1 (6%) 4 (22%) 9 (50%)
SCL 0 (0%) 5 (42%) 4 (33%) 1 (8%) 2 (17%)
(A) (B)
Figure 3. Soft tissue healing two weeks after surgery (EMD/BCP group): (A) EHI 1 and closed flap;
(B) EHI 5 and flap dehiscence. EMD/BCP: enamel matrix derivative/biphasic calcium phosphate; EHI:
early healing index.
Table 3. Contingency table for flap dehiscences (yes/no) noted two weeks after surgery. Significant
difference favouring the SCL group (p = 0.024, Pearson’s Chi2 test). EMD/BCP: enamel matrix
derivative/biphasic calcium phosphate; SCL: surgical crown lengthening.
EMD/BCP SCL
flap dehiscence 13 (72%) 3 (25%)
no dehiscence 5 (28%) 9 (75%)
2.6. GCF/WF/Cytokine Levels at Sites with or without Flap Dehiscence
Sixteen of thirty surgical sites displayed dehiscent inter-proximal flaps after two weeks, when the
results for all sites of both groups were pooled. In these sites, the amount of GCF/WF was 1.5-fold
elevated (p = 0.049, Figure 4A). In GCF/WF of sites with dehiscence, the total amounts/sample of
IL-1β and of TNF-α were 4-fold and 2.5-fold increased, when compared to closed sites (p = 0.033 and
p = 0.021, Figure 4B). Other cytokine parameters were unaffected by the course of soft tissue healing
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(A) (B) 
Figure 4. GCF/WF and cytokine levels in sites with/without dehiscence (pooled results for all
sites/both groups): (A) Significantly higher GCF/WF volume were found in sites with flap dehiscence,
when compared to closed flaps (*: p < 0.05); (B) Significantly higher total amounts/sample of IL-1β
and TNF-α were found in sites with flap dehiscence, when compared to closed flaps (*: p < 0.05).
Dehiscence: grey, closed flap: green.
3. Discussion
The main events of periodontal wound healing are completed within two to three weeks of
wound closure, followed by tissue maturation and remodelling [4]. The aim of this descriptive study
was to characterize this early phase of wound healing in terms of soft tissue closure, changes of
microcirculation, and expression of pro- and anti-inflammatory cytokines.
Maintenance of inter-proximal flap closure was assessed using both the Early Healing Index (EHI)
and a dichotomous classification (dehiscence yes/no). EHI values ranging from 2–3 (complete flap
closure with presence of a fibrin line or fibrin clot) were found in 75% of patients treated with SCL,
while 25% of SCL sites showed EHI values of 4–5 (incomplete flap closure with partial or complete
inter-proximal necrosis), or dehiscence of the flap. Suchlike inter-proximal flap dehiscences despite
initial primary closure occur frequently after resective periodontal surgeries and heal by second
intention [24]. Healing by second intention causes formation of gingival clefts and craters, but these
soft tissue deformities may even out over time and are of limited clinical relevance after resective
surgery [25].
Significantly greater proportions of dehiscent flaps were found in EMD/BCP patients (72%),
which is an unexpected finding. The frequency of incomplete flap closure ranged from 0%–10% in
similar studies combining minimally invasive techniques with EMD [26–28], and therefore, the high
proportion of inter-proximal dehiscence is surprising. Generally, local anaesthesia and flap elevation
disturb microcirculation and induce ischemia [29], while maintenance of blood flow is essential for
survival of the operated tissue [30]. In our study, the effects of surgery on flap perfusion were evaluated
using Laser Doppler flowmetry (LDF). LDF measurements of microcirculation detect disturbances
in blood flow caused by surgical trauma and are able to discriminate surgical techniques according
to different extents of tissue traumatisation [31,32]. Further, LDF has been shown to predict flap
dehiscence after surgery [32]. Both groups showed significant reductions of microcirculation directly
after surgery and after one day, when compared to untreated control sites. However, microcirculation
returned quickly to unimpaired levels, and no significant difference with regard to reduction of blood
flow was found between EMD/BCP and SCL sites. Since suchlike alterations of microcirculation
are normal responses to surgery, the poor outcome of soft tissue healing in the EMD/BCP group
should not be attributed to insufficient blood flow caused by allegedly excessive tissue traumatisation








Int. J. Mol. Sci. 2017, 18, 283
normal convex inter-proximal bony contour by adding grafting material supra-crestally beyond the
remaining margins of the bone defect. The ideal amount of granular materials for periodontal defects
is not known. Enhancement of flap support at non-containing defects is an important rationale for
implantation of defect fillers; however, the placement of bone substitutes and the selection of graft type
is considered subordinate to primary closure and wound stability [33]. In our study, overfilling of the
bony defects may have promoted flap dehiscence in EMD sites, especially since coronal advancement
of the flaps had not been carried out. Consequently, clinicians applying bone substitutes during
regenerative periodontal surgery should always consider resultant difficulties in maintaining primary
closure of the flap.
Irrespective of the treatment applied, surgery resulted in elevated volumes of GCF/WF samples
and the levels of IL-1β, TNF-α, and IL-6 were markedly increased as early as after one day. The early
peak of these pro-inflammatory cytokines relates to the physiologic reaction to tissue injury, the
early inflammatory phase of wound healing [34]: IL-1β and TNF-α are necessary for inducement of
expression of adhesion molecules and chemokines, secretion of other inflammatory mediators, and of
matrix metalloproteinases [35]. Lack of these pro-inflammatory cytokines in the early phase, however,
delays or even impairs wound healing [36–38]. After the initial peak, an incremental reduction of
the amount of GCF/WF and the levels of IL-1β and TNF-α was found at most sites during 14 days,
which may correspond to the transition between different phases of wound healing [34]. In contrast to
IL-1β and TNF-α, the elevated levels of IL-6 were maintained over the entire observation period of
14 days. Levels of IL-6 are generally elevated during the early phase of cutaneous wound healing, since
IL-6 has been shown to be involved in regulation of leukocyte infiltration and angiogenesis [37,39].
Unlike IL-1β, TNF-α, and IL-6, IL-10 is an immunosuppressive cytokine and regulates innate
and adaptive immune responses [34]. Both surgical groups showed significant reductions of IL-10
concentrations in GCF/WF one day after surgery and the reduced levels were maintained for one
week. Considering the contrasting levels of IL-1β and TNF-α, the decreased levels of Il-10 may truly
reflect the first inflammatory phase of wound healing [34].
Given the well-known anti-inflammatory effects of EMD found in vitro, reduced levels of
pro-inflammatory cytokines or enhanced levels of IL-10 were to be expected in GCF/WF samples
of EMD/BCP sites. Interestingly, we failed to reproduce the effects of EMD found in vitro in our
clinical study. This is in line with a recent report by Villa et al., who found a similar discrepancy
between cytokine levels in clinical samples of wound fluid after periodontal surgery and in vitro
measurements [40]. However, in contrast to “clean” in vitro assays focusing on one particular cell
type such as PDL fibroblasts, osteoblasts, or keratinocytes, a wide variety of different cell types and
exudates will always contribute to GCF/WF samples, which may obscure the detectable effects of
biological mediators on a given cell population within the periodontal wound. Further, in the study by
Villa et al. [40], conventional macro-surgical flap designs and suture materials were used instead of
micro-surgical or minimally invasive techniques and materials, which may have negatively affected
the parameters assessed for characterization of early wound healing. Similarly, the poor outcome
of soft tissue healing in EMD/BCP sites in our study may have contributed to the lack of detectable
effects of EMD on cytokine levels. Inflammation, as characterized by high levels of IL-1β, reduces the
beneficial effects of EMD on wound healing: wound fill rate, cell proliferation and adhesion, synthesis
of growth factors and collagen as well as mineralization were negatively affected under concomitant
challenge with IL-1β in vitro [41]. In our study, a suchlike interrelation between inflammation and
scarce effect of EMD may be clinically reflected by the fact that significantly higher levels of GCF/WF,
IL-1β, and TNF-α were found in sites with inter-proximal flap dehiscence, despite application of EMD.
Flap dehiscence always leads to bacterial colonization of the surgical site and especially of implanted
materials [42,43]. Subsequently, the early physiologic inflammatory response to wounding cannot be
resolved and becomes chronic due to the bacterial infection, with detrimental effects on the attempted
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inhibition of collagen synthesis [45,46]. In contrast, inflammation at non-infected sites with maintained
flap closure can be reduced promptly by pro-resolving mediators, and normal healing can occur [44].
In conclusion, periodontal surgery immediately increased the amount of GCF/WF and the levels
of pro-inflammatory cytokines, which was reflected by contrasting effects on the anti-inflammatory
cytokine IL-10. Increased measures of inflammation were temporary in case of maintained closure of
the flap. However, flap dehiscence caused prolonged inflammatory exudation from the periodontal
wound. If the biological pre-conditions for periodontal wound healing are considered important for
the clinical outcome, care should be taken to maintain primary closure of the flap.
4. Materials and Methods
4.1. Treatment Groups
The study protocol was approved by the institutional Ethics Committee of the Witten/Herdecke
University (no. 39/2011; 24 April 2011). The study was conducted in accordance with the guidelines
of Good Clinical Practice (GCP-ICH) and the principles of the Helsinki Declaration of 1975, as revised
in 2008. Written informed consent was obtained from all patients. Two groups of patients were treated
with periodontal surgery and monitored during the first two weeks of healing:
(1) regenerative periodontal surgery of intrabony defects, using enamel matrix derivative and
a granular bone substitute (EMD/BCP group).
(2) surgical crown lengthening prior to prosthetic treatment (SCL group).
4.2. Study Patients
Participants were recruited from the patient pool of the Witten/Herdecke University’s Dental
School (first patient in: 17 May 2011; last patient out: 27 September 2012). Patients presenting
a periodontal site in need of regenerative therapy (probing depth (PD) ≥ 6mm, and radiographic
evidence of a vertical bone defect of at least 4 mm, assessed at a supportive periodontal therapy
visit three months after completion of non-surgical therapy for moderate to advanced generalized
chronic periodontitis) were assigned to the EMD/BCP group. A minimal width of 2 mm of keratinized
gingiva at the prospective surgical site and an inter-proximal control site considered “clinically healthy”
(PD ≤ 3 mm, negative for bleeding on probing and suppuration) were also required.
Periodontally healthy patients (no site with PD > 3 mm, full-mouth bleeding on probing score <25%,
mean full-mouth plaque score <25%) were recruited to the SCL group in case of presence of a site in
need of surgical crown lengthening for prosthetic reasons (distance of a planned restoration margin to
bone crest ≤2 mm). A minimal width of 2 mm of keratinized gingiva at the prospective surgical site
and presence of a control site considered “clinically healthy” (PD ≤ 3 mm, negative for bleeding on
probing and suppuration) were also required.
Exclusion criteria included pregnancy, lactation period, use of antibiotics or anti-inflammatory
drugs in the previous six months, systemic diseases and medications affecting periodontal inflammation
or surgical procedures, and any condition requiring premedication before dental treatment.
4.3. Surgery
All surgeries were carried out by the same experienced surgeon (GG). Patients were advised
to abstain from brushing the surgical area, and to use a 0.2% chlorhexidine mouth rinse twice daily
for 1 min until removal of sutures.
4.3.1. Access Flap with EMD and Granular Bone Substitute (EMD/BCP)
The simplified papilla preservation flap technique (SPPF) [47] was used in case of an interdental
width of ≤2 mm, as measured at the papilla base. A modified papilla preservation flap (MPPF) [48]
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were avoided. After flap elevation, thorough debridement of the root surface, and degranulation, the
defect was rinsed with sterile saline. A 24% ethylenediamine tetraacetic acid gel (PrefGel, Institut
Straumann AG, Basel, Switzerland) was applied to the exposed root surface and removed after 2 min
using saline. Then, EMD (Emdogain, Institut Straumann AG, Basel, Switzerland) was administered
to the root surface. The bone defect was filled with a granular bone substitute (biphasic calcium
phosphate (BCP); Bone Ceramic, Institut Straumann AG, Basel, Switzerland) mixed with EMD, using
a sterile amalgam gun. BCP was not only applied into the bone defect for flap support, but also
used for vertical augmentation beyond the remaining defect margins in order to compensate for
both vertical and horizontal bone loss and to re-establish the physiologic convex inter-proximal bone
contour (Figure 5A,B). Then, the flaps were closed with modified vertical mattress sutures, using fine
monofilament suture material (6.0). Sutures were removed after two weeks.
(A) (B) 
Figure 5. Pre- and post-surgical radiographs (EMD/BCP group). (A) Deep vertical infra-bony defect is
visible on the mesial aspect of tooth 27; (B) The bone defect is filled with radio-opaque bone substitute
(BCP) beyond the residual contour of the alveolar crest.
4.3.2. Surgical Crown Lengthening (SCL)
After placement of bevelled internal and sulcular incisions, a mucoperiosteal flap was reflected
and the bone was exposed. Vertical releasing incisions were avoided. Ostectomy and osteoplasty were
carried out with burs and hand instruments in order to establish a distance of up to 3 mm from the
projected restoration margin to the new bony crest, as described previously [2,49]. Then, the flaps were
closed with vertical mattress sutures with periosteal anchorage for apical repositioning, using fine
monofilament suture material (6.0). Sutures were removed after two weeks.
4.4. Assessment of Microcirculation
A laser Doppler flowmeter (Periflux 5010, Perimed AB, Jarfalla, Sweden) equipped with a PF 416
probe (outside diameter 1.0 mm, fibre separation 0.25 mm; wavelength 780 nm) was used for assessing
changes of microcirculation at surgical and control sites before surgery (D0a), directly after completion
of surgery (D0b), and one (D1), three (D3), seven (D7), and 14 days (D14) after surgery. The LDF probe
was aligned at a custom-made acrylic stent and the measurements were carried out always at the same
position (base of the buccal papilla) for 1 min, perpendicular to the tissue and at a distance of 0.5 mm to
the flap. The flowmeter recordings were monitored using the Perisoft software (Perisoft 2.10, Perimed
AB, Jarfalla, Sweden), measured in perfusion units (PU), and analysed as changes relative to the baseline
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4.5. Sampling of Gingival Crevicular Fluid/Wound Fluid (GCF/WF)
Samples of gingival crevicular fluid or wound fluid (GCF/WF) were harvested at one surgical
and one healthy control site/patient before surgery (D0a), and after one (D1), three (D3), seven (D7),
and 14 days (D14). For sampling, sites were isolated with cotton rolls and gently air-dried. A paper strip
(Perio paper, Oraflow, Amityville, NY, USA) was inserted into the site until mild resistance was felt and
left in place for 30 s. The GCF/WF sample volume was immediately determined with a micro-moisture
meter (Periotron 8000, Oraflow, Amityville, NY, USA) and calculated in microliters from a standard
curve. Samples were stored at −80 ◦C in dry vials until further processing.
4.6. Determination of GCF/WF Cytokine Levels
The GCF/WF levels of cytokines (IL-1β, TNF-α, IL-6, IL-10) were determined with a multiplex
immunoassay (Magpix, Luminex, Austin, TX, USA) following the manufacturer’s instructions.
The samples were thawed in assay buffer, shaken for 1 min with a vortex mixer, and centrifuged
for 5 min at 3000× g for recovery of GCF. Data are presented in pg/mL for concentration and in
pg/sample for total amount of cytokine per sample.
4.7. Assessment of Clinical Soft Tissue Healing
Pictures were taken from all surgical sites two weeks after surgery (D14). Using the photographs,
wound closure was independently evaluated by two calibrated examiners blinded to the group
allocation, using the Early Healing Index (EHI; 1: complete flap closure—no fibrin line in the
inter-proximal area; 2: complete flap closure—fine fibrin line in the inter-proximal area; 3: complete
flap closure—fibrin clot in the inter-proximal area; 4: incomplete flap closure—partial necrosis of the
inter-proximal tissue; 5: incomplete flap closure—complete necrosis of the inter-proximal tissue) [28];
in addition, wound closure was assessed dichotomously (soft tissue dehiscence yes/no).
4.8. Statistical Analysis
Statistics were calculated with the patient as the unit of analysis (split-mouth design, using
one surgical site and one control site/patient). Non-parametric statistical tests were used according
to the non-normal data distribution (confirmed with Kolmogorov-Smirnov test, data not shown).
Medians and inter-quartile ranges (IQ) were calculated for metric parameters (LDF, GCF/WF
volume, cytokine concentration, and total amount/sample). Wilcoxon’s signed-rank test was used
for longitudinal comparisons of repeated measurements within the groups. Cross-sectional analyses
were carried out with the Mann–Whitney U test. Categorical data were analysed using Pearson’s Chi2
test. A statistical software program was used for all calculations (SPSS 22 for OSX, SPSS Inc., Chicago,
IL, USA). Statistical significance was defined as p < 0.05.
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Abstract: Skin wounds may lead to scar formation and impaired functionality. Remote ischemic
preconditioning (RIPC) can induce the anti-inflammatory enzyme heme oxygenase-1 (HO-1) and
protect against tissue injury. We aim to improve cutaneous wound repair by RIPC treatment via
induction of HO-1. RIPC was applied to HO-1-luc transgenic mice and HO-1 promoter activity
and mRNA expression in skin and several other organs were determined in real-time. In parallel,
RIPC was applied directly or 24h prior to excisional wounding in mice to investigate the early and
late protective effects of RIPC on cutaneous wound repair, respectively. HO-1 promoter activity
was significantly induced on the dorsal side and locally in the kidneys following RIPC treatment.
Next, we investigated the origin of this RIPC-induced HO-1 promoter activity and demonstrated
increased mRNA in the ligated muscle, heart and kidneys, but not in the skin. RIPC did not change
HO-1 mRNA and protein levels in the wound 7 days after cutaneous injury. Both early and late RIPC
did not accelerate wound closure nor affect collagen deposition. RIPC induces HO-1 expression in
several organs, but not the skin, and did not improve excisional wound repair, suggesting that the
skin is insensitive to RIPC-mediated protection.
Keywords: remote ischemic preconditioning; heme oxygenase-1; tissue injury; wound repair
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1. Introduction
Severe skin wounds following burns, trauma, or surgery often lead to scar formation and impaired
functionality [1]. Cutaneous wound repair is a dynamic and highly regulated process, involving several
overlapping phases: inflammation, proliferation, and remodelling [2]. Aberrant wound repair and
scarring occurs following prolongation of the inflammatory phase that together with oxidative
stress fuels (myo)fibroblast proliferation and interferes with myofibroblast apoptosis [2]. This leads
to excessive deposition of extracellular matrix proteins, subsequently promoting excessive scar
formation [3,4]. Unfortunately, conventional therapies to accelerate wound repair and to prevent
scarring are insufficient [5–7]. Therefore, adjuvant therapies aimed at resolving inflammation are
warranted. Pharmacological preconditioning has been shown to improve wound repair, as exemplified
by heme and curcumin that also induce the cytoprotective protein heme oxygenase-1 (HO-1) [8–14].
HO-1 is one of the most important enzymes protecting against oxidative and inflammatory insults [15].
HO catabolizes heme to biliverdin, free iron, and carbon monoxide (CO). Biliverdin is then rapidly
converted to the antioxidant bilirubin by biliverdin reductase [16,17]. The iron scavenger ferritin is
co-induced by HO-1 and renders iron inactive [18]. Recent studies have shown that induction of HO-1
expression attenuates the inflammatory response and accelerates wound healing in HO-1-deficient
mice; whereas, decreased HO activity in mice results in slower cutaneous wound closure [9,19].
In addition, intraperitoneal administration of the HO-effector molecule bilirubin accelerates wound
repair [20]. Since increased HO-1 expression improves wound repair, its induction may be a good
candidate for preventing aberrant cutaneous wound repair.
A promising novel preconditioning strategy is ischemic preconditioning (IPC), hereby, short cycles
of ischemia/reperfusion to an organ protects against subsequent more harmful insults to the same
organ. In remote ischemic preconditioning (RIPC), the target organ is not subjected to the initial
stress, but a remote organ, e.g., the hind limb, is exposed. [21,22]. Interestingly, RIPC protects against
injury in the liver [23–26], lung [27], intestines [28], heart [29,30], and kidneys [31,32] often via the
induction of HO-1, since inhibition of HO-activity abrogates the protective effects of RIPC [23,26,33].
Following RIPC, there exists both a rapid phase of protection initiated within 1h after preconditioning,
and a later phase after one to several days [21,34]. In addition, different modes of action have been
reported between single and repeated RIPC procedures, as demonstrated by differential expression
of genes involved in autophagy, endoplasmic reticulum stress, mitochondrial oxidative metabolism,
and cell survival [35,36].
Successful translation towards its clinical use was recently established by inducing temporary
occlusion and restoration of blood flow in arm or thigh of patients [29,30,37]. Patient outcome
after myocardial surgery was significantly improved when RIPC was applied before surgery [27].
However, recently conflicting results have been reported showing that RIPC does not always
mediate protection [38–41]. Data from animal and human studies demonstrated the need for
careful interpretation because of translational differences [38–43]. RIPC improves microcirculation
by an increase in tissue oxygenation and capillary blood flow in the skin [44] and skin flaps [45],
and forms a novel target for skin flap transplantation [46] and the healing of diabetic foot ulcers [47,48].
Although RIPC has been shown to protect in several models of tissue injury, its role in cutaneous
excisional wound healing is still unclear. We postulated that RIPC induces HO-1 expression and
improves skin repair following excisional skin injury.
2. Results
2.1. Effects of RIPC on HO-1 Promoter Activity and HO-1 mRNA Expression in Mice
RIPC can induce HO-1 expression in different organs. In order to evaluate if RIPC can induce
HO-1 expression, we used a combination of HO-1 promoter activity and HO-1 mRNA analyses in
HO-1-luc transgenic (Tg) mice. We previously demonstrated that treatment with cadmium chloride
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model [49]. To validate the RIPC model, we corroborated that blood flow was indeed hampered
after applying elastic rings (Figure A1). After RIPC treatment, HO-1 promoter activity was measured
using the In Vivo Imaging System at 1, 6, and 24 h. Measurements of HO-1 promoter activity were
acquired at the dorsal aspect of each mouse (Figure 1a). Because of variations in HO-1 promoter
activity, each mouse served as its own control. Relative HO-1 promoter activity of the dorsal side
of the mice after RIPC treatment is shown over time (Figure 1b). We found a significant increase in
HO-1 promoter activity after 6 and 24 h of RIPC treatment compared to 1 h after RIPC. HO-1 promoter
activity was strongly observed in the renal area, suggesting RIPC induced HO-1 promoter activity in
an organ-specific manner 6 and 24 h after RIPC treatment when compared to 1 h after RIPC treatment
(Figure 1c).
To discriminate whether the skin or underlying organs were responsible for the increase in HO-1
promoter activity, and to test whether RIPC induced HO-1 expression in a tissue-specific manner,
we measured HO-1 mRNA expression levels in the skin and several organs 1, 6 and 24 h after RIPC
using RT-PCR and then compared these results to untreated controls. First, HO-1 mRNA expression in
the hind limb muscles that had been exposed to repeated ischemia/ reperfusion cycles were measured
and significantly increased 6 h after RIPC treatment when compared to untreated controls and other
time points after RIPC (Figure 1d). We then analyzed the effects of RIPC on HO-1 mRNA levels in
remote organs like kidney, heart, and skin. We also observed a significant increase in HO-1 mRNA
expression in the kidney 6h after RIPC treatment when compared to untreated controls and other time
points after RIPC (Figure 1e). Similarly, in the heart, HO-1 mRNA levels significantly increased 6h
after RIPC treatment when compared to untreated controls (Figure 1f). No significant induction was
found at other time points compared to untreated controls. After 24 h, HO-1 mRNA levels returned to
control levels. However, no significant induction in HO-1 mRNA expression was detected in the skin
at any time point (Figure 1g). In conclusion, we demonstrated a tissue- and time-specific induction of
















Figure 1. Heme oxygenase-1 (HO-1) promoter activity (a–b) and mRNA expression (b–g) after remote
ischemic preconditioning (RIPC) treatment. (a) Representative dorsal images of HO-1 promoter activity
after RIPC over time. Both the overall dorsal side (inserted orange rectangles) and the specific regions
of the kidneys (inserted red circles) were analyzed and the total flux of emitted photons per second was
quantified. Quantification of HO-1 promoter activity in the overall dorsal area after RIPC treatment
(b); and locally in the regions of the kidneys (c), and HO-1 mRNA expression in muscle at the place of
ligation (d); kidney (e); heart (f); and dorsal skin (g), 1, 6 and 24 h after RIPC treatment compared to
untreated controls (n = 6 animals per group). Data are expressed as mean ± SD of six individual mice.
* p < 0.05, ** p < 0.01, *** p < 0.001.
2.2. Effects of Early or Late RIPC on Excisional Cutaneous Wound Closure in Mice
Since RIPC was observed to improve the cutaneous microcirculation [44], we next investigated
whether RIPC could also modulate cutaneous wound repair. RIPC induced HO-1 expression in several
organs, but not in the skin. Interestingly, HO-1 can also promote regeneration in a paracrine fashion
via its versatile effector molecules biliverdin/bilirubin, CO, and ferritin [20,50–54], which are increased
following (R)IPC [55–58]. Moreover, RIPC-mediated protection can act via various alternative signaling
pathways, including humoral, neuronal, and systemic mechanisms [22,59]. Since there are early and
late protective effects of RIPC, we evaluated whether early (5 min) and/or late (24 h) RIPC treatment
before wounding improved full-thickness excisional wound closure. Examples of untreated excisional
wounds are shown in Figure 2a. Wound sizes were normalized to the wound size at day 0 (Figure 2b).
As expected, after quantification of the wound surface area, we found a reduction in the wound size
over time. However, no significant differences were observed in wound closures between early or late
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(a)
(b)
Figure 2. Excisional wound closure in time after RIPC treatment 24 h and directly after wounding
compared to the control group. Representative images of the wounds of a single mouse receiving no
RIPC treatment at day 0, and at 1, 3, and 7 days after wounding (ruler is incorporated in the pictures
and each bar represent 1 mm) (a) and their relative wound sizes after different treatments in time,
compared to control group at day 0 (b). Data are expressed as mean ± SD. No significant differences
were observed between the different groups: no RIPC (n = 8), RIPC 5 min (n = 6) and RIPC 24 h (n = 6).
2.3. HO-1 mRNA and Protein Expression in Wounds After RIPC
To further elucidate the role of RIPC-induced HO-1 expression during wound repair,
we investigated whether RIPC modulates HO-1 mRNA and protein expression in day-7 wounds.
Using RT-PCR, HO-1 mRNA expression was assessed in the wounds and compared to non-wounded
day-0 skin (Figure 3a). Here, we found no significant differences between the wounds and their
corresponding control skins for both RIPC-treated and control groups as well as between the different
treatment groups.
HO-1 protein was found in the epithelial cells of the epidermis and in recruited leukocytes in
the dermis (Figure 3b). In the epidermis, HO-1-positive cells were clustered in the re-epithelialized
tissue underneath the wound crust and were likely newly-formed keratinocytes [60,61]. In the dermis,
HO-1-positive cells in inflamed tissues were individually spread, and based on their location and
morphology, they appear to be macrophages [60–63]. Moreover, in unpublished data from a previous
experiment on excisional wound healing in C57Bl/6 mice at day-2 post-wounding, fluorescent staining
for HO-1 (red) and F4/80 (green) clearly showed co-localization (orange) of HO-1 and macrophages in
a majority of cells (Figure A2).
The wounds were scored for the levels of HO-1 expression in the epidermal and dermal regions,
and compared between the different treatment groups (Figure 3c). RIPC treatment did not modulate
HO-1 protein expression in either region of day-7 wounds when compared to controls. Variations in
HO-1 expression was found between animals, but was independent of RIPC treatment. In summary,













Figure 3. HO-1 expression in wounds. (a). HO-1 mRNA expression in unwounded (control) skin at
day 0 and wounds after 7 days for the different treatments compared to control skin; (b) HO-1 protein
expression in control, and early and late RIPC-treated wounds after 7 days of healing. Region above
the marked blue line is the epidermis and underneath the blue line is the dermal layer (bars represent
1 mm); (c) Scored HO-1 protein staining in epidermis and dermis of the wounds after 7 days in arbitrary
units (AU). Data are expressed as mean ± SD. No significant differences were observed between the
different groups: no RIPC (n = 8), RIPC 5 min (n = 6) and RIPC 24 h (n = 6).
2.4. Effects of RIPC on Wound Morphology and Collagen Deposition
To determine if RIPC modulates other processes during wound repair, we performed H&E staining
to examine wound morphology, and AZAN staining to investigate the effects on collagen deposition.
H&E staining revealed that the wound area could be easily distinguished from non-injured skin
by a disruption of the epidermis, subcutaneous fat, and muscle layers. Figure 4a shows H&E staining
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of the wound, the re-epithelialized tissue had marked epithelial hyperplasia under the crust of the
wound. More distally, the highly cellularized granulation tissue was less organized, and consisted
of inflammatory cells, such as macrophages, granulocytes, and (myo)fibroblasts. Variations in
the thickness and size of the wounds were observed between the tissue sections of the animals.
When comparing the different treatment groups, no differences were found in morphology and in the
presence of different cell types in day-7 wounds.
Figure 4a (right) shows collagen deposition by AZAN staining. The wound regions were marked
after which the level of collagen deposition in the wounds were measured and corrected for the
total wound area (Figure 4b). No significant differences were observed between the different groups.
Summarizing, RIPC did not affect wound morphology and collagen deposition of day-7 wounds.
(a)
(b)
Figure 4. Effects of early and late RIPC on morphology of 7-day-old excisional wounds. (a) H&E
and AZAN staining were performed to evaluate wound morphology (bars represent 1 mm);
(b) Quantification of collagen deposition to assess the level of wound remodeling using AZAN staining.
Data are expressed as mean ± SD. No significant differences were observed between the different
groups: no RIPC (n = 8), RIPC 5 min (n = 6) and RIPC 24 h (n = 6).
3. Discussion
We postulated that RIPC increases HO-1 induction and improves cutaneous wound repair.
RIPC induced HO-1 in kidney, heart, and skeletal muscles, but not in the skin. Although RIPC
had previously been shown to target the skin [44–46,48], both early and late RIPC did not affect
cutaneous wound closure. In addition, skin morphology and collagen deposition at day-7 wounds did
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RIPC-mediated protection to organs seems therefore tissue-specific and/or dependent on the
insult. Organ- and time-specific protective effects of RIPC have also previously been demonstrated.
For example, RIPC does not improve wound healing in small bowel anastomoses [64,65]. Although late
RIPC (24 h) attenuates ischemia/reperfusion injury (IRI) in muscle flaps, it is ineffective in
adipocutaneous flaps [66]. In contrast, early RIPC (30 min) enhances adipocutaneous flap survival [67].
IPC improves the survival of myocutaneous and skin flaps subjected to secondary ischemia of 1h in
rats [68,69]. Since these RIPC protocols vary from ours, and IPC and RIPC are different procedures,
these studies cannot be directly extrapolated to our study. The protective actions of RIPC are thus
dependent on the targeted organ and the type of RIPC treatment [70]. Remote preconditioning by
trauma (RPCT) by abdominal incision, has previously been reported to improve cardiac outcome
following induced heart infarcts by coronary artery occlusion in murine and canine models [71–73].
Similarly, the inflicted injuries in our study could have led to the induction of overlapping
cytoprotective pathways. When these RPCT-induced protective pathways were stronger than the
effects by RIPC or used similar pathways, this could explain in part the observed lack of protective
effects by RIPC on cutaneous wound repair. Similar protective pathways of RIPC and RPCT include
the activation of protein kinase C, mitogen-activated protein kinases and mitochondrial potassium
ATP channels, bradykinin and adenosine [71,73,74].
Previously, the stress enzyme HO-1 was found to be important in wound repair and is generally
expressed at wound sites [60,75,76]. HO-1 and HO-2 knockout mice showed a delayed wound
repair; whereas, induction of HO-1 or administration of its effector molecule bilirubin accelerated
wound repair [19,20,77]. Since some of the protective effects of RIPC were shown to be dependent
on HO-1 expression in IRI of diverse organs, like the liver [23,24,26], lungs [33], and intestines [28],
we further evaluated the role of RIPC on HO-1 in excisional wound healing. HO-1-luc Tg mice allowed
monitoring the effects of RIPC on HO-1 promoter activity levels in different organs in real-time. 6 and
24 h after RIPC treatment, HO-1 promoter activity was significantly induced compared to 1h after
RIPC. This correlates well with our RT-PCR data showing significantly increased endogenous HO-1
mRNA levels in muscle, heart, and kidney 6h after RIPC treatment. However, despite RIPC improving
cutaneous microcirculation [44], no HO-1 mRNA induction was found in the skin, and may thus not
affect the skin directly. HO-1 induction in the skin is possible using pharmacological preconditioning
since we previously observed that i.p. administration of the HO-1 inducer cobalt protoporphyrin at a
concentration of 25 mg/kg body weight in HO-1 luc Tg mice induced HO-1 mRNA specifically in the
skin after 24 h (Figure A3). This underscores the tissue- and time-dependent effects of RIPC, which is
probably due to the structural and physiological differences between different organs. Since organs
that have induce HO-1 expression upon RIPC treatment correlate with the organs that are protected by
RIPC, it is tempting to speculate that HO-1 facilitates these protective effects.
Also the long-term protective effects of RIPC via activation of HO-1 were absent in the skin.
Both HO-1 mRNA and protein expression levels were observed to be independent of RIPC treatment in
the epidermal and dermal regions of day-7 wounds. Like others, we found HO-1-positive keratinocytes
in the hyperproliferative epithelia of the wound margins covering the wound [60,61,78]. In the
dermis, we also observed HO-1-positive infiltrating leukocytes that are likely macrophages [60,62,79].
HO-1-positive macrophages are thought to protect the wound environment against oxidative
stress [60,80]. The pro-inflammatory HO substrate heme is abundantly released at the edges of
the wound site and stimulates recruitment of leukocytes [60,63,78]. HO-1 is thought to attenuate these
inflammatory and oxidative triggers at the wound site.
The effect of both early and late RIPC on wound closure was monitored regularly. However,
the (immuno)histochemical and PCR analysis was only performed on day 7 wounds, which limits
our insight in wound repair processes, like inflammatory signaling, during the first days. Using the
HO-1-luc Tg mice we previously found that HO-1 promoter activity was indeed significantly induced
on day 3 post-wounding, however the level of HO-1 promoter activity did not decline significantly at
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expression in the skin were observed, we cannot exclude that paracrine effects of HO-1 or other
protective signaling pathways may have been triggered by RIPC. HO-effector molecules biliverdin,
bilirubin, CO, and ferritin, have all shown to improve wound repair [20,51–54], suggesting that
RIPC-induced HO-1 induction in various organs stimulate wound repair in a paracrine fashion.
Interestingly, increased systemic levels of bilirubin augment vascular function [81,82] and may
contribute to the reported RIPC induced improvement of cutaneous microcirculation. In a previous
study, no adverse effects of HO inhibition following RIPC were observed in a kidney injury
model, suggesting that other mediators may have been protective [31]. Alternative protective
pathways triggered by RIPC include humoral, neural, or systemic anti-inflammatory, anti-apoptotic
responses [22,59]. In addition, RIPC may have more effects in more stringent wound repair models
where there is a shortage of cytoprotective molecules, such as in diabetic wound repair models and
pressure ulcers [47]. Although our method has shown to be effective in diverse animal models [32],
other RIPC regimens may enhance these protective effects such as combinations with remote ischemic
postconditioning [35,36,47]. Recently, it was found that the sex of the animal may play a role in the
efficacy of RIPC treatment, and was observed to be lower in experimental groups of mixed sexes,
which we also used in our wound repair study [83].
4. Materials and Methods
4.1. Animals
The Committee for Animal Experiments of the Radboud University Nijmegen approved all
procedures involving animals (RU-DEC 2010-248) on 1 February 2011. Fifty mice (strain: HO-1-luc
FVB/N-Tg background; see Table 1) of 4–5 months in age, and weighing 21–35 g were provided with
food and water ad libitum and maintained on a 12 h light/dark cycle and specific pathogen-free
housing conditions at the Central Animal Facility Nijmegen. The transgene consists of the full-length
mouse HO-1 promoter fused to the reporter gene luciferase (luc). More details on the housing
conditions are previously described [84]. Mice were originally derived from Stanford University
(Stanford, CA, USA) as previously described [85]. An overview of the animals used for the different
experiments can be found in Table 1. No animals died during the experiments and no animals
were excluded during the experiments or data analyses. All mice were randomly divided over the
experiments, and split evenly over their sex and age. All outcomes were measured by an observer
who was blinded for the allocation of the animals to the experimental groups, when possible.
Table 1. Overview animal experiments.
Aim Experiment Read Out Animals (n: ♂/♀)
Investigate the effects of RIPC on
HO-1 promoter activity
HO-1 promoter activity at 1, 6 and 24 h after
RIPC treatment 6: 0/6
Investigate the effects of RIPC on
HO-1 gene expression in different
organs during time
HO-1 mRNA levels at 0, 1, 6, and 24 h after
RIPC treatment
24: 0/24
(6 per time point)
Investigate the effects of RIPC on
dermal wound healing
Early (5 min before wounding) and late
(24 h before wounding) effects of RIPC on
wound healing compared to controls
without receiving RIPC treatment
(endpoint: day 7)
6: 4/2 (early RIPC)
6: 4/2 (late RIPC)
8: 4/4 (controls)
4.2. RIPC Treatment
RIPC by brief hind limb ischemia was induced by applying elastic latex-free O-rings
(Miltex Integra: 28–155) using a hemorrhoidal ligator (Miltex McGivney: 26–154B) bilaterally around
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the elastic rings with scissors, confirmed by the disappearance of blue color to the limbs (Figure A1) as
described previously [86–88]. The mice were anesthetized with isoflurane in O2/N2O (5% isoflurane
for induction and 2%–3% to maintain anesthesia) during RIPC treatment and treatment consisted of
three cycles of 4-min ischemia interspersed with 4-min reperfusion. This RIPC regime is based on a
previous study in which we found that bilateral repetitive (3 times 4 min) ischemia/reperfusion gave
the most potent protection in a kidney injury model [32].
4.3. Measuring of HO-1 Promoter Activity
In order to monitor HO-1 promoter activity after RIPC treatment in time, HO-1-luc Tg mice
underwent RIPC treatment as described above. HO-1-luc expression was measured in vivo and the
mice were sacrificed at 24 h. In vivo bioluminescence imaging was performed as described before
on the IVIS Lumina System (Caliper Life Sciences, Hopkinton, MA, USA) [89]. Images taken were
quantified using Living Image 3.0 software (Caliper Life Sciences) by selecting the regions of interest
(ROI). ROIs included both the dorsal images encompassing the back region below the head and above
the tail to cover the area where the wounds would be made and the renal area. Emitted photons per
second (or total flux) per region of interest (ROI) was measured, and then calculated as fold change
from baseline levels and related to 1 h after RIPC.
4.4. Excisional Wound Model
Wounds were made 24 h or 5 min after RIPC. Control mice did not receive RIPC, but underwent
the same anesthetic procedure 1h before wounding. Two full-thickness excisional wounds of 4 mm in
diameter were made on the shaved dorsal side of anesthetized mice using a sterile disposable biopsy
punch (Kai Medical, Seki City, Japan), as previously described by our group [77]. The wounds were
created on the dorsum to either side of the midline, with approximately 1cm between the wounds,
and just below the shoulders and pelvis. Skin biopsies taken to create the 4-mm wounds served as
control skin. Wounds were photographically documented immediately, and 1, 3 and 7 days after
wounding with a ruler placed perpendicular to the wounds for wound size normalization. The area
of the wounds was blindly measured twice using ImageJ v1.44p software (http://imagej.nih.gov/ij;
NIH, Bethesda, MD, USA).
4.5. Sample Collection
At day 7, the mice were anesthetized with 5% isoflurane in O2/N2O and sacrificed by
exsanguination, followed by cervical dislocation. Kidney and muscle (m. quadriceps femoris) were
dissected, and wound tissue was collected using a 4-mm biopsy punch. Half of the tissue was fixated
with 4% paraformaldehyde and processed for paraffin embedding and (immuno)histochemistry,
and the other half was snap frozen in liquid nitrogen and stored at −80 ◦C until use for RT-PCR.
4.6. (Immuno-)histochemical Staining and Analyses
Standard H&E, Weigert-AZAN staining (azo carmine and aniline blue), and immunohistochemical
HO-1 staining were performed on paraffin sections of the wounds as previously described [77].
Stained sections were analyzed and photographed using the Zeiss Imager Z1 microscope
(Zeiss, Sliedrecht, The Netherlands) and Axiovision software version 4.8 (Zeiss).
Analysis of collagen deposition in AZAN stained wound sections was performed by image
analysis using a macro built in Image J [90]. The wound area was manually defined using the edges of
the panniculus carnosus and epithelium as boundaries before running the macro. Measurements were
averaged per mouse and mean intensity/mm2 was used for further analysis.
HO-1 immunoreactivity was evaluated by blindly scoring the epidermal zone and the dermal
region of the wounds. A single section per wound of each animal was semi-quantitatively scored as
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4.7. RNA Isolation and Quantitative-RT-PCR
Tissue was pulverized in TRIzol (Invitrogen, Carlsbad, CA, USA) using a micro-dismembrator
(Sartorius BBI Systems GmbH, Melsungen, Germany) and RNA was further extracted as previously
described [13]. All values were normalized to the household gene gapdh, which is often used in RIPC
experiments [91,92] according to the comparative method (2−ΔΔCt). Gapdh mRNA expression levels
were stable and were not affected by RIPC treatment. The sequences of the mouse-specific primers
for gapdh are forward 5′GGCAAATTCAACGGCACA3′, and reverse 5′GTTAGTGGGGTCTCGC
TCCTG3′, and for Hmox1 (HO-1) forward 5′CAACATTGAGCTGTTTGAGG3′, and reverse
5′TGGTCTTTGTGTTCCTCTGTC3′.
4.8. Statistics
Data were analyzed using GraphPad Prism 5.01 software (San Diego, CA, USA). Outliers were
tested using the Grubbs’ test, but no outliers were found (except for the data in Figure A3 where one
outlier was found in the skin and one in the kidney group). Data were analyzed using two-sided
t-tests to compare two variables or a one-way analysis of variance when comparing multiple variables.
Bonferroni’s multiple comparison post hoc test was applied as correction for multiple comparisons
when investigating multiple dependent research questions. Results were considered significantly
different at p < 0.05 (* p < 0.05, ** p < 0.01, and *** p < 0.001).
5. Conclusions
RIPC treatment induced HO-1 mRNA expression in kidney, heart, and ligated muscle, and may
therefore directly contribute to enhanced protection to injurious stressors and/or microcirculation in
these tissues. However, RIPC did not alter HO-1 in the skin and was not modulated in day-7 skin
wounds, demonstrating organ- and time-specific effects. Both early and late RIPC treatment did not
affect dermal wound closure time, collagen deposition, or wound morphology. A better understanding
of the mechanistic insight by which RIPC mediates organ protection is needed.
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Appendix A
 
Figure A1. Hind limb ischemia by ligation using elastic ring (red arrow). Note the difference in the
color of the legs after obstruction of the blood flow, confirming RIPC treatment was successful.
 
Figure A2. Co-localization of HO-1 and macrophages during excisional wound healing. Fluorescent
staining from a previous experiment on excisional wound healing in C57Bl/6 mice at day 2 post
wounding, showing cell nuclei stained with DAPI (blue), HO-1 (red), macrophages stained for
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Figure A3. Pharmacological preconditioning with cobalt protoporphyrin (25 mg/kg body weight)
in HO-1 luc Tg mice (n = 6) induced HO-1 mRNA expression in both the skin and kidney 24 h
after treatment when compared to saline-injected control mice (n = 6). Dashed line represents the
mRNA expression levels in the corresponding control organs after saline injection, which are set at 1.
Data represents the relative mean ± SD. One significant outlier was found in both skin and kidney
group and therefore excluded in the graph.
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Abstract: Absorbed collagen sponge (ACS)/bone morphogenetic protein-2 (BMP-2) are widely used
in clinical practise for bone regeneration. However, the application of this product was found to
be associated with a significant pro-inflammatory response, particularly in the early phase after
implantation. This study aimed to clarify if the pro-inflammatory activities, associated with BMP-2
added to ACS, were related to the physical state of the carrier itself, i.e., a wet or a highly dehydrated
state of the ACS, to the local degree of vascularisation and/or to local biomechanical factors.
ACS (0.8 cm diameter)/BMP-2 were implanted subcutaneously in the back of 12 eight-week-old
Sprague Dawley rats. Two days after surgery, the implanted materials were retrieved and analysed
histologically and histomorphometrically. The acute inflammatory response following implantation
of ACS was dependent of neither the presence or absence of BMP-2 nor the degree of vascularization
in the surrounding tissue nor the hydration state (wet versus dry) of the ACS material at the
time of implantation. Differential micro biomechanical factors operating at the implantation site
appeared to have an influence on the thickness of inflammation. We conclude that the degree of the
early inflammatory response of the ACS/BMP-2 may be associated with the physical and chemical
properties of the carrier material itself.
Keywords: bone morphogenetic protein-2 (BMP-2); absorbed collagen sponge (ACS); inflammation;
vascularization; biomechanical
1. Introduction
Recombinant human bone morphogenetic protein-2 (BMP-2), a member of the transforming
growth factor beta (TGF-β) superfamily, is in clinical use since more than a decade [1,2]. It is used
in clinical practice for spinal fusion [3] and for treatment of non-unions to enhance bone formation
processes and to accelerate the bony healing response; in dental practice it is used for oral and
maxillofacial reconstruction [4,5].
Even though the clinical use of BMP-2 is very successful, its clinical application is associated with
some serious unwanted effects such as heterotopic bone formation [6], bone resorption (by osteoclast
activation) and formation of cyst-like bone voids [7], as well as postoperative inflammatory
swelling [8,9] and neurological symptoms, etc.
BMP-2 is clinically applied as a free factor (Infuse® (USA), Inductos® (Europe)) together with
an ACS as a carrier. BMP-2 of this product is used in very high dosage, and it is believed that it is
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this high dosage level of BMP-2 that leads to extensive inflammatory responses. This use-associated
inflammation is one of the main reasons why several of the above-described unwanted effects do
occur. It is also believed by many authors that BMP-2 itself contributes significantly to the enhancing
of the inflammatory response during and after the implantation of the construct in this kind of a tissue
engineering approach. Indeed, several publications report that BMP-2 itself enhances the swelling
and the inflammatory response in the surrounding soft tissues in conjunction with the carrier material
(ACS) [10].
Seroma formation is, for example, a frequently observed side effect of BMP-2-use, encountered
most commonly in the first week postoperatively, as described in several studies [8,11].
Rihnet et al. [12] found that lumbar seromas occurred in 1.2% of rhBMP-2 treated patients compared
to 0% in the control patient population. Robin et al. [8] described postoperative seroma formations
associated with BMP-2 use in the surrounding soft tissues in the cervical region that led to bilateral
paresthesia of the upper extremities. In clinical cases with BMP-2-induced seromas, elevated serum
levels of inflammatory cytokines were found, such as those of IL-6, IL-8, and TNF-α [13], as well as
those of IL-10 [10].
Indeed in the publication of Lee et al. [10], a dose-dependency of the inflammatory response
to high dosage levels of BMP-2 was found. However, in a report of Wu et al. [14] it was described
that BMP-2, in particular when delivered in a slow release system, is able to attenuate inflammatory
responses. In other in vivo animal experiments [15], microcomputed tomography and histological
analyses confirmed that PCL/PLGA/collagen/rhBMP-2 scaffolds (long-term delivery mode) showed
the best bone healing quality at both weeks 4 and 8 after implantation without inflammatory response.
Thus, conflicting data are encountered in the scientific literature respecting the role of BMP-2 and it
use-associated inflammation.
The purpose of this study was to investigate if the use of BMP-2, when applied at high
concentrations as a free factor together with a carrier material (ACS), is indeed associated with
a pro-inflammatory response in the acute phase of the body response, i.e., in the initial two days after
implantation of this growth factor with the carrier material. It is, indeed, conceivable that it is not
the BMP-2 itself that triggers the intensive inflammatory response, but that the inflammation may be
elicited by a number of other factors operating in close topographical vicinity to the deposited collagen
carrier. Such candidate factors may be the degree of tissue vascularity, or the local micromechanical
conditions of different physiological stress fields, i.e., depend on differences in the local biological
environment (differential niche biology). Another role may be played by the physical state in which
the collagen carrier itself is deposited, i.e., inserted in a dry state or in a wet state into the living
tissue spaces. Since burst release of BMP-2 (in surgical practise poured onto the ACS sponge) does
readily occur, among others due to mechanical manipulation of the construct itself during surgical
implantation [16], we set up in our experiments a specific control group in which the collagen carrier
was kept in a dry state to assess the possible role of such mechanical stress-modulated release profiles
of BMP-2 in the inflammatory response.
In order to clarify the possible role of these various candidate factors, the Sprague Dawley (SD)
rat was used as the animal model. ACS carrier material was implanted in the subcutaneous space in
the back area (lumbar level). By this set up the deposited collagen carrier patch is exposed on one
side towards the skin, where the skin muscles of the rat generate a continuous instability situation,
i.e., a high biomechanical instability [17]. On the opposite side of the collagen patch, facing the
large underlying lumber muscle package, a relatively stable micromechanical environment is present.
In addition, the two different biomechanical niches around these implants are also characterized
by specific differential densities of blood vessels. The differential blood vessel densities at these
two opposite locations (skin side versus lumbar body side) were quantified in this study in order to
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2. Results
Figure 1A–D illustrated that already on the 2nd day after implantation, all collagen implants were
surrounded by a capsule of inflamed tissue (delineated by a red line), and was highly vascularized.
The inflammatory response involved large numbers of macrophages around each of the implanted
collagen sponges (Figure 1E). The outer border of the inflammation border of the collagen implant was
delineated by a red line and the inner border of the inflammatory zone by a yellow line (Figure 1A–D).
 
Figure 1. Microscopic findings following subcutaneous implantation of: (A) dry Absorbed Collagen
Sponge (ACS); (B) dry bone morphogenetic protein-2 (BMP-2)/ACS; (C) wet ACS; (D) wet ACS/BMP-2;
(E) high magnification of inflamed zone. Red arrow: macrophage. The inflammatory zone was
delineated by two different lines: the outer border in red, the inner border in yellow. Bar = 500 μm
(in A–D). The upper side is skin side and the lower side is lumber body side. Numerous macrophages
were identified in the highly vascularized inflamed zone (cf. 1E, bar = 20 μm).
The degree of inflammation activity was gauged by estimation of the volume of the implanted
sample and the volume of the inflamed tissue. As Figures 2 and 3 showed, the volumes of the implanted
collagen sample and the inflammation area were increased when the carrier (ACS) was loaded with
BMP-2. However, there were no significant differences observed between the collagen sponge volumes






































Figure 2. Mean volumes of collagen implants. No significant differences were found between dry ACS
and dry ACS/BMP-2 nor between wet ACS and wet ACS/BMP-2. Data were present as Means ± SEM.



























Figure 3. Periimplant inflammation volume. No significant differences were found between dry ACS
and dry ACS/BMP-2 nor between wet ACS and wet ACS/BMP-2. Data were present as Means ± SEM.
n.s.: no significant difference.
As Figure 4 illustrates, the mean thickness of the inflamed tissue at the skin side and the lumbar
body side is different, and significant differences were indeed found around the dry ACS implants in
the absence of BMP-2 (p = 0.001), and in the wet ACS groups in the presence (p = 0.0009) or absence
(p = 0.009) of BMP-2.
The differential blood vessel densities at these two opposite locations (skin side versus lumbar
body side) were quantified in this study in order to elucidate their possible role to contribute to the
proinflammatory response. As Figure 5 shows, the area density of blood vessels on both sides were
different, the area density of blood vessels in the dry group without BMP-2 on the lumbar body side
was significantly higher than that on the skin side (p = 0.014) but no significance was found in the
wet group. In the group with BMP-2, the area density of blood vessels in the dry group was found to
be higher on the lumbar body side than on the skin side, but was not significantly different (due to
a high degree of variation; cf. SEM-error bar in Figure 5), in the wet group, the area density of blood
vessels on the lumbar body side was significantly higher than that on the skin side (p = 0.032). Figure 6
illustrates typical areas and blood vessel densities as encountered on the skin side (Figure 6A,C) and
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Figure 4. Comparison of the mean thickness of the inflammation zone on the skin side and the body
side. There are significant differences in the thickness of the inflammatory zones between the skin side
and the lumbar body side in the dry ACS implant group without BMP-2, and in both the wet ACS
groups with or without BMP-2. **: p < 0.01, ***: p < 0.001, n.s.: no significant difference.
μ






























Figure 5. Area density of blood vessels in the dry and wet ACS implant groups, comparing the skin
side blood vessel density with the lumbar body side blood vessel density. The data reveal that the
density is significantly different physiologically. *: p < 0.05, n.s.: no significant difference.
μ
Figure 6. Illustration of blood vessel density in the inflamed area at the skin side (A,C) and the
lumbar body side (B,D) from the dry (A,B) and wet (C,D) ACS. Arrows point to selected blood vessels.
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3. Discussion
This study is focusing on the initial response of the tissue to the implantation of a sterile scaffold
i.e., collagen matrix scaffold, available commercially for use in human patients.
The acute phase of inflammation within the two initial days after implantation is a sterile type
of inflammation in the absence of an infection. It is a non-specific tissue response to the foreign
body material implanted (carriers, biomaterials) [18]. Moreover, it is associated with tissue swelling,
formation of edema as well as the influx of a cell population of the acute inflammatory response type,
represented mainly by macrophages, and later on by foreign body giant cells [19]. This inflammatory
response is not to be confused with infection, which is caused by foreign agents such as bacteria,
viruses, etc. In this study, no infection was observed, and the inflammatory responses were all sterile
in nature.
The comparison between wet ACS and dry ACS implanted in the subcutaneously space of rats
revealed no difference in extent of inflammation in the acute phase (Figure 3). In addition, the sample
size of the ACS, implanted the same way in all experimental groups, exhibited no differences occurring
during these two early postimplantation days, i.e., no differences in early degradation activities
(Figure 2); also the degree of inflammation, quantified by the inflammation volume around the
implanted materials (Figure 3) during this acute inflammation phase did not reveal any significant
differences between the control group and ACS/BMP-2 groups. These findings indicate that the acute
inflammatory response in such cases is most likely based on the non-specific tissue reactions to foreign
materials placed into the body, and it is not dependent on other factors in its extent.
In particular, the comparison between the extent of inflammation in topographically different areas
such as the skin area compared to the lumbar body area, which are subjected to different biomechanical
stress fields [17], and also to different degrees of vascularity (Figures 5 and 6), that both physiologically
do occur at these sites, revealed no differences in the extent of the inflammatory response (Figure 3).
This basically implies that the degree of vascularity is irrelevant respecting the extent of the acute
inflammation response that can be expected following implantation of foreign materials into the body.
The same applies to the state of the hydration of the implant material which is similarly irrelevant to the
acute inflammation response with these materials i.e., implanted in a wet hydrated state or implanted
into the body in a dry state. Due to the absence of the difference in the inflammatory response in 2 days
it is probably implied that the dry material implanted get hydrated very rapidly inside the body so
that no difference in inflammatory response can be monitored. However, the thickness of the local
inflammation appeared quite irregular in the groups carrying BMP-2, represented by larger coefficient
of variation (Figure 5) (dry ACS/BMP-2 group: coefficient of variation (CV) = 100%, coefficient of error
(CE) = 45%) The thickness of the local inflammatory response was thus the only factor identified to
show any differences between the two chosen topographical locations (skin versus lumbar body), and
was thus associated with an asymmetrical response and a high degree of variation (dry ACS/BMP-2
group: CV = 100%, CE = 45%). This finding maybe a consequence of the angiogenetic activity of
BMP-2 that has been proved previously by various authors [20–22], and may be related to a more rapid
formation of blood vessels during the inflammation response when BMP-2 is present, and thus lead
to the observed high irregularity of the extent of the inflammatory response. However, as a whole,
the total inflammatory response remains the same in all experimental groups (Figure 3).
In the literature, it is described that in the subcutaneous tissue of rats, close to the skin, this area
is biomechanically very instable, due to continuous skin muscle activities which are associated
with irregular mechanical forces to occur, whereas in deeper areas near the lumber spine muscles,
less biomechanical instability is present in the associated tissues [17]; thus, the implanted materials are
physiologically exposed at the skin side and at the lumbar body side to differential mechanical force
fields with differential instability conditions. However, no major difference were observed respecting
the extent of inflammation around the implanted materials at the different site, minor differences
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surprising finding in this study is the fact that the presence or absence of BMP-2 has no effect on the
extent of the initial acute inflammatory response.
From studies in various animal models, BMPs are known to have species-specific osteoinductive
dose requirements [23]. For example, in 2002, ACS/rhBMP-2 was FDA-approved as an autograft
replacement for interbody spinal fusion procedures in human patients (at a concentration of
1.5 mg/cc) [24]. The BMP-2 concentration necessary for inducing consistent bone formation is
substantially higher in nonhuman primates (0.75–2.0 mg/mL) than in rodents (0.02–0.4 mg/mL) [23].
In a recent publication, Luginbuehl et al. [25] found that 25 μg/mL in rodents, 50 μg/mL in
dogs, 100 μg/mL in non-human primates and 800 μg/mL in humans, are quite different optimal
osteoinductive BMP-2 concentrations, compared to the presently use clinical setting (0.75 and
1.5 mg/mL BMP-2) [26].
In a study of Lee et al. [10], the total amounts of BMP-2 used were 10 and 20 μg, and were
diluted to 1 and 2 mg/mL, for addition to the ACS carrier, and resulted in a final BMP-2 /ACS carrier
concentration of 3.3 and 6.67 mg/g for use. These authors found the inflammatory response to this
construct not only to be dependent on the presence of BMP-2, but also proportionally related to
its concentration. In our study, we used a total BMP-2 amount of 20 μg, dissolved and diluted to
1 mg/mL, and resulting in an ACS/BMP-2 carrier concentration of 10 mg/g, i.e., used BMP-2 in the
same order of magnitude. However, we were unable to observe any additional pro-inflammatory
response by the presence of BMP-2, as described by other authors [10,27]. Thus we conclude that the
primary factors leading to the inflammatory response in the body are actually associated with the
carrier itself and its chemical properties, but not to the presence of BMP-2. The materials used and
the experimental conditions chosen in our study were the same (BMP-2, collagen) or quite similar
(experimental conditions) to these previous studies [10].
It was interesting to find that in the different local areas (skin vs. lumbar body site), the thickness
of the inflammatory response was indeed significantly different (Figure 4) and/or of high variability
(see discussion above). We hypothesized that at sites of higher blood vessel densities on body side,
we would expect more inflammation to occur, since inflammatory responses are dependent on the
presence of an extensive blood vasculature, and would expect less inflammation at sites where the
blood vessel density is lower. Since this was not the case in our study (see Figure 5), and this
factor obviously overpowered by another biological influence, we attribute this finding to a higher
biomechanical stability condition on the site with thicker inflammatory response, i.e., on the skin side.
As Figure 5 illustrates in the group with dehydrated collagen sponges without BMP-2 and wet collagen
sponges with BMP-2, the blood vessel density at the body side is significantly higher than that of the
skin side. In the group with a dehydrated collagen sponge with BMP-2 and wet collagen sponges
without BMP-2, the thickness of the inflammation zone between these two topographical sites did
not show a significant difference, which would not be expected if the suggested hypothesis would
be operative. The difference in inflammation thickness may thus be related to other factors, such as
discussed above and in a recent review article of James et al. [5], in which the authors describe that
specific anatomic locations can be associated with distinctive adverse events to implanted materials.
We thus conclude that according to our experimental findings the use of BMP-2 is not associated
with the enhancement of pro-inflammatory effects in the initial phase of scaffold material implantation.
The acute inflammatory response appears to be triggered predominately by the carrier material
itself, its chemistry and physical properties, irrespective of the presence of BMP-2 or its absence.
The aforementioned unwanted side effects, such as postoperative inflammatory swelling [8,9],
possibly attribute to the carrier material itself, not by the BMP-2. As for a surgeon, should be very
careful to select an optimal carrier for BMP-2. Given the fact that BMP-2 has been described by
several authors to have an attenuating effect on inflammatory responses in the later phases of the
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4. Materials and Methods
4.1. Animal Preparation
Twelve eight-week-old male SD rats (mean weight 230 g, range from 190–250 g) were used in
this study and divided into 4 experimental groups (n = 6 samples per group). ACSs (Medtronic
Sofamor Danek, Memphis, TN, USA) were cut into identically sized circular samples (8 mm diameter).
The experimental groups were defined as follows: Group1: ACS + 20 μL sterile water, group 2:
ACS + 20 μL BMP-2 solution containing 20 μg BMP-2 (The dosage of BMP-2 was determined as
previously described [10]); the samples of these two groups were stored under aseptic conditions
overnight. Group 3: ACS + 20 μL sterile water and group 4: ACS + 20 μL BMP-2 were prepared freshly
before surgery.
For induction of a general anesthesia 3% pentobarbital were intraperitoneally injected.
Aseptic techniques were used during the surgical procedures. The iliac crest was used as the landmark
for determining the location of the skin incision, a 25 mm posterior longitudinal incision was made
bilaterally, 5–10 mm laterally from the midline. ACSs were implanted with or without BMP-2 into the
subcutaneous space of the lumbar back. Right after implantation, the soft tissues were repositioned
and the wound was closed using standard non-resorbable suture materials. The wound was then
disinfected with 10% povidone-iodine. Animals were kept at 23 ◦C ambient temperature conditions
until awakening.
4.2. Animal Husbandry
The SD rats were kept in animal experiment center (Zhejiang Chinese Medical University
Laboratory Animal Research Center, Hangzhou, China). Temperature for keeping the SD rats was
18–23 centigrade, day/night light cycle time were 14/10 (h/h), humidity 60%–80%, sterile complete
feed(Anlimo, Nanjing, China) and filtered water were freely available.
4.3. Tissue Processing
The rats were sacrificed on postoperative day 2, at which point the collagen samples were
retrieved with the adhering/surrounding tissues and chemically fixed in buffered 10% formaldehyde
solution [17] for 1 day at ambient temperature, they were rinsed in tap water, dehydrated in ethanol
and embedded in methylmethacrylate [14]. Using a Leica diamond saw (Leco VC-50, St. Joseph,
MO, USA), the tissue blocks were cut into 5–7 slices, 600-μm-thick and 1mm apart, according to
a systematic random sampling protocol [28]. All slices were then glued to plastic specimen holders and
ground down to a final thickness of 80–100 μm. They were then surface-polished and surface-stained
with McNeal’s Tetrachrome, basic Fuchsine and Toluidine blue, according to the publication of
Schenk et al. [29].
4.4. Histomorphometry
4.4.1. Sample Volume and Volume of Inflammation
The sections were photographed at a final magnification of ×40 in a Nikon light microscope
(Eclipse 50i Microscope, Tokyo, Japan), and photographic subsampling performed according to
a systematic random-sampling protocol [28]. Using the photographic prints, the volume of the implants
and the inflammation areas (associated with each sample) were determined by point counting [30],
respecting stereological principles. The final volumes were estimated using Cavalieri’s principle [28].
4.4.2. Thickness of Inflammation Volume
It was visually observed that the inflammation thickness of the periimplant inflammation zone
was different when comparing the skin side and lumber body side areas. It therefore was decided to
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lines across the sample and vertically to its surface; thickness measurements were performed along
these lines between the implant surface boundary and the end of the inflammation zone.
4.4.3. Blood Vessel Density
In dry ACS and ACS/BMP-2 group, using the photographic prints (magnification ×40), areas for
high magnification imaging (×200) were chosen according to a systematic random protocol to be
photographed and for morphometrical determination of the area density of blood vessels, again both
on the skin side and on the opposite body side [28].
4.4.4. Statistical Analysis
Independent t-tests were applied to the data to obtain specific comparisons between experimental
and control groups of the histomorphometrical data. All statistical analyses were performed with
SPSS® 21.0 software (SPSS, Chicago, IL, USA), and statistical significance was defined as p < 0.05.
5. Conclusions
It is the collagen carrier itself that is the determining factor in eliciting and regulating the degree
of the inflammatory response in the acute phase after implantation of an ACS/BMP-2 carrier construct
in the bodily environment. This finding suggests that further development and optimization of the
carrier material may be a promising way to reduce in the future the incidence and extent of the
early inflammatory response as an unwanted side-effect in the soft tissue reactions around this type
of implants.
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Abstract: Epithelial cells are involved in the regulation of innate and adaptive immunity in response
to different stresses. The purpose of this study was to investigate if alkali-injured corneal epithelia
activate innate immunity through the nucleotide-binding oligomerization domain-containing protein
(NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome pathway. A unilateral
alkali burn (AB) was created in the central cornea of C57BL/6 mice. Mice received either no
topical treatment or topical treatment with sodium butyrate (NaB), β-hydroxybutyric acid (HBA),
dexamethasone (Dex), or vehicle (balanced salt solution, BSS) quater in die (QID) for two or
five days (d). We evaluated the expression of inflammasome components including NLRP3,
apoptosis-associated speck-like protein (ASC), and caspase-1, as well as the downstream cytokine
interleukin (IL)-1β. We found elevation of NLRP3 and IL-1β messenger RNA (mRNA) transcripts,
as well as levels of inflammasome component proteins in the alkali-injured corneas compared to
naïve corneas. Treatment with NLRP3 inhibitors using NaB and HBA preserved corneal clarity and
decreased NLRP3, caspase-1, and IL-1β mRNA transcripts, as well as NLRP3 protein expression
on post-injury compared to BSS-treated corneas. These findings identified a novel innate immune
signaling pathway activated by AB. Blocking the NLRP3 pathway in AB mouse model decreases
inflammation, resulting in greater corneal clarity. These results provide a mechanistic basis for
optimizing therapeutic intervention in alkali injured eyes.
Keywords: alkali injury; NLRP3 inflammasome; sodium butyrate; β-hydroxybutyric acid
1. Introduction
Chemical injuries to the eye represent between 11.5% and 22.1% of ocular injuries [1],
often resulting in an aggressive inflammatory response that can impair corneal re-epithelization,
promote keratolysis, and lead to globe perforation at the acute stage. Despite medical and surgical
management, most ocular chemical injuries still result in loss of vision or the eye. It is possible
that the poor therapeutic response stems largely from an incomplete understanding of the host
inflammatory response.
Although the mechanisms initiated in wound healing have not been fully elucidated, there
is increasingly evidence that epithelial cells serve not only as an effective barrier against most
microorganisms, but also are central participants in the bridging of innate and adaptive immunity [2,3].
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The innate immune response relies on evolutionarily ancient germline-encoded receptors, the
pattern-recognition receptors (PRRs). Pattern-recognition receptors are expressed by a variety of
cells to identify microbial pathogens known as pathogen-associated molecular patterns (PAMPs)
and to recognize cell components that are released during cell damage or death known as
damage-associated molecular patterns (DAMPs). The main families of PPRs, Toll like receptors (TLRs)
and nucleotide-binding oligomerization domain-containing protein (NOD)-like receptors (NLRs), have
been shown to be expressed on certain epithelial cells [4]. Airway epithelial cells express a variety
TLRs that help them to sense bacterial, fungal, or viral exposure and respond accordingly by secreting
a large array of molecules that initiate adaptive immune response [5]. Human corneal epithelial cells
also express a variety of TLRs (TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, and TLR9) that may help them
mount an adequate response to microbial exposure and other environment stimuli such as oxidative
and desiccating stress [6–8].
NOD-like receptor family pyrin domain containing 3 (NLRP3), a major inflammatory innate
defense mechanism, participates in inflammasome formation through the recruitment of the adapter
apoptosis-associated speck-like protein (ASC) with subsequent activation of caspase-1, which leads
to secretion of interleukin (IL)-1β or IL-18. NOD-like receptor family pyrin domain containing 3
inflammasome (NLRP3) has been described as an innate sensor of host-derived DAMPs that are
released following tissue injury or cell death to activate pro-inflammatory pathways [9,10]. The role of
the innate immune response of corneal epithelial cells to sterile wounds is still unknown.
Sodium butyrate (NaB) is a fatty acid that is produced by fermentation of dietary fiber by
anaerobic bacteria in the colon [11]. Sodium butyrate has been shown to block inflammasome-mediated
inflammatory disease in experimental models of obesity-induced inflammation [12]. Ketone body
β-hydroxybutyric acid (HBA) has a similar chemical structure as NaB and was also reported to inhibit
NLRP3 activation [12], and has been shown to decrease apoptosis of rat corneal epithelia in dry eye
conditions [13]. Therefore, we hypothesize that alkali burns may activate the inflammasome and
that inhibition of this pathway with NaB and HBA would improve the fate of injured corneas by
suppressing inflammation.
Here, we show that a novel innate immune signaling pathway (NLRP3–ASC–caspase-1–IL-1β) is
activated in corneal epithelial cells by alkali burn. Blocking the NLRP3 pathway reduced inflammation,
leading to improved wound healing and corneal clarity.
2. Results
2.1. Corneal Alkali Burn Upregulates NLRP3 and Adaptor Protein ASC in Corneal Epithelium
To determine the NLRP3 inflammasome expression in the alkali burned cornea, we first assessed
the expression of NLRP3 mRNA transcript by real-time PCR using whole corneas harvested from 2
or 5 days post-alkali burns and naïve corneas as a comparator. As shown in Figure 1A, there was a
remarkable increase in NLRP3 transcripts at two days (up to a 30-fold) and five days (up to a 10-fold)
in wounded corneas compared to normal corneas.
Next, immunoreactivity of corneas to NLRP3 was evaluated by immunostaining (Figure 1B).
Minimal levels of NLRP3 were present in the control corneas, while increased immunoreactivity
against NLRP3 was observed in the corneal epithelium of wounded corneas at both 2 and 5 days
post-alkali burns. Based on the immunostaining results which showed NLRP3 expression exclusively
in the corneal epithelial layer, we repeated the experiment, but only collected corneal epithelium
for western blot. Consistent with PCR and immunostaining results, the protein production levels of
NLRP3 were increased at 2 days post-injury and slightly decreased at 5 days, but remained elevated
compared to the naïve corneas (Figure 1C).
Upon activation, NLRP3 associates with the adaptor protein ASC to recruit pro-caspase-1. In order








Int. J. Mol. Sci. 2017, 18, 562
ASC expression by immunostaining in frozen sections. In contrast to normal control, ASC expression
increased both at 2 and 5 days post-injury (Figure 2).
Figure 1. Upregulation of nucleotide-binding oligomerization domain-containing protein (NOD)-like
receptor family pyrin domain containing 3 (NLRP3) expression by corneal epithelium in animals
subjected to alkali burn (AB) at 2 days (2 d) and 5 days (5 d) post-injury. (A) Gene expression
analysis of NLRP3 messenger mRNA (mRNA) transcript in whole cornea of animals subjected
to alkali burn (n = 8 animals/group). Graphs show means ± standard error of the mean (SEM).
**** p < 0.0001; (B) Representative merged digital images of laser scanning confocal microscopy of
corneas cryosections immunostained for NLRP3 (green) with propidium iodide nuclei counterstaining
(DNA in red) in corneas subjected to alkali burn (images are representative of n = 6 animals/group).
Scale bar: 50 μm; (C) Representative digital images of western blot of NLRP3 and β-actin in cornea
epithelium of animals subjected to alkali burn for 2 and 5 days. Each lane is a different sample
(n = 12 animals/3 samples/group). MW: Molecular weight; UT: untreated control; 2 d and 5 d refer
to mice subjected to alkali burn and euthanized 2 or 5 days post-injury, respectively (1 and 2 indicate
different samples).
These data demonstrate that both NLRP3 and its adaptor protein ASC in cornea epithelial cells are
upregulated following alkali injury, and prompted us to investigate the role of NLRP3 inflammasome
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Figure 2. Upregulation of apoptosis-associated speck-like protein (ASC) in corneal epithelium of
animals subjected to alkali burns (AB) at 2 days (2 d) and 5 days (5 d) post-injury. Representative
merged digital images of laser scanning confocal microscopy in corneal cryosections immunostained
for ASC (green) with propidium iodide nuclei counterstaining (DNA in red) in corneas subjected to
alkali burn (n = 6 animals/group). Scale bar: 50 μm.
2.2. Caspase-1 Activation in Alkali-Injured Corneas
Upon interaction of NLRP3 with ASC, the ASC recruits pro-caspase at the caspase activation and
recruitment domain (CARD), thus forming active inflammasome complexes in response to a variety of
exogenous and endogenous stressors [14,15]. We evaluated the expression of caspase-1 gene in injured
corneas and compared findings with normal corneas. As shown in Figure 3A, alkali-injured corneas
had higher expression of caspase-1 transcripts at both 2 and 5 days compared with normal controls.
Immunoreactivity of corneas to caspase-1 was evaluated by immunostaining (Figure 3B).
Although barely detected in naïve corneas, increased reactivity against caspase-1 was noted in
cornea epithelia of wounded corneas at 2 and 5 days. Caspase-1 activity in the corneal epithelium
demonstrated significantly higher levels of activated caspase-1 at both 2 and 5 days compared to
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Figure 3. Caspase-1 activation in corneal epithelium in animals subjected to alkali burn (AB) at 2 days
(2 d) and 5 days (5 d) post-injury. (A) Gene expression analysis of caspase-1 mRNA transcript in whole
cornea of animals subjected to alkali burn (n = 8 animals/group). Graphs show mean ± standard error
of the mean (SEM); * p < 0.05; (B) Representative merged digital images of laser scanning confocal
microscopy in corneal cryosections immunostained for caspase-1 (green) with propidium iodide nuclei
counterstaining (DNA in red) in animals subjected to alkali burn (n = 6 animals/group). Scale bar:
50 μm; (C) Caspase-1 activity in whole cornea lysates from eyes subjected to alkali burn (n = 12 animals/
3 samples/group). Graphs show mean ± SEM; * p < 0.05, ** p < 0.01.
These results show that caspase-1 is increased and activated in corneal alkali-burned corneas.
Taken together, these findings show that the NLRP3–ASC–caspase-1 inflammasome is assembled in
alkali-injured corneas.
2.3. The NLRP3–ASC–Caspase-1 Inflammasome Directs IL-1β Secretion in Alkali-Injured Corneas
The NLRP3 inflammasome is critical for IL-1β production [16,17]. To investigate whether NLRP3
inflammasome formation can lead to IL-1β production in the alkali corneal burn model, we evaluated
the expression of IL-1β in wounded corneas by PCR and immunostaining. As shown in Figure 4A,
wounded corneas had higher expression of IL-1β mRNA at 2 and 5 days compared to naïve corneas.
Consistent with PCR results, increased reactivity to IL-1β in the corneal epithelium was seen in
wounded corneas at 2 and 5 days.
Taken together, our results demonstrated that NLRP3 inflammasome is involved in corneal alkali
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Figure 4. Upregulation of interleukin (IL)-1β in corneal epithelium in animals subjected to alkali
burns (AB) at 2 days (2 d) and 5 days (5 d) post-injury. (A) Gene expression analysis of IL-1β mRNA
transcripts in whole corneas of eyes subjected to alkali burn (n = 8 animals/group). **** p < 0.0001;
(B) Representative merged digital images of laser scanning confocal microscopy in corneal cryosections
immunostained for IL-1β (green) with propidium iodide nuclei counterstaining (DNA in red) in corneas
subjected to alkali burn (n = 6 animals/group). Scale bar: 50 μm.
2.4. Sodium Butyrate and β-Hydroxybutyric Acid Topical Treatment Inhibits Activation of NLRP3
Inflammasome in Alkali-Injured Corneas
Recent studies described NaB and HBA as inhibitors of NLRP3 inflammasome that can inhibit
IL-1β release and reduce inflammation [12,18,19]. To test the hypothesis that blocking NLRP3 would
improve clinical parameters and reduce inflammation, alkali-burned corneas were treated with either
NaB, HBA, or vehicle for 2 or 5 days post-injury. To compare the relative potency of these molecules,
a group of alkali-injured corneas treated with dexamethasone (Dex) was also included, as our previous
study showed that Dex is very efficacious in preserving corneal clarity and suppressing inflammation
in the most severe model of alkali burn and dry eye [20].
Since there is no evidence of the safety of NaB and HBA application on the ocular surface, NaB
and HBA toxicity to the corneal epithelium was first investigated by topically applying NaB or HBA
eyedrops quater in die (QID) in naïve mice. Corneal epithelial integrity was assessed using corneal
fluorescein staining after 5 days. As shown in Figure 5A, naïve corneas that received NaB or HBA for
5 days had no corneal epithelial defect, indicating that both HBA and NaB were safe to use in vivo.
Next, mice were subjected to alkali burn (AB) and topically treated with NaB, HBA, or BSS
(QID), and clinical parameters of cornea opacity and wound healing were evaluated on a daily basis.
Representative color digital images used to score corneal opacity (top row) and fluorescein stained
corneas used to measure wound closure rate (bottom row) are shown in Figure 5B. At 5 days post-injury,
HBA treated corneas had significantly higher wound closure rate (Figure 5C) and both NaB and HBA
treated corneas had lower corneal opacity scores (Figure 5D) compared to vehicle controls, respectively.
β-hydroxybutyric acid-treated corneas healed significantly faster than vehicle treated corneas, with
100% wound closure at 4 days post-injury.
To determine if blocking NLRP3 inflammasome can suppress inflammation in alkali-injured
corneas, the expression of NLRP3, caspase-1, and IL-1β mRNA transcripts in alkali burned corneas
treated with NaB or HBA were evaluated using real-time PCR and compared with vehicle-treated
corneas. Polymerase chain reaction results showed that both NaB treatment and HBA treatment after
alkali burn significantly decreased NLRP3, caspase-1, and IL-1β mRNA transcripts at both 2 and
5 days compared to BSS-treated corneas (Figure 5E). Western blot confirmed the real-time PCR results
with decreased protein expression of NLRP3 in corneal epithelia in AB + HBA and AB + NaB groups
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Alkali-burned corneas treated with Dex showed significant improvement in corneal opacity
(Figure 5A–C), and impressive decreases in inflammatory cytokines (Figure 5E). Although the
anti-inflammatory effect of Dex was greater than NaB and HBA, NaB and HBA treatment can decrease
corneal opacity scores to the level of Dex treated groups, indicating that NaB and HBA are very
efficacious in preserving corneal clarity. These data indicated that blocking the NLRP3 inflammasome
pathway using NaB and HBA drops improves clinical parameters and decreases inflammation in
animals subjected to alkali burns at 2 and 5 days post-injury.
Figure 5. Sodium butyrate (NaB) and hydroxybutyric acid (HBA) eyedrops improve clinical parameters
and decrease inflammation in animals subjected to alkali burns (AB). (A) Digital images of corneas
stained with 0.1% sodium fluorescein demonstrating intact corneal epithelium after topical NaB, HBA
or balanced salt solution (BSS) treatment for 5 days quater in die (QID) in untreated mice (n = 5
animals/group). Scale bar: 1000 μm; (B) Representative color digital images used to score corneal
opacity (top row) and representative fluorescein stained corneas used to create wound closure rate
(bottom row) at 5 days (n = 15 animals/group) after alkali burn. Scale bar: 1000 μm; (C) Corneal
opacity in corneas subjected to alkali burn and topically treated with either NaB, HBA, or BSS and
compared with dexamethasone (Dex) (n = 15 animals/group); (D) Wound closure rate in corneas
subjected to alkali burn and topically treated with either NaB, HBA, or BSS and compared with Dex
(n = 15 animals/group); (E) Mean ± SEM of results of gene expression analysis of NLRP3, Caspase-1,
and IL-1β in whole cornea of animals subjected to alkali burn for 2 or 5 days and topically treated
with either NaB, HBA, or BSS and compared with Dex (n = 5 animals/group). * p < 0.05, *** p < 0.001,
**** p < 0.0001. (F) Representative digital images of western blot of NLRP3 and β-actin in cornea
epithelium of animals subjected to alkali burn for 2 days and topically treated with either NaB, HBA,
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3. Discussion
In the present study, we demonstrated that corneal epithelial cells participated in innate immunity
through the NLRP3–ASC–caspase-1–IL-1β pathway in response to sterile corneal injuries. Blocking the
NLRP3 pathway with NaB and HBA in the injured corneas can suppress inflammation and preserve
cornea clarity post injury.
Damage to the cornea from an ocular chemical burn is severe, leading to overwhelming sterile
inflammatory responses, and corneal epithelial defects or sterile corneal ulceration at the acute stage.
The role of corneal epithelium in this inflammatory cascade has not been established. Studies have
shown that epithelial cells play a vital role in innate immunity by expressing the main families of
PPRs, including TLRs and NLRs, in response to various ocular surface stimuli [6–8]. In the context of
infection, Pseudomonas aeruginosa flagellin elicits inflammatory response of corneal epithelium through
the TLR5–nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling pathway [7].
Human corneal epithelial cells exposed to Aspergillus fumigatus can trigger innate immune response
via activating NOD 1 receptors on human corneal epithelial cells, leading to the secretion of IL-6, IL-8,
and tumor necrosis factor-α (TNF-α). NOD1 knockdown attenuated Aspergillus fumigatus triggered
expression of IL-6, IL-8, and TNF-α [4].
It is now evident that PPRs can recognize endogenous molecules that are released during cellular
injury termed DAMPs. Damage-associated molecular patterns released by dying cells can stimulate
severe inflammation [21]. How corneal epithelial cells response to DAMPs and how this process affects
the immune network has not been fully elucidated. The NLRP3 inflammasome has been described
as an innate sensor of host-derived DAMPs that are released following tissue injury or cell death
to activate pro-inflammatory pathways [9]. NOD-like receptor family pyrin domain containing 3 is
expressed by hematopoietic and non-hematopoietic cells, such as keratinocyte and osteoblasts. In this
study, we showed that the naïve corneal epithelial cells express low levels of NLRP3, while wounded
corneal epithelium upregulated NLRP3 expression, indicating that NLRP3 participates in the wound
healing process of a sterile corneal injury in response to DAMPs.
NOD-like receptor family pyrin domain containing 3 contains domains that can interact
with adaptor protein ASC which has a CARD to recruit pro-caspase-1, thus forming the
inflammasome [22–24]. Once activated, the NLRP3 inflammasome causes the activation of caspase-1
by cleaving pro-IL-1β into biologically active IL-1β. The adaptor protein ASC and pro-caspase-1 are
also crucial to induce caspase-1 activation. Shrikant et al. [25] showed that calcium oxalate crystals
induce renal inflammation by NLRP3 mediated IL-1β secretion. Interleukin-1β secretion was found
to be reduced in NLRP3−/−, ASC−/−, and Caspase-1−/− mice. In our study, low levels of ASC and
caspase-1 were found in naïve mouse corneas, while there was remarkably increased expression of ASC
and caspase-1 in the wounded corneal epithelium, suggesting the activation of NLRP3 inflammasome
in the corneal epithelia in response to corneal alkali injuries.
NOD-like receptor family pyrin domain containing 3 inflammasome has been implicated in the
pathogenesis of many eye diseases. Zheng and colleagues [26] showed that reactive oxygen species
induced NLRP3 expression by the corneal epithelium in a dry eye mouse model. We have also
reported that NLRP3 and NLRC4 inflammasomes were activated in cultured human corneal epithelial
in response to hyperosmolar stress [27]. In the context of infection, Staphylococcus aureus activates the
NLRP3 inflammasome in human and rat conjunctival goblet cells [28]. In patients with age-related
macular degeneration (AMD), increased mRNA levels of NLRP3, IL-1β, and pro-IL-18 in lesions of the
retinal pigment epithelium and photoreceptors were detected [29]. Activation of NLRP3 inflammasome
also contributed to retinal ganglion cell death following partial optic nerve crush injury [24] in a mouse
model, while NLRP3 deficient mice have significantly reduced neuroinflammation and delayed retinal
ganglion cell loss. Therefore, inhibiting NLRP3 assembly would be a novel therapeutic approach to
limit many diseases, including eye diseases.
Recently, studies of targeted anti-NLRP3 therapy have opened a new chapter in the treatment
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alternative energy source during fasting or exercise. However, in vivo and in vitro studies have
demonstrated that HBA is more than just a metabolite. It has important cellular signaling roles as well.
Youm et al. [19] reported HBA specifically inhibits NLRP3 inflammasome activation and decreases the
production of active IL-1β and IL-18. Sodium butyrate has a similar chemical structure to HBA and
also has been reported to inhibit the NLRP3 pathway [12]. To investigate if blocking NLRP3 pathway
activation in injured corneas can improve clinical parameters and suppress inflammation, we used
NaB and HBA topically in the alkali-burned eyes and evaluated corneal wound healing and corneal
clarity, as well as the expression of NLRP3, caspase-1, and IL-1β in the burned corneas, and compared
results with vehicle and Dex treated corneas. Dexamethasone therapy has been proven to be very
efficacious in preserving corneal clarity and suppressing inflammation [20]. In this study, we observed
that HBA and NaB treatment can preserve cornea clarity at a similar level to Dex treated corneas,
indicating that HBA and NaB are efficacious in preserving corneal clarity. In agreement with a study
by Nakamura et al. [13] who showed that HBA has a protective effect on corneal epithelia in dry eye
conditions, our results showed HBA can promote wound healing at 5 days post-injury. In addition
to the improvement of clinical parameters, the expression of the key component of NLRP3 pathway
also decreased in HBA and NaB treated corneas. Thus, our results suggest that blocking the NLRP3
pathway leads to improved clinical parameters and suppresses inflammation.
In conclusion, this study reveals that the NLRP3 expressed by corneal epithelial cells may respond
to DAMPs released after sterile corneal injury, leading to the production of IL-1β via the innate immune
signaling pathway (NLRP3–ASC–caspase-1–IL-1β). We have shown for the first time that NLRP3
inflammasome is involved in the sterile corneal injury and provided mechanistic and therapeutic
considerations. Inhibiting NLRP3 assembly would be a novel therapeutic approach to limit cornea
damage after alkali burns.
4. Materials and Methods
4.1. Animals
All animals were treated in accordance with the Association of Research in Vision and
Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research, and
the protocols were approved by the Baylor College of Medicine Institutional Animal Care and Use
Committee (IACUC protocol number AN-5076, first approved on 24 October 2011). Female C57BL/6J
mice (6–8 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA).
4.2. Unilateral Alkali Burn
After systemic anesthesia with isoflurane using a vaporizer (SomnoSuite; Kent Scientific,
Torrington, CT, USA), a unilateral alkali burn was created on the right eye of 6- to 8-week-old
C57BL/6 mice. This was achieved by placing one 2-mm diameter filter paper disc that had been
presoaked with 1 N NaOH on the central cornea for 10 s, followed by extensive rinsing with balanced
salt solution (Alcon, Fort Worth, TX, USA), as previously described [20]. Precautions were taken to
avoid damage to the peripheral cornea, conjunctiva, and lids. Alkali burn was created at day 0 and
animals were euthanized 2 or 5 days post-injury.
4.3. Histology and Immunostaining
For immunohistochemistry, eyes and adnexae from each group/time point (n = 6/group) were
excised, embedded in optimal cutting temperature compound (VWR, Suwanee, GA, USA), and flash
frozen in liquid nitrogen. Sagittal 8 μm tissue sections were cut with a cryostat (HM 500; Micron,
Waldorf, Germany) and placed on glass slides that were stored at −80 ◦C.
Immunofluorescent staining was performed in frozen tissue sections with rat monoclonal antibody
anti-NLRP3 (MAB7578, 10 μg/mL, R&D Systems, Minneapolis, MN, USA), anti-ASC (SC-22514-R,
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Biotechnology, Dallas, TX, USA), and goat anti-IL-1β (1:50 dilution, #12426, Cell Signaling Technology,
Beverly, MA, USA). Secondary goat anti-rabbit or donkey anti-goat Alexa Fluor 488-conjugated
antibodies were used, as previously described [30]. The images were captured and photographed by a
laser scanning confocal microscope (LSM 510, with Kr–Ar and He-Ne laser; Carl Zeiss Meditec, Inc.,
Thornwood, NY, USA).
4.4. RNA Isolation and Quantitative PCR
Whole corneas or corneal epithelium (n = 4/group per experiment; total of eight corneas/group)
were collected and minced, and total RNA was extracted using a Qiagen MicroPlus RNeasy isolation
Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions, quantified by a
NanoDrop ND-2000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA), and stored
at −80 ◦C. First-strand complement DNA was synthesized with random hexamers by M-MuLV reverse
transcription (Ready-To-Go You-Prime First-Strand Beads; GE Healthcare, Inc., Arlington Heights, NJ,
USA), as previously described [20].
Real-time PCR was performed with specific Taqman MGB probes (Applied Biosystems, Inc.,
Foster City, CA, USA) and PCR master mix (Taqman Gene Expression Master Mix), in a commercial
thermocycling system (StepOnePlus Real-Time PCR System, Applied Biosystems, Inc.), according to the
manufacturer’s recommendations. Quantitative real time PCR was performed using gene expression
assay primers and probes specific for murine targets, as described in Table 1. The β-2-microglobulin
(B2M) gene was used as an endogenous reference for each reaction to correct for differences in the
amount of total RNA added. The results of quantitative PCR were analyzed by the comparative cycle
threshold (CT) method where the target change equals 2–ΔΔCT. The results were normalized by the CT
value of B2M and the relative mRNA level in the untreated group was used as the calibrator.
Table 1. Oligonucleotide primers used for real-time PCR.




NLR family, pyrin domain containing 3 NLRP3 Mm00840904
* Identification number from Thermo Fisher Scientific [31].
4.5. Caspase-1 Activation Fluorometric Assays
The activation of caspase-1 was measured in corneal epithelial lysates according to the
manufacturer’s protocol (K110-200, BioVision, Inc., Mountain View, CA, USA). One sample was
pooled from four right corneas and there were a total of three samples per time point. Total protein
concentration was measured by the bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific,
Waltham, MA, USA), as previous described [32]. Three samples per group were used. Caspase-1
activities were measured (50 μg/sample) by following the cleavage of the fluorescent substrate
analogs in a fluorescent plate reader (Tecan Infinite M200, Magellan V6.55 software, Tecan, Männedorf,
Switzerland) with 400 nm excitation filter and 505 nm emission filter. The results were exported
and averaged.
4.6. Western Blot
Corneal epithelium was scraped with a scalpel and placed in 100 μL RIPA buffer (R0278;
Sigma–Aldrich, St. Louis, MO, USA) with protease inhibitor cocktail (11836170001, Roche, Basel,
Switzerland). One sample was pooled from four right corneas and there were a total of three samples
per time point. A BCA assay was performed to measure total protein concentration of each sample.
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(2X Laemmli Sample Buffer, 161-0737; Bio-Rad Laboratories, Inc., Hercules, CA, USA), boiled for
5 min, and loaded on to the polyacrylamide gel. The gel (mini-PROTEAN TGX stain free Precast
Gel 7.5%, 456-8024; Bio-Rad laboratories, Inc., Hercules, CA, USA) was run at constant current at
100V for approximately 90 min at room temperature before the proteins were transferred onto a
polyvinylidene difluoride (PVDF) membrane (Immobilion Transfer membranes, IVPH07850; Millipore,
Billerica, MA, USA) at 20 V over night at 4 ◦C. Next, the membranes were incubated in 100 mM
Tris-HCl, 0.9% NaCl, 0.1% Tween 20 (TTBS) with 5% fat-free milk for 60 min, followed by incubation
in primary antibody NLRP3 (MAB7578, 2 μg/mL, R&D Systems, Minneapolis, MN, USA) or β-actin
(#4970, 1 μg/mL, Cell Signaling technology, Beverly, MA, USA) overnight at 4 ◦C. Subsequently,
the membranes were washed in TTBS and incubated in secondary horseradish peroxidase goat
anti-rat (629520; Thermo Fisher Scientific), then washed again with TTBS, and finally, developed
and photographed.
4.7. Treatment Regimen
Mice subjected to corneal alkali burn were topically treated either with 2 μL of sodium butyrate
(0.5 Mm, Sigma–Aldrich), 2 μL of hydroxybutyric acid (80 mM, Sigma–Aldrich), sodium phosphate
dexamethasone (0.1%, Spectrum Laboratory, Gardena, CA, USA), or vehicle (balanced salt solution,
Alcon, Fort Worth, TX, USA) QID for 2 or 5 days. These doses were chosen based on published
manuscripts [12,13,19,33] and also based on our pilot studies.
4.8. Clinical Findings: Opacity Score
Biomicroscopic examination was used to grade corneal edema and opacity by two masked
observers in images taken by a color digital camera DS-Fi1 (Melville, NY, USA) by the way described
by Yoeruek (2008) [34]. Corneal opacity was scored using a scale of 0–4 where grade 0 represented
completely clear conditions; grade 1 slightly hazy, iris, and pupils easily visible; grade 2 slightly opaque,
iris, and pupils still detectable; grade 3 opaque, pupils hardly detectable, and grade 4 completely
opaque with no view of the pupils.
4.9. Measurement of Corneal Epithelial Defect
Corneal epithelial healing was assessed daily in the experimental groups (four mice per group per
experiment; three sets of experiments). Briefly, 1 mL of 0.1% liquid sodium fluorescein was instilled
onto the ocular surface. Corneas were rinsed with phosphate-buffered saline and photographed with a
stereoscopic zoom microscope (SMZ 1500; Nikon, Melville, NY, USA) under fluorescence excitation at
470 nm (digital camera DS-Qi1Mc, Nikon). Corneal epithelial defect area was graded in digital images
by two masked observers in a categorical manner (present/absent) to generate a survival curve [35].
Biological replicate scores were transferred to an Excel database (Microsoft, Redmond, WA, USA) and
results analyzed.
4.10. Number of Animals and Statistical Analysis
One hundred and thirty-three C57BL/6J mice were used in this study. Fifty-eight animals were
used per time point (2 and 5 days): 6 for histology, 16 for real-time PCR, 12 for caspase-1 activity assay,
and 24 for western blot. Contralateral eyes in the alkali burn group were used as untreated controls.
Fifteen naïve mice were used to evaluate drug toxicity.
Results are presented as the mean ± SEM. One-way analysis of variance (ANOVA) with Bonferroni
post hoc testing was used for statistical comparisons of gene expression. p ≤ 0.05 was considered
statistical significant. These tests were performed using GraphPad Prism 6.0 software (GraphPad
Incorporation, San Diego, CA, USA).
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NOD nucleotide-binding oligomerization domain-containing protein
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Abstract: Centella asiatica has potent antioxidant and anti-inflammatory properties. However, its
anti-dermatitic effect has not yet been reported. In this study, we investigated the anti-dermatitic
effects of titrated extract of Centella asiatica (TECA) in a phthalic anhydride (PA)-induced atopic
dermatitis (AD) animal model as well as in vitro model. An AD-like lesion was induced by the
topical application of five percent PA to the dorsal skin or ear of Hos:HR-1 mouse. After AD
induction, 100 μL of 0.2% and 0.4% of TECA (40 μg or 80 μg/cm2) was spread on the dorsum of the
ear or back skin three times a week for four weeks. We evaluated dermatitis severity, histopathological
changes and changes in protein expression by Western blotting for inducible nitric oxide synthase
(iNOS), cyclooxygenase-2 (COX-2), and NF-κB activity, which were determined by electromobility
shift assay (EMSA). We also measured TNF-α, IL-1β, IL-6, and IgE concentration in the blood
of AD mice by enzyme-linked immunosorbent assay (ELISA). TECA treatment attenuated the
development of PA-induced atopic dermatitis. Histological analysis showed that TECA inhibited
hyperkeratosis, mast cells and infiltration of inflammatory cells. TECA treatment inhibited expression
of iNOS and COX-2, and NF-κB activity as well as the release of TNF-α, IL-1β, IL-6, and IgE.
In addition, TECA (1, 2, 5 μg/mL) potently inhibited Lipopolysaccharide (LPS) (1 μg/mL)-induced
NO production, expression of iNOS and COX-2, and NF-κB DNA binding activities in RAW264.7
macrophage cells. Our data demonstrated that TECA could be a promising agent for AD by inhibition
of NF-κB signaling.
Keywords: titrated extract of Centella asiatica; skin inflammation; atopic dermatitis; NF-κB;
cytokine; IgE
1. Introduction
Atopic dermatitis (AD) is a common chronic inflammatory skin disease inducing intense itching,
edema, erythema, thickening, severe pruritus, and eczematous lesions of the skin. Several genetic and
environmental factors and immune responses are implicated for the development of AD [1]. Elevated
production of serum IgE against many kinds of inhaled allergens and secretion of T helper (Th) 2
cytokines are the main causes of AD [2,3]. Mast cell activation mediated by IgE leads to a release of
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various chemical mediators which results in infiltration of inflammatory cells such as eosinophils and
lymphocytes into the skin lesion [4]. CD4+ T cells and mast cells in the skin lesions are also involved
in the pathogenesis of AD [5–8]. It has been reported that 2,4-dinitrochlorobenzene (DNCB)-induced
AD-like skin lesion mouse model showed increased serum IgE and Th2 cytokines such as IL-4, IL-5,
and IL-13 [9,10]. These cytokines have direct effects on epidermal keratinocytes, which produce
pro-inflammatory cytokines that induce infiltration of immune cells into inflammatory skin lesions [11].
These data indicate that inflammation and activation of immune cells could be significant for the
development of AD.
Nuclear factor-κB (NF-κB) is an important transcription factor associated with the allergic
inflammatory response in AD. Many studies have shown that NF-κB is an important factor in the
regulation of various immune responses in allergic disorders such as AD, asthma, and rheumatoid
arthritis [12–14]. Since the activation of NF-κB may exacerbate the allergic inflammation by enhancing
the production of inflammatory cytokines and chemokines, various methods have been developed to
inhibit NF-κB activation. Moreover, NF-κB inhibitor, IMD-0354 inhibited abnormal proliferation of
mast cells, and reduced the allergic response [15]. Potent immunosuppressive drugs such as tacrolimus,
corticosteroids, and cyclosporine have been studied as therapeutic agents for AD through inhibition of
cytokine production [16]. However, these agents cause severe reverse effects such as tachyphylaxis,
recurrence, and exacerbation of AD [17,18]. Thus, other new drugs showing no side effects with strong
pharmacological properties could be developed.
Centella asiatica, known by the common name Gotu kola, is a traditional herbal medicine that has
been used to exert pharmacological effects in dermatology [19]. The Centella asiatica herb is used in the
treatment of skin lesions such as burn wounds, excoriations, or eczema as well as in non-dermatological
diseases such as diabetic complications [20], and neurodegenerative disorders [21]. Centella asiatica
has also been effective in chronic venous insufficiency by improvement of microcirculation [22].
The Centella asiatica extract was registered in International Nomenclature of Cosmetic Ingredients
(INCI) as an ingredient of cosmetics [23]. Although various pharmacological effects of Centella asiatica
have been reported, its anti-dermatitic effect has not yet been reported. Therefore, we investigated
the anti-dermatitic effects of titrated extract of Centella asiatica and action mechanism in a phthalic
anhydride-induced atopic dermatitis animal model as well as in vitro model.
2. Results
2.1. Effects of TECA Treatment on Ear Thickness and Morphology
Changes in body weight were measured during the experimental period. No significant difference
in body weight was detected after any of the treatments (Figure 1A). To investigate whether or not
treatment with TECA can suppress the changes in ear phenotype induced by PA treatment, ear
thickness and morphology of ear were observed. Ear thickness rapidly increased in PA treated mice
compared to control or vehicle treated mice. On the other hand, ear thickness in TECA treated mice
was slowly increased in a dose-dependent manner (Figure 1B). Furthermore, symptoms consisting of
erythma, edema, and erosion were observed in the PA treated group compared with the control or
vehicle treated group. These changes of ear and back morphology and ear thickness were dramatically
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Figure 1. Differences in body weight, ear thickness, ear phenotypes, and back phenotypes. Phthalic
anhydride (PA) solution was repeatedly applied to the dorsum of ear and back three times a week
during topical application of Titrated extract of Centella asiatica (TECA). After four weeks, body weight
(A) and ear thickness (B) were observed at least three times by following the procedure described in
Materials and Methods. Phenotypes (C) were randomly selected by one mouse/group. Data shown
are the mean ± SD (n = 10).
2.2. Effect of TECA Treatment on Lymph Node Weight and IgE Concentration as Well as on Expression of
iNOS and COX-2
We investigated whether or not TECA could suppress the increases in lymph node weight and
IgE concentration. To accomplish this, we evaluated the auricular lymph node weight and serum IgE
concentration. PA treatment induced an increase in lymph node weight compared with control or
vehicle treated mice. However, the weight of lymph node was significantly reduced in the TECA treated
mice (Figure 2A). In addition, protein expressions of iNOS and COX-2 were significantly upregulated
in PA treated AD mice, but significantly suppressed by TECA 0.4% treatment (Figure 2B). It is well
known that hyperproduction of IgE is one of the characteristic features of allergic hypersensitivity
as well as an indicator of the magnitude of the allergic immune responses in the development of
AD [24]. The serum IgE concentration was measured in the blood of mice to determine whether
TECA suppressed the allergic responses induced by PA treatment. Repeated topical application of PA
solution induced a significant increase in serum IgE concentration. However, a significant decrease of
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Figure 2. Changes in auricular lymph node weight, expression level of iNOS and COX-2 protein in
lymph node, and serum cytokine concentration. After final treatment, mice from each group were
sacrificed under anesthesia. The auricular lymph nodes were then harvested from the neck regions of
the mice using a microscissor, after which they were weighed (A); Alteration of the expression of the
two proteins was measured by Western blotting (B); Serum used to measure the cytokine concentration
was prepared from blood samples collected from the abdominal veins of mice. Serum IgE (C), TNF-α,
IL-6, and IL-1β (D) concentration were quantified by enzyme-linked immunosorbent assay (ELISA).
Data shown are gained from the same mice treated shown in Figure 1. Data shown are the mean ± SD
(n = 10). * p < 0.05 is the significance level compared to the control group. # p < 0.05 is the significance
level compared to the PA treated group.
2.3. Effect of TECA Treatment on the Release of Inflammatory Cytokines
To determine if TECA treatment could induce alterations in the inflammatory cytokines release in
PA-induced skin inflammation, the level of TNF-α, IL-6, and IL-1β was measured in mouse serum of
control, vehicle, PA and PA + TECA treated group. The level of TNF-α, IL-6, and IL-1β was generally
higher in the PA treated group than the control or vehicle treated group. However, these levels in the
TECA treated group were dramatically decreased to the level of the control or vehicle treated group
(Figure 2D).
2.4. Effect of TECA Treatment on Inflammatory Responses in Ear and Back
To investigate the suppressive effect of TECA treatment on ear and back histology, histological
analysis of the ear and back skin were performed (Figures 3A and 4A). The epidermis and dermis of
the ear (Figure 3B), and the epidermis of the back (Figure 4B) were thicker in PA treated group than
in the control or vehicle treated group. However, the thickness of them was greatly decreased in the
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were significantly upregulated in PA treated AD mice, but significantly suppressed by TECA 0.4%
treatment (Figures 3C and 4C).
 
Figure 3. Histopathological analysis of ear tissue and the inhibitions of NF-κB DNA binding activity
by topical application of TECA in ear skin. Histopathology of ear skin in control (A-1), vehicle (A-2),
PA (A-3), PA + TECA 0.2% (A-4), and PA + TECA 0.4% (A-5). PA solution was repeatedly applied to
the dorsum of ears during topical application of TECA. Histopathological changes in the slide sections
of ear tissue were identified by staining with hematoxylin and eosin followed by observation at 200×
magnification (Scale bars, 100 μm). (A) Histological images and (B) thickness of the epidermis and
dermis. Alteration of the expression of iNOS and COX-2 proteins were measured by Western blotting
(C); (D) Effect of TECA on NF-κB DNA binding activity in ear skin. The activation of NF-κB was
investigated using electromobility shift assay (EMSA) as described in Materials and Methods. Nuclear
extracts from homogenized ear skin tissue were incubated in binding reactions of 32P-end-labeled
oligonucleotide containing the NF-κB sequence (numbers: relative expression). (E) Effect of TECA on
translocation of the subunits of NF-κB (p50 and p65) into nucleus, and phosphorylation of IκBα in
cytosol in ear skin. Equal amounts of nuclear proteins (20 μg/lane) or total proteins (20 μg/lane) were
subjected to 10% SDS-PAGE, and expression of p50, p65, IκBα, and p-IκBα protein were detected by
Western blotting using specific antibodies. Histone h1 protein and β-actin protein were used here as an
internal control. Data shown are gained from the same mice treated shown in Figure 1. Data shown are
the mean ± SD (n = 10). * p < 0.05 is the significance level compared to the control group. # p < 0.05 is
the significance level compared to the PA treated group.
2.5. Effect of TECA on NF-κB DNA Binding Activity in PA-Induced AD Mice
NF-κB is implicated for inflammatory responses in AD model. To investigate whether TECA
can inhibit NF-κB activation in PA-induced AD model, nuclear extracts from ear and back skin tissue
were prepared and assayed with NF-κB DNA binding by EMSA. PA treated mice showed significant
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NF-κB binding activity in TECA treated mice was significantly inhibited when compared with PA
treated mice (Figures 3D and 4D). In addition, as shown in Figures 3E and 4E, PA treated mice showed
significant IκBα degradation in cytosolic fraction when compared to the control group in both ear and
back skin. On the contrary, IκBα degradation in TECA treated mice was reduced significantly when
compared with PA treated mice. PA treated mice also showed increase in the relocalization of p65
and p50 in nucleus. In contrast, TECA inhibited translocation of p65 and p50 into the nuclear in a
dose-dependent manner (Figures 3E and 4E).
Figure 4. Histopathological analysis of back tissue and the inhibitions of NF-κB DNA binding activity
by topical application of TECA in back skin. Histopathology of back skin in control (A-1), vehicle (A-2),
PA (A-3), PA + TECA 0.2% (A-4), and PA + TECA 0.4% (A-5). PA solution was repeatedly applied
to the back skin during topical application of TECA. Histopathological changes in the slide sections
of back tissue were identified by staining with hematoxylin and eosin followed by observation at
200× magnification (Scale bars, 100 μm). (A) Histological images and (B) thickness of the epidermis.
Alteration of the expression of iNOS and COX-2 proteins were measured by Western blotting (C);
(D) Effect of TECA on NF-κB DNA binding activity in back skin. The activation of NF-κB was
investigated using EMSA as described in Materials and Methods. Nuclear extracts from homogenized
back skin tissue were incubated in binding reactions of 32P-end-labeled oligonucleotide containing the
NF-κB sequence (numbers: relative expression); (E) Effect of TECA on translocation of the subunits of
NF-κB (p50 and p65) into nucleus, and phosphorylation of IκBα in cytosol in back skin. Equal amounts
of nuclear proteins (20 μg/lane) or total proteins (20 μg/lane) were subjected to 10% SDS-PAGE, and
expression of p50, p65, IκBα, and p-IκBα protein were detected by Western blotting using specific
antibodies. Histone h1 protein and β-actin protein were used here as an internal control. Data shown
are gained from the same mice treated shown in Figure 1. Data shown are the mean ± SD (n = 10).
* p < 0.05 is the significance level compared to the control group. # p < 0.05 is the significance level
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2.6. Effect of TECA on LPS-Induced NO Production, and iNOS and COX-2 Expression in RAW264.7 Cells
The effect of TECA on LPS-induced NO production in RAW264.7 cells was investigated by
measuring the released nitrite in the culture medium by Griess reaction. After co-treatment with LPS
and TECA (1, 2, 5 μg/mL) for 24 h, LPS-induced elevation of nitrite concentration in the medium were
decreased in a concentration-dependent manner (Figure 5A). In addition, we determined iNOS and
COX-2 expression by Western blot analysis. As shown in Figure 5B, LPS-induced iNOS and COX-2
expression were significantly inhibited by TECA (1, 2, 5 μg/mL) in a concentration-dependent manner.
Figure 5. Effects of TECA on LPS-induced NO production, and iNOS and COX-2 expression in
RAW264.7 cells. RAW 264.7 cells were pre-treated with different concentration (1, 2, and 5 μg/mL)
of TECA for 2 h and then stimulated with LPS (1 μg/mL) for 24 h. Effect of TECA on LPS-induced
NO production was measured by the Griess reaction as described in Materials and Methods (A); The
expression of iNOS and COX-2 after stimulated 24 h was determined by Western blot (B); Effect of TECA
on LPS-indcued NF-κB DNA binding activity was measured by EMSA as described in Materials and
Methods (C); Effects of TECA on LPS-induced phosphorylation of IκBα in cytosol, and translocation of
the subunits of NF-κB (p50 and p65) into nucleus were measured by Western blot (D). Data shown
are gained from the same mice treated shown in Figure 1. Data shown are the mean ± SD (n = 10).
* p < 0.05 is the significance level compared to the control group. # p < 0.05 is the significance level
compared to the PA treated group.
2.7. Effect of TECA on NF-κB DNA Binding Activity in RAW 264.7 Cells
Because activation of NF-κB is critical for induction of both iNOS and COX-2 by LPS or
other inflammatory cytokines, we determined whether TECA might suppress NF-κB activation in
LPS-activated RAW264.7 cells. RAW264.7 cells were co-treated with LPS and TECA for 1 h, respectively,
which is the time to activate NF-κB maximally from its LPS treatment (data are not shown). Nuclear
extracts from co-treated cells were prepared and assayed NF-κB DNA binding by EMSA. In RAW264.7
cells, LPS induced a strong NF-κB binding activity, which was markedly inhibited by co-treatment
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effect of TECA on the translocation of NF-κB subunit and IκB phosphorylation. Consistent with
the inhibitory effect on NF-κB activity, nuclear translocation of p65 and p50 was inhibited in a
concentration-dependent manner, and the LPS-induced phosphorylation of IκBα was also inhibited by
TECA in a concentration-dependent manner (Figure 5D).
3. Discussion
Topical application of corticosteroids have been used for the treatment of AD because of their
great anti-inflammatory and anti-allergic activities [25]. However, they cause irreversible side effects
from long-term usage such as common pathogenic infections and immune suppression [26]. For this
reason, usage of natural products including various plants, herbs, flowers, yeasts, and fungi is being
emphasized as anti-inflammatory and anti-allergic agents. AD is characterized by skin inflammation
with eczema-like lesions, itching, and dry skin [27]. In an experimental model, the thickness of
ear, epidermis and dermis were important indexes to evaluate the severity of skin inflammation.
We found that TECA effectively reduces the skin inflammation and allergic responses induced
by PA treatment. In in vitro assay, we also found that TECA inhibited LPS-induced inflammatory
responses. It was proven that Centella asiatica has an excellent effect on deposition of extracellular
matrix proteins. It stimulates proliferation of fibroblasts, increases the synthesis of collagen, decreases
metalloproteinases activity and thus increases the deposition of collagen and intracellular free proline
levels [28–31]. It also inhibits the inflammatory phase of wound healing [32]. TECA contains asiatic
acid (30%), madecassic acid (29–30%), and asiaticoside (40%). The influence of asiatic acid, madecassic
acid, and asiaticoside on human skin fibroblast type I collagen synthesis was also found [33]. In a recent
study, it was reported that components of Centella asiatica, asiaticoside and madecassoside possess
wound healing, collagen synthesis, as well as vasodilation activities [34]. These effects are associated
with the reduced activation of macrophages and the production of IL-1β [35]. Furthermore, it has been
reported that the component of Centella asiatica, madecassic acid, plays a role in anti-inflammatory
activity through the downregulation of iNOS and COX-2 expression and TNF-α, IL-1β, and IL-6
release in RAW264.7 macrophage cells [36]. Centella asiatica applied in the recommended doses is not
toxic and possible side effects are rare [19]. These data thus indicate that TECA could be applicable
for AD.
It is well known that macrophages play an important role in both acquired and nonspecific
immune responses. Activation of macrophage leads to various series of responses including the
production of pro-inflammatory cytokines which exert their inflammatory effects by activating a
diverse spectrum of signaling cascades in the cells that lead to the induction of inflammatory genes
such as iNOS and COX-2 [37]. In this study, PA-induced expression of iNOS and COX-2 was also
reduced by TECA in the skin as well as cultured macrophage. IgE-induced activation of mast cells,
which resulted in the release of various allergic mediators such as cytokines and histamine [38].
Therefore, the low level of IgE induces lesser allergic responses, and reduces the levels of cytokine.
In this regard, TECA potently reduced the level of IgE and release of inflammatory cytokine. These
data indicate that TECA could inactivate macrophage in the skin, thus lead to less skin inflammation
and atopic responses.
NF-κB is implicated for cytokine release, which is important for anti-inflammatory activity.
Pro-inflammatory cytokines, including IL-4, IL-6, IL-1β, and TNF-α, commonly contribute to the
regulation of inflammation and immune responses in AD skin lesion [39]. Release of IL-4 primarily
regulates hyper-production of IgE [40], and expression of TNF-α and IL-6 stimulate the synthesis
of acute phase response protein, which attenuates secretion of IgE and disruption of skin barrier
function during allergic reactions [41,42]. In a recent study, Spirodela polyrhiza remarkably inhibited
expression levels of NF-κB and p-IκBα as well as inflammatory cytokines such as IL-4, IL-6, and
TNF-α in AD mice model [43]. Tanaka et al. demonstrated topical application of IMD-0354, an NF-κB
inhibitor, is effective in suppressing the activation of NF-κB and in reducing the development of
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Xanthii fructus (XF) strongly suppressed IL-4, IL-1β, IFN-γ and TNF-α in AD-like skin lesions [45].
In addition, several natural products inhibited AD development through inhibition of cytokine releases.
In TPA-induced skin inflammation, TNF-α and IL-1β in the serum were reduced by 70% ethanol
extract from Asparagus cochinchinensis [46]. Following treatment with Liriope platyphylla (LP) extract,
expression of IL-6 and VEGF was significantly reduced in ear tissue of IL-4/Luc/CNS-1 Tg mice treated
with PA [5]. In the present study, the levels of two cytokines (TNF-α and IL-6) were elevated in the
serum of mice treated with PA, but significantly reduced cytokine release was observed in the TECA
treated group. In both PA-induced atopic dermatitis animal model and RAW 264.7 murine macrophage
cells, TECA also decreased the degradation of IκBα and nuclear translocation of NF-κB. It has been
reported that asiaticoside, a component of Centella asiatica, plays a role in the anti-inflammatory effect
via downregulation of NF-κB signaling pathway [47]. In our present study, the data demonstrated
that TECA attenuates activation of NF-κB, contributing to the reduced TNF-α, IL-6, and IL-1β level
and expression of iNOS and COX-2. Therefore, our data suggest that TECA should be considered a
candidate agent for AD.
4. Materials and Methods
4.1. Ethical Approval
The experimental protocols were carried out according to the guidelines for animal experiments of
the Institutional Animal Care and Use Committee (IACUC) of the Laboratory Animal Research Center
at Chungbuk National University, Korea (CBNUA-929-16-01). All efforts were made to minimize
animal suffering, and to reduce the number of animals used. All mice were housed in three mice
per cage with an automatic temperature control (21–25 ◦C), relative humidity (45–65%), and 12 h
light–dark cycle illuminating from 08:00 a.m. to 08:00 p.m. Food and water were available ad libitum.
They were fed a pellet diet consisting of crude protein 20.5%, crude fat 3.5%, crude fiber 8.0%, crude
ash 8.0%, calcium 0.5%, and phosphorus 0.5% per 100 g of the diet (collected from Daehan Biolink,
Chungcheongbuk-do, Korea). During this study, all mice were particularly observed for normal body
posture, piloerection, ataxia, urination, etc., 2 times per day.
4.2. Preparation and Extraction of Centella asiatica
Collected aerial parts of Centella asiatica were oven-dried at 50 ◦C and then powdered using a
milling machine. The powdered plant (1 kg) was extracted with 75% (v/v) ethanol (3 × 4 L, 3 days
each) at room temperature. The extracts were filtrated with a depth-filter coated with active carbon and
concentrated at 80 ◦C under reduced pressure. The concentrate was divided to precipitate and filtrate
fraction by filtration. The precipitate fraction was dried at 50 ◦C to make asiaticoside powder; its yield
was 0.12% (w/w) of dried plant. Subsequently, the filtrates fraction was hydrolyzed with an alkaline
solution containing sodium hydroxide (1% w/v) at 80 ◦C. It was then concentrated, precipitated and
dried using the procedure described above. The yield of the genins (asiatic acid and madecassic acid)
powder obtained from the filtrate fraction was 0.18% (w/w) of dried plant. Both powder extracts
were mixed to give the titrated extract of Centella asiatica. The components of the titrated extract of
Centella asiatica were asiaticoside (40%), asiatic acid (30%), and madecassic acid (29–30%) (Table 1).
All solvents used were of commercial grade and obtained from Dongkook Pharmaceutical Company,
Chungbuk, Korea.
Table 1. Composition of titrated extracts of Centella asiatica.
Extract Composition of Extract
Titrated extract of Centella asiatica (TECA) Asiaticoside (40%), Asiatic acid (30%), Madecassic acid (29–30%)
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4.3. Animal Treatment
The protocols for the animal experiment used in this study were carefully reviewed for ethical and
scientific care procedures and approved by the Chungbuk National University-Institutional Animal
Care and Use Committee (Approval Number CBNUA-929-16-01). Hos:HR-1 mice (eight-week-old,
n = 40) were randomly divided into one of four groups. In the first group (Vehicle, n = 10), 100 μL of
AOO (4:1 acetone: olive oil, v/v: AOO) was spread on the dorsum of the ears and back skin three times
a week for four weeks. In the second group (phthalic anhydride (PA), n = 10), 100 μL (20 μL/cm2) of
5% phthalic anhydride solution was applied. The third group (TECA 0.2%, n = 10) and fourth group
(TECA 0.4%, n = 10) were applied with PA, and 3 h later 100 μL of 0.2% and 0.4% titrated extract of
Centella asiatica (40 μg or 80 μg/cm2) were applied. Age-matched Hos:HR-1 mice were used as the
control group (Control, n = 10).
4.4. Measurement of Ear Thickness, and Body and Lymph Node Weight
Body weights of all mice were measured during the experimental period using an electronic
balance (Mettler Toledo, Greifensee, Switzerland) once a week for 4 weeks. Additionally, weights of
lymph nodes were measured using an electronic balance lymph nodes were collected from sacrificed
mice and weighed using an electronic balance (Mettler Toledo, Greifensee, Switzerland). Thickness of
ear skin was measured using a thickness gauge (Digimatic Indicator, Matusutoyo Co., Tokyo, Japan).
4.5. Histological Techniques
The ear and back skins were removed from mice, fixed with 10% formalin, embedded in paraffin
wax, routinely processed, and then sectioned into 5 μm thick slices. The skin sections were then stained
with hematoxylin and eosin (H & E). The thickness of the epidermis and dermis were also measured
using the Leica Application Suite (Leica Microsystems, Wetzlar, Germany).
4.6. Mesurement of Serum IgE Concentration
IgE level in the serum was measured by enzyme-linked immunosorbent assay (ELISA) using
the mouse IgE kit (Shibayagi, Inc., Gunma, Japan), according to the manufacturer’s instructions.
The final concentration of IgE was calculated using a linear regression equation obtained from standard
absorbance values.
4.7. Cytokine Assay
By the end of the study period, blood specimens were collected. Serum levels of mouse TNF-α,
IL-6, and IL-1β were measured by enzyme-linked immunosorbent assay (ELISA) kits provided by
Thermoscientific Inc. (Meridian Rd, Rockford, IL, USA) according to the manufacturer’s protocol.
4.8. Western Blot Analysis
One hundred milligrams of skin or ear tissues or about 1 × 106 cells were harvested and
homogenized with a lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.2% Sodium dodecyl sulfate
(SDS), 1 mM phenyl methylsulfonyl fluoride (PMSF), and 0.5% sodium deoxycholate). After lysis,
the lysates were centrifuged at 13,000 rpm for 20 min. Equal amounts of protein (20 μg) were
denatured at 95 ◦C for 5 min after mixing with 5 μL of SDS loading buffer were applied on SDS/10%
polyacrylamide gel for electrophoresis and were transferred to nitrocellulose membranes (Hybond
ECL, Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). The membrane was incubated for 4 h
at room temperature with specific antibodies: rabbit polyclonal antibodies against iNOS, COX-2, p65
and IκB-α (1:500), and mouse monoclonal antibody against p50 (1:500) (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) were used in study. The blot was then incubated with the corresponding
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Santa Cruz, CA, USA). Band signals were detected on X-ray film using enhanced chemiluminescence
(ECL) detection reagents.
4.9. Gel Electromobility Shift Assay (EMSA)
Gel shift assays were performed according to the manufacturer’s recommendations (Promega,
Madison, WI, USA). The oligonucleotide sequences for NF-κB were 5′-AGT TGA GGG GAC TTT CCC
AGG C-3′. Consensus oligonucleotides were end-labeled using T4 polynucleotide kinase and [32P]
ATP for 10 min at 37 ◦C. Briefly, 10 μg nuclear protein were incubated with the labeled probe for 20 min
at room temperature. Subsequently, 1 μL of gel loading buffer was added to each reaction and loaded
onto a 5% non-denaturing gel and electrophoresis until the dye was three-fourths of the way down the
gel. The gel was dried at 80 ◦C for 1 h and exposed to film overnight at 70 ◦C. Quantification and the
relative density of the protein bands were performed by phosphorimaging (UVP Inc., Upland, CA,
USA).
4.10. Cell Culture
The RAW 264.7 murine macrophage cell line was obtained from the Korea Cell Line Bank (Seoul,
Korea). These cells were grown at 37 ◦C in Dulbecco’s modified Eagle’s medium (DMEM) medium
supplemented with 10% FBS, penicillin (100 units/mL) and streptomycin sulfate (100 μg/mL) in
humidified atmosphere of 5% CO2. Cells were incubated with TECA at various concentrations (1, 2,
or 5 μg/mL) or positive chemicals and then stimulated with LPS 1 μg/mL for the indicated time in
figure legends. Various concentrations of TECA dissolved in ethanol were added together with LPS.
The final concentration of ethanol used was less than 0.05%. Cells were treated with 0.05% ethanol as
vehicle control.
4.11. Nitrite Quantification Assay
The NO was determined through the indication of nitrite level in the cell culture media.
The RAW264.7 murine macrophages were seeded in 6-well plates (1 × 106 cells/well) with 2 mL
of cell culture media and incubated for 24 h. This was followed by discarding the old culture media
and replacing them with the new media to maintain the cells. Different concentrations of TECA
(1, 2, and 5 μg/mL) were pretreated with the RAW264.7 macrophages. Induction of RAW264.7
macrophages with LPS (1 μg/mL) for all samples was conducted except in control for another
24 h. Then, 100 μL of the collected supernatants was added with 100 μL of Griess reagent (0.1%
N-1-napthylethylenediamine dihydrochloride (NED), 1% sulphanilamide, and 2.5% phosphoric acid)
and incubated in room temperature for 10 min in dark condition. The absorbance was determined
by using a microplate reader at 540 nm wavelength. The NO concentration was determined by
comparison to the standard curve.
4.12. Statistical Analysis
The experiments were conducted in triplicate, and all experiments were repeated at least three
times with similar results. All statistical analysis was performed with GraphPad Prism 5 software
(Version 5.03; GraphPad software, Inc., San Diego, CA, USA). Group differences were analyzed
by one-way ANOVA followed by Tukey’s multiple comparison test. All values are presented as
mean ± SD. Significance was set at p < 0.05 for all tests.
5. Conclusions
In our present study, TECA treatment inhibited activation of NF-κB contributing to the reduced
pro-inflammatory cytokine and expression of iNOS and COX-2 in PA-induced allergic dermatitis
animal model as well as RAW 264.7 murine macrophage. Therefore, our data suggest that TECA could
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Abstract: Multiple evidence in animal models and in humans suggest a beneficial role of cold physical
plasma in wound treatment. Yet, risk assessment studies are important to further foster therapeutic
advancement and acceptance of cold plasma in clinics. Accordingly, we investigated the long-term
side effects of repetitive plasma treatment over 14 consecutive days in a rodent full-thickness ear
wound model. Subsequently, animals were housed for 350 days and sacrificed thereafter. In blood,
systemic changes of the pro-inflammatory cytokines interleukin 1β and tumor necrosis factor α
were absent. Similarly, tumor marker levels of α-fetoprotein and calcitonin remained unchanged.
Using quantitative PCR, the expression levels of several cytokines and tumor markers in liver,
lung, and skin were found to be similar in the control and treatment group as well. Likewise,
histological and immunohistochemical analysis failed to detect abnormal morphological changes
and the presence of tumor markers such as carcinoembryonic antigen, α-fetoprotein, or the neighbor
of Punc 11. Absence of neoplastic lesions was confirmed by non-invasive imaging methods such as
anatomical magnetic resonance imaging and positron emission tomography-computed tomography.
Our results suggest that the beneficial effects of cold plasma in wound healing come without apparent
side effects including tumor formation or chronic inflammation.
Keywords: dermal full-thickness wounds; kINPen plasma jet; plasma medicine; reactive oxygen and
nitrogen species; risk evaluation; SKH1 mouse model
1. Introduction
Cold atmospheric pressure plasma has emerged as a promising tool for biomedical and clinical
applications [1]. In this field called plasma medicine, encouraging results have been achieved for
disinfection purposes [2], in vitro [3–5] and in patients [6–8]. Notably, a key feature determining
healing is the state of wound oxygenation [9], and evidence suggests that the scavenging of active
oxygen species impairs wound healing [10]. Accordingly, strategies influencing redox signaling may
be used as an accessory therapy in chronic wound management [11–13], establishing a link to plasma
medicine [14–16].
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Cold physical plasmas are partially ionized gases that mediate biological responses especially via
generation of reactive oxygen (ROS) and nitrogen species (RNS) [17–19]. Crucially, such species are
translated in cells via redox enzymes [20] and therefore actively participate in intracellular signaling
events [21–23]. Most mammalian cells maintain and benefit from a residual concentration of ROS and
possess a complex system to sense a relay of ROS-related signals [24,25]. In contrast to low ROS and
RNS quantities, higher concentrations are known to be responsible for apoptotic signaling [26–28] or
finally for DNA damage [29]. Previous studies assessed the mutagenic risks of plasma in vitro [30–32].
The data provided in these studies demonstrated the absence of mutagenic or genotoxic effects in
plasma-treated cells or in a hen’s egg test model for micronuclei induction (HET-MN), suggesting
that a clinical application of the argon plasma jet does not pose mutagenic risks. This is confirmed
by a clinical long-term observation of laser skin lesions which were treated by cold atmospheric
plasma [33,34]. However, systematic in vivo studies investigating any malignant side effects of plasma
have not carried out to date.
To detect tumorigenicity, the usage of rodent models is commonly proposed. With regard to
potential plasma applications in human wound healing, we utilized a full-thickness immunocompetent
mouse model subjected to plasma treatment to monitor long-term effects. Non-invasive methods such
as magnetic resonance imaging (MRI) and positron-emission tomography/computed tomography
(PET/CT) are able to detect neoplastic lesions throughout the body. Using both technologies,
tumorigenic effects were investigated in animals one year after plasma treatment. Using quantitative
PCR, ELISA measurements, and immunohistochemical analysis of several tumor markers, we also
investigated primary tumor formation or metastasis of malignant tumors.
2. Results
2.1. Evaluation of Histological Architecture and Inflammation Status after One Year
The aim of this study was the risk evaluation of cold plasma 350 days after wound treatment
in a total of 84 hairless mice. In our long-term observation, plasma-treated mice showed typical
health state, nutrition, and behavior. Moreover, we did not identify any toxic side effects or chronic
wound infections. Two untreated animals developed a hepatocellular carcinoma (HCC, male) or
skin abnormalities (female), which served as positive controls for ex vivo analyses. One of forty-two
animals in the plasma group showed an enlargement of the organ spleen (data not shown). Structurally,
wound areas were similar between experimental groups (arrowhead in Figure 1A–C). Yet, hematoxylin
and eosin (H&E) staining showed some histologic changes in the dermal wound region. We found
a separation and disconnection of dermal layers (I) without inflammatory cell infiltration into the
dermis (I`). This effect was observed in most animals independent from treatment regime or gender
(controls, A; males, B; females, C), indicating a normal healing output without excessive scar formation
on day 350. Macroscopically, the organs of plasma-treated animals did not exhibit morphological
changes, signs of tumor formation or metastatic processes, or differences in size or weight, such as in
lung, liver, brain, thyroid gland, kidney, spleen, and heart (II, clockwise rotation).
Next, H&E staining was performed for the heart, kidney, brain, and thyroid tissues (Figure 2).
Normal architecture of the heart with cardiac myocytes and centrally placed nuclei (I) was observed.
Similarly, kidney tissues showed typical glomeruli and convoluted tubule structures without signs of
necrosis (II). Brain sections from mice treated with plasma did not reveal either neuronal injury, focal
inflammatory cell infiltration, hyperchromatic cells, or cellular shrinkage or swelling (III). In thyroid
histology, follicles were surrounded with thyrocytes without cellular infiltrations (IV).
Similar to the controls (A), H&E-stained liver sections from mice treated with plasma showed
normal hepatic architecture with the central vein (cv), radially surrounding hepatocytes (h), sinusoids
(s), and nuclei (n) in males (B) and females (C). Additionally, we could not identify swollen or
multinucleated macrophages in H&E staining, or scattered inflammatory cell aggregation (Figure 3A–C).
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with a non-activated state. In an untreated control mouse we found a hepatocellular carcinoma (HCC)
with a remarkable cellular infiltration in the liver (inlet in 0), which served as the “positive control”
(+ve ctrl). The major histologic finding in the liver of the HCC-bearing mouse was a broad F4/80
positive cell staining, suggesting a strong inflammation with inflammatory foci (arrows, 0I). Contrary
to that, we found in all mice studied a normal ramified structure of Kupffer cells. In addition, we
observed no differences in the quality and amount of F4/80 positive cells, which were not swollen or
amoeboid (AI–CI). One remarkable pathological characteristic of the liver is increased production of
collagen, which is the main component of the extracellular matrix in fibrotic tissue [35]. Depositions
of collagen fibers were examined in liver sections showing no hyperplasia of the fibrous tissue in
plasma-treated mice (II). In contrast, arrows indicate a high level of collagen deposition stained by
picrosirius red (PSR) in the fibrotic septa between nodules of HCC-bearing liver tissue (0II). Moreover,
mRNA for the pro-inflammatory cytokine tumor-necrosis factor α (TNFα) was not elevated in the liver
of plasma-treated mice relative to controls after one year (D). This finding was confirmed systemically
in blood plasma, with a small but significant down-regulation of TNFα in females (E) 15 days after
wounding (Figure 3).
 
Figure 1. Macro- and microscopic skin wounds and organs 350 days after plasma treatment. Similar
to untreated control animals (A), stereo microscopy of wound region revealed no differences of
morphology (arrowheads) in ear tissue 350 days after injury in plasma- and untreated males (B)
and females (C). Hematoxylin and eosin (H&E)-stained skin sections of dermal layers in control and
plasma-treated mice were similar showing normal dermal architecture with a disconnection between
the cartilage layer (cl) and dermis (de, ep, epidermis) at the wound site without inflammatory cell
infiltration into the dermis (I–I`). Macroscopic evaluation of different organs (lung, spleen, liver, heart,
kidney, thyroid glands, and brain) lacking visible tumor formation (II). Representative images are
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Figure 2. Histology in different organs of mice treated with plasma. H&E-stained heart sections
showing normal architecture with cardiac myocytes and centrally placed nuclei (I) in controls (A), and
plasma-treated males (B) and females (C). Kidney sections showing normal histological structure with
glomerulus and convoluted tubules without necrosis (II). Brain sections from mice treated with plasma
showing no signs of either neuronal injury or focal inflammatory cell infiltration nor hyperchromatic
cells or cellular shrinkage or swelling (III). Normal thyroid histology showing follicles surrounded
with thyrocytes without cellular infiltrations (IV). One representative picture of H&E staining is shown
for selected organs. Scale bar 50 μm.
Histological examination of the lung sections did not show changes consistent with lung pathology.
Macroscopically, lungs were not less aerated or covered with white fibrin patches. Moreover, in
H&E stained sections we did not find scattered inflammatory cell aggregations with interstitial
neutrophilic infiltration, septal thickening of the alveolar capillary membrane, or focal hemorrhage of
the mesenchyme in plasma-treated males (B) or females (C) similar to the controls (A). Likewise, TNFα
mRNA expression was not altered in the lungs of plasma-treated mice relative to controls (Figure 4D).
Next, no morphological abnormalities of the spleen or excessive neutrophil infiltration in the red
splenic pulp were found in plasma-treated mice (B,C) similar to untreated controls (A). Immunostaining
with F4/80 antibody was performed to visualize macrophages (II) in the spleen and immunostaining
with Ly6G showed the granulocytes distribution (III). Taken together, experimental groups exhibited
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Figure 3. Liver histology, Kupffer cells, local and systemic tumor necrosis factor α (TNFα) levels.
Similar to controls (A), H&E-stained liver sections from mice treated with plasma showing normal
hepatic architecture with central vein (cv) and surrounding hepatocytes (h), sinusoids (s), and nuclei (n)
in males (B) and females (C). Scale bar 100 μm. Immunostaining with F4/80 antibody was performed
to show scattered inflammatory cell aggregations and to visualize ramified Kupffer cells in liver
sections, which were not swollen or amoeboid (AI–CI). A hepatocellular carcinoma in liver (from the
untreated control group) showed a strong cell infiltration (inlet, (0)) hyperplasia of liver tissue and
a broad F4/80 positive cell-staining (inlet in (0I)) with inflammatory foci (arrows in (0I), +ve ctrl).
Picrosirius red (PSR) staining of tissue slices from liver showing collagen fibers in cancer tissue of
a hepatocellular carcinoma (HCC)-bearing mouse (arrow, (0II)) in contrast to non-tumor sections of
plasma- and untreated animals (A–CII). Representative images are shown with scale bars of 50 μm
(I–II). Using quantitative polymerase chain reaction (qPCR), TNFα mRNA expression was quantified
in the liver of plasma- and untreated mice (D). Analysis of blood samples has shown a significant
down-regulation of TNFα in females 15 days after wounding (E). Results are means + S.D. for n > 4 (D;
ns, not significant) or nine mice (E, ** p < 0.01).
Cervical lymph nodes are normally subject to a number of different pathological conditions
including tumor development and inflammation [36]. Therefore, cervical lymph nodes were removed
from plasma-treated animals and compared to untreated animals. The size of lymph nodes were similar
in both experimental groups indicating the absence of lymphomas (data not shown). H&E staining
showed neither follicular hyperplasia nor dilated parafollicular zones (Figure 6A–C). In the lymph
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(Figure 6D). Moreover, blood plasma levels of IL-1β were similar in all treatment groups 15 days
after wounding (Figure 6E). Additionally, parafollicular hyperplasia, plasmocytosis, and increased
collagen density in the lymph nodes of several tumor models are reported [37]. We clearly obtained
a follicular hyperplasia in the HCC-bearing mouse (Figure 6FI) in contrast to the plasma-treated mice
(Figure 6GI). The collagen fiber density in cervical and mesenteric lymph nodes from this mouse
was significantly increased compared to plasma and untreated mice, indicating no transformational
changes in the latter groups. Collagen fibers are shown in red in a PSR staining using light microscopy
(Figure 6FII) or by fluorescence microscopy (Figure 6GII) [38]. No histologic abnormalities of bones
and other unmentioned organs were observed (data not shown).
Figure 4. Lung histology and TNFα expression. Similar to controls (A), H&E staining did not show
scattered inflammatory cell aggregations with interstitial lymphocytic and neutrophilic infiltration,
thickening of the alveolar capillary membrane, or focal hemorrhage in the mesenchyme of lungs of
plasma-treated males (B) or females (C). Using qPCR, TNFα mRNA expression was quantified in
the lungs of plasma- and untreated mice (D). Representative images with 100 μm (I) or 50 μm (I`).
Results are means + S.D. for n > 4 (D; ns, not significant).
2.2. Evaluation of Tumor Marker (TM) Expression and Secretion
To explore the safety aspects of cold plasma as a precondition for a clinical application, we next
investigated the tumor marker (TM) expression in several organs, skin tissue, and blood plasma
using immunohistochemistry, quantitative polymerase chain reaction (qPCR), and ELISA 350 d after
plasma treatment. Representative images of immunohistochemical staining revealed no enhanced
tumor marker expression in liver, brain, lung, and skin tissue (Figure 7A). The immunohistochemical
staining of α-fetoprotein (AFP, I), a traditional tumor marker for hepatocellular carcinoma (HCC), β2
microglobulin (β2M, II), a tumor marker for some blood cell cancers such as lymphoma and multiple
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marker in patients with non-small cell lung cancer [40], were significantly enhanced in organs of the
HCC-bearing mouse (+ve ctrl, left panel) compared to plasma-treated mice (right panel). Additionally,
the neuron specific enolase (NSE), a TM of neuroendocrine tumors such as Merkel-cell carcinoma
of the skin [41], was obviously increased in skin sections of the positive control mouse (+ve ctrl),
which has developed a skin abnormality (IV, left). Nevertheless, no positive NSE staining was found
in plasma-treated mice (IV, right). Blood plasma analysis of tumor markers revealed no differences
between groups in AFP (I) or calcitonin level (CT, II), a TM of medullary thyroid carcinoma [42]
(Figure 7B).
 
Figure 5. Macrophage and granulocyte distribution in spleens. Similar to controls (A), H&E staining
did not show abnormalities in spleens in plasma-treated males (B) or females (C); rsp, red splenic pulp;
ca, central artery; wsp, white splenic pulp. Intra-individual differences appeared in relation to the size
of white and red pulp without a clear tendency. Immunostaining with F4/80 and Ly6G antibodies were
performed to visualize macrophages (II) as well as normally dispersed granulocyte distribution (III).
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Figure 6. Lymph node histology, IL-1β expression, and comparison to tumor samples. H&E staining did
not show hypertrophy, hyperplasia, or dilated parafollicular zones in lymph nodes of plasma-treated
animals in comparison to controls (A) in males (B) and females (C). IL-1β mRNA expression
was quantified by qPCR in cervical lymph nodes ((D), n > 4) and cytokine measurement of
IL-1β concentration in blood samples 15 days after injury ((E), n > 9). Parafollicular hyperplasia,
plasmocytosis, and increased collagen fiber density in lymph nodes of mice carrying a primary
hepatocellular carcinoma (F) in contrast to plasma-treated mice (G) was visualized by H&E (I) and PSR
staining (II) using light (I–II) or fluorescence microscopy (II`). Scale bar 50 μm (A–C), 100 μm (F,G).
Next, we performed quantitative PCR analysis of five tumor markers such as AFP, NOPE
(neighbor of Punc 11), a novel TM of the liver [43], β2 microglobulin (β2M), carcinoembryonic antigen
(CEA), or neuron-specific enolase (NSE). No changes were observed in, e.g., liver, brain, lung, or ear
skin tissue relative to the controls and in contrast to organs of the HCC-bearing mouse (+ve ctrl).
Actin-containing elements of the cytoskeleton are changed in pathophysiological conditions such as
malignant tumors [44]. We investigated alteration of either β-actin protein expression in skin tissue
sections using IHC as well as gene expression using qPCR. Structural changes of the cytoskeleton and
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Figure 7. Unchanged tumor marker levels in liver, lung, brain, and skin of plasma-treated mice.
Representative images of immunohistochemistry of different tumor markers (TM): AFP (I) in liver,
β2M in brain (II), CEA in lung (III), as well as NSE staining in skin tissue (IV) after one year in positive
control (+ve ctrl, left) and plasma-treated (right) animals (A). Scale bar 50 μm (right columns) or 100 μm
(left columns). Using ELISA, we analyzed AFP (I), and calcitonin (CT) (II), a TM of medullary thyroid
carcinoma, in blood serum (B; * p < 0.05; (n > 9). The mRNA expression levels of five TM and β-actin
in liver, brain, lung, and ear skin tissues from plasma- and untreated (ctrl) mice were compared with
organs from a HCC-bearing mouse (+ve ctrl). At least three independent experiments were performed
and summarized in the indicated experimental groups (m, male; f, female). AFP, α-fetoprotein; NOPE,
neighbor of Punc 11; β2M, β2-microglobulin; NSE, neuron specific enolase; CEA, carcinoembryonic
antigen (C).
2.3. Multimodal Imaging of Mice 350 Days after Plasma Treatment
Positron-emission tomography/computed tomography (PET/CT) and anatomical magnetic
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In PET/CT imaging with 18F-FDG, indicating tissue metabolic activity corresponding to glucose
uptake, the plasma-treated male as well as female mice showed no significant differences in tracer
uptake in the heart (III), brain (IV), liver (V), or kidney (VI). Throughout the body (VII), pathological
differences in tracer uptake were absent in the organs (e.g., thymus) of plasma-treated and control mice
(Figure 8). Similarly, representative three-dimensional MRI scans derived from T2-weighted rapid
acquisition with relaxation enhancement (RARE)-sequences (at an in-plane resolution of 180 μm) did
not show any indication of tumor formation in control (A) or plasma-treated mice (B) one year after
plasma treatment (Figure 9). Longitudinal and axial whole body view did not show pathophysiological
glucose uptake in the kidneys (I) or stomach (II). This was confirmed by lateral scans of the abdomen
with liver (III), kidney (IV), and head with brain (V). By contrast, glucose uptake is shown in two
representative images of a liver tumor in non-plasma-treated animals (CI–II).
 
Figure 8. Positron emission tomography-computed tomography (PET/CT) imaging with
18F-fluorodeoxyglucose (18F-FDG) tracer for risk estimation after plasma treatment. (PET/CT with
18F-FDG tracer indicates tissue metabolic activity corresponding to glucose uptake. The spatial
resolution was 1.5 mm. Representative scans of control (A), plasma-treated male (B), and female
(C) mice after one year: whole body (I,II), heart (III), brain (IV), liver (V), and kidney (VI) scans and
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Figure 9. Risks evaluation in plasma-treated mice using anatomical magnetic-resonance imaging (MRI).
Representative MRI scans of control (A) and plasma-treated mice one year after plasma treatment (B).
Images derived from T2-weighted rapid acquisition with relaxation enhancement (RARE)-sequences
with a deliverable spatial resolution of 0.18 mm in-plane, echo time (TE/TR 29/4100 ms): coronal
slices with obvious visualization of kidneys (I) or stomach (II), as well as axial scans of abdomen with
liver (III), kidney (IV), and head with the brain (V). Two representative images of a liver tumor are
shown in a control (not plasma-treated) mouse (CI–II).
3. Discussion
Chemical and physico-chemical clinical interventions require safety testing with regard to
cytotoxicity and genotoxicity. Although cell culture experiments are commonly used to investigate
the extent of damage of substances, animal experiments are more meaningful studies with regard
to long-term effects. Plasma application was shown to lack genotoxic effects in vitro [30,32] and
using an egg HET-MN model [31], which takes an intermediate position between cell culture and
rodent models. Here, we have further quantitatively characterized the long-term side effects using
an immunocompetent mouse model. In this model, inflammation and immune responses in wound
repair are not attenuated, allowing us to follow not only wound healing in a physiological setting [45]
but also the long-term impact on organs and skin tissue.
Cold plasmas are a significant source of reactive oxygen species (ROS, e.g., HO, O2−, O3,
and H2O2) and reactive nitrogen species (RNS, e.g., NO, ONOO−, and NO2−) [46]. At low
concentration, some of these reactive components are beneficial—leading to cell proliferation and
survival pathways—and are considered second messengers in the field of redox biology. Nevertheless,
these species can be detoxified and metabolically controlled in cells and organisms via anti-oxidant
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anti-oxidant and phase II detoxification enzymes and proteins such as glutathione peroxidases,
catalase, superoxide dismutase, heme oxygenase 1, NAD(P)H dehydrogenase 1, mitogen-activated
protein kinases, molecules of the Jun pathway, and growth factors to protect skin cells from oxidative
stress [47–50]. At higher quantities, reactive species may be tumorigenic [51] and mutagenic [52].
Regardless of the plasma device or the treatment time, no genotoxic effects of the kINPen plasma
were found using a HPRT1 mutation assay [30] or the HET-MN model [31]. In the latter study, the
global antioxidant defense was also not significantly challenged in fertilized plasma-treated chicken
eggs. Furthermore, a long exposure time of test agents is recommended to increase the possibility
of tumor development and to receive resilient statements about tumorigenicity. The regular clinical
protocol for plasma treatment of chronic wounds aims for two to three treatments per week and
a treatment time of 30 to 60 s per cm2 [53]. Regarding these observations and preclinical plasma
studies in humans [54–57], we decided on a daily treatment procedure of 20 s over 14 consecutive
days, which seems advisable for toxicological investigations. Because of the brief exposure during the
plasma treatment, acute health risks via ozone formation are not to be expected. The kINPen expels
maximum ozone concentrations of 0.10–0.13 ppm at lower distances (<10 cm), which is in the range of
the maximum working concentration value (MAK) of 0.1 ppm in the air [53].
Using whole body imaging as well as histological and biochemical analysis, our data suggest
the absence of long-term side effects in the skin tissue and other organs of plasma-treated mice.
This is in agreement with the literature where no histological damage was observed in human skin
after 1 min [58] or 10 min of plasma treatment [59]. The absence of expression of a panel of tumor
markers in liver, lung, brain, and ear tissue using qPCR suggests that plasma can support wound
healing [45] without alterations in the tissue architecture and/or function. Additionally, serum levels
were measured for AFP, a screening substance for a subset of abnormalities such as hepatocellular
carcinoma [42] and calcitonin, which is produced in humans and rodents primarily by the parafollicular
cells in the thyroid. A malignancy of thyroid glands (e.g., medullary thyroid carcinoma, C-cell
hyperplasia, non-thyroidal carcinoma) typically produces elevated serum calcitonin levels of >5 ng/L
in females, and 12 ng/L in males [60] and can therefore be used diagnostically as a tumor marker.
Calcitonin and AFP serum levels were in the physiological range in plasma-treated and untreated
animals of both genders.
Moreover, cervical and mesenteric lymph node and liver sections showed a strong inflammatory
pathology in the HCC-bearing mouse as a response to a primary tumor formation in contrast to
our plasma-treated animals. In the tumor-bearing mouse of the control group, alterations in the
macrophage population indicated an activated state in the liver [36]. In all other animals in the plasma
and control group, F4/80 positive cells within the liver confirmed the classic morphology of Kupffer
cells consistent with an unaltered state of the liver. We also characterized the presence, morphology,
and localization of granulocytes and macrophages in spleens suggesting that the mice exhibited
dominant healthy features. Ly6G has also been implicated in the development of antitumor responses:
It has been demonstrated that lymphoid cancers derive by chronic stimulation or dysfunction of B cells
in association with a sustained inflammatory reaction [61]. Here, multisystem inflammatory reactions
with cell infiltrations in several organs such as thyroid glands, spleen, and lymph nodes, or secretion
of pro-inflammatory cytokines were not observed 350 days after plasma treatment.
Our study has limitations. First, we did not include positive controls in the animal experiments.
Yet, in our view, it is not only experimentally too demanding but also unethical to include several
dozens of different (possible) tumor groups with many animals each only for the sake of “generating”
positive controls for downstream assays. Second, it was beyond the scope of this study to investigate
every single tissue and organ in the animal body for possible side effects. Yet, using MRI and PET/CT
scans, we believe to have sufficiently searched for any tumor formation in a large number of animals.
Altogether, the findings of this study show the absence of long-term side effects after one year in mice
receiving 14 consecutive plasma treatments. Hence, and given a profound efficacy, clinical plasma
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4. Materials and Methods
4.1. Animals
A total of 84 SKH1-hr hairless immunocompetent mice (Charles River Laboratories, Sulzfeld,
Germany) were housed under standard conditions in an animal facility (Rostock University Medical
Center, Rostock, Germany). All experiments were approved by the local ethics committee according to
the guidelines for care and use of laboratory animals (number 7221.3-1-013/14).
4.2. Wounding and Exposure to Cold Physical Plasma
Wounding was performed on the left and right ears of 10–12 weeks old animals as previously
described [45]. Full-thickness circular dermal wounds of approximately 3 mm2 size were created by
removing the epidermis and dermis but not the cartilage using a micro-scissor. For reproducibility, the
procedure was carried out by a single operator. Mice were assigned randomly into four groups (n = 21,
males and females), and either received daily treatment of plasma (20 s) or were left untreated over
14 consecutive days. The argon plasma jet kINPen 11 (neoplas tools, Greifswald, Germany) ionizes
a flow (5 standard liters per minute) of argon gas at a frequency of 1 MHz [53]. Organs and tissues
were collected 350 days post intervention.
4.3. Wound Closure Observations and Histological Evaluation
Wound tissues was fixed in 4% paraformaldehyde, and 5 μm-sections were stained with
hematoxylin/eosin (H&E) to visualize morphological changes by means of light microscopy.
The collagen content of lymph nodes was qualitatively determined within picrosirius red (PSR) stained
paraffin-embedded tissue sections using fluorescence microscopy [38]. For immunohistostaining,
paraffin sections were deparaffinized, rehydrated, and boiled for 5 min for antigen retrieval. Prior to
imaging by light microscopy, sections were incubated with α-fetoprotein (MAB1368, R&D Systems,
Germany), β-2-microglobulin (sc-15366, Santa Cruz, Heidelberg, Germany), neuron-specific enolase
(#R30242, NSJ Bioreagents, Hamburg, Germany), and carcinoembryonic antigen (AF6480, R&D
Systems, Wiesbaden, Germany) overnight at 4 ◦C. Detection of Kupffer cells and macrophages
in paraffin-embedded liver and spleen sections was performed using anti-mouse F4/80 antibody
(#14-4801; Affymetrix, Frankfurt, Germany). For the identification of monocytes and macrophages
in the spleen, Ly6G was used (#14-5931; Affymetrix, Frankfurt, Germany). After washing, sections
were incubated with an immuno-peroxidase polymer (N-Histofine staining reagent; Medac, Wedel,
Germany). Stained sections were mounted onto glass microscope slides using mounting medium
containing DAPI (VectaShield; Biozol, Eching, Germany) prior to analysis using an Axio Observer Z.1
(Zeiss, Jena, Germany).
4.4. Homogenisation of Tissues and Gene Expression Analysis
For expression analysis, tissue and organ samples were collected at day 350 (n = 84). Fresh tissues
from ear and several organs (e.g., lung, liver, brain, thyroid, and lymph nodes) were snap-frozen in
liquid nitrogen, and stored at −80 ◦C. For gene expression analysis, homogenization was performed in
RNA lysis buffer (Bio&Sell, Nürnberg, Germany) using a FastPrep-24 5G homogenisator (Biomedicals,
Heidelberg, Germany). Total RNA was isolated (Bio&Sell) and quantitative PCR (qPCR) was performed
as described previously [49]. Briefly, 1 μg of RNA was transcribed into cDNA, and qPCR was conducted
in triplicate using SYBR Green I Master in a 96-well LightCycler 480 qPCR system (Roche Diagnostics,
Mannheim, Germany). Gene primers were used from Biomol (Hamburg, Germany) and Biotez
(Berlin, Germany; Table A1). The housekeeping gene GAPDH expression was unaffected by plasma
and was used as an internal control for normalization. Genes expression was analyzed using the
ΔΔCt method [62]. The final value for gene expression was determined by calculating the ratio of
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ImageQuantTL Software (GE Healthcare, Freiburg, Germany), and expressed as fold change compared
to the corresponding control. Experiments were performed with six to ten mice for each group.
4.5. ELISA Measurements and Bead-Based Cytokine Analysis
Blood serum were collected retrobulbar in EDTA-tubes (d0, d15 or d350), and centrifuged. Samples
were stored until use at −80 ◦C. TNFα and IL-1β secretion was measured using bead-based multiplex
cytokine analysis (BioLegend,Uithoorn, The Netherlands). Enzyme-linked immunosorbent assay
(ELISA) for a liver specific tumor marker “α fetoprotein” (AFP, BioLegend, Uithoorn, The Netherlands)
and a medullary thyroid carcinoma specific tumor marker “calcitonin” (CT, BioLegend, Uithoorn,
The Netherlands) was performed.
4.6. MRI, PET/CT Scans, and Interpretation of Data
For positron emission tomography-computed tomography (PET/CT) and magnetic resonance
imaging (MRI) sessions 350 days post intervention, animals were anaesthetized with isoflurane
(1.5–2.5%) supplemented with oxygen. During both scans, respiration of the mice was monitored
and adjusted to a breathing rate of 35–50 breaths/min. All MRI scans were additionally respiration
triggered. Temperature of mice were also controlled during the entire imaging period of all scans.
Anatomical MRI T2-weighted TurboRARE sequences with coronal and axial slices over the whole
body were acquired with the following parameters: TE/TR: 29/4100 ms, FoV: cor. 94.4 mm × 35 mm,
axial 33.7 mm × 37 mm, in-plane resolution 0.18 mm, slice thickness 1 mm. For small animal PET/CT
imaging, mice were injected intravenously with 15 MBq 18F-FDG via a microcatheter placed in the tail
vein. Static PET scans in prone position (duration: 15 min) were performed starting 60 min after tracer
application using the Inveon dedicated PET/CT scanner (Siemens Preclinical Solutions, Knoxville,
TN, USA). Whole body CT scans were acquired for attenuation correction and anatomical reference.
CT images were reconstructed with a Feldkamp algorithm. PET data were first Fourier rebinned into
a 2D dataset from which real-space images were reconstructed with an ordered subset expectation
maximization (OSEM) algorithm with 16 subsets and 4 iterations. Attenuation correction was carried
out using the CT data.
4.7. Statistical Analysis
Means of at least three independent experiments were calculated using prism software (GraphPad,
La Jolla, CA, USA). Data were subjected to statistical analysis using the unpaired Student’s t test or
one-way analysis of variance (ANOVA) followed by the Dunnett’s post hoc test. Significant differences
were indicated as mean + S.D. with p-values from * p < 0.05, ** p < 0.01, *** p < 0.001.
5. Conclusions
One year after fourteen consecutive treatments of murine full-thickness ear wounds with the
argon plasma jet kINPen, we were able to conclude key aspects with regard to efficacy and safety
of that device. First, skin tissue healed physiologically without excessive scar formation similar
to control animals. Second, the application of plasma was safe as demonstrated by the absence of
tumor formation at the treatment site. Third, no malignant tissue was found in any other major
organ including liver, lymph node, spleen, heart, lung, and brain. Fourth, the lack of neoplastic
markers in blood plasma of plasma-treated animals suggested an absence of tumor tissue at sites
in the murine body not investigated in this study. Fifth, the analysis of cytokines and immune cells
indicated a physiological immune regulation without pathological or excessive inflammation. These
data suggest that cold plasma applied topically is a safe adjuvant strategy in dermatology with regard
to the absence of neoplastic side effects.
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Table A1. Murine primer sequences or catalog numbers (Biomol, Germany) for use in quantitative
real-time PCR.
Name Gene Sequences/# (Biomol)
mGAPDH_s House keeping gene CATGGCCTCCAAGGAGTAAG
mGAPDH_as TGTGAGGGAGATGCTCAGTG
mTNFα_s Tumor necrosis factor α TCTCATGCACCACCATCAAGGACT
mTNFα_as ACCACTCTCCCTTTGCAGAACTCA
mIL-1β_s Interleukin 1β GCAACTGTTCCTGAACTCAACT
mIL-1β_as ATCTTTTGGGGTCCGTCAACT
mAFP_s α fetoprotein CCAGGAAGTCTGTTTCACAGAAG
mAFP_as CAAAAGGCTCACACCAAAGAG
mβ2M β2 microglobulin VMPS-563
mCEA1 Carcinoembryonic antigen VMPS-1054
mCT Calcitonin VMPS-785
mNSE Neuron specific enolase VMPS-1942
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Abstract: Fingertip response to trauma represents a fascinating example of tissue regeneration.
Regeneration derives from proliferative mesenchymal cells (blastema) that subsequently differentiate
into soft and skeletal tissues. Clinically, conservative treatment of the amputated fingertip under
occlusive dressing can shift the response to tissue loss from a wound repair process towards
regeneration. When analyzing by Immunoassay the wound exudate from occlusive dressings,
the concentrations of brain-derived neurotrophic factor (BDNF) and leukemia inhibitory factor (LIF)
were higher in fingertip exudates than in burn wounds (used as controls for wound repair versus
regeneration). Vascular endothelial growth factor A (VEGF-A) and platelet-derived growth factor
(PDGF) were highly expressed in both samples in comparable levels. In our study, pro-inflammatory
cytokines were relatively higher expressed in regenerative fingertips than in the burn wound exudates
while chemokines were present in lower levels. Functional, vascular and mechanical properties of
the regenerated fingertips were analyzed three months after trauma and the data were compared to
the corresponding fingertip on the collateral uninjured side. While sensory recovery and morphology
(pulp thickness and texture) were similar to uninjured sides, mechanical parameters (elasticity,
vascularization) were increased in the regenerated fingertips. Further studies should be done to
clarify the importance of inflammatory cells, immunity and growth factors in determining the
outcome of the regenerative process and its influence on the clinical outcome.
Keywords: fingertip regeneration; clinical assessment; Doppler imaging; angiogenesis
1. Introduction
Humans maintain regenerative capability of fingertips [1,2], replacing the lost tissue following
substantial trauma. This regeneration occurs in a level dependent manner as long as the proximal
nail matrix remains intact [3]. Regenerative mechanisms in humans are not elucidated but the
involvement of Wnt activation in nail stem cells and fibroblast growth factor 2 (FGF-2) signaling
have been described in mice and amphibian models for limb regeneration [3–6]. Fingertip regeneration
derives from proliferative mesenchymal cells (blastema) [7] that subsequently differentiate into
soft and skeletal tissues [8,9]. In humans the conservative treatment of the amputated fingertip
under occlusive dressing is essential to shift the response of tissue loss from a wound repair process
towards regeneration [10]. Therefore, the regenerative microenvironment created under the occlusive
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dressing should play an important role in providing signals that initiate regeneration and control
proliferation and patterning [11]. Following skin injury in humans, immediate release of various
growth factors, cytokines and chemokines triggers and controls sequential steps of wound repair.
The role and importance of these factors in the repairing microenvironment of wounds has been well
established [12]. Among these growth factors, platelet-derived growth factor (PDGF) is known to
have a central role in all different steps of wound repair by triggering cell migration into the wound,
enhancing the proliferation of fibroblasts and extracellular matrix production and also contraction [13].
Epidermal growth factor (EGF) family of growth factors is also important for reepithelialization
and vascularization during wound repair [12,14]. Vascular endothelial growth factor (VEGF) and
other growth factors that increase expression such as hepatocyte growth factor (HGF) [15] have
crucial roles in wound angiogenesis [16] which then affects overall wound repair processes [17].
Apart from angiogenesis, nerve in-growth is also important in wound healing [18] and the growth
factors that have an effect on innervation such as nerve growth factor (NGF) have been shown to
be essential to normal wound repair [19]. Along with several growth factors, chemokines such
as macrophage inflammatory protein 1-α (MIP 1-α) play an important role in the recruitment of
inflammatory cells to the wound site [20] and initiation of wound repair processes [21] within the
inflammatory phase that implicates several proinflammatory cytokines such as IL1-α, IL1-β, IL-6
and TNF-α [22]. There might be similarities between the implication of the above mentioned factors
between wound repair and wound regeneration. However, knowledge on the role of these factors
during regeneration is lacking and limited to animal models. PDGF is shown to promote the expansion
of the blastema mesenchymal precursor population which is differentiated to bone and dermis [23]
while VEGF is considered to be inhibitory for regeneration [24]. The implication of immune signaling
in regeneration is shown in axolotl model of regeneration with an increase in the expression of
several proinflammatory cytokines early after limb amputation [25]. However, cellular and molecular
mechanisms in human fingertip regeneration remain poorly understood. In this preliminary study,
we investigated the early pro-regenerative microenvironment of human fingertip amputations treated
with occlusive dressing. Our primary purpose was to determine factors that favor regeneration over
repair in these wounds. In three consecutive patients, growth factor, chemokine and cytokine contents
of the regenerating wound fluid were analyzed. Since burn wounds are considered to be repairing
rather than regenerating wounds [26], we compared the fingertip wound fluid cytokine and growth
factor content, with burn wound fluid from three burn patients. Our secondary goal was to assess the
quality of the regenerated tissue. We quantified the functional, vascular and mechanical properties
of the regenerated fingertips three months after trauma and compared the data to the corresponding
fingertip on the collateral uninjured side. Clinical (sensory recovery), morphological (pulp thickness
and texture) and mechanical parameters (elasticity, vascularization) were recorded and analyzed.
2. Results
2.1. Clinical Evaluation of Regenerated Fingertips
Five healthy male patients (mean age 50 ± 15 years) were included in this preliminary study
(Table 1). The occlusive dressing was applied upon admission (Figure 1a) and after primary
debridement and changed once a week without rinsing the wound for a mean duration of 5 weeks
(4–7). Patients had 9 (7–12) consultations within the first 6 months. Mean follow-up was 6 months
(5–7). Clinical and morphologic evaluation was done at three months post-trauma (Figure 1b).
Sensitivity of the regenerated fingertips was assessed by two points discrimination that was
measured less than 4 mm and overlapped with the uninjured side for each finger. We assessed
eventual pain using the Verbal Descriptor Scale representing different growing intensities of pain
varying from none to very severe pain. Our patients had no or mild pain in the regenerated fingertips.
Thumb-finger Pinch was recorded as an index of functional force that did not reveal substantial
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Patient 1 30 Middle/left ≤4 mm on both fingers 2 kg/2 kg 0/0
Patient 2 45 Middle/right ≤4 mm on both fingers 2.5 kg/2 kg 0/0
Patient 3 76 Index/right ≤4 mm on both fingers Not obtained 0/0
Patient 4 47 Middle/left ≤4 mm on both fingers Not obtained 0/0
Patient 5 52 Middle/right ≤4 mm on both fingers 1.5 kg/2.5 kg 1/0
 
Figure 1. Representative images of amputated fingers. (a) At admission and before the application of
occlusive dressing; (b) Three months post-trauma and at clinical and morphological evaluation.
2.2. Evaluation of Morphological, Mechanical and Vascular Properties of Regenerated Fingertips
We used different modalities of Ultrasound imaging (aixplorer®, Aix-en-Provence, France) to
measure the above parameters. Pulp thickness assessment was based on B-mode echography, pulp
vascularization was measured by Doppler ultrasound test and the elasticity of the regenerative tissue
was assessed by the elasticity modulus from Shear Wave Elastography (SWE).
We observed no significant differences in pulp thickness between regenerated fingertips and
the collateral control finger (Figures 2a and 3). The average soft tissue coverage was 7.2 ± 0.6 mm
(6.7–8.2) compared to 7.7 ± 0.6 mm (6.9–8.3) in control collateral finger with no significant difference
observed. Interestingly, elasticity (Figures 2b and 3) was measured 4.8 ± 1.3 m/s (3.5–6.7) compared
to 3.6 ± 0.6 m/s (3.1–4.4) in control collateral fingers and this represented a significant increase of
132.3 ± 23% in regenerated fingertips. Likewise, vascularization (Figures 2c and 3) was significantly
higher (162.4 ± 53.8%) in the regenerated fingertip 58.8 ± 8.6 % (50.7–72.1) compared to controls with
a vascularization percentage of 38.6 ± 10% (26.3–51.4).
Figure 2. Representative echo-doppler images of regenerated (upper row) and un-injured collateral
(lower row) fingertips. (a) Ultrasound b-mode imaging for the measurement of the pulp thickness;
(b) b-mode imaging with superimposed share wave mapping for the measurement of the pulp elasticity.
The white circle has a diameter of 5 mm; (c) b-mode imaging with superimposed power Doppler for
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Figure 3. Morphologic, mechanical and vascular characteristics of regenerated fingertips compared to
control collateral healthy finger. (a) Soft tissue coverage, (b) Elasticity, (c) vascularization. Data are
presented as mean ± SD for five patients (* p < 0.05).
2.3. Regenerative Wound Microenvironment
We measured the concentrations of different inflammatory cytokines, chemokines and growth
factors in the wound exudate from three amputated fingertips and three burn patients using Luminex
technology. Despite a large variation in wound cytokine levels among different patients (Figure 4),
the concentrations of brain-derived neurotrophic factor (BDNF), EGF and leukemia inhibitory factor
(LIF) were higher in fingertip exudates than in burn wounds. VEGF-A, PDGF and HGF were highly
expressed in both samples in comparable levels (Figure 4a). We observed a general trend towards
higher values of inflammatory cytokines in fingertip exudates whereas chemokine levels of burn
wound exudates were globally higher (Figure 4b). Bone Morphogenetic Protein signaling has been
shown to be important during fingertip regeneration in mice [27] but we did not observe detectable
levels of BMP in the fingertip exudate samples.
Figure 4. Measured levels of (a) growth factors, (b) cytokines and chemokines in fingertip exudate
samples (FT) and burn wound exudate samples (B), seven days post-trauma.
3. Discussion
General belief is that the ability to regenerate fingertips is lost or decreased in human by
age [10]. Here we show that in all our adult patients (mean age 50 years) fingertips underwent
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regeneration replace both form and function in damaged organs [28]. Indeed, clinical assessment of the
regenerated fingertips in our patients revealed that they have comparable morphological and functional
characteristics with contralateral uninjured fingertips. However, we observed key mechanical
modifications in the regenerated fingertips. Increase in elasticity paralleled high vascularization
in regenerated fingertips suggesting that the enhanced vascularity during regeneration affects the
elasticity of these tissues. Nevertheless, long-term studies are necessary to confirm whether these
events are associated and if they persist in time after the regeneration process is completed. Increased
vascularization could be transient and a result of increased expression of pro-angiogenic factors in
the regenerative microenvironment of the fingertips as we observed in this study. We analyzed the
wound fluid that was accumulated under the occlusive dressing over amputated fingertips over the
primary phase of regeneration and most probably blastema formation [29]. We measured high levels
of VEGF in the wound fluid that explains increased vascularity which seems to be essential for the
complete regeneration in human fingertips. Interestingly, in mouse models of regeneration, an inverse
phenomena is observed where the expression of VEGF is down regulated in blastema [11] and even
induction of angiogenesis by VEGF inhibited the regeneration by altering the transition of blastema to
the differentiation phase [24]. Thus, for the first time, our results reveal discrepancies between mice and
human fingertip regeneration. However, in a recent study, regenerated fingertips in fast-healing mice
showed 70% increased vascularization compared to non-healing mice with impaired regeneration [30].
These data along with our observations, suggest an important role for higher blood flow in the fingertip
regeneration in mammalians. In surgical wounds and chronic vascular ulcers, high expression of
b-FGF, which is another pro-angiogenic factor, is observed at very early phases of wound healing and
the levels further decline over-time during healing [31,32]. We did not detect this growth factor in
the accumulative exudates collected at day 7, which is most probably too late for b-FGF expression.
A more comprehensive analysis of pro-angiogenic factors over time in fingertip exudate is necessary
and will help to determine the factors that control angiogenesis during regeneration.
Deficiency in inflammatory response has been suggested to be an explanation for the absence of
fibrotic response during fingertip regeneration [33]. However, our preliminary data showed that, at
least during the first seven days post-amputation in human fingertips, a strong inflammatory response
is ongoing in the regenerative microenvironment compared to healing microenvironment of burn
wounds as shown in Figure 4. The central role of inflammation and innate immune response are
known in wound healing but still poorly understood in regeneration models [34], where a prominent
expression of inflammatory and immune-related genes was revealed [35,36]. In these models, both pro-
and anti-inflammatory cytokines are highly expressed during the first two weeks of regeneration with
pro-inflammatory molecules being prominent during the first week and anti-inflammatory cytokines at
the second week and after [34]. Classical models of regeneration such as salamander [25], Xenopus [35]
or mice digit tip [37] also show that protein factors triggering the immediate events following traumatic
injury are similar in both wound healing and organ regeneration [25,35], but the immune factors
that favor one pathway over the other remain unknown. In our study, pro-inflammatory cytokines
were relatively higher expressed in regenerative fingertips than in the burn wound exudates while
chemokines where present in lower levels. Further studies should be done to clarify the importance of
inflammatory cells and immunity in determining the outcome of the regenerative process.
In amphibians and mice, complete regeneration is dependent to nerve-derived growth factors
that are secreted by nerve-associated Schwann cell precursors and promote the expansion of blastema
and digit regeneration [38,39]. Transcriptome analysis these cells revealed that PDGF, LIF and could
be potential paracrine factors that might be important for digit tip regeneration [23]. We observed
an increased expression of LIF and BDNF in the regenerating fingertip exudates compared to burn
wound exudates. The role of enervation as a regeneration triggering factor in humans is not known
but our clinical observations with restoration of normal sensitivity seems to reveal an important nerve
regeneration process (supported by increased expression of growth factors such as BDNF) to be active
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that provides necessary signals to initiate regeneration which is influenced by local microenvironment
rather than systemic factors [40].
We detected the expression of other growth factors that promote wound reepithelialization, in
fingertip exudates such as HGF and EGF that should have a role in the proliferation and further
redifferentiation of blastema cell mass. Further work with higher number of patients is required to
establish eventual difference between growth factor profiles and signaling differentiation pathways
in regenerating or healing wounds. Moreover, in this study we were focused only on the first week
post-amputation that we considered being crucial for the initiation of regeneration and blastema
formation in regenerative fingertips. In further studies, it would be important to perform sample
collection at different time points of regeneration in order to investigate which signaling molecules are
involved in different phases of regeneration and how their expression might change over time.
4. Materials and Methods
4.1. Ethics
Written consent was obtained from all patients, and the procedures were performed in line with
the Helsinki Declaration of 1975 (Recommendations guiding medical doctors in biomedical research
involving human subjects). Exudate collection were approved by the State Ethics Committee (Protocol
488/13) and regulated by the DAL (Department of Musculoskeletal Medicine) and Institutional
Biobank Procedures.
4.2. Fingertip Exudate Collection and Analysis
Fingertip exudates were collected from occlusive dressing at the first dressing change seven days
after trauma. Samples were diluted in assay buffer, centrifuged and the supernatants were stored at
−80 ◦C until further analysis.
4.3. Burn Wound Exudate Collection
Burn wound exudate was collected as described in [41] and with ethical approval. Briefly,
a negative pressure dressing was applied over second-degree burn wounds that collected the
accumulated fluid into a reservoir bottle. Samples were collected by changing the reservoir bottle and
storedat −80 ◦C until further analysis.
4.4. Wound Exudate Immunoassay
Wound exudate levels of different cytokines, chemokines and growth factors were quantified
using Luminex analysis on samples collected from three patients with regenerating fingertips under
occlusive dressing and three burn patients according to the instructions of the manufacturer (R&D
systems, Minneapolis, MN, USA). Absorbance was read on a Luminex 200 IS device and absorbance
data were converted to protein concentrations with Luminex 100 IS Software (version 2.3, Luminex,
Oosterhout, The Netherlands). Patient samples were tested in triplicate, and the mean value was used
for analysis.
4.5. Clinical Assessment of the Regenerated Fingertips (Two Point Discrimination, Force and Pain)
Two-point discrimination was performed with the 2pt Disk-criminator from Alimed®. Control
finger was tested first and regenerated fingertip afterwards. Fingertips were tested in 1 and 2 point
discrimination. The patient, with closed eyes, stated whether he felt one or two points. We began the
test at 15 mm distance and then moved the two points closer until the patient could not discriminate
anymore (until 4 mm).
Two fingers round pinch (tip to tip pinch) was measured using 50 lb hydraulic pinch gauge
(FE-120601) Jamar®. The gauge was place between the tip of the thumb and the tip of the concerned
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visual descriptor scale representing different growing intensities of pain varying from zero to five
(0 corresponding to no pain; 1 mild pain; 2 moderate pain; 3 severe pain; 4 very severe pain and 5 worst
pain imaginable).
4.6. Power-Doppler and Elastography Assessment of Regenerated Fingertips
Digital pulp thickness assessment was based on B-mode echography (aixplorer®, Aix-en-Provence,
France). Pulp vascularization was measured by power doppler ultrasound test and the elasticity of
the regenerative tissue was assessed by the elasticity modulus from Shear Wave Elastography (SWE).
Power Doppler sonography is a technique that displays the strength of the Doppler signal in color,
rather than the speed and direction information. It has three times the sensitivity of conventional color
Doppler for detection of flow and is particularly useful for small capillaries with low-velocity flow.
SWE on the other hand is a technique measures the elasticity of tissue by measuring the propagation
speed of shear waves, resulting in mechanical disturbances of ultrasonic waves applied to the tissue
by the ultrasound probe [42].
The SWE measurements were taken using equipment (Aixplorer®, Aix-en-Provence, France),
with a high-frequency SHL 15-4 probe (medium frequency 12 kHz). We first used normal ultrasound
imaging in B-mode for topographic orientation and then superimposed and further shear wave
elastography mapping in penetration mode. A mapping of the shear wave velocity, from blue
(soft tissue, low speed) to red (hard tissue, high speed), produced the first qualitative information.
A 3 mm2 Q-Box (quantitative box) focus area was established in the middle of the digital pulp, and
the quantitative values were obtained in m/s (shear wave velocity) and in kPa (elasticity modulus).
To asses microvascularisation we performed echo-doppler in the same manner. After positioning of
the ultrasound probe in B-mode, and then superimposed the ultrasound Doppler mapping. All images
were saved in dicom format.
4.7. Image and Statistical Analysis
The pulp vascularization of regenerated fingertips and of collateral control fingers was observed
by Doppler ultrasound (aixplorer®, Aix-en-Provence, France) and images were recorded as DICOM
files. In absence of vascularization, the pixels remained gray or black. Regions that were vascularized
appeared in color varying from red to white depending on the intensity. Images were processed within
ImageJ software (NIH, Bethesda, MD, USA) to extract vascularization pixels which were selected
with a color threshold based on Hue Saturation and Brightness (HSB) color mode. Pixels with Hue
between 0 and 60, saturation between 5 and 255 and brightness between 15 and 255 were selected and
considered as vascularization. The percentage of vascularization was calculated as a ratio between
vascularization pixels divided by total number of pixels in the evaluation zone.
Independent 2-sided t test was used to evaluate statistical difference between the morphological
and mechanical characteristics of regenerated fingertips and control healthy fingers. p < 0.05 was
considered as significant.
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Abstract: Diabetes Mellitus Type II (DM2) is a growing international health concern with no end in
sight. Complications of DM2 involve a myriad of comorbidities including the serious complications
of poor wound healing, chronic ulceration, and resultant limb amputation. In skin wound healing,
which has definite, orderly phases, diabetes leads to improper function at all stages. While the
etiology of chronic, non-healing diabetic wounds is multi-faceted, the progression to a non-healing
phenotype is closely linked to poor vascular networks. This review focuses on diabetic wound
healing, paying special attention to the aberrations that have been described in the proliferative,
remodeling, and maturation phases of wound angiogenesis. Additionally, this review considers
therapeutics that may offer promise to better wound healing outcomes.
Keywords: diabetes; wound healing; angiogenesis
1. Introduction
Diabetes mellitus type II (DM2) is a metabolic disorder defined by hyperglycemia due to insulin
resistance. DM2 has become a major global health epidemic with a particularly large incidence in the
United States. As of 2010 the global prevalence of DM2 was estimated at 280 million people, with recent
measures by the Centers for Disease Control and Prevention (CDC) in 2014 indicating that 86 million
Americans are in the pre-diabetic state and 29.1 million have been diagnosed with the disease [1].
DM2 is associated with numerous co-morbidities, including, but not limited to, cardiovascular disease,
stroke, chronic renal failure, peripheral neuropathy, and diabetic skin wounds or ulcerations [2].
Diabetic skin ulcerations present as painful sores with disintegration of dermal tissue including the
epidermis, dermis, and in many cases, subcutaneous tissue [3]. In diabetes, chronic skin ulcerations are
common on the lower extremities, particularly the foot. Diabetic foot ulcers (DFU) affect 15% of diabetic
patients. Of those patients with DFUs, 14–24% subsequently experience a lower extremity amputation,
with the mortality rate from amputation approaching 50–59% five-year post-amputation [3–6]. Studies
of the pathology of diabetic foot ulceration have focused on microbial invasion, epithelial breakdown,
and impaired immune function as some of the causative factors for the non-healing phenotype [7].
One underlying factor that accompanies all diabetic ulcerations is poor vascular flow, a circumstance
that impedes proper wound healing. Numerous studies have highlighted the importance of adequate
vascular sufficiency and vessel proliferation in tissue repair and the lack thereof in diabetic wound
healing [8]. More studies, albeit limited, have looked at whether disarrayed capillary remodeling
and maturation of vessels might play a role in impaired diabetic wound healing. This review will
synthesize the current findings in the literature about the role of appropriate capillary growth, function,
and maturation in the context of diabetic wound healing.
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2. The Anatomy and Maintenance of Blood Vessels
The human body is composed of a vast network of blood vessels that receive nutrient-rich,
oxygenated blood from the heart starting with the largest in size called arteries, then subsequently
decreasing in diameter to the arteriole, and finally to the capillary, where actual gas, nutrient, and waste
exchange between vessels and tissue occurs. Waste is then carried back to the great veins of the venous
system through venules. Capillaries, the cornerstone of nutrient diffusion, are so abundant in the body
that no cell is more than 100–200 microns from one [9]. The anatomy of a capillary can be described
as a microvessel that is composed of a one-cell layer thick lumen of endothelium with a diameter of
8–20 microns, just wide enough for the flow of erythrocytes and leukocytes [10]. The endothelial cells
(EC) that constitute capillaries are dynamic cell types that have only recently been appreciated for their
many activities. Endothelial cells line the lumen of every blood vessel in the body and are involved
in filtration, hemostasis, barrier function, inflammation, and angiogenesis [11]. In the unwounded
state, endothelial cells lining vessels are in a setting of quiescence demonstrated by the mostly basal
expression of pro or anti-angiogenic stimuli in the vascular bed [12].
At the level of the capillaries, endothelial cells are in an intimate relationship with an enigmatic
cell type called the pericyte. The pericyte is a type of mural cell embedded in the vascular basement
membrane that wraps around endothelial cells [13,14]. Much remains to be discovered about this
cell. Studies suggest that pericytes participate in regulation of capillary blood flow, clearance of
cellular debris, stabilization, and paracrine communication of endothelial cells [15–17]. Loss of
pericytes perturbs capillary function and results in extravascular leakage and edema [18]. The clear-cut
identification of pericytes has long been a source of consternation. Due to their morphological
similarities to vascular smooth muscle, the detection of distinct and ubiquitous markers that identify
the unique pericyte population in vessels has proved to be an arduous task. Markers used with some
success include α-smooth muscle actin (α-SMA) neural/glial antigen-2 (NG-2), desmin, Regulator
of G-protein signaling 5 (RGS5), and platelet-derived growth factor receptor (PDGFR)-β [15,19].
Unfortunately, none of these markers are truly specific for the pericyte, and each marker is known to
be expressed in other cell types. Nonetheless, several studies have linked some of these markers with
pericyte function. Of note, PDGFR-β has been shown to be responsible for the recruitment of pericytes,
and inhibition of PDGFR-β by imantinib results in decreased pericyte recruitment and migration
in vitro [20]. In a mouse model, imantinib treatment caused decreased levels of NG-2+ pericytes in
dermal wound tissue [21]. The role of PDGFR-β derives from interaction with its ligand, PDGF-β.
PDGF-β deficient embryos show insufficient mural cell recruitment, resulting in uncontrolled EC
development, vessel enlargement, permeability, and impaired perfusion [22,23]. Other factors that have
been implicated in the maintenance of pericytes include the endothelial cell receptor, angiopoietin-2
receptor (Tie2) and its ligand, angiopoietin-1 (Ang1). Many studies showcase the importance of the
Tie2/Ang1 complex to vessel maturity and integrity, including down regulation of the pro-angiogenic
factor vascular endothelial growth factor (VEGF), and in turn, prevention of vascular leakage [24,25].
3. Vasculogenesis and Angiogenesis
Vasculogenesis is defined as the formation of new vessels from precursor cells that coalesce into
primitive vascular networks. This process, which is prominent during development, contrasts with
angiogenesis, which is the formation of new capillaries from established vasculature [26]. Angiogenesis
occurs primarily during embryonic and post-natal development and is quite rare in the healthy adult
state except in the female reproductive system [27]. Several female reproductive organs, including
the ovary, endometrial lining of the uterus, and placenta undergo angiogenesis as part of their
normal physiologic responses [28]. Both physiologic and pathologic angiogenesis are regulated by a
balance of proangiogenic factors and anti-angiogenic factors. Vessels produced during non-pathologic
angiogenesis are characterized by their refinement, integrity, and ability to deliver nutrients to tissues
in a controlled, timely manner [29]. Disarrayed, runaway angiogenesis is a distinguishing feature of
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disease states, angiogenesis can be persistent, disorganized, and never reaches attenuation [31,32].
While basal levels of pro-angiogenic factors and the expression of their corresponding receptors
are maintained during the healthy state of homeostasis, the diseased state exhibits upregulated
expression of pro-angiogenic factors such as VEGF, fibroblast growth factor (FGF), and others to
promote unfettered growth of vessel beds and continual proliferation and migration of endothelial
cells [33]. Pathological angiogenesis is most often associated with malignancy, where excessive
angiogenesis can continue without order or end as tumor growth [34]. Dysfunctional angiogenesis is
also seen in Crohn’s disease, psoriasis, endometriosis, and rheumatoid arthritis [35]. Dysfunctional
angiogenesis has been implicated in the pathophysiology of atherosclerosis and diabetic retinopathy
as well as many other comorbidities that affect diabetic patients [36].
4. Angiogenesis in Wound Healing
Wound healing is a complex process that can be divided into a series of stages that include
hemostasis, inflammation, proliferation, and remodeling [37]. Prior to injury, the vasculature is in
a state of quiescence in which blood vessels are adequately perfused to deliver sufficient nutrients,
and oxygen to the tissue. Basal levels of pro-angiogenic factors such as VEGF and FGF in addition to
anti-angiogenic factors such as Ang-1 and pigment epithelium derived factor (PEDF) are expressed to
maintain a functional vascular network that is neither proliferating nor diminishing [38,39]. When an
assault to tissue occurs that produces injury, this homeostasis is interrupted, leading to a hypoxic state.
Hypoxia is an important activator of the endothelial cells in the injured and adjacent vasculature [40].
In this hypoxic environment, the innate immune system recruits leukocytes to the site of injury, with
neutrophils being the first responders in the acute phase of inflammation [41]. Following the influx of
neutrophils comes the later arrival of macrophages, and shortly thereafter the tissue reaches the zenith
of the proliferative phase of wound healing. Here macrophages, emerging new capillaries, and loose
connective tissue, characterized by edema and immaturity, form granulation tissue [42]. One hallmark
of the proliferative phase of wound healing is robust angiogenesis. Following the oxygen gradient that
was established by injury, numerous proangiogenic factors are produced in wounds. These factors, the
most notable of which is VEGF, stimulate capillaries to form nascent immature loops and branches
(Figure 1). VEGF has been shown to be one of the most important angiogenic factors in wounds, and
its production lies downstream of hypoxia. Hypoxia following injury activates hypoxia-inducible
factor-1 (HIF-1), a transcriptional activator that promotes angiogenesis by upregulating target genes
such VEGF-A [43]. VEGF-A, the main isoform in the wound, binds to its receptors on endothelial cells,
directing vessel growth [44]. VEGF and other pro-angiogenic factors guide vascular growth to areas of
low oxygen starting from the wound periphery into the wound bed [40,45].
One of the defining attributes of wound angiogenesis is the creation of a disorganized and poorly
perfused vasculature, characterized by a malformed capillary bed with blind-ended sprouts and
torturous loops [29]. Although malformed, the amount of capillaries in wounds reaches numbers much
higher than normal skin and peaks at approximately day 7–10 post wounding [46,47]. Following the
apex of angiogenesis, a switch from pro- to anti-angiogenic factors is ushered in, and vessels begin to
regress with the help of programmed cell death, termed apoptosis (Figure 1) [48,49]. The proliferative
phase, which can be characterized as chaotic, robust, and abundant, is contrasted by maturation, a
process that refines and selects for competent nascent vessels to become durable mature vessels similar
to the pre-injured state [50]. As capillary refinement occurs, vessel stabilization is mediated by smooth
muscle cell recruitment in the form of pericytes [51]. Pericytes are important to the stabilization and
maturation of newly formed vascular bed. In wounds, pericytes are actively recruited in response to
several factors, with the best described being PDGF [52,53].
Once pericytes arrive in the healing wound, they interact with endothelial cells and the basement
membrane (Figure 1). Pericyte-covered capillaries in the wound bed are resistant to the anti-angiogenic
factors which are produced during the remodeling phase of repair. Capillary pruning in wounds is
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best described including pigment epithelium derived factor (PEDF) and sprouty-2 (SPRY2) [54,55].
PEDF is a member of the serine protease inhibitor (SERPIN) family, and is one the most potent
anti-angiogenic factors in the vasculature [56]. It is constitutively expressed in unwounded skin
and serves a powerful homeostatic factor. PEDF has been shown to induce EC apoptosis and to
reduce the permeability of leakage-prone neovasculature [57]. A role for PEDF has been described
in several other tissue pathologies with dysregulated angiogenesis, with one of the most widely
studied being cancer. In a study by Chen et al., a popular drug used for the treatment of diabetes,
metformin, was shown to decrease prostate cancer cell proliferation, migration and tumor growth
through a mechanism that involved the upregulation of PEDF [58]. PEDF anti-angiogenic activity
has been shown to reduce tumor growth and vascularity, and PEDF is currently under investigation
as an anti-tumor and anti-angiogenic therapy [59]. In the context of skin wound healing, studies
by our laboratory have shown that the production of PEDF is essential to vascular remodeling and
maturation [60,61]. Sprouty-2 (SPRY2) is a second factor that has been demonstrated to assist in
capillary remodeling in wounds. SPRY2 is an intracellular protein that inhibits mitogen-activated
protein kinase (MAPK) signaling, ultimately downregulating the effect of VEGF on EC proliferation in
wounds [55,62].
Figure 1. Events in wound angiogenesis. In the normal quiescent state, capillaries (pink) are surrounded
by pericytes (blue). Following injury, the hypoxia that is created by the disruption of the vasculature
stimulates the production of pro-angiogenic factors (green triangle), resulting in the sprouting of
immature and disorganized new capillaries. In the remodeling phase, anti-angiogenic factors (red
triangle) cause most of the newly formed capillaries to undergo apoptosis, and the capillary bed is
pruned. Maturation factors (gray triangle) support the recruitment of stabilizing pericytes and the
maturation of the basement membrane on the new capillaries. The result is a stable, well perfused
capillary bed with a vessel density similar to normal uninjured tissue.
In addition to PEDF and SPRY2, another group of factors known to influence the normal
progression of wound capillary growth and remodeling are the angiopoietins 1 and 2, which work
in concert with the Tie2 receptor [63]. Ang1 is a potent maturation factor that stabilizes pericytes
and ECs in capillaries. Angiopoietin-2 (Ang2) has an antagonistic effect and destabilizes vessels [64].
Both angiopoietins compete for binding to Tie2 tyrosine kinase receptor [65]. Consequently, during the
normal angiogenic process, high levels of Ang2 are seen during the proliferative and pro-angiogenic
phase of wound healing, while increased levels of Ang1 are seen during the maturation phase [66].
As the remodeling phase of wound healing ends, the tissue achieves normal vascular permeability,
blood flow, and shows normal vascular branching [32]. Additionally, the high oxygen demand of the
early stages of wound healing, a situation that activates many immune mediators and pro-angiogenic
factors, returns to pre-injury levels [67]. The return to normoxia and normal oxygen demands signals
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mediators that ensure that vessel integrity is maintained and that endothelial cell migration, vessel
sprouting, and branching are kept in check [68] (Figure 1).
In healing wounds, angiogenesis supports and intersects with the other ongoing proliferative
activities and with the remodeling phase of repair [69]. During the proliferative phase, the new capillary
growth in wounds is interwoven with multiple components of dermal repair. Fibroblast migration,
proliferation, and collagen synthesis all occur during the same period as the angiogenic response.
Similarly, epithelial proliferation and closure of the wound is also ongoing during the time of capillary
growth. These many proliferative processes occur nearly simultaneously and support one another.
For example, while new capillaries respond to the oxygen and nutrient needs of the proliferating tissues,
stimulated epithelial cells produce VEGF to spur the capillary growth. During the remodeling phase,
a phase triggered as oxygen levels return to normal, capillaries are pruned, the hyperproliferative
epithelium thins to normal thickness, and the collagen in the wound bed undergoes maturation
and cross-linking to achieve greater tissue strength. Recent studies suggest that capillary pruning
and collagen maturation may interact in the remodeling phase, as the pruning of capillaries has
been suggested to influence the final extracellular matrix (ECM) structure [70]. Like the proliferative
phase, then, the remodeling phase exhibits a confluence of remodeling in capillaries, connective tissue,
and epithelium.
5. Diabetes: An Altered Angiogenic State
As described above, angiogenesis in normal wound healing relies on a delicate balance between
the promotion of vessel growth and proliferation and the promotion of vessel maturation and
quiescence. The diabetic disease state can significantly perturb this balance, disrupting proper wound
healing, tissue regeneration, and the restoration of a healthy vascular system. Perturbations in
vascular integrity are also a feature of diabetes. Diabetic hyperglycemia, particularly in DM2, has
been implicated in the progression of vascular disease in a multitude of both animal and clinical
studies. The elevated systemic glucose levels seen in diabetic patients are the root cause of many
micro and macrovascular complications that ultimately can affect angiogenesis [71]. ECs exposed
to elevated blood glucose for extended periods of time have been shown to become dysfunctional,
leading to integrity loss and increased susceptibility to apoptosis, detachment, and circulation into
the bloodstream [72,73]. Free flowing, detached ECs have been shown to be a predictive marker of
coronary heart disease and other pro-atherosclerotic processes in diabetes [74].
Insufficient angiogenesis plays a significant role in the pathogenesis of diabetic wound healing
and micro and microvascular disease. Interestingly, though, while diabetic wounds have an
angiogenic deficit, diabetes can lead to either increased or decreased angiogenesis depending upon
the pathologic process. Numerous studies have shown that the diabetes-related changes in the
angiogenic response can be tissue and/or organ dependent. For example, in diabetic retinopathy
(DR) excessive angiogenesis occurs, leading to a pathology that is characterized by microaneurysms,
hemorrhages, and vascular edema [75]. Along with increased capillary growth, a hallmark vascular
modification seen in diabetic retinopathy is the loss of pericyte coverage in the retinal capillary
network. This loss of pericytes is conducive to vascular edema and leakage. In response, the damaged
capillaries experience hypoxia, leading to increased, abnormal expression of HIF-1 transcription
factor and subsequent upregulation of VEGF-A, a known factor for increasing vascular permeability.
This situation further contributes to the formation of an excessive neovasculature that is leaky and
unrefined [75]. Importantly, an increase in the vitreous plasma levels of VEGF-A correlates with the
severity of DR in diabetic patients [76]. Diabetic nephropathy (DN) is also characterized by excessive
angiogenesis and resulting damage of the glomerular filtration system. The diabetic kidney may
secrete excessive levels of VEGF-A in the initial stages of DN, which can lead to hyperpermeability of
vessels, accelerated EC proliferation, and inhibition of apoptosis [77]. Studies by Cooper et al. showed
in the early pathogenesis of diabetic nephropathy, mRNA levels of VEGF-A and its receptor VEGFR-2
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signaling is closely tied to impaired VEGF receptor activation, which is responsible for EC cell activation
and proliferation, in addition to monocyte and endothelial progenitor cell (EPC) recruitment [75].
Abnormal receptor activation leads to increased circulating VEGF-A, due to decreased VEGF-A sensing
in the vasculature, leading to such phenomena as plaque destabilization, and as mentioned previously,
retinopathy [79].
6. Diabetes and Wound Angiogenesis
In contrast to diabetic nephropathy and retinopathy, diabetes leads to a decrease in angiogenesis in
healing wounds. Diabetic wounds, impacted by insufficient angiogenesis, show decreased vascularity
and capillary density [80]. Wound closure is greatly delayed in diabetes, and chronic non-healing
wounds are common. An association of impaired angiogenesis to the pathologic wound repair seen
in diabetic patients has been suggested by many studies. Below we review many of the described
alterations in wound angiogenic response that are seen in the context of diabetes.
Macrophages, an important cell type of the innate immune system that are required for wound
repair, have been shown to have altered functions in diabetic wounds [81]. In normal wounds,
macrophages switch from a proinflammatory to pro-reparative phenotype, with the latter supporting
tissue regrowth. In diabetic wounds, macrophage deficits include altered phenotypes that fail to
stimulate tissue repair. One animal model of diabetes that has been widely used for wound healing
studies is the db/db mouse. The db/db mouse is a genetic model of obesity, diabetes, and dyslipidemia
that results from a mutation in the leptin receptor gene, and db/db mice are well documented to
have significantly delayed healing [82]. In regard to macrophage function, Khanna et al. showed that
macrophages at the wound site of db/db mice showed decreased efferocytosis, leading to increased
apoptotic burden and inflammatory profile in the wound [83]. Since macrophages are an important
source of VEGF and other pro-angiogenic mediators in wounds, the macrophage deficit may be linked
to the documented decrease in wound angiogenesis that is seen in diabetic wounds. In one of the first
studies to investigate the mechanisms that influence angiogenesis in diabetic skin wounds, Seitz et al.
showed that VEGF-A protein and mRNA levels in wounds of db/db mice were significantly decreased
compared to normal healthy controls [84]. Subsequent studies by Galiano et al. also identified this
deficit, and went on to show that wounds of db/db mice treated with VEGF-A exhibited accelerated
wound closure compared to untreated mice [85]. Of note, this study also showed that VEGF-A treated
mice exhibited more of an early leaky, malformed vasculature and more edema until VEGF therapy
was ceased [85].
In addition to the decrease in pro-angiogenic stimulus, several studies now demonstrate
diabetes-associated changes in anti-angiogenic factors and capillary maturation factors in wounds.
The production of the anti-angiogenic factor PEDF has been examined in the context of diabetic wound
healing, although these studies investigated systemic serum levels rather than tissue expression levels.
In one such study, PEDF was shown to occur at higher circulating levels in patients with diabetic foot
ulcers compared to both non-diabetic and diabetic patients without DFU [86]. While this study might
suggest that elevated levels of PEDF could negatively impact wound healing outcomes, the PEDF level
was quantified only systemically and not within wound tissue.
One vascular maturation pathway that has been implicated in the deficits seen in diabetic wound
angiogenesis is the Ang1/Ang2/Tie2 complex. In diabetic wounds it has been shown that the ratio
of Ang1 to Ang2 is decreased, meaning that the ability of diabetic wound vasculature to progress
to a mature phenotype is likely disturbed [87,88]. A role for Ang 1 as a maturation factor has also
been described in streptozotocin (STZ)-induced diabetic mice. These studies have shown that topical
application of neutralizing antibodies to Ang1 on wounded skin reduced the maturation of nascently
formed blood vessels [89] Another study has shown that treatment of wounds of STZ-induced diabetic
mice with transplanted bone marrow treated with Ang1 led to increased endothelial progenitor cells
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MicroRNAs (miRNAs) are another class of molecule that can regulate angiogenesis and other
aspects of wound repair, and miRNAs are known to be differentially expressed in the diabetic wound
milieu. miRNAs are small, non-coding RNAs that are involved in post-translational modifications
or gene silencing. Many miRNAs have been shown to be perturbed in diabetic wound healing, and
specific miRNAs have been demonstrated to have modified expression in diabetic wound healing [91].
miR26-b is one miRNA that is highly expressed in diabetic ECs, and neutralization of this miRNA
in diabetic wound models leads to increased wound closure and granulation tissue production [92].
Downregulation of miR-200b, shown to enhance TNF-α expression, leads to increased angiogenesis in
diabetic wound skin [93]. In vivo and in vitro studies using local miR27-b, believed to affect levels of
the anti-angiogenic molecule thrombospondin 1 (TSP1) in the wound bed, showed that restoration of
miR27-b regulates angiogenesis in diabetic mouse models [94].
In the resolution and maturation phase of wound angiogenesis, platelet derived growth factor
(PDGF) is one maturation factor that appears to be perturbed in the diabetic state. As mentioned
above, PDGF encourages capillary maturation by nurturing and recruiting pericytes and retarding
vessel regression [95]. PDGF has been extensively studied in diabetic skin wound healing, and db/db
mice express lower levels of PDGF and its receptor in wounds [96]. Moreover, the topical application
of PDGF has been shown to accelerate closure rates in diabetic wound healing [97]. PDGF is likely to
have effects beyond capillary stabilization, as this factor is also a mitogen for fibroblasts. As further
discussed below, recombinant PDGF is one of the only currently available growth factor therapies for
non-healing diabetic ulcers.
In addition to changes in the production of pro-angiogenic and vascular maturation factors, the
diabetic state leads to an inherently decreased population of endothelial progenitor cells (EPCs) from
the bone marrow [98]. This deficit in turn, reduces the baseline vascularity in diabetic tissues and likely
affects wound angiogenesis [99]. The EPCs of diabetics have a reduced capacity to produce functional
angiogenic sprouts and tubes in ischemic models [100]. Without the appropriate function of these vital
cells, processes such as granulation tissue formation, capillary growth, and collagen deposition are
impaired in the wound bed [37,101]. Several studies suggest that EPC therapy might benefit diabetic
wounds. For example, studies by Asai et al. showed that topical introduction of the sonic hedgehog
(Shh) gene induced EPC proliferation, adhesion, and tube formation in vitro and increased wound
vascularity in vivo in diabetic mice [102].
Given the many changes in pro-angiogenic and vascular maturation factors in diabetes, it is
perhaps not surprising that the vascular architecture is known to be perturbed both in the normal skin
and in the wounds of diabetics. Corrosion casting and scanning electron microscopy (SEM) studies
have shown that diabetic patients suffering from diabetic microangiopathy in the toe region exhibit
damaged capillary architecture and evidence of vascular leakage [103]. Deficiencies in the vascular
architecture in diabetic wounds have also been noted. Recent studies in our laboratory have found
that wounds of mice subjected to a high fat diet (HFD), a diet induced obesity model (DIO) that
closely approximates DM2, present with more tortuous and aberrant architecture [104]. Overall, the
diabetic state creates a large array of angiogenic deficits that occur during both the early and late stages
of wound healing and affect both the proliferation and maturation of vessels. Many of the known
anti-angiogenic and maturation factors in wounds have not yet been studied in the context of diabetes.
In recent preliminary studies, though, we found that excisional wounds from db/db mice express
lower levels of multiple anti-angiogenic and maturation factors during wound healing resolution as
compared to control [105]. Conceptually, this suggests that vascular pruning and maturation may be
delayed in diabetic wounds, a situation that might lead to chronic wounds or recurring wounds due
to lack of a well-perfused and durable vascular bed. Table 1 gives a brief overview of the angiogenic
events that are altered in diabetes. Further investigations of anti-angiogenic and maturation factor
levels in the diabetic wound will need to be conducted to further evaluate the changes that occur in
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Table 1. Diabetes-associated changes in wound healing.
Event Diabetes-Associated Changes References
Normal Quiescent
Capillary Bed Microangiopathies, loss of pericytes [80]
Proangiogenic Stimulus
in Wounds
Decreased response to hypoxia, decreased production of










Not yet well studied, but altered production of
anti-angiogenic factors reported [17,86,89]
7. Current Therapies to Ameliorate Diabetic Wound Healing
The hunt for effective therapies to treat the sizable patient population affected by the chronic,
non-healing wounds brought on by diabetes has been elusive. While there has been research that
has progressed from laboratory, to clinical trials, and finally to clinical practice, these treatments have
failed to be the silver bullet that will heal chronic diabetic wounds. Here we discuss those available
therapies that involve mechanisms that improve angiogenesis and vascular perfusion.
One therapy that has been heavily relied upon in the clinic has been hyperbaric oxygen therapy
(HBOT). HBOT requires that a patient inhale 100 per cent oxygen in an enclosed chamber where the
pressure has been increased to above that found at sea level. The treatment has been shown to improve
tissue hypoxia, vessel perfusion, reduce inflammation and edema, and increase angiogenesis [106].
Numerous studies in patients with DFUs have shown that patients undergoing HBOT show increased
healing rates and reduced risk of a major limb amputation [107,108]. Unfortunately, HBOT is
cost-prohibitive to the average patient, and while it has an over 20-year track record in the clinic, is still
not a complete answer for treating non-healing diabetic foot wounds. Another therapy that has been
attempted is the use of growth factors such as VEGF and PDGF. As mentioned before, these factors
are important in the proliferative and maturation phase of wound healing, respectively. Numerous
animal studies have shown that topical application of VEGF and its isoforms improve wound healing
in diabetic mice [85,109,110]. However, topical VEGF therapy in human DFUs with recombinant
VEGF (rh-VEGF) (Telbermin) has been met with limited success. Although Phase I trials suggested
that patients who received topical VEGF compared to placebo exhibited improved healing, the drug
was abandoned after Phase II clinical trials demonstrated no significant effect [111]. PDGF treatment
has also been investigated in both mouse model and clinical trials. Recombinant PDGF became
available as becaplermin (Regranex) in 1997 for the treatment of DFUs [112–114]. Topical treatment
with becaplermin in clinical trial showed a 43 per cent increase in wound closure versus placebo in
patients, in addition to reduced time to wound close of 32 per cent and complete healing of ulcers in
57.5% of patients [112–114]. Unfortunately, becaplermin has been met with many issues. Firstly, it is
an expensive treatment that may not be readily accessible or feasible for many patients. Additionally,
adverse side effects of rash and burning sensation at the site of application, as well as increased risks
of osteomyelitis and cellulitis have been reported [113]. The most worrisome adverse side effect
from the drug is the possible increased risk of malignancy in users who undergo more than 3 tubes
of topical treatment, warranting the FDA to release a black box warning for the drug in 2008 [111].
Consequently, topical growth factors, while having promising results in animal models, have not yet
translated well to the clinic. While single growth factors have met with limited success in the treatment
of wounds, the use of platelet derived therapies has been suggested as a possible improvement as
it provides a myriad of factors [115]. Platelets themselves are a rich source of many growth factors,
including PDGF, transforming growth factor β (TGFβ), FGF-2, epidermal growth factor (EGF), and
VEGF. Platelet derivatives such as platelet-rich plasma, platelet gel, and platelet-rich fibrin therefore
have been explored for repair and regenerative strategies for both hard and soft tissues. Some of the
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the derivatives from the patient’s own platelets, thus limiting patient exposure to exogenous agents.
Beyond growth factors, multiple promising new therapies for diabetic wounds are currently under
investigation. These include the application of cells such as stem cells and macrophages, and the use
of sophisticated bioengineering approaches to provoke tissue repair responses.
8. Limitations of Current Knowledge and Future Directions
Our current knowledge of the pathology of DFUs and of the angiogenic response in diabetic
wounds is incomplete. One major stumbling block to our understanding has been the lack of
readily available animal models that sufficiently approximate human diabetic wound healing,
especially chronic wounds. Moreover, many of the preclinical animal studies to date have focused on
monotherapies, an approach which seems unlikely to be adequate for the treatment of the multifactorial
problem of diabetic chronic skin wounds. Furthermore, work in diabetic wound healing has until
recently focused only on the initial stages of wound healing and not the deficits that might prevent
diabetic wound resolution. Adequate healing requires vascular maturation, including a return to
quiescence and a normal vascular network. Much more work is needed to understand the differences
during all stages of wound healing that occur in the diabetic state, with the goal of finding therapies and
interventions to help drive these non-healing wounds to a state of health and integrity. Considering the
enormous health care costs, decreased quality of life, and numerous comorbidities that are associated
with diabetes, it is imperative that a holistic and multi-factorial approach to treating diabetes and to
advancing wound care is sought.
Acknowledgments: Research in the authors’ laboratory is currently supported by NIH R01-GM50875 and
NIH R21-DE025926.
Author Contributions: Uzoagu A. Okonkwo and Luisa A. DiPietro planned the content. Uzoagu A. Okonkwo
drafted the review. Luisa A. DiPietro provided guidance and edited the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
α-SMA α-smooth muscle actin
Ang angiopoietin
CDC Centers for Disease Control and Prevention
db/db genetically diabetic mouse model
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RGS5 regulator of G-protein signaling 5
SERPIN serine protease inhibitor
Shh sonic hedgehog
SPRY2 sprouty homolog 2
STZ streptozotocin
Tie2 angiopoietin-2 receptor
TGFβ transforming growth factor β
TNF-α tumor necrosis factor-α








Int. J. Mol. Sci. 2017, 18, 1419
References
1. Centers for Disease Control and Prevention. National Diabetes Statistical Report: Estimates of Diabetes and Its
Burden in the United States, 2014; US Department of Health and Human Services: Atlanta, GA, USA, 2014.
2. Nathan, D.M. Long-Term Complications of Diabetes Mellitus. N. Engl. J. Med. 1993, 328, 1676–1685.
[CrossRef] [PubMed]
3. Alavi, A.; Sibbald, R.G.; Mayer, D.; Goodman, L.; Botros, M.; Armstrong, D.G.; Woo, K.; Boeni, T.; Ayello, E.A.;
Kirsner, R.S. Diabetic foot ulcers: Part I. pathophysiology and prevention. J. Am. Acad. Dermatol. 2014, 70,
1.e1–1.e18. [CrossRef] [PubMed]
4. Jeffcoate, W.J.; Harding, K.G. Diabetic foot ulcers. Lancet 2003, 361, 1545–1551. [CrossRef]
5. Martins-Mendes, D.; Monteiro-Soares, M.; Boyko, E.J.; Ribeiro, M.; Barata, P.; Lima, J.; Soares, R.
The independent contribution of diabetic foot ulcer on lower extremity amputation and mortality risk.
J. Diabetes Complicat. 2013, 28, 632–638. [CrossRef] [PubMed]
6. Wu, S.C.; Driver, V.R.; Wrobel, J.S.; Armstrong, D.G. Foot ulcers in the diabetic patient, prevention and
treatment. Vasc. Health Risk Manag. 2007, 3, 65–76. [PubMed]
7. Noor, S.; Zubair, M.; Ahmad, J. Diabetic foot ulcer—A review on pathophysiology, classification and
microbial etiology. Diabetes Metab. Syndr. Clin. Res. Rev. 2015, 9, 192–199. [CrossRef] [PubMed]
8. Prompers, L.; Schaper, N.; Apelqvist, J.; Edmonds, M.; Jude, E.; Mauricio, D.; Uccioli, L.; Urbancic, V.;
Bakker, K.; Holstein, P.; et al. Prediction of outcome in individuals with diabetic foot ulcers: Focus on the
differences between individuals with and without peripheral arterial disease. The EURODIALE Study.
Diabetologia 2008, 51, 747–755. [CrossRef] [PubMed]
9. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. Molecular Biology of the Cell, 4th ed.;
Garland Science: New York, NY, USA, 2002.
10. Pittman, R.N. Regulation of Tissue Oxygenation. Morgan Claypool Life Sci. 2011, 3, 100. [CrossRef]
11. Galley, H.F.; Webster, N.R. Physiology of the endothelium. Br. J. Anaesth. 2004, 93, 105–113. [CrossRef]
[PubMed]
12. Aird, W.C. Endothelium in health and disease. Pharmacol. Rep. 2008, 60, 139–143. [PubMed]
13. Caporali, A.; Martello, A.; Miscianinov, V.; Maselli, D.; Vono, R.; Spinetti, G. Contribution of pericyte
paracrine regulation of the endothelium to angiogenesis. Pharmacol. Ther. 2017, 171, 56–64. [CrossRef]
[PubMed]
14. Shepro, D.; Morel, N.M. Pericyte physiology. FASEB J. 1993, 7, 1031–1038. [PubMed]
15. Armulik, A.; Genové, G.; Betsholtz, C. Pericytes: Developmental, Physiological, and Pathological
Perspectives, Problems, and Promises. Dev. Cell 2011, 21, 193–215. [CrossRef] [PubMed]
16. Armulik, A.; Abramsson, A.; Betsholtz, C. Endothelial/pericyte interactions. Circ. Res. 2005, 97, 512–523.
[CrossRef] [PubMed]
17. Geevarghese, A.; Herman, I.M. Pericyte-endothelial crosstalk: Implications and opportunities for advanced
cellular therapies. Transl. Res. 2014, 163, 296–306. [CrossRef] [PubMed]
18. Dulmovits, B.M.; Herman, I.M. Microvascular remodeling and wound healing: A role for pericytes. Int. J.
Biochem. Cell Biol. 2012, 44, 1800–1812. [CrossRef] [PubMed]
19. Mills, S.J.; Cowin, A.J.; Kaur, P. Pericytes, mesenchymal stem cells and the wound healing process. Cells 2013,
2, 621–634. [CrossRef] [PubMed]
20. Van Dijk, C.G.M.; Nieuweboer, F.E.; Pei, J.Y.; Xu, Y.J.; Burgisser, P.; Van Mulligen, E.; El Azzouzi, H.;
Duncker, D.J.; Verhaar, M.C.; Cheng, C. The complex mural cell: Pericyte function in health and disease.
Int. J. Cardiol. 2015, 190, 75–89. [CrossRef] [PubMed]
21. Rajkumar, V.S.; Shiwen, X.; Bostrom, M.; Leoni, P.; Muddle, J.; Ivarsson, M.; Gerdin, B.; Denton, C.P.;
Bou-Gharios, G.; Black, C.M.; et al. Platelet-derived growth factor-β receptor activation is essential for
fibroblast and pericyte recruitment during cutaneous wound healing. Am. J. Pathol. 2006, 169, 2254–2265.
[CrossRef] [PubMed]
22. Hellström, M.; Gerhardt, H.; Kalén, M.; Li, X.; Eriksson, U.; Wolburg, H.; Betsholtz, C. Lack of pericytes leads
to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 2001, 152, 543–553. [CrossRef]
23. Abramsson, A.; Berlin, Ö.; Papayan, H.; Paulin, D.; Shani, M.; Betsholtz, C. Analysis of mural cell recruitment








Int. J. Mol. Sci. 2017, 18, 1419
24. Sato, T.N.; Tozawa, Y.; Deutsch, U.; Wolburg Buchholz, K.; Fujiwara, Y.; Gendron Maguire, M.; Gridley, T.;
Wolburg, H.; Risau, W.; Qin, Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel
formation. Nature 1995, 376, 70–74. [CrossRef] [PubMed]
25. Sundberg, C.; Kowanetz, M.; Brown, L.F.; Detmar, M.; Dvorak, H.F. Stable expression of angiopoietin-1 and
other markers by cultured pericytes: Phenotypic similarities to a subpopulation of cells in maturing vessels
during later stages of angiogenesis in vivo. Lab. Investig. 2002, 82, 387–401. [CrossRef] [PubMed]
26. Kolte, D.; McClung, J.A.; Aronow, W.S. Vasculogenesis and Angiogenesis. In Translational Research in Coronary
Artery Disease: Pathophysiology to Treatment; Aronow, W.S., McClung, J.A., Eds.; Academic Press: Cambridge,
MA, USA, 2015; pp. 49–65.
27. Geudens, I.; Gerhardt, H. Coordinating cell behaviour during blood vessel formation. Development 2011, 138,
4569–4583. [CrossRef] [PubMed]
28. Reynolds, L.P.; Grazul-Bilska, A.T.; Redmer, D.A. Angiogenesis in the female reproductive organs:
Pathological implications. Int. J. Exp. Pathol. 2002, 83, 151–163. [CrossRef] [PubMed]
29. Fukumura, D.A.I.; Jain, R.K. Imaging angiogenesis and the microenvironment. APMIS 2008, 116, 695–715.
[CrossRef] [PubMed]
30. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27–31.
[CrossRef] [PubMed]
31. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249–257. [CrossRef]
[PubMed]
32. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932–936. [CrossRef] [PubMed]
33. Papetti, M.; Herman, I.M. Mechanisms of normal and tumor-derived angiogenesis. AJP Cell Physiol. 2002,
282, C947–C970. [CrossRef] [PubMed]
34. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358, 2039–2049. [CrossRef] [PubMed]
35. Nissen, N.N.; Polverini, P.J.; Koch, A.E.; Volin, M.V.; Gamelli, R.L.; DiPietro, L.A. Vascular endothelial growth
factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 1998, 152,
1445–1452. [PubMed]
36. Fowler, M.J. Microvascular and macrovascular complications of diabetes. Clin. Diabetes 2011, 29, 116–122.
[CrossRef]
37. Guo, S.; DiPietro, L.A. Factors affecting wound healing. J. Dent. Res. 2010, 89, 219–229. [CrossRef] [PubMed]
38. Demidova-Rice, T.N.; Durham, J.T.; Herman, I.M. Wound healing angiogenesis: Innovations and challenges
in acute and chronic wound healing. Adv. Wound Care 2012, 1, 17–22. [CrossRef] [PubMed]
39. Tonnesen, M.G.; Feng, X.; Clark, R.A.F. Angiogenesis in wound healing. J. Investig. Dermatol. Symp. Proc.
2000, 5, 40–46. [CrossRef] [PubMed]
40. Tandara, A.A.; Mustoe, T.A. Oxygen in wound healing—More than a nutrient. World J. Surg. 2004, 28,
294–300. [CrossRef] [PubMed]
41. Turabelidze, A.; Dipietro, L.A. Inflammation and Wound Healing. In Oral Wound Healing: Cell Biology and
Clinical Management; Larjava, H., Ed.; John Wiley and Sons: Hoboken, NJ, USA, 2013; pp. 39–56.
42. Koh, T.J.; DiPietro, L.A. Inflammation and wound healing: The role of the macrophage. Expert Rev. Mol. Med.
2011, 13, e23. [CrossRef] [PubMed]
43. Liu, L.; Marti, G.P.; Wei, X.; Zhang, X.; Zhang, H.; Liu, Y.V.; Semenza, G.L.; Harmon, J.W. Age-dependent
Impairment of HIF-1α expression in diabetic mice: Correction with electroporation-facilitated gene therapy
increases wound healing, angiogenesis, and circulating angiogenic cells. J. Cell Physiol. 2008, 217, 319–327.
[CrossRef] [PubMed]
44. Eming, S.A.; Brachvogel, B.; Odorisio, T.; Koch, M. Regulation of angiogenesis: Wound healing as a model.
Prog. Histochem. Cytochem. 2007, 42, 115–170. [CrossRef] [PubMed]
45. Broughton, G.; Janis, J.E.; Attinger, C.E. The basic science of wound healing. Plast. Reconstr. Surg. 2006, 117,
12S–34S. [CrossRef] [PubMed]
46. Johnson, K.E.; Wilgus, T.A. Vascular endothelial growth factor and angiogenesis in the regulation of
cutaneous wound repair. Adv. Wound Care 2014, 3, 647–661. [CrossRef] [PubMed]
47. Szpaderska, A.M.; Zuckerman, J.D.; DiPietro, L.A. Differential injury responses in oral mucosal and
cutaneous wounds. J. Dent. Res. 2003, 82, 621–626. [CrossRef] [PubMed]









Int. J. Mol. Sci. 2017, 18, 1419
49. Dimmeler, S.; Zeiher, A.M. Endothelial cell apoptosis in angiogenesis and vessel regression. Circ. Res. 2000,
87, 434–439. [CrossRef] [PubMed]
50. Chen, R.R.; Silva, E.A.; Yuen, W.W.; Mooney, D.J. Spatio-temporal VEGF and PDGF delivery patterns blood
vessel formation and maturation. Pharm. Res. 2007, 24, 258–264. [CrossRef] [PubMed]
51. Hirschi, K.K.; D’Amore, P.A. Pericytes in the microvasculature. Cardiovasc. Res. 1996, 32, 687–698. [CrossRef]
52. Allt, G.; Lawrenson, J.G. Pericytes: Cell biology and pathology. Cells Tissues Organs 2001, 169, 1–11. [CrossRef]
[PubMed]
53. Lindblom, P.; Gerhardt, H.; Liebner, S.; Abramsson, A.; Enge, M.; Hellström, M.; Bäckström, G.;
Fredriksson, S.; Landegren, U.; Nyström, H.C.; et al. Endothelial PDGF-B retention is required for proper
investment of pericytes in the microvessel wall. Genes Dev. 2003, 17, 1835–1840. [CrossRef] [PubMed]
54. Pries, A.R.; Secomb, T.W. Making Microvascular Networks Work: Angiogenesis, Remodeling, and Pruning.
Physiology 2014, 29, 446–455. [CrossRef] [PubMed]
55. Wietecha, M.S.; Cerny, W.L.; Dipietro, L.A. Mechanisms of vessel regression: Toward an understanding of
the resolution of angiogenesis. Curr. Top. Microbiol. Immunol. 2013, 367, 3–32. [PubMed]
56. Filleur, S.; Nelius, T.; De Riese, W.; Kennedy, R.C. Characterization of PEDF: A multi-functional serpin family
protein. J. Cell. Biochem. 2009, 106, 769–775. [CrossRef] [PubMed]
57. Broadhead, M.L.; Becerra, S.P.; Choong, P.F.M.; Dass, C.R. The applied biochemistry of PEDF and implications
for tissue homeostasis. Growth Factors 2010, 28, 280–285. [CrossRef] [PubMed]
58. Chen, X.; Li, C.; He, T.; Mao, J.; Li, C.; Lyu, J.; Meng, Q.H. Metformin inhibits prostate cancer cell proliferation,
migration, and tumor growth through upregulation of PEDF expression. Cancer Biol. Ther. 2016, 17, 507–514.
[CrossRef] [PubMed]
59. Becerra, S.P.; Notario, V. The effects of PEDF on cancer biology: Mechanisms of action and therapeutic
potential. Nat. Rev. Cancer 2013, 13, 258–271. [CrossRef] [PubMed]
60. Wietecha, M.S.; Krol, M.J.; DiPietro, L.A. PEDF functions as an endogenous anti-angiogenic during dermal
wound repair. Wound Repair Regen. 2012, 20, A45.
61. Wietecha, M.S.; Król, M.J.; Michalczyk, E.R.; Chen, L.; Gettins, P.G.; DiPietro, L.A. Pigment
epithelium-derived factor as a multifunctional regulator of wound healing. Am. J. Physiol. Heart Circ.
Physiol. 2015, 309, H812–H826. [CrossRef] [PubMed]
62. Wietecha, M.S.; Chen, L.; Ranzer, M.J.; Anderson, K.; Ying, C.; Patel, T.B.; DiPietro, L.A. Sprouty2
downregulates angiogenesis during mouse skin wound healing. Am. J. Physiol. Heart Circ. Physiol. 2011, 300,
H459–H467. [CrossRef] [PubMed]
63. Fagiani, E.; Christofori, G. Angiopoietins in angiogenesis. Cancer Lett. 2013, 328, 18–26. [CrossRef] [PubMed]
64. Staton, C.A.; Valluru, M.; Hoh, L.; Reed, M.W.R.; Brown, N.J. Angiopoietin-1, angiopoietin-2 and Tie-2
receptor expression in human dermal wound repair and scarring. Br. J. Dermatol. 2010, 163, 920–927.
[CrossRef] [PubMed]
65. Maisonpierre, P.C. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science
1997, 277, 55–60. [CrossRef] [PubMed]
66. Brudno, Y.; Ennett-Shepard, A.B.; Chen, R.R.; Aizenberg, M.; Mooney, D.J. Enhancing microvascular
formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation
factors. Biomaterials 2013, 34, 9201–9209. [CrossRef] [PubMed]
67. Hickey, M.M.; Simon, M.C. Regulation of Angiogenesis by hypoxia and hypoxia-inducible factors. Curr. Top.
Dev. Biol. 2006, 76, 217–257. [PubMed]
68. Jain, R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9, 685–693. [CrossRef] [PubMed]
69. Gurtner, G.C.; Werner, S.; Barrandon, Y.; Longaker, M.T. Wound repair and regeneration. Nature 2008, 453,
314–321. [CrossRef] [PubMed]
70. DiPietro, L.A. Angiogenesis and wound repair: When enough is enough. J. Leukoc. Biol. 2016, 100, 1–6.
[CrossRef] [PubMed]
71. Altabas, V. Diabetes, endothelial dysfunction, and vascular repair: What should a diabetologist keep his eye
on? Int. J. Endocrinol. 2015, 2015, 1–14. [CrossRef] [PubMed]
72. Piconi, L.; Quagliaro, L.; Assaloni, R.; Da Ros, R.; Maier, A.; Zuodar, G.; Ceriello, A. Constant and intermittent
high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction.








Int. J. Mol. Sci. 2017, 18, 1419
73. Yu, J.Q.; Liu, X.F.; Chin, L.K.; Liu, A.Q.; Luo, K.Q. Study of endothelial cell apoptosis using fluorescence
resonance energy transfer (FRET) biosensor cell line with hemodynamic microfluidic chip system. Lab Chip
2013, 13, 2693–2700. [CrossRef] [PubMed]
74. McClung, J.A.; Naseer, N.; Saleem, M.; Rossi, G.P.; Weiss, M.B.; Abraham, N.G.; Kappas, A. Circulating
endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c. Diabetologia
2005, 48, 345–350. [CrossRef] [PubMed]
75. Kota, S.; Meher, L.; Jammula, S.; Kota, S.; Krishna, S.V.S.; Modi, K. Aberrant angiogenesis: The gateway to
diabetic complications. Indian J. Endocrinol. Metab. 2012, 16, 918. [CrossRef] [PubMed]
76. Okamoto, T.; Yamagishi, S.I.; Inagaki, Y.; Amano, S.; Takeuchi, M.; Kikuchi, S.; Ohno, S.;
Yoshimura, A. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis
in vitro. Biochem. Biophys. Res. Commun. 2002, 297, 419–424. [CrossRef]
77. McGinn, S.; Saad, S.; Poronnik, P.; Pollock, C.A. High glucose-mediated effects on endothelial cell
proliferation occur via p38 MAP kinase. Am. J. Physiol. Endocrinol. Metab. 2003, 285, E708–E717. [CrossRef]
[PubMed]
78. Cooper, M.E.; Vranes, D.; Youssef, S.; Stacker, S.A.; Cox, A.J.; Rizkalla, B.; Casley, D.J.; Bach, L.A.; Kelly, D.J.;
Gilbert, R.E. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor
VEGFR-2 in experimental diabetes. Diabetes 1999, 48, 2229–2239. [CrossRef] [PubMed]
79. Simons, M. Angiogenesis, arteriogenesis, and diabetes: Paradigm reassessed? J. Am. Coll. Cardiol. 2005, 46,
835–837. [CrossRef] [PubMed]
80. Dinh, T.; Veves, A. Microcirculation of the Diabetic Foot. Curr. Pharm. Des. 2005, 11, 2301–2309. [CrossRef]
[PubMed]
81. Mirza, R.; Koh, T.J. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. Cytokine
2011, 56, 256–264. [CrossRef] [PubMed]
82. Michaels, J.; Churgin, S.S.; Blechman, K.M.; Greives, M.R.; Aarabi, S.; Galiano, R.D.; Gurtner, G.C. db/db mice
exhibit severe wound-healing impairments compared with other murine diabetic strains in a silicone-splinted
excisional wound model. Wound Repair Regen. 2007, 15, 665–670. [CrossRef] [PubMed]
83. Khanna, S.; Biswas, S.; Shang, Y.; Collard, E.; Azad, A.; Kauh, C.; Bhasker, V.; Gordillo, G.M.; Sen, C.K.; Roy, S.
Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS ONE
2010, 5, e9539. [CrossRef] [PubMed]
84. Seitz, O.; Schürmann, C.; Hermes, N.; Müller, E.; Pfeilschifter, J.; Frank, S.; Goren, I. Wound healing in mice
with high-fat diet- or ob gene-induced diabetes-obesity syndromes: A comparative study. Exp. Diabetes Res.
2010, 2010. [CrossRef] [PubMed]
85. Galiano, R.D.; Tepper, O.M.; Pelo, C.R.; Bhatt, K.A.; Callaghan, M.; Bastidas, N.; Bunting, S.; Steinmetz, H.G.;
Gurtner, G.C. Topical vascular endothelial growth factor accelerates diabetic wound healing through
increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am. J. Pathol. 2004,
164, 1935–1947. [CrossRef]
86. Qi, W.; Yang, C.; Dai, Z.; Che, D.; Feng, J.; Mao, Y.; Cheng, R.; Wang, Z.; He, X.; Zhou, T.; et al. High levels of
pigment epithelium-derived factor in diabetes impair wound healing through suppression of Wnt signaling.
Diabetes 2015, 64, 1407–1419. [CrossRef] [PubMed]
87. Isidori, A.M.; Venneri, M.A.; Fiore, D. Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: Therapeutic
strategies to restore the highs and lows of angiogenesis in diabetes. J. Endocrinol. Investig. 2016, 39, 1235–1246.
[CrossRef] [PubMed]
88. Kampfer, H.; Pfeilschifter, J.; Frank, S. Expressional Regulation of Angiopoietin-1 and -2 and the Tie-1 and -2
receptor tyrosine kinases during cutaneous wound healing: A comparative study of normal and impaired
repair. Lab. Investig. 2001, 81, 361–373. [CrossRef] [PubMed]
89. Li, C.; Yu, T.; Liu, Y.; Chen, X.; Zhang, X. Topical Application of insulin accelerates vessel maturation
of wounds by regulating angiopoietin-1 in diabetic mice. Int. J. Low. Extrem. Wounds 2015, 14, 353–364.
[CrossRef] [PubMed]
90. Balaji, S.; Han, N.; Moles, C.; Shaaban, A.F.; Bollyky, P.L.; Crombleholme, T.M.; Keswani, S.G. Angiopoietin-1
improves endothelial progenitor cell-dependent neovascularization in diabetic wounds. Surgery 2015, 158,
846–856. [CrossRef] [PubMed]
91. Xu, J.; Zgheib, C.; Hu, J.; Wu, W.; Zhang, L.; Liechty, K.W. The role of microRNA-15b in the impaired








Int. J. Mol. Sci. 2017, 18, 1419
92. Icli, B.; Nabzdyk, C.S.; Lujan-Hernandez, J.; Cahill, M.; Auster, M.E.; Wara, A.K.M.; Sun, X.; Ozdemir, D.;
Giatsidis, G.; Orgill, D.P.; et al. Regulation of impaired angiogenesis in diabetic dermal wound healing by
microRNA-26a. J. Mol. Cell. Cardiol. 2016, 91, 151–159. [CrossRef] [PubMed]
93. Chan, Y.C.; Roy, S.; Khanna, S.; Sen, C.K. Downregulation of endothelial MicroRNA-200b supports cutaneous
wound angiogenesis by desilencing GATA binding protein 2 and vascular endothelial growth factor receptor
2. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1372–1382. [CrossRef] [PubMed]
94. Wang, J.M.; Tao, J.; Chen, D.D.; Cai, J.J.; Irani, K.; Wang, Q.; Yuan, H.; Chen, A.F. MicroRNA miR-27b rescues
bone marrow-derived angiogenic cell function and accelerates wound healing in type 2 diabetes mellitus.
Arterioscler. Thromb. Vasc. Biol. 2014, 34, 99–109. [CrossRef] [PubMed]
95. Hellberg, C.; Östman, A.; Heldin, C.-H. PDGF and Vessel Maturation. Recent Results Cancer Res. 2010, 180,
103–114. [PubMed]
96. Beer, H.D.; Longaker, M.T.; Werner, S. Reduced expression of PDGF and PDGF receptors during impaired
wound healing. J.Investig. Dermatol. 1997, 109, 132–138. [CrossRef] [PubMed]
97. Brown, R.L.; Breeden, M.P.; Greenhalgh, D.G. PDGF and TGF-α act synergistically to improve wound healing
in the genetically diabetic mouse. J. Surg. Res. 1994, 56, 562–570. [CrossRef] [PubMed]
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Abstract: Much of current research investigates the beneficial properties of mesenchymal stem cells
(MSCs) as a treatment for wounds and other forms of injury. In this review, we bring attention to
and discuss the role of the pericyte, a cell type which shares much of the differentiation potential
and regenerative properties of the MSC as well as specific roles in the regulation of angiogenesis,
inflammation and fibrosis. Pericytes have been identified as dysfunctional or depleted in many
disease states, and observing the outcomes of pericyte perturbation in models of disease and wound
healing informs our understanding of overall pericyte function and identifies these cells as an
important target in the development of therapies to encourage healing.
Keywords: pericyte; MSC; wound healing; cell therapy
1. An Introduction to Pericytes
1.1. Morphology, Location and Function
Pericytes are cells found on the outside of blood vessels [1]. Their long processes encircle the
abluminal surface of those vessels and attribute structural integrity to the vessel wall. Pericyte
morphology is characterised by minimal cytoplasm, a prominent nucleus and projecting processes
which wrap around associated capillaries (Figure 1) [2].
 
Figure 1. SEM showing pericyte processes spanning a venous capillary of the rete mirabile from an eel
swimbladder. Image was kindly supplied by Professor Roger C. Wagner, University of Delaware.
From their position on the outer surface of the blood vessel, pericytes interact with endothelial
cells (ECs), which reside on the other side of the basement membrane, through adhesion plaques
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which provide adherence between the ECs and the pericytes. Peg-and-socket contacts facilitate the
diffusion of molecules between the two cell types [3]. Pericytes and ECs together create and maintain
the shared basement membrane, the acellular component of the vessel wall [4]. This relationship
allows pericytes to regulate the blood flow within vessels by virtue of high levels of α-smooth muscle
actin (αSMA) and myosin expression, which can bring about vessel constriction [5]. Pericyte density
and the EC to pericyte ratio is found to differ between organs, with ratios estimated to range from
1:1 in the central nervous system (CNS) to 10:1 in tissues such as skeletal muscle [6]. Consequently,
in any given organ the proportion of the abluminal vessel surface which is covered by pericytes can
be anywhere from 10–70% [7]. At the interface between the endothelial tube and the surrounding
tissue, pericytes are ideally located to regulate processes associated with the vasculature, including
the control of angiogenesis, which is well documented for these cells both in the context of general
homeostasis and in response to trauma. Pericytes mechanically regulate vessel wall integrity, and
serve as signalling mediators of EC behaviour. Paracrine pericyte signalling directs EC proliferation
and migration to form new vessel sprouts when appropriate and inhibits aberrant pro-angiogenic
behaviour in ECs when vessel sprouting is not required [8]. Pericytes have also recently been found to
regulate the diffusion of cells and proteins from the vessel to the surrounding tissue, influencing the
infiltration of neutrophils [9,10] and macrophages [11], which suggests an additional role for pericytes
as mediators of the inflammatory process.
1.2. Pericyte Origin and MSC Properties
The developmental origins of the pericyte across all tissues are still not fully understood. For the
most part, pericytes develop from the mesoderm during embryogenesis, with the origins of pericytes
in the gut [12], lungs [13] and liver [14] having been tracked to the mesothelium. Similarly, cardiac
pericytes have been shown to stem from the epicardial mesothelium [15,16]. In the central nervous
system, however, chick-chimera studies show that while pericytes in the spinal cord and brain stem
have developed from the mesoderm, pericytes of the forebrain are more likely to be derived from
neural crest cells of the neuroectoderm [17].
The diverse origins of tissue-specific pericytes are reflected in the antigenic heterogeneity of
pericytes observed between tissues. Currently, there are no markers identified as being expressed
exclusively by pericytes, nor any constitutively expressed across pericytes of all locations. Within
varying tissues, pericytes are found to display morphological changes and differential expression
of markers dependent on their differentiation state and specific function within that tissue [18].
Changes in expression are also noted between different developmental stages and disease states [7].
Further, some markers are only expressed when pericytes are actively involved in remodelling of the
vasculature, such as RGS5, which is expressed on activated pericytes in tumour development and
vascular remodelling but is absent at other times [2,19]. While the list of recognised pericyte markers
is growing, there remains a distinct absence within the field of a method by which pericytes can be
identified indiscriminately of tissue, disease or developmental factors. As such, pericyte identification
still relies on the concurrent identification of perivascular location, morphology and expression of
multiple markers. For example, pericytes express many of the same markers as fibroblasts and
exhibit similar morphology, so colocalisation between blood vessels and pericytes is often necessary to
distinguish between the two cell types. The current struggles in pericyte identification and therefore
isolation have been comprehensively reviewed in recent years [7,20,21]. Ansell and Izita discuss the
difficulties encountered when comparing previous studies of pericyte function, particularly in vitro,
and identify the potential for confounding results due to the unintentional selection of different
pericyte subtypes for inclusion in experimental studies [22]. Much of the discussion of pericytes in the
literature today addresses the current limitations in our ability to accurately define and isolate pericyte
subtypes for experimental purposes.
There is significant overlap between markers expressed by pericytes and mesenchymal stem cells
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populations. Expression of CD105, CD73, CD90 and CD44 is observed in both pericytes and MSCs [23],
and the observation that some subsets of pericytes express αSMA while others do not leads some
researchers to postulate that αSMA+ pericytes are more likely to carry out a structural support role at
the blood vessel wall while αSMA− pericytes possess a more regenerative MSC-like phenotype [24].
Much of the current research in regenerative medicine is invested in evaluating the potential of
cells with MSC-like properties as treatments to improve wound healing. We now understand that
pericytes not only express MSC markers but also possess MSC-like properties, and display the ability
to differentiate in vitro into an array of mesenchymal cell types. These include adipocytes [25],
osteoblasts, chondrocytes [26], phagocytes and granulocytes [2]. The potential for pericytes to
differentiate into beneficial cell types during the proliferative and regenerative stages of wound
healing is an exciting prospect, and in the context of wound healing a cell type with the potential to
positively contribute to direct regeneration of lost tissue represents a possible target for therapeutics
or a source for the development of a cell-based therapy. Prior to the consideration of these cells for
application in cell therapies however, the differentiation potential of all pericyte populations must be
comprehensively understood.
Pericyte differentiation potential is extensive and highly dependent on lineage and the
surrounding environment [27]. In fact there is a body of observations surrounding pericyte plasticity
which, in conjunction with a shared perivascular location, suggests that MSCs and pericytes are, in fact,
the same cell type [28]. Recently however, only CD146+ bone marrow MSCs (BM-MSCs) and pericytes
(also CD146+) were found to maintain endothelial tube networks and improve angiogenic sprouting
in vitro, while CD146− subtypes of the BM-MSC population did not, suggesting that pericytes are
perhaps a subset of MSCs with vascular biology functions which not all MSCs possess [29]. One school
of thought with regards to the difficulty of defining the difference between a pericyte and an MSC
suggests that a pericyte which is in direct contact through gap junctions with ECs should be termed
a pericyte, but that upon liberation of a pericyte from the vessel wall, that same cell should then be
termed an MSC [30].
2. Pericytes in Wound Healing
Wound healing is a complex process made up of a series of overlapping events that include
inflammation, matrix formation and remodelling. Further to our initial understanding of their
involvement in the stabilisation of blood vessels and the control of blood pressure, the number
of recognised functions of pericytes has broadened drastically, with many of these functions involved
in wound healing (Table 1).
Table 1. Pericyte functions and their contributions to wound healing.
Wound Healing Process Pericyte Functions
Angiogenesis
Structural support of existing blood vessels [19]
Regulation of EC proliferation and migration to form new vessels [8]
Prevention of capillary tube regression by TIMP-3 expression [31]
Stabilisation of newly formed capillaries [32,33]
Inflammation
Regulation of vessel permeability [34–36]
Regulation of neutrophil extravasion [9,10]
Regulation of macrophage extravasion [11,37]
Control of leukocyte trafficking [38]
Control of T cell activation [39,40]
Response to inflammatory signals [41,42]
Re-epithelialisation Regulation of keratinocyte migration [43]
Fibrosis
Production of collagen [44,45]
Differentiation into myofibroblasts [46]
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2.1. Pericytes and Inflammation
Inflammation is one of the key phases during wound healing, and any perturbation in this
carefully controlled process can lead to delayed healing, fibrosis or the incomplete healing seen in
chronic wounds. It is triggered within 30–40 min of wounding and begins with the influx of neutrophils
from the blood vessels to the wound site. Once in the wound, neutrophils act to phagocytose invading
pathogens and cellular debris to clear the wound of infection. Early studies of pericytes in inflammation
have noted that these cells form umbrella-like covers over gaps between ECs following histamine
treatment, which prevents cells and proteins from leaving the vessel. Interestingly, the opposite
is seen after IL-2 treatment, which causes pericytes to realign at EC junctions and results in leaky
microvessels [34,35]. Neng et al. showed that pericytes also regulate tight junctions in a paracrine
manner in EC monolayers in the mouse ear. This was shown to in turn regulate EC monolayer
permeability and to control the diffusion of proteins and cells out of the blood [36]. These studies
suggest that pericytes play a significant role in controlling inflammation. More recently, pericytes have
been shown to be directly involved in the extravasion of neutrophils from the vessels. Direct contact
between neutrophils and pericytes induces a relaxation of the pericyte cytoskeleton via the inhibition
of RhoA/ROCK signalling, which allows neutrophils to leave the vessel at regions displaying low
expression of matrix proteins, termed “low expression regions” (LERs) [10]. This process is facilitated
by the expression of Intercellular Adhesion Molecule-1 (ICAM-1), Macrophage antigen-1 (Mac-1) and
Leukocyte function associated antigen-1 (LFA-1) [9]. ICAM-1 expression by pericytes, in conjunction
with the expression of chemoattractant MIF, has also been shown not only to attract and activate
neutrophils and macrophages, but also to facilitate efficient trafficking of these cells to areas of
infection [38]. Pericytes have also been shown to influence T cell activity: brain pericytes are able to
present antigens to T cells in order to induce lymphocyte activation [39], whereas retinal pericytes
inhibit T cell action [40]. Whether these inherent differences in action are due to differences in the
local population of pericytes or a result of microenvironmental cues is unclear. Brain pericytes also
respond to inflammatory signals, such as lipopolysaccharides (LPS), resulting in activated NF-κB and
expression of Interferon gamma-induced protein 10 (IP-10) and Monocyte Chemoattractant Protein-1
(MCP-1) [41]. Blockade of pericyte recruitment to vessels and therefore pericyte-EC intractions induces
inflammatory reactions in ECs and results in increased extravasion of macrophages in an adult mouse
model of diabetic retinopathy, again illustrating the importance of pericyte influence in the correct
regulation of inflammatory infiltration [37]. Hung et al. suggest a role for pericytes not only in the
recruitment of immune cells but also in the direct detection of proinflammatory molecules during
infection, and show that decreasing the presence of pericyte-like cells in a model of lung injury leads
to decreased inflammatory response to infection, leading the authors to propose that pericytes be
considered “interstitial immune sentinel cells” [42]. Together, these studies intimately link pericyte
action with regulation of the inflammatory response.
2.2. Pericytes and Re-Epithelialisation
Another key process during wound healing is the reformation of the epithelial barrier
post-wounding. This helps to prevent wound infection and begins to restore some of the vital functions
of the skin, such as the prevention of excess water loss and the regulation of temperature. Pericytes
have been implicated in this process, and this action is quite distinct from pericyte action at the surface
of the vessels. Paquet-Fifield et al. isolated pericytes from skin by means of FACS sorting with a
pericyte specific antibody, and created organotypic cultures (OCs), with or without pericytes, which
also contained fibroblasts and keratinocytes. When pericytes were present in the OCs there was a
drastic improvement in the epidermal layer formed: the epidermis in these OCs was multilayered and
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2.3. Pericytes and Angiogenesis
Pericytes have been known to play a role in blood vessel formation from some of the earliest
studies of their function, which identified these cells as being distinct from endothelial cells and
originally labelled them Rouget cells [47]. More recently, they have been shown to respond to platelet
derived growth factor β (PDGFβ) and transforming growth factor β (TGF-β) released by platelets
upon injury [2]. The chemotactic response of pericytes to PDGFβ causes these cells to leave the outer
layers of blood vessels and migrate into the wound site. This was established by Rajkumar et al.
in studies using the PDGFβ inhibitor imatinib [48]. This migration allows ECs to proliferate into
the wound site in response to vascular endothelial growth factor (VEGF), which is also released
upon platelet activation [49]. This process is aided by the production of fibronectin, vitronectin and
laminins, which provide a structure to support EC migration and capillary tube formation [50,51]. The
provisional matrix, formed by these ECM components, is frequently remodelled during healing by
proteases released by macrophages [52]. This can expose matricryptic sites such as Arg-Gly-Asp (RGD),
which act as adhesion sites for EC receptors and can, therefore, regulate EC migration, proliferation
and survival [52]. Interestingly, pericytes may regulate protease action via their expression of tissue
inhibitor of metalloproteinase-3 (TIMP-3), which prevents capillary tube regression normally caused
by matrix metalloproteinase-1 (MMP-1) and -10 (MMP-10) [31]. Pericytes also act to stabilise newly
formed capillaries by the expression of TGF-β [32] and by Rho GTPase regulated alterations in pericyte
contractility, which inhibit EC proliferation [33]. PDGFβ also appears to be essential in this process, as
PDGFβ and PDGFRβ knockout mice exhibit endothelial hyperplasia with a distinct lack of pericytes
present on blood vessels [53]. Interestingly, control of PDGFβ expression appears to be via Tie2
and Ang1/Ang2 interactions, where Tie2/Ang1 interaction leads to PDGFβ expression and pericyte
recruitment, while Tie2/Ang2 interaction leads to the opposite [54]. In addition to PDGFβ and
PDGFRβ, the PDGFβ retention motif is also crucial for pericyte-EC signalling. This sequence of amino
acids acts to hold PDGF in close proximity to the EC for it to be recognised by the PDGFRβ expressing
pericytes. This allows direct pericyte-EC interaction, as well as creating a PDGF gradient which enables
pericytes to migrate to ECs [55]. This motif has been studied using a pdgf-bret/ret mouse knockout
model, and has been shown to be crucial for maintaining vascular function in the retina, brain and
liver [56–58].
2.4. Pericytes and Matrix Deposition/Fibrosis
Under normal conditions, matrix deposition is initiated once the wound has been cleared of
infection and cellular debris. The main cell type responsible for this is the fibroblast. These cells
initially deposit fibronectin and collagen III, but in later phases replace these proteins with collagen I
and elastin. Fibroblasts, like pericytes, are attracted to the wound site by the expression of PDGF by
resident cells and platelets [48]. Once in the wound, fibroblasts may become activated to differentiate
into myofibroblasts, expressing α-SMA to physically contract the wound [59]. Interestingly, pericytes
are also able to produce collagen [44,45]. The pericytes in these studies appear to remain as collagen
secreting cells and don’t express αSMA, suggesting that they do not convert to myofibroblasts unlike
the resident fibroblasts within the wound. In an interesting study, Dulauroy et al. were able to use a
Cre-transgenic mouse to label ADAM12, which is induced only during embryogenesis and fibrosis.
They showed that the majority of collagen producing cells were positive for αSMA and thus were
myofibroblasts. These perivascular cells were also shown to be positive for PDGFRβ and NG2, and
were presumed to be pericytes [60]. In other studies, pericytes have been shown to differentiate into
myofibroblasts to promote fibrosis, particularly in the kidneys where the pericytes present are called
mesangial cells [46]. Interestingly, deletion of pericytes does not alter the recruitment of myofibroblasts
or alter kidney fibrosis, which suggests that resident MSCs may also play a role in promoting fibrosis,
and lends credence to the theory that pericytes are derived from MSC populations rather than the
reverse [61]. Birbrair et al. suggest that pericytes could be split into two subsets dependent on their
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accumulate near sites of fibrosis but are not solely responsible for the resultant fibrosis, whereas
type-2 pericytes appear to play a role in angiogenesis [62,63]. Pericytes have also been show to play a
significant role in fibrosis in the liver as hepatic stellate cells. Mederacke et al. use a Cre-transgenic
mouse that marks all stellate cells to show that 82–96% of myofibroblasts in a model of toxic, cholestatic
and fatty liver disease are of stellate origin [64]. These studies illustrate that pericytes have a major
role in important matrix deposition, but under negative circumstances may promote fibrosis.
Clearly, pericytes can influence each phase of the wound healing process (Table 1), and as such
should be considered a major cell type that can regulate healing. With increasing evidence that
pericytes can promote fibrosis, these cells may not only be a potential target for therapies to accelerate
healing but also to prevent fibrosis. Many of the beneficial aspects of pericytes are due to their
plasticity and ability to act in a stem cell-like manner to regulate the microenvironment, resulting in
improved healing.
3. Pericytes in Other Pathologies
Pericytes mediate both angiogenesis and vessel permeability, consequently they are important in
the development of solid tumours, which rely on sufficient vascularization and therefore blood supply
to grow.
Pericyte stabilization of the vessel wall supports vascularization within a tumour and can
prevent the passing of cancer cell-targeting drugs such as chemotherapeutic agents from the blood
stream to the tumour tissue [65]. Consequently, there has been some anti-angiogenic targeting of
pericytes within tumours, with a view to destabilizing the vessels that feed tumours and increasing
the permeability of cancer drugs into the tumour. Under normal circumstances, however, pericyte
signaling represents a fine balance between pro- and anti-angiogenic activities, as pericyte presence not
only stabilizes the function of preexisting vessels but also prevents the aberrant proliferation of ECs
to form new vasculature. As such, insufficient pericyte coverage in tumours can also be detrimental,
resulting in excessive vascular sprouting and increased vascularization of tumours. This suggests that
pro-angiogenic targeting of pericytes in tumours may also be beneficial. Additionally, pericyte-EC
cross-talk and the resultant regulation of ECs in tumours limits the metastasis of cancer cells, and
depleted pericyte coverage of vessels in PDGFβ-deficient mice leads to increased metastasis of solid
tumours [66]. Research into the targeting of pericytes in cancer aims to balance pro- and anti-angiogenic
signaling to achieve ‘vascular normalisation’ within the tumour microenvironment. Interestingly the
neuron-glial antigen 2 (NG2) proteoglycan, which is often used as a pericyte marker in conjunction
with the expression of other proteins, appears to play an important role in pericyte biology within the
context of tumour angiogenesis. Altered vascularity, including vessel leakiness and decreased pericyte
coverage, is noted in models of brain and breast cancer in NG2 null mice [67,68], and this is thought to
be the result of decreased pericyte-EC crosstalk. NG2 knockout in a mouse brain melanoma model
also appears to decrease tumour blood supply and increase hypoxia, hinting at a possible therapeutic
pathway for the treatment of this disease [69,70]. The result of pericyte perturbation in the context
of tumour growth however is complex and multifaceted, directly reflecting the delicate nature of
normal angiogenic control, and as such the development of pericyte-targeted therapeutics for cancer
is difficult.
Pericyte numbers decline in the dermal and muscle capillary networks of diabetic patients,
where they also exhibit an altered morphology with hypertrophy, abnormal cytoplasmic branching
and gaps in the basement membrane [71]. These pericytes also appear to promote a fibrotic or
sclerotic vessel [72,73]. A study which investigated pericyte changes in patients with chronic venous
insufficiency found that 31 out of 42 patients displayed an altered pericyte phenotype [74]. Significantly
diminished pericyte coverage is also observed on blood vessels in the retinas of diabetic patients
experiencing retinopathy, and in fact this is identified as one of the main mechanisms of disease
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pericyte apoptosis leading to increased production of acellular capillaries in the retina [76]. Mechanistic
studies identify activation of NF-κB, PKCδ and SHP-1 as effectors in this outcome [76,77].
Given that one of the most common diabetic pathologies is angiogenic dysregulation, pericyte
dysfunction is not a surprising observation in diabetic patients and models, and indicates the
normalisation of pericyte number and function as a promising therapeutic approach for the treatment
of diabetic complications.
In humans, a two-fold increase in the pericyte number observed on pulmonary arteries is noted in
the lungs of patients with pulmonary arterial hypertension (PAH) when compared with the vessels of
healthy control samples. Ricard et al. [78] show that these finding are recapitulated in vivo in models of
PAH, and show that these additional pericytes serve as a source of smooth muscle-like cells leading to
endothelial dysfunction and excessive remodelling of the pulmonary vasculature which is associated
with PAH.
Table 2. Pathologies exhibiting pericyte perturbation and likely outcomes of altered pericyte number
or function.
Disorder Pericyte Aberrance Observed




Decreased pericyte numbers in
dermis, pericytes exhibit altered
morphology [72–75]
Angiogenesis-decreased vascularisation
Vessel permeability-leaky vessels lead to
prolonged and uncontrolled inflammation
Fibrosis-pericytes promote fibrotic vessels
Stem cell properties-replacement of lost
cell/tissue types
Diabetic retinopathy Decreased pericyte numbers,
increased pericyte apoptosis [76]
Angiogenesis-decreased control of
endothelial proliferation
Vessel permeability-leakiness of vessels
Solid tumour
Unknown, however control of
angiogenesis has long been
recognised as an important target
in treatment of solid tumours
Angiogenesis-tumour relies on new
vasculature for blood supply
Endothelial control-metastasis of cancer
Vessel permeability-ability of
chemotherapeutic agents to pass from
bloodstream to tumour tissue
Pulmonary arterial
hypertension (PAH)
Increased pericyte coverage on
pulmonary arteries [78]
Angiogenesis-excessive remodelling of
pulmonary vasculature and endothelial
dysfunction
Alzheimers (AD) Degeneration at blood brain
barrier (BBB) [79]
Angiogenesis-break down of vessels causes
decreased cereberal bloodflow leading to
neurodegeneration
Vessel permeability-accumulation of
damaging molecules in the brain
Chronic kidney
disease (CKD)
Differentiation of pericytes into
myofibroblasts [80]
Fibrosis-pericytes thought to be source of
myofibroblasts contributing to excessive
fibrotic activity
Angiogenesis-differentiation of pericytes
into myofibroblasts leaves less pericytes to
stabilise vasculature
Degeneration of pericytes is also observed at the blood brain barrier (BBB) in patients with
Alzheimers disease (AD) [79]. This leads to neurodegeneration, caused by vascular breakdown
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neurodegeneration by allowing increased permeability of blood vessels, leading to the buildup of
damaging molecules such as plasmin, fibrin and thrombin in the brain [81]. Here, in yet another model
of disease, the importance of vascular stability and permeabilisation and how these parameters are
regulated by pericytes is illustrated once again.
Pericytes have also been implicated in fibrosis of the kidney. Mouse models of kidney fibrosis
indicate that collagen-producing myofibroblasts appear to originate from a perivascular location [83],
and genetic tagging of pericytes illustrates these cells can gain αSMA expression and differentiate into
myofibroblasts [80]. It is suggested that the activation of pericytes in the kidney to differentiate into
myofibroblasts not only leads to fibrosis but also leaves the endothelium of capillaries unstable, leading
to the decreased renal vascularization which is documented in chronic kidney disease [83]. With
investigations into pericyte action, uncovering the greater role that pericytes play in many divergent
pathologies (Table 2) increases the possibilities for future therapeutic treatments targeting pericytes.
4. Pericytes as a Therapeutic Agent
With an ever-growing understanding of pericyte potential and function comes new possibilities in
the form of pericyte-based therapies. In comparison to the significant momentum that MSC application
has gained in recent years, the therapeutic potential of pericytes is under-investigated, however
early preclinical studies in mice indicate that pericytes can contribute positively to healing in several
different tissues.
The myogenic potential of in vitro pericytes is recapitulated by in vivo studies of pericyte function
in mouse models of muscle damage. Human pericytes isolated by expression of CD146, NG2 and
PDGFRβ from both skeletal muscle and nonmuscular tissues produce myofibres and contribute to
muscle regeneration when injected into a cardiotoxin-induced mouse model of muscle damage [84].
Similarly, cells positive for pericyte markers CD146, NG2 and PDGFRβ isolated from the culture of
human pluripotent stem cells (hPSCs) promote muscle regeneration and increased vascularization
when applied to a mouse model of limb ischemia. At 21 days, these transplanted cells are found
incorporated into both the vasculature and the muscle tissue of the recovering limb [85]. In another
study, human placental cells isolated with a CD146+CD34−CD45−CD56− expression profile are shown
to produce myofibres and promote increased angiogenesis in the muscles of SCID/mdx mice [86]. With
their myogenic abilities confirmed in vivo, the development of a pericyte-based therapy holds great
potential to enhance the healing of muscles.
Chen et al. have also investigated the therapeutic potential of CD146+CD34−CD45−CD56−
pericytes on the ischemic heart. In their study, pericyte application to a mouse model of myocardial
infarction (MI) resulted in improved cardiac recovery and contractility, as well as decreased fibrosis and
decreased infiltration of inflammatory cell types [11]. The authors report superior recovery following
pericyte transplantation when compared to transplantation of CD56+ myogenic progenitor cells, which
suggests that the positive outcome was not solely due to the myogenic capabilities of pericytes but
rather a cumulative effect of pericyte function which may also include regulation of angiogenesis
and inflammation. This study also suggests an anti-fibrotic function for pericytes, in contrast to other
studies which identify pericytes as significant contributors to fibrosis by way of differentiation into
myofibroblasts [87–89]. It is possible that in this model the tissue signalling environment did not
induce pericyte differentiation into myofibroblasts, and this highlights the fact that pericyte function
and heterogeneity are heavily influenced not only by pericyte origin but also by the surrounding
tissue environment.
Pericytes (CD146+NG2+CD45−) isolated from mouse fat tissue display osteogenic potential
in vitro which is mirrored in vivo by contributing to the regeneration of mouse bone injury
when applied in a seeded scaffold [26]. Similarly, human adipose derived pericytes
(CD146+CD34−CD45−CD31−) enhance bone healing and encourage bone-union in mouse bone
fractures with equal efficacy to BM-MSCs [90]. Given this, the authors suggest that adipose derived
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abundantly from fat tissue such as that resulting from liposuction and represent a more defined and
homogenous population that BM-MSCs.
In the diabetic retina, there is a loss of pericytes which leads to collapse of the vasculature and
ultimately blindness. Human cells derived from adipose stem cells and expressing αSMA, PDGFRβ
and NG2 can protect against diabetic retinopathy in a mouse model, causing revascularisation of the
retina after injection which was not achieved by injection of human BM-MSCs [91]. This effect of
pericyte injection was enhanced when the cells were pre-treated with TGF-β1. These results indicate
that replacement of lost endogenous pericytes in a diabetic setting can encourage angiogenesis and
vascular support, as is seen in acute models of injury, and are particularly promising when considering
the possibility that pericyte therapies may hold for treating diabetic pathologies associated with
pericyte loss.
Human umbilical cord perivascular cells (HUCPV) isolated by expression pattern
CD45−CD34−SH2+SH3+Thy-1+CD44+ and also expressing the pericyte marker 3G5 cause enhanced
healing at 3 and 7 days when applied in a fibrin gel to full thickness skin defects in Balb/C mice,
as assessed by dermal thickness and re-epithelialisation [92]. In another study, the application of
human adipose derived stem cells expressing pericyte markers αSMA, PDGFRβ, NG2 and Ang1 in
a PEG-fibrin gel to a rat model of excisional wounding resulted in earlier collagen deposition and
remodelling, as well as increased angiogenesis [93]. Contrastingly, the application of human neonatal
foreskin dermal pericytes (CD45−VLA-1/α1/CD49abright) to a mouse model of excisional wound
healing did not enhance re-epithelialisation and in fact resulted in a decrease in dermal wound closure
at day 7 when compared to wounds treated with CD45−VLA-1dim fibroblasts [94]. The authors suggest
that as this model assessed the capability of applied human pericytes to influence the migration of
endogenous keratinocytes in wounded mouse skin, signalling between the human and murine cells
in question may not have been successful. In addition, this study applied cells isolated based on a
different expression pattern when compared to other studies investigating the application of pericytes
to wounded skin, and serves to further illustrate the heterogeneity of pericytes and how important
standardisation of identification and isolation will be before these cells can be considered a realistic
source for the development of cell therapies.
Overall, early studies of pericyte application to mouse models of muscle, heart, bone and skin
injury show promising signs that these regenerative and plastic cells can positively contribute to
healing, but also raise questions as to how the origin of cell isolation and method of delivery can affect
the ability of these cells to carry out beneficial functions. Little is known about the effect of pericyte
delivery to chronic tissues, including chronic wounds, but the demonstration in other tissues that
applying pericytes can encourage enhanced angiogenesis and decreased inflammatory infiltration as
well as regenerating lost tissue is promising when considering the treatment of non-healing wounds.
The fibrotic activity of the pericyte and how this is influenced by tissue-specific environments remains
incompletely understood, and this is an area which would require significant investigation before the
use of pericytes as a clinical cell therapy for wound healing could be considered.
5. Conclusions
The functions and capabilities of pericytes are impressive and, as yet, incompletely understood.
These cells regulate the vasculature and the inflammatory response, and in addition possess MSC-like
regenerative qualities. As such, the pericyte is well placed to significantly influence healing outcomes.
A decrease in pericytes associated with the vasculature is well documented in the retinas of diabetic
patients, and this results in the onset of diabetic retinopathy. Loss of pericytes is also documented
in other disease states, and aberrant pericyte function is identified as an important target in the
development of cancer therapies. With each observation of pericyte function or dysfunction in the
context of new disease environments, the body of knowledge illustrating the importance of pericytes in
the regulation of homeostatic and healing processes grows. There has been a lot of interest in the idea
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behaviours and distinct regulatory roles in angiogenesis and inflammation, may represent another
promising cell population for the development of treatments. In fact, recent in vivo studies show that
the transplantation of isolated pericytes can positively influence the healing of bone, muscle and skin
and can support revascularisation in a mouse model of diabetic retinopathy. It seems that pericytes
have an important part to play in chronic and acute healing processes, and must be considered a
crucial cell type as we continue to work towards a comprehensive understanding of healing processes
to better advise the development of effective therapies.
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Abstract: The cornea and the skin are both organs that provide the outer barrier of the body. Both
tissues have developed intrinsic mechanisms that protect the organism from a wide range of external
threats, but at the same time also enable rapid restoration of tissue integrity and organ-specific
function. The easy accessibility makes the skin an attractive model system to study tissue damage
and repair. Findings from skin research have contributed to unravelling novel fundamental
principles in regenerative biology and the repair of other epithelial-mesenchymal tissues, such as the
cornea. Following barrier disruption, the influx of inflammatory cells, myofibroblast differentiation,
extracellular matrix synthesis and scar formation present parallel repair mechanisms in cornea
and skin wound healing. Yet, capillary sprouting, while pivotal in proper skin wound healing,
is a process that is rather associated with pathological repair of the cornea. Understanding the
parallels and differences of the cellular and molecular networks that coordinate the wound healing
response in skin and cornea are likely of mutual importance for both organs with regard to the
development of regenerative therapies and understanding of the disease pathologies that affect
epithelial-mesenchymal interactions. Here, we review the principal events in corneal wound healing
and the mechanisms to restore corneal transparency and barrier function. We also refer to skin repair
mechanisms and their potential implications for regenerative processes in the cornea.
Keywords: cornea; skin; wound healing; inflammation; regeneration; repair
1. Introduction
The cornea is the most anterior part of the eye and accounts for about 70% of its refractive power.
The transparent nature and defined curvature of the cornea assure that light is focused and transmitted
without scatter through the lens and onto the retina. Therefore, the tissue integrity of the cornea is
of particular importance for clear vision. Eye injuries such as physical or chemical trauma or severe
infections may result in permanent corneal damage leading to opacification and loss of visual acuity.
Thus, rapid restoration of corneal integrity after injury is key to prevent intraocular inflammation that
can cause permanent loss of vision or even loss of the eye itself.
Like in skin wound healing, inflammation is a fundamental process in corneal wound healing [1].
While a prolonged inflammatory response may exacerbate tissue damage, therapeutic suppression of
the inflammatory response (e.g., by glucocorticosteroids) may also impair healing and might lead to a
delay in epithelial wound closure [2,3] or promote infections [4,5]. This review will focus on the corneal
immune system as an important factor in corneal wound healing and regeneration. We will first give
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an overview of corneal (microscopic) anatomy and physiology. Second, we will focus on corneal
angiogenic and immune privileges, which are essential for corneal function and homeostasis. Finally,
we will provide deeper insight into the cellular events in corneal inflammation, their consequences for
non-immune cell function and the outcome of the healing response.
2. Corneal Anatomy
The cornea consists of five layers, with different regenerative capacities: (1) a stratified
non-keratinizing squamous epithelial layer, which together with the tear film forms the outermost
barrier of the eye; (2) the Bowman layer, an acellular collagenous layer beneath the epithelial basement
membrane; (3) a collagen-rich stromal layer, which accounts for 80–90% of the corneal thickness in
humans and 60–70% in mice; (4) Descemet’s membrane, which forms the basement membrane for the
(5) endothelial cell layer on the posterior side of the cornea. The endothelial cell layer is a monolayer
of polygonal cells that is in contact with the aqueous humor (Figure 1).
The corneal epithelium is developmentally derived from surface ectoderm and consists of
stratified squamous epithelial cells. The epithelial surface is protected against damage and pathogens
by the tear film, which also contains growth factors like epidermal growth factor (EGF) to promote
epithelial regeneration [6]. Consisting of a lipid top layer to prevent evaporation, an aqueous middle
layer and a mucin layer, the tear film protects the epithelial cells, washes away foreign particles
and creates a smooth surface for clear vision. The tear film is uniformly spread across the cornea
through the interaction of the mucin layer with the glycocalyx of the surface epithelial cells. Tight
junctions connect the superficial cells to create an impenetrable barrier [7]. Beneath the superficial
cell layer, the corneal epithelium consists of 2–3 layers of suprabasal wing-shaped cells, which rest
on a single layer of basal cells attached to a basement membrane via hemidesmosomes. The basal
cells are capable of proliferation and constantly replenish wing cells and superficial cells in the upper
layers. In this process, proliferating basal cells move upwards and take on a more flattened shape.
Superficial cells are continuously shed from the epithelial surface supported by eyelid blinking [7].
Similar to the skin, the epithelial basement membrane consists of various collagen types (IV, VII, XII,
XV, XVII, XVIII), heparin sulfate proteoglycans, fibronectin, laminins and nidogens. Interestingly, the
composition of the membrane has been shown to undergo changes during postnatal development and
is not homogeneous, but considerably varies between the limbal region and the central regions above
the Bowman layer [8–10]. The regions differ in collagen type IV and laminin isoforms [11], as well as
fibrillin and tenascin expression [8]. The Bowman layer is located between the epithelial basement
membrane and the anterior stroma. This layer is acellular and consists of randomly-arranged fibrils of
collagen types I, III, V and VI [12,13]. It is well developed in humans, birds and higher mammals, such
as cattle, whereas the Bowman layer is considerably thinner in rodents, such as mouse, rat, rabbit and
guinea pig, while the collagen fiber diameters do not seem to vary among species [14].
While the epithelium provides a smooth surface to avoid light scatter, the stroma provides the
corneas’ spheroid shape and accounts for its transparent nature and refractive power. The unique shape
of the cornea generates only small spherical aberration, ensures that light is transmitted without scatter
and is focused on the lens and retina. The stroma consists of tightly-packed collagen fibers (mainly
consisting of fibrillary collagen types I and V), which form lamellae with parallel distributions. These
collagen complexes are surrounded by small leucine-rich proteoglycans [15]. In the central cornea, the
collagen lamellae are arranged in right angles relative to the fibers in neighboring layers, while towards
the corneal periphery lamellae, they are orientated circumferentially [7]. This uniquely arranged
network of collagen fibers is assumed to reduce light scatter and provide corneal clarity. The corneal
stroma is devoid of blood and lymphatic vessels, but contains a dense network of autonomic and
sensory nerve fibers. To ensure transparency, the central corneal axons lack myelin sheaths. As the
primary cell type, the stroma contains sparsely-spread resting keratocytes, which continuously secrete
collagen and proteoglycans to assure turnover of the extracellular matrix (ECM), although corneal
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in corneal repair. After injury, these mesenchymal-derived cells become activated and are able to
transform into two phenotypes: fibroblasts and myofibroblasts.
 
Figure 1. Parallels and differences in corneal and skin wound healing. Injury and wound healing in
cornea and skin involves a similar sequence of events: inflammation, myofibroblast differentiation,
extracellular matrix (ECM) deposition and eventually development of fibrosis. Yet, specific cellular
responses, such as immediate keratocyte apoptosis after wounding, are unique events in corneal wound
healing and presumably serve to avoid excessive corneal inflammatory reactions and opacification
after tissue injury. Due to the physiological avascular nature of the cornea, hemostasis and activation
of platelets are absent in corneal healing; however, both processes provide an important source of
growth factors and cytokines in skin wound healing. Instead, in cornea, several of these factors
(e.g., platelet-derived growth factor (PDGF)) are provided by epithelial cells [17]. Furthermore, to
maintain its transparency, the cornea does not respond with the induction of capillary sprouts to minor
injuries, which is essential to maintain good vision; however, chronic injury leads to an angiogenic
response. (A) Histological view of the unwounded mouse cornea (HE staining); Ep: epithelium; BM:
Bowman layer; St: stroma; DM: Descemet’s membrane; En: endothelium; (B) Histological view of the
unwounded mouse skin (HE staining); EP: epidermis; PD: papillary dermis; RD: reticular dermis; Pc:
panniculus carnosus; HF: hair follicle; (C) Infiltration of inflammatory cells into the physiologically
avascular cornea and sprouting of blood and lymphatic vessels from the limbus after severe corneal
injury (modified from Hos et al. [18]). Of note, corneal angiogenesis is a rare event and usually does
not occur during wound healing. However, in severe and eye-threatening conditions, proangiogenic
stimuli might overcome the corneal antiangiogenic mechanisms and lead to the secondary ingrowth
of pathological vessels from the limbus into the corneal center. This is in contrast to skin wound
healing, where capillary sprouts are important for an adequate healing response; (D) In skin wound
healing, hemostasis, platelet activation and angiogenesis are key repair mechanisms. Similar to corneal
wound healing, skin repair involves immune cell recruitment, activation and transdifferentiation
of fibroblasts, which synthesize and remodel extracellular matrix and mediate wound contraction;
(E) Murine corneal whole mount after experimentally-induced corneal injury and neovascularization
(green: blood vessels, CD31 stain; red: lymphatic vessels, lymphatic vessel endothelial hyaluronan
receptor 1 (LYVE-1) stain); the dashed white line indicates the limbal border. (F) Skin wound three
days post-injury; immunohistochemical double staining for fibrin and blood vessels (blue: DAPI stain;








Int. J. Mol. Sci. 2017, 18, 1257
The corneal endothelium like the stroma is derived from the neural crest and consists of a
single layer of hexagonal-shaped cells resting on a basal membrane, named Descemet’s membrane.
Descemet’s membrane is mainly composed of collagen type VIII, but also contains collagen type IV.
The function of endothelial cells is of particular importance for corneal homeostasis, as endothelial cells
feature a high number of Na+-K+-ATPases on their lateral membranes, creating an osmotic gradient
that ensures that the cornea remains relatively dehydrated. The cornea ideally remains at a 78%
hydration level, for which a sufficient number of endothelial cells is required to counteract corneal
swelling and opacification. At birth, endothelial cell density amounts to 6000 cells/mm2 and decreases
at a rate of about 0.6% a year. To preserve a sufficient dehydration rate, a minimum number of about
500–800 cells/mm2 is needed [7,19,20].
3. Distinct Regenerative Capacities of the Different Cellular Corneal Layers
The epithelium as the outer barrier is constantly self-renewing and has the highest regenerative
capacity, as epithelial cells are replenished every 7–10 days. Epithelial stem cells reside in the limbal
palisades and migrate towards the corneal center, where they differentiate to transient amplifying
cells and basal cells [21,22]. Thus, renewal of epithelial cells not only involves a vertical movement
of differentiating cells from deep to superficial layers, like in skin, but also a centripetal migration of
stem cells from the limbus to the central cornea as they undergo differentiation [22]. The limbal stem
cell niche is essential for corneal epithelial homeostasis, and patients suffering from limbal stem cell
deficiency, e.g., due to severe chemical trauma to the limbal region or inherited diseases affecting limbal
stem cells, often show severe and vision-limiting corneal alterations [23]. In these patients, overgrowth
of the adjacent conjunctiva on the cornea (conjunctivalization) can frequently be observed, indicating
that limbal stem cells are not only important to provide a cellular source for corneal epithelial turnover,
but also to maintain the identity and barrier between various cellular compartments in the eye.
While stromal cell populations are quickly replenished, the challenge in stromal wound healing is
to restore the exceptionally regular collagen organization, which is initially lost at the site of injury.
This remodeling process and restoration of normal transparency can take several years [24]. Among
all corneal layers, the endothelium has the lowest mitotic activity and lowest regenerative capacity.
Therefore, to close small endothelial ruptures, the remaining endothelial cells will migrate and enlarge
to remodel the monolayer. Consequently, cells will re-establish barrier function and resume their
pumping activity [25]. As the endothelium is essential for the constant dehydration and thereby
the transparency of the cornea, diseases or injuries leading to extensive loss of endothelial cells
generally lead to corneal opacification due to excessive fluid accumulation and swelling. To date,
the only treatment available to treat patients suffering from endothelial dysfunction or endothelial
cell loss is corneal transplantation (keratoplasty) by procedures like DSAEK (Descemet’s stripping
automated endothelial keratoplasty) or DMEK (Descemet’s membrane endothelial keratoplasty) where
the endothelial cell layer and Descemet’s membrane (with or without stromal parts, respectively) are
replaced by donor tissue.
4. The Corneal Angiogenic and Immune Privilege
In almost all organs, blood and lymphatic vessels form extensive networks that are vital for
multiple functions, including the transport of nutrients, liquids, signaling molecules and cells.
The cornea is one of the few tissues of the body that in its healthy state is entirely devoid of blood and
lymphatic vessels. However, corneal homeostasis also depends on oxygen and nutrients, which the
cornea receives via the tear film from the outside, the aqueous humor from the anterior chamber at the
inner side and the limbal vasculature from the corneal periphery. Furthermore, in contrast to other
tissues including the skin, the cornea usually does not respond with the induction of blood and/or
lymphatic vessels to minor injuries and angiogenic stimuli. Such reactions would interfere with its
transparency and result in vision loss. Therefore, the avascular state of the cornea, termed corneal
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In this regard, it was demonstrated that the corneal epithelium expresses soluble forms
of the three major vascular endothelial growth factor (VEGF) receptors (sVEGFR-1, sVEGFR-2,
sVEGFR-3), which are all assumed to act as decoy receptors to trap the key angiogenic growth factors
VEGF-A, VEGF-C and VEGF-D, which might contribute to maintaining corneal avascularity [26–28].
Additional potent antiangiogenic molecules that are expressed in the cornea are angiostatin, endostatin,
thrombospondin-1, thrombospondin-2 and pigment epithelium-derived factor [29–32]. These factors
exert their antiangiogenic functions by blockade of vascular endothelial cell migration and/or
proliferation or interfere with growth factor bioavailability. In addition to these molecules, the cornea
also expresses inhibitory PAS domain protein (IPAS), a negative regulator of hypoxia inducible factor
(HIF). It has been shown that IPAS inhibits HIF-mediated upregulation of VEGF in the cornea and
supports to maintain corneal angiogenic privilege even under hypoxic conditions [33].
Although the corneal angiogenic privilege is essential for good vision and is therefore strictly and
(in part) redundantly regulated, this condition is not invulnerable. In fact, severe inflammatory and
potentially eye-threatening conditions can result in a massive upregulation of proangiogenic growth
factors, which might overwhelm the antiangiogenic mechanisms of the cornea and result in a secondary
ingrowth of both blood and lymphatic vessels from the limbal area into the corneal center (Figure 1).
This angiogenic response immolates the transparency of the cornea and its functionality for the safety
of the whole eye. Therefore, after the immune response is complete and barrier function has been
achieved, corneal blood and lymphatic vessels need to resolve promptly to restore corneal transparency
and functionality. However, in certain pathological conditions, corneal blood and lymphatic vessel
regress very slowly, and may even persist and contribute to detrimental corneal diseases [34–36].
In addition to its angiogenic privilege, the cornea also belongs to the so-called immune privileged
sites of the body [37]. In this regard, it has been shown that antigens (e.g., alloantigens) introduced
into the anterior chamber result in the generation of antigen-specific regulatory T cells (Tregs), leading
to tolerance and suppression of immune responses against these antigens. The immune privilege of
the cornea has been attributed to several components: The healthy cornea contains only a few major
histocompatibility complex (MHC) II-positive antigen-presenting cells (APCs), and corneal expression
of MHC I molecules is reduced compared to other tissues. Furthermore, immunomodulatory factors,
such as Fas ligand (CD95L) and programmed death ligand 1 (PD-L1), are present in the cornea at
high levels and are able to suppress excessive immune responses by inhibiting T cell proliferation
and inducing T cell apoptosis [38,39]. One additional and important factor responsible for corneal
immune privilege is the so-called anterior chamber-associated immune deviation (ACAID). ACAID
causes immune tolerance by antigen-specific downregulation of delayed-type hypersensitivity (DTH)
reactions. This mechanism suppresses cell-mediated immune responses that are potentially caused
by tissue damage. Antigens introduced into the anterior chamber are captured by APCs migrating
to the marginal zone of the spleen, where they are involved in the activation of regulatory T cells,
which subsequently suppress DTH immune reactions [40–43]. The spleen is indispensable for the
development of ACAID, as it has been shown that removal of the spleen during introduction of
various antigens into the anterior chamber prevents the development of ACAID and leads to rapid
antigen-mediated rejection [44]. The immune and angiogenic privilege of the cornea are closely linked,
as corneas with pathological corneal neovascularization often show a loss of their immune privilege in
parallel [45,46]. In this context, it is generally accepted that the presence of pathological corneal blood
and lymphatic vessels are the main risk factor for immunological graft rejection episodes after corneal
transplantation [47,48].
5. Immune Cells in the Resting Cornea
Initially, it was assumed that antigen-presenting cells (APCs) were virtually absent from
corneal tissue, which was believed to be one of the underlying mechanisms of the corneal immune
privilege [49,50]. Since then, the view of the corneal cellular immune system has dramatically changed,
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of the naive cornea. Immunohistological analyses in mice carried out with the pan-leukocyte marker
CD45 could identify leukocytes located mostly in the corneal periphery, but also in the epicentral and
central cornea [50,51]. CD45+ cells are distributed through the entire depth of the stroma, although
most cells are either located in the anterior or posterior third of the stroma [51]. In bone marrow
transplantation experiments after corneal irradiation, it was demonstrated that these myeloid-derived
CD45+ cells are constantly reconstituted from the bone marrow, with 75% of cells being replenished
within eight weeks [52]. However, one has to keep in mind that irradiation of the cornea might have
substantially affected the turnover rate of these cells.
Macrophages stained positive for CD11b were shown to make up about 50% of the resident corneal
leukocytes [51]. They are localized primarily in the posterior stroma and are uniformly distributed
in the periphery and center of the cornea [50]. Recently, the origin of these corneal macrophages
has been investigated in detail, considering their CCR2 expression profiles. The current concept
divides macrophages and monocytes into a proinflammatory CX3CR1low CC R2positive type and a
tissue resident, anti-inflammatory CX3CR1high CCR2negative type [53]. Liu and colleagues reported
that CCR2negative macrophages possibly originating from the yolk sac or fetal liver can be detected in
the stroma starting from E12.5, while CCR2positive macrophages in the cornea are presumably fetal
liver- or bone marrow-derived and appear at later stages in embryonic development starting from
E17.5. Additionally, this work could demonstrate that CCR2negative macrophages in the cornea are, for
the most part, replenished by resident macrophage proliferation, whereas a large proportion of the
CCR2positive population is continuously reconstituted from the bone marrow [54].
Langerhans-cells (LCs), an epithelial type of dendritic cell, are found in the corneal epithelium
in the limbus region, periphery and central cornea. Notably, central cells have been described to be
MHC II negative, while peripheral cells are mainly MHC II positive [55]. In rat cornea, slow-cycling
MHC II+ cells have been identified in the limbal basal epithelium, which are putative LC precursor
cells [56]. Similar to the LC distribution, stromal dendritic cells (DCs) are found in the periphery
and center of the anterior stroma, with the central cells lacking MHC II expression [50,57]. These DC
populations have been shown to be replenished by bone marrow-derived cells [58]. In this regard,
it has also been shown that the fractalkine receptor CX3CR1 is involved in homeostatic homing of
corneal MHC II+ cells to the cornea [59].
LysM-positive neutrophils are located around the limbal vessels in the periphery, but are not
found in the central cornea [60]. Similarly, mast cells are found in the corneal limbus and conjunctival
parenchyma, but not in the central cornea of adult mice. They are present in the developing cornea
starting from E12.5 and accumulate around the corneal vasculature, during embryonic development.
Interestingly, the distribution of mast cells is influenced by eye-opening, as cells in the central cornea
have been observed to disappear after eye-opening and thus after the first contact of the cornea with
external factors [61]. Although in earlier reports, CD3+ T cells have been reported to be absent from the
cornea [51], by now, resident CD4+ and CD8+ T cells have been identified in the central and peripheral
region of naive corneas [62].
6. Corneal Wound Healing
Corneal wound healing involves a complex cascade of cellular events of which we can only
highlight some aspects in this article. Depending on the extent of the injury, cells of the epithelium,
stroma and endothelium react differently to restore corneal integrity. Corneal repair is orchestrated by
a complex network of growth factors that largely overlaps with those factors reported in skin repair
(reviewed in: [63–66]).
6.1. Epithelial Healing
Epithelial healing in the cornea has been studied extensively. As the outermost layer, the
epithelium is prone to injuries and needs to repair quickly to prevent infection of deeper layers.
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of the injured cells leads to disruption of the attachment to the underlying basement membrane.
Subsequently, cells from the wound margin rapidly respond with flattening and centripetal migration.
As cell-to-cell adhesions are partially maintained, the defect is slowly covered by a sliding cellular
sheet. This process is followed by proliferation and differentiation of basal cells to restore the cell layer.
During epithelial wound healing, a temporary ECM facilitates epithelial migration to cover the wound.
Fibrin, fibronectin and hyaluronic acid are some of the molecules identified in this matrix [67]. During
the terminal phase of epithelial healing, the cells generate new hemidesmosomes for anchorage to
the underlying layer [67,68]. Multiple growth factors, also identified as key mediators of epidermal
repair in skin, are involved in epithelial healing, including EGF, transforming growth factor β (TGFβ),
hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) [69].
Epithelial regeneration is also supported by corneal nerves, which regulate the blinking reflex
and thereby the turnover of corneal epithelial cells. Furthermore, corneal nerves have been shown
to provide epitheliotropic factors, such as substance P, calcitonin gene-related peptide (CGRP) and
nerve growth factor (NGF), among others [70–75]. Patients suffering from degeneration of corneal
nerves (called neurotrophic keratopathy), e.g., due to herpetic disease or systemic diseases such as
diabetic polyneuropathy, often show delayed epithelial wound healing and might even suffer from
persistent and potentially sight-threatening epithelial wounds that might lead to corneal perforation
or serve as entry for, e.g., bacteria into the eye, with devastating consequences. Topical treatment with
recombinant NGF was shown to promote epithelial healing [75,76] and is currently in clinical trials for
the treatment of several diseases of the ocular surface, like dry eye disease and neurotrophic keratitis,
and for the promotion of corneal nerve regeneration after refractive and cataract surgery. Besides
NGF, several other growth factors have already entered clinical trials, including EGF, fibroblast growth
factor (FGF) and insulin-like growth factor (IGF), with promising results [77–79].
6.2. Stromal Healing
The first response observed in the corneal stroma after epithelial damage is keratocyte apoptosis
beneath the wound, which is assumed to be initiated by cytokines released from damaged epithelial
cells, including IL-1α, IL-1β, Fas ligand and TNFα [80–84]. Keratocyte death results in an area beneath
the wound site virtually devoid of cells. The remaining keratocytes become activated, differentiate
into fibroblasts and begin to migrate to the wound site within 24 h after injury [67]. Using a rabbit
model of transcorneal freeze injury, it was recently observed that during this migration process, the
fibroblasts form connected streams aligned in parallel to the collagen lamellae, suggesting that lamellae
provide “contact guidance” for fibroblast migration [85]. Subsequently, fibroblasts proliferate to
repopulate the wound site. During stromal healing, their migration and activation are assumed to be
mediated by several growth factors, including TGFβ, platelet-derived growth factor (PDGF), FGF-2
and EGF [85–88]. TGFβ and PDGF have also been identified as the main growth factors involved in
the transdifferentiation from fibroblasts to myofibroblasts, which occurs in stromal wounds [88–94].
Myofibroblasts are identified by their expression of contractile α-smooth muscle actin (αSMA)
stress fibers, which enable them to mediate wound closure and contraction [95,96]. Additionally,
myofibroblasts are characterized by the expression of vimentin and desmin and reduced transparency,
compared to quiescent keratocytes [97,98]. The number of myofibroblasts at the wound site seems
to vary between different types of wounds: In incisional wounds, where wound contraction is
fundamental for proper healing, myofibroblasts seem to be most abundant [99,100]. Studies indicate
that myofibroblast are not solely generated by local fibroblast proliferation and transformation, but by
a large proportion are derived from bone-marrow cells recruited to the cornea as observed to some
extent in skin [101–103]. As soon as the myofibroblast/fibroblast-mediated stromal wound closure is
complete, the number of myofibroblasts in the stroma slowly decreases. The following remodeling
of the stroma to restore transparency can take several years. In this process, the disorganized repair
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6.3. Endothelial Damage Response
Endothelial wound healing is in most situations limited to the reorganization and enlargement
of the remaining endothelial cells, as in humans their mitotic activity is negligible. As soon as the
cells close the damaged areas, usually after a few days, they resume their pumping activity and
begin to secrete new basement membrane. After corneal injury, endothelial cells may also undergo a
process of endothelial mesenchymal transition (EnMT), similar to epithelial-mesenchymal transition
(EMT) observed in skin. During EnMT, the usually quiescent endothelial cells attain fibroblast-like
characteristics and begin to proliferate. EnMT is characterized by loss of cell-junctions, loss of
apical-basal polarity and actin-skeleton reorganization (reviewed in [104]). Apart from numerous
other factors possibly involved, this process has been shown to rely on TGFβ, FGF-2, IL-1β and
involves NFκB activation [105–108]. EnMT may lead to fibrous ECM deposition (so-called retrocorneal
fibrous membrane) posterior to Descemet’s membrane. The consequences of EnMT are therefore
considered undesirable, as it might result in loss of endothelial cells and corneal opacification due to
ECM deposition [109]. Moreover, EnMT is also observed in ex vivo cultured endothelial cells, leading
to a loss of endothelial cell characteristics during attempts of bioengineering endothelial grafts. Efforts
to expand endothelial cells in vitro aim to inhibit the process of EnMT and preserve cell morphology
for instance by using inhibitors of TGF-β signaling or the Rho-kinase/ROCK pathway [108,110–112].
7. The Fibrotic Response in Corneal Repair
Corneal injury extending into the corneal stroma causes fluid influx and fibrin deposition, leading
to swelling and subsequent local loss of transparency. During corneal stromal repair, fibroblasts and
myofibroblasts deposit multiple elements of the ECM including type III collagen, fibronectin, tenascin
and glycosaminoglycans, facilitating the migration of fibroblasts [113]. Prolonged myofibroblast
activation and ongoing deposition of repair matrix can cause long-lasting corneal opacification.
In addition, the collagens and glycosaminoglycans produced in the early phase of the repair response
show irregularities in their fibril size, arrangement and composition, which are likely to contribute
to permanent opacification and scarring [114,115]. The contraction of repair tissue may also alter the
curvature of the cornea and its optic properties. However, corneal stromal injuries do not always
result in corneal scaring and permanent opacification. Smaller and superficial wounds often heal with
restitutio ad integrum. The exact mechanisms leading to full restoration or scarring of the injured
cornea are so far poorly understood.
It has been shown that epithelial abrasion alone does not activate the fibrotic response. Fibrosis
is only observed in corneal injuries that include rupture of the epithelial basement membrane and
wounding of the stroma [116]. Similar to dermal repair in the skin, PDGF and TGF-β are pivotal
mediators of the corneal fibrotic response [117]. Due to the angiogenic privilege, platelets as critical
source of PDGF and TGF-β are virtually absent, although their accumulation around the limbal
vessels after wounding has been reported [118]. In the cornea, PDGF is produced by epithelial cells
and (like TGFβ) has been detected in tears [119–121]. For controlling the impact of these factors on
stromal keratocytes, the integrity of the epithelial basement membrane appears important, by creating
a barrier for the growth factors produced by epithelial cells and derived from tears. In the case of
basement membrane rupture, PDGF gains access to the stroma and subsequently acts on keratocytes,
stimulating their migration and proliferation [122]. Likewise, it was shown that upon loss of the
basement membrane, TGF-β2 produced by the epithelial cells can get in contact with the stroma and
induces keratocyte activation [116]. Accordingly, Han and colleagues recently reported that epithelial
cells produce exosomes that after rupture of the basement membrane gain access to the stroma. These
exosomes subsequently fuse with stromal keratocytes and are able to promote their differentiation into
myofibroblasts in wounds affecting epithelium and stroma [123].
Interestingly, similar to scarless healing in embryonic skin, also corneal wounds in the embryo heal
without a scar. In the chick embryo, incisional wounds affecting epithelium, basement membrane and
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in the embryo does not involve enhanced keratocyte apoptosis or proliferation and re-epithelialization
in these wounds is observed to be very slow compared to adult [124]. The underlying cellular
mechanisms involved in this scarless type of healing and whether this alternative pathway can still be
activated in adulthood remain to be elucidated.
An exaggerated fibrotic response after corneal injury may rarely result in hypertrophic scar or
keloid formation, characterized by excessive fibrous tissue. Compared to skin, the development of
keloids is a very uncommon event in the cornea following corneal trauma or disease. As opposed to
hypertrophic scars, which are restricted to the initial site of injury, keloids may overgrow the initial
lesion covering large parts of the corneal surface and are often observed to be recurrent. Keloids
clinically appear as defined, white, elevated tissue and are characterized by a hyperplastic epithelium,
disruption of the Bowman layer and contain disorganized stromal collagen fibers, as well as activated
fibroblasts and may be paralleled by neovascularization [125–128]. Interestingly, also spontaneous
keloid formations without previous corneal injury have been reported [129–131]. It is unresolved
whether a predisposition for dermal keloid formation, as observed in patients from Asian or African
American ethnicity, is associated with a higher risk to develop corneal keloid after corneal injury or
surgery [131]. However, corneal keloids have been observed to occur in genetic syndromes such as
Lowe’s syndrome [132,133] and Rubinstein–Taybi syndrome [131,134], the latter of which has been
shown to be accompanied by dermal keloid formation, which may occur spontaneously or after
preceding trauma in up to 24% of the patients affected [135–137].
8. Cellular Events in Corneal Inflammation
Knowledge acquired about wound healing and cellular infiltration into the cornea has mostly been
provided by corneal injury models in rabbit and mice, including epithelial abrasion [138], intrastromal
suture placement [139], chemical burn injuries [140] or corneal incisions (for a review, see [141]).
As each of these injury models is characterized by a different wound healing response, kinetics and
quality of inflammation, combining the results into an overall picture of cellular events after injury is
a difficult task. The results obtained may vary among the nature of injury, species and strains [142].
In general, immune cell recruitment after corneal injury is mediated by proinflammatory cytokines
released from epithelial cells and keratocytes at the injured site. Il-1, Il-6 and TNFα have been shown
to be important mediators [143–147]. Being attracted by these and several other cytokines, recruited
leukocytes from the limbal blood vessels enter the stroma and migrate towards the wound site [148].
Neutrophils are the first cells infiltrating the cornea after injury: they can be detected as soon as 2 h
after injury and have been observed to enter the cornea in two major waves at 18 and 30 h after epithelial
abrasion; as soon as 48 h after injury, their numbers normalize again [149]. Neutrophils seem to be
involved in several processes in corneal wound healing, as in neutropenic mice, re-epithelialization
after abrasion was observed to be delayed [149,150]. Moreover, the absence of neutrophils was reported
to affect the recovery of the corneal nerves, which was attributed to their secretion of VEGF-A as a
neurotrophic factor [151,152]. Interestingly, the recruitment of neutrophils into the cornea seems to
be dependent on platelet accumulation and vice versa, as it was shown that depletion of platelets
decreased neutrophil influx, and in turn, the depletion of neutrophils led to reduced numbers of
platelets accumulating around the limbal vessels [117].
Comparable to myeloid cell recruitment in skin injury, shortly after neutrophils have entered
the cornea, macrophages extravasate from the limbal vessels, infiltrate the stroma from superficial to
deeper layers and migrate towards the corneal center [148]. Macrophages remove debris and apoptotic
cells at the wound site, but have also been shown to be essential mediators of angiogenesis after
severe and prolonged corneal injury. The newly-formed blood and lymphatic vessels presumably
serve to supply oxygen, growth factors and immune cells and in turn mediate their clearance. During
corneal inflammation, macrophages express high levels of VEGF-A, VEGF-C and VEGF-D, thereby
inducing the proliferation of vascular endothelial cells [153,154]. In addition, studies indicate that
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reconfirmed that macrophages are capable of forming tubular structures, by demonstrating that they
form non-endothelial vascular channels in a subcutaneous tumor model [156]. Macrophages also
take part in corneal wound closure by secreting TGF-β to promote the differentiation of fibroblasts to
myofibroblasts. The experimental depletion of macrophages in both cutaneous and corneal injury in
mice leads to a delay in wound healing and a reduction of αSMA-positive fibroblasts [157], as well as
a delay in epithelial closure after abrasion [53,158].
Corneal injury also leads to an increase in Langerhans cell numbers in the corneal epithelium.
LC recruitment into the cornea upon central corneal cautery was shown to be mediated by IL-1, TNF
and CCR5 signaling in mice [159]. In rats, centripetal migration of MHCII+ LCs from the limbus to
the central corneal epithelium was observed 4 h after central cauterization. The majority of these
cells were shown to be recruited from the limbal basal epithelium [160]. The rise in LC numbers at
the corneal surface increases the antigen presenting capacity of the cornea, which is important to
adequately respond to foreign antigens, which might have been introduced through the wound. This
might also apply to stromal DCs: while most DCs in the corneal center are MHC II negative, in the
case of inflammation, their MHC II and costimulatory molecule expression are induced [160,161]. Yet,
little is known about the role of stromal DCs in corneal wound healing, although it has been shown
that corneal DCs migrate together with the epithelial sheet to cover the wound after epithelial abrasion
in mice. Consistently, the experimental depletion of DCs delays epithelial closure and alters epithelial
gene expression [162,163].
Natural killer (NK) cells, which are rare in the naive, intact cornea, accumulate around the
limbal vessels and infiltrate the corneal stroma from the periphery to the center. Their influx peaks
at 24 h after epithelial abrasion [164]. Experimental depletion of NK cells in mice results in delayed
epithelial wound closure and impaired regeneration of corneal nerves. Moreover, in the absence of NK
cells, neutrophil numbers were observed to be elevated [164], while DC numbers were reduced [162],
indicating that NK cells possibly play a role in orchestrating the corneal inflammatory response [164].
However, the mechanisms involved are not yet resolved. Similar to findings in skin wound healing,
a possible role in modulating the corneal immune response is also proposed for γδ T cells. This type of
T cell, recruited via ICAM1 and CD18, was shown to promote wound healing and influence neutrophil
and platelet numbers in corneal inflammation [165–167].
To date, it is still an open question by which mechanisms immune cells are recruited to the injured
cornea during the inflammatory phase. Several chemokines and their receptors have been identified
in the inflamed cornea, yet their functional role in immune cell recruitment to the cornea is poorly
characterized. For instance, the CXC chemokines CXCL1 and CXCL5 [149], as well as CXCL10, CCL7
and macrophage chemoattractant protein 1 (MCP-1) expression [164] were found to be elevated after
epithelial abrasion in mice. Correspondingly, CXCL1, CXCL8 and MCP-1 mRNA levels were found to
be elevated in human inflamed corneas [168]. CCL5 and MCP-1 have also been shown to be secreted
by corneal keratocytes after stimulation with IL-1 or TNF [143]. Additionally, CCR7 and its ligand
CCL21 were found to be upregulated in inflamed corneas, mediating MHC II+ cell recruitment [169].
For the recruitment of neutrophils, it has been postulated that recruitment is mostly mediated
by P- and E-selectins, but also involves ICAM-1 and CD18 interaction [149], whereas myeloid
cell/macrophage recruitment to the cornea is assumed to be (partially) mediated by the chemokine
receptor CCR2 and its main ligand MCP-1 [170,171]. In the cornea, MCP-1 is expressed by epithelial
cells, as well as keratocytes [171] and was shown to be upregulated after epithelial scrape injury [144].
Furthermore, MCP-1 introduced into the rabbit cornea in a corneal-micropocket-assay led to increased
macrophage infiltration and angiogenesis [172]. Consistently, in CCR2- or MCP-1-deficient mice,
macrophage recruitment was demonstrated to be impaired, while neutrophil numbers were not
affected [170]. The latter is unexpected given the critical role of macrophages in neutrophil phagocytosis
and clearance. The number of corneal CD11b+ cells was also reduced in a model of topical CCR2
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recruitment of VEGF-A-expressing macrophages is critical for the initiation of capillary sprouting
during the wound healing response [174].
Although macrophage polarization has been extensively studied in cutaneous wound
healing [1,174], macrophage polarization phenotypes have hardly been investigated during corneal
repair. It has been shown that CCR2-positive, as well as CCR2-negative macrophages are required
for proper corneal epithelial healing [53]. In addition, alterations in gene expression levels of
inflammatory factors such as inducible nitric oxide synthase (iNOS), but also an impaired transition
of macrophages to the M2-like phenotype are associated with impaired wound healing following
epithelial injury [158]. An experimental study by Uchiyama and colleagues in a rat alkali burn
model has shown that treatment with a peroxisome proliferator-activated receptor gamma agonist
prevents excessive corneal inflammation and results in a decreased profibrotic response with less
corneal opacification. Interestingly, this study also demonstrated that although the overall number of
macrophages was decreased in the treatment group, M2-like macrophage numbers were significantly
higher, suggesting a superior role of this macrophage subpopulation in corneal wound healing, after
chemical trauma [175]. Although the literature suggests that alterations in macrophage numbers and
polarization phenotypes are associated with impaired corneal wound healing, definitive evidence for
a functional role is missing.
Apart from MCP-1, it was shown that stromal fibroblasts upregulate a variety of additional
chemokines after stimulation with proinflammatory molecules such as IL-1α or TNFα. Among
those are granulocyte colony-stimulating factor (G-CSF), monocyte chemotactic and activating factor
(MCAF), neutrophil-activating peptide (NAP) and monocyte-derived neutrophil chemotactic factor
(MDNCF) [144], which all might be involved in monocyte/macrophage and granulocyte recruitment
and activation after corneal damage. Collectively, current findings propose that homing and
inflammatory influx of leucocytes into the cornea are mediated by multiple recruitment mechanisms.
As yet, the predominant mechanisms are not identified. Furthermore, it remains unclear how tissue
resident immune cells are involved in the inflammatory response. Due to the corneal immune privilege,
these mechanisms may possibly vary from those observed in other tissues. After the repair response
is complete and corneal integrity is reestablished, inflammation also has to resolve rapidly. In this
regard, it is still unclear how inflammatory cells sense that tissue integrity is finally restored and how
these cells are removed from the cornea. The mechanisms involved in immune cell clearance from the
cornea still remain to be investigated.
9. Stem Cells in Corneal Regeneration
The limbus region provides the primary niche for corneal stem cells [176]. This area contains
both the corneal epithelial and mesenchymal (stromal) stem cells [176–178]; although the term limbal
stem cells (LSCs) is exclusively used for the epithelial progenitor subpopulation. LSC biology has
been extensively studied over the past decades, and already several years ago, LSC transplantation
has been transferred to the clinic for the treatment of various corneal epithelial deficiencies (reviewed
in [179,180]). Recent experimental studies showed that some cells (3–4%) in the adult corneal stroma
subjacent to the epithelial basement membrane also express markers of ocular progenitor cells that
are not present in differentiated keratocytes [178,181]. These cells, termed corneal stromal stem cells
(CSSCs), have the ability to divide extensively, generate adult keratocytes and have the potential to
give rise to several non-corneal cell types, such as cartilage or neural cells [181]. CSSCs express genes
indicative for mesenchymal stem cells (such as BMI1, CXCR4, ABCG2), as well as genes indicative
for pluripotent cells (such as SOX2, KLF4, OCT4, NANOG). Furthermore, CSSCs express genes that
are present in early corneal development (such as PAX6 and Six2) and genes associated with neural
development (CDH2, NESTIN, NGFR) [182].
Several studies have analyzed the function of CSSCs in the corneal steady state and after
injury. In vitro, CSSCs can produce connective tissue including collagen fibrils when cultured under
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or polycarbonate substrates, CSSCs produce layers of highly parallel collagen fibrils with uniform
diameter and regular interfibrillar spacing similar to that of the normal corneal stroma [184–186].
An important function of CSSCs is their support of the LSC population in the limbal stem cell
niche [187,188]. Furthermore, experimental studies in mice have shown that CSSCs have the ability to
support stromal regeneration and prevent scarring [189,190]: injection of CSSCs into the corneal stoma
of Lumican-deficient mice, which have opaque corneas due to increased corneal thickness and altered
collagen organization, results in restoration of the normal corneal architecture and reestablishment
of corneal transparency [190]. Moreover, the application of CSSCs to surgical wounds comprising
the epithelium and the anterior stroma (which usually leads to the deposition of disorganized and
opaque scar tissue) results in deposition of extracellular matrix with normal collagen organization
and clear corneas [189]. In addition, CSSCs have been reported to modulate immune responses in the
cornea [190].
Collectively, CSSCs have been shown to facilitate corneal stromal regeneration without scarring
and excessive inflammation. Although the therapeutic use of CSSCs is still far behind the use of LSCs,
novel CSSCs-based therapeutic strategies might open up novel and effective treatment strategies for
corneal stromal wound healing in the future.
10. Concluding Remarks and Future Directions
Corneal transparency is essential for proper vision, and a detailed understanding of the
mechanisms involved in corneal wound healing and regeneration is of great importance to treat
patients suffering from corneal diseases. At present, epithelial regeneration can be supported relatively
satisfactorily, and it is possible to treat superficial corneal scars, e.g., with laser therapy. However,
for deep corneal scars or endothelial diseases, which are frequent, corneal transplantation is still
the only option to restore clear vision. Nonetheless, due to the scarcity of corneal donor tissue or
limited access to corneal surgery, corneal opacification is still one of the major causes of blindness
worldwide [191–193].
Ongoing research aims to support corneal regeneration by stem cell-based therapies. To support
epithelial regeneration, research focuses on the ex vivo expansion and subsequent transplantation of
LSCs derived from limbal biopsies, as already performed to treat patients suffering from limbal stem
cell deficiency. As mentioned earlier, studies using LSCs and CSSCs have demonstrated beneficial
effects in several disease models, promoting epithelial and stromal repair [189,190,194]. Due to
the limited availability of corneal stem cells and the potential risks related to biopsy excision from
donor eyes, several non-ocular tissues have been investigated as potential autologous sources of
epithelial-like cells [195]. Apart from potentially simplifying the process of cell harvesting and
culture conditions, these approaches would avoid immune reaction to donor tissue in patients with
bilateral corneal disease. Here, oral mucosa epithelial cells [196,197] and conjunctival epithelial
cells [198–200], already in clinical use, have been shown to successfully support epithelial regeneration
in limbal stem cell deficiency, though data on long-term outcomes are limited. Interestingly, alternative
approaches demonstrate that corneal epithelial-like cells may also be transdifferentiated from dermal
sources: skin-derived precursor cells, epidermal adult stem cells and hair follicle stem cells were
shown to attain corneal epithelial-cell like properties [201,202] and improve corneal healing [203].
For stromal regeneration, it has been demonstrated that adult stem cells isolated from dental pulp
may be differentiated to attain a keratocyte-like phenotype, secreting collagen fibrils and corneal
proteoglycans [204].
Innovative approaches show that corneal epithelial cell-like or keratocyte-like cells can also be
differentiated from induced pluripotent stem cells (iPSCs) generated from corneal and non-ocular
cells that might be used in future treatment options [205–209]. In an experimental therapeutic
approach, iPSCs generated from human corneal keratocytes enhanced corneal healing in rats, when
topically applied to cornea after epithelial abrasion [210]. Moreover, a broad area of research
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and skin regeneration. MSCs derived from bone marrow, adipose tissue, umbilical cord or dental
pulp [211,212] were demonstrated to acquire both epithelial cell-like [213,214] and keratocyte-like
characteristics [215–217] (see [195] for a systematic review). The therapeutic use of bone-marrow
or adipose tissue-derived MSCs, by local injection or topical application in animal models of
chemical burns, was shown to improve corneal healing and reduce corneal inflammation and
neovascularization [218–221].
Ongoing efforts in the field of endothelial regeneration focus on the establishment of methods for
the isolation, cultivation, expansion and transplantation of corneal endothelial cells, with promising
results [222–224]. These techniques are novel approaches to substitute for corneal transplantation
procedures like DMEK in patients suffering from endothelial cell loss or dysfunction. Conclusively,
cell-based therapies have the potential to accelerate corneal wound healing, compensate for epithelial
cell, keratocyte and endothelial cell loss in certain injuries and might promote the substitution of
opaque repair tissue with regular transparent corneal ECM. Further research will reveal whether these
novel approaches will be successful in supporting corneal regeneration.
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217. Demirayak, B.; Yüksel, N.; Çelik, O.S.; Subaşı, C.; Duruksu, G.; Unal, Z.S.; Yıldız, D.K.; Karaöz, E. Effect of
bone marrow and adipose tissue-derived mesenchymal stem cells on the natural course of corneal scarring
after penetrating injury. Exp. Eye Res. 2016, 151, 227–235. [CrossRef] [PubMed]
218. Yao, L.; Li, Z.-R.; Su, W.-R.; Li, Y.-P.; Lin, M.-L.; Zhang, W.-X.; Liu, Y.; Wan, Q.; Liang, D. Role of mesenchymal
stem cells on cornea wound healing induced by acute alkali burn. PLoS ONE 2012, 7, e30842. [CrossRef]
[PubMed]
219. Almaliotis, D.; Koliakos, G.; Papakonstantinou, E.; Komnenou, A.; Thomas, A.; Petrakis, S.; Nakos, I.;
Gounari, E.; Karampatakis, V. Mesenchymal stem cells improve healing of the cornea after alkali injury.
Graefe’s Arch. Clin. Exp. Ophthalmol. 2015, 253, 1121–1135. [CrossRef] [PubMed]
220. Zeppieri, M.; Salvetat, M.L.; Beltrami, A.P.; Cesselli, D.; Bergamin, N.; Russo, R.; Cavaliere, F.; Varano, G.P.;
Alcalde, I.; Merayo, J.; et al. Human adipose-derived stem cells for the treatment of chemically burned rat








Int. J. Mol. Sci. 2017, 18, 1257
221. Lin, H.-F.; Lai, Y.-C.; Tai, C.-F.; Tsai, J.-L.; Hsu, H.-C.; Hsu, R.-F.; Lu, S.-N.; Feng, N.-H.; Chai, C.-Y.; Lee, C.-H.
Effects of cultured human adipose-derived stem cells transplantation on rabbit cornea regeneration after
alkaline chemical burn. Kaohsiung J. Med. Sci. 2013, 29, 14–18. [CrossRef] [PubMed]
222. Mimura, T.; Shimomura, N.; Usui, T.; Noda, Y.; Kaji, Y.; Yamgami, S.; Amano, S.; Miyata, K.; Araie, M.
Magnetic attraction of iron-endocytosed corneal endothelial cells to Descemet’s membrane. Exp. Eye Res.
2003, 76, 745–751. [CrossRef]
223. Patel, S.V.; Bachman, L.A.; Hann, C.R.; Bahler, C.K.; Fautsch, M.P. Human corneal endothelial cell
transplantation in a human ex vivo model. Investig. Ophthalmol. Vis. Sci. 2009, 50, 2123–2131. [CrossRef]
[PubMed]
224. Okumura, N.; Koizumi, N.; Ueno, M.; Sakamoto, Y.; Takahashi, H.; Tsuchiya, H.; Hamuro, J.; Kinoshita, S.
ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo
endothelial tissue. Am. J. Pathol. 2012, 181, 268–277. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution








 International Journal of 
Molecular Sciences
Review
Macrophage Phenotypes Regulate Scar Formation
and Chronic Wound Healing
Mark Hesketh, Katherine B. Sahin, Zoe E. West and Rachael Z. Murray *
The Institute for Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health,
Queensland University of Technology, Brisbane QLD 4059, Australia; m.hesketh@connect.qut.edu.au (M.H.);
katherine.sahin@connect.qut.edu.au (K.B.S.); zoe.west@connect.qut.edu.au (Z.E.W.)
* Correspondence: rachael.murray@qut.edu.au; Tel.: +61-7-3138-6081
Received: 27 May 2017; Accepted: 16 July 2017; Published: 17 July 2017
Abstract: Macrophages and inflammation play a beneficial role during wound repair with
macrophages regulating a wide range of processes, such as removal of dead cells, debris
and pathogens, through to extracellular matrix deposition re-vascularisation and wound
re-epithelialisation. To perform this range of functions, these cells develop distinct phenotypes
over the course of wound healing. They can present with a pro-inflammatory M1 phenotype, more
often found in the early stages of repair, through to anti-inflammatory M2 phenotypes that are
pro-repair in the latter stages of wound healing. There is a continuum of phenotypes between
these ranges with some cells sharing phenotypes of both M1 and M2 macrophages. One of the less
pleasant consequences of quick closure, namely the replacement with scar tissue, is also regulated
by macrophages, through their promotion of fibroblast proliferation, myofibroblast differentiation
and collagen deposition. Alterations in macrophage number and phenotype disrupt this process and
can dictate the level of scar formation. It is also clear that dysregulated inflammation and altered
macrophage phenotypes are responsible for hindering closure of chronic wounds. The review will
discuss our current knowledge of macrophage phenotype on the repair process and how alterations
in the phenotypes might alter wound closure and the final repair quality.
Keywords: macrophage; monocyte; wound healing; fibrosis; chronic wound; diabetes; chronic
venous disease
1. Introduction
To overcome the repeated dermal insults and injuries that occur on a daily basis, evolution has
provided a swift but robust mechanism for tissue repair. The drawback of this hasty mechanism is
scar formation and imbalances in this mechanism can lead to non-healing wounds. The repair process
is highly complex, consisting of four stages: haemostasis, followed by inflammatory, proliferative
and remodeling phases, that involve complex interactions between skin cells, immune cells and
extracellular matrix (ECM) components, as well as a plethora of soluble mediators that help orchestrate
the process [1,2]. At the start of the repair process, blood loss is stemmed by formation of a blood
clot containing platelets, red blood cells, white blood cells and fibrin fibers. These fibers then act as
a scaffold for immune cells that are attracted by soluble factors released from platelets and injured
tissue, to enter the wound. Mouse wound models have shown that within hours neutrophils enter
the injured skin along with a small wave of pioneer monocytes that leak into tissue through areas
of microhemorrhaging [3,4]. Neutrophil numbers peak around days 1–2 [4]. These cells are the first
responders and kill potential pathogens, debride the wound, and release a number of soluble mediators
that attract other immune cells to the site of injury. Once they have undergone their role in the repair
process, they apoptose. Monocytes begin migrating into the wound and en route they differentiate into
wound associated macrophages in a process driven by factors in the extracellular milieu [2]. Wound
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associated macrophage numbers then increase until day 2 when their numbers remain stable until
around day 5 when they begin to gradually decrease to steady state levels by day 14 [5]. During this
time in the wound, macrophages remove spent neutrophils and secrete various cytokines, growth
factors and other mediators [6]. Through these mediators, macrophages either directly or indirectly
regulate the proliferative stage. They stimulate fibroblasts, keratinocytes and endothelial cells to
differentiate, proliferate and migrate, leading to the deposition of new ECM, re-epithelialisation and
neovascularisation of the wound [7]. In the remodelling phase, macrophages can release enzymes that
alter the composition of the ECM and the structure of the wound.
2. Macrophages Phenotypes
Differentiated wound macrophages are not a homogeneous population of cells but exist as
multiple phenotypes that can be broadly classified as M1 and M2 phenotypes (Table 1) [8–10]. These
are not discrete populations in vivo but instead they represent a continuum of phenotypes from M1-M2
that evolve as the wound matures. Pro-inflammatory mediators interferon-γ (IFN-γ) and tumour
necrosis factor (TNF), and damage associated pattern molecules (DAMPs) activate cells to produce
‘classically activated’ M1 macrophages (Figure 1) [11]. This results in a pro-inflammatory macrophage
phenotype that prolifically produces pro-inflammatory cytokines, such as TNF and Interleukin-6
(IL-6), and other mediators that facilitate the initial stages of wound healing (Figure 1). These M1
cells are highly phagocytic, enabling them to phagocytose neutrophils that have apoptosed and
remove any pathogens or debris in the wound. Alternatively activated M2 macrophages are typically
anti-inflammatory and can be produced in vitro through the addition of IL-4 or IL-13 or through their
phagocytosis of apoptosed neutrophils. M2 cells have been divided into four discrete types—M2a,
M2b, M2c and M2d—in vitro based on their function and key markers (Table 1) [12]. Whether they
all exist in wounds is currently unclear. There is some controversy in the literature as to how the
M2 wound phenotype is derived [13]. Different wound macrophage subsets could be derived from
monocytes with different phenotypes recruited at different times that differentiate into macrophages
with distinct phenotypes, or monocytes could be recruited at different times in the course of wound
healing where the ever-changing wound milieu affecting their polarisation, or M1 macrophages could
differentiate into M2 macrophages driven by cues in the local wound environment [13]. A number of
studies point to the latter suggestion that it is the same macrophages that regulate early inflammatory
functions and later wound reparative functions [13,14]. This suggests that the local environment or
some function of the macrophage results in their switch in phenotype in wounds.
 
Figure 1. M1 and M2 polarisation of macrophages. Monocytes can be classically or alternatively
activated to form M1 and M2 macrophages respectively. M1 macrophages can also differentiate into
M2 macrophages through local cues and after efferocytosis. The M1 phenotype is pro-inflammatory,
phagocytic and bactericidal, while the M2 macrophages act to switch off inflammation and regulate
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Table 1. Human M1 and M2 phenotypes.

























































STAT-3 SOCS3+ STAT-6,SOCS3+ [18,20]
Proteases MMP-1, 2, 3, 7,9 & 12 MMP-1, 2, 9, 12,13, 14, TIMP-1 [18]
Growth







−, negative; + positive (low); ++ positive (high); IL, interleukin; MMP, matrix metalloproteinase; TNF, tumour
necrosis factor; MHC, major histocompatibility complex; NOS, Nitric Oxide Synthase; Arg, arginase; ROS, reactive
oxygen species; RNS, reactive nitrogen species; EGF, epidermal growth factor; TGFβ, transforming growth factor β;
IGF1, Insulin-like growth factor 1; VEGF, vascular endothelial growth factor.
3. Macrophages Regulate Wound Closure and Scar Formation
Historically, a number of studies addressing the role of macrophages in wound healing provided
some doubt as to the necessity and role of these cells in the repair process [22,23]. Depletion of
macrophages using anti-serum suggested that macrophages were necessary for the repair process [22].
However, these studies required steroids to deplete most macrophages and so this may also have
affected the repair process. The advent of genetic engineering mice has since improved our
understanding of the role in macrophages in repair. Mice that lack macrophages (PU.1 mice)
repair skin at the same rate as control mice with greatly reduced scar formation, suggesting that
macrophages regulate scar formation but not wound closure [23]. However, the PU.1 mice also lack
functioning neutrophils [23]. More recently, elegant studies using diphtheria toxin-driven lysozyme
M-specific ablation or CD11b specific cell lineage ablation to selectively deplete all macrophage
phenotypes, show that these cells are necessary for timely wound healing and they regulate scar
formation [24–26]. Depletion of macrophages using the diphtheria toxin driven (DTR) lysozyme
M-specific strategy just prior to and throughout the repair process leads to impaired wound healing
compared with control mice [24]. Without macrophages, wounds are not cleared of neutrophils
and contain high levels of pro-inflammatory cytokines [24]. They contain less anti-inflammatory
cytokines, so the ability to dampen inflammation in the wound is reduced, as is the expression of
transforming growth factor-beta 1 (TGF-β1), a growth factor that has roles in regulating proliferation,
migration, differentiation, and ECM production during the repair process [24]. Consequently, reduced
myofibroblast differentiation leads to less wound contraction, and a temporal shift in VEGF expression
to later time points resulting in a reduction in angiogenesis [24]. Similar results were seen when
ablating CD11b macrophages with diphtheria toxin, except, curiously, there were no changes in wound
neutrophil levels [25]. These results suggest that macrophages are necessary for efficient repair.
Wound macrophages are not a homogenous population of cells and at different stages of the repair
process they can have distinct phenotypes. Using the diphtheria toxin driven lysozyme M-specific
strategy, macrophages have been selectively depleted at distinct times in the repair process to tease
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during the final stages of repair had no impact on tissue maturation, the removal of macrophages in
the mid repair stage resulted in wounds that were significantly delayed with signs of haemorrhaging,
suggesting they play a crucial role at this point of the repair process. The mid repair macrophages,
presumably M2 macrophages, were found to be required for vascular stability through their production
of vascular epithelial growth factor-A (VEGF-A) and TGF-β1 [26]. Depletion of macrophages only in
the early stages (days 1–5) suggests macrophages regulate the degree of scar formation and that this
pool might be a good target for reducing scar formation [26]. Loss of the early pool of macrophages
did significantly delay wound closure, but macrophage repopulation of the wound rescued this delay
with wounds reepithelialised by day 14 similar to the control mice [26]. Attractively, these latter
wounds have reduced fibrosis, indicating that this early pool of macrophages is necessary for scar
formation [26]. This suggests that having less macrophages in the early stages of the repair process
might be beneficial in terms of reducing scar formation. This data together suggests that macrophages
regulate wound closure and scar formation, and macrophages at different stages of the repair process
perform different functions. Interestingly, the distinct roles of different macrophage populations in
fibrosis and on the repair process is not limited to skin repair [27]. In liver injury, macrophage depletion
using a CD11b-DTR macrophage mouse model shows that during the progressive inflammatory liver
injury stage a lack of macrophages reduces fibrosis [27]. However, macrophage depletion during the
recovery phase leads to failure of resolution with persistence of cellular and matrix components of
the fibrotic response [27]. This suggests that macrophages can also play dual roles during the repair
process in other types of injury.
While macrophages found in the wound are derived predominantly from circulatory monocytes,
skin does contain low numbers of resident macrophages [8]. The exact contribution of these resident
macrophages during the repair process is currently unclear. They potentially play a role in the
initial recruitment of immune cells to the site of injury, although the absence of skin macrophages
prior to wounding does not affect the overall recruitment of neutrophils [24]. It is known that
alternatively activating macrophages derived from monocytes and from tissue macrophages can
produce phenotypically and functionally distinct macrophages [28]. This suggests that the small
population of resident macrophages might play different roles to the recruited macrophages derived
from monocytes during the wound repair process, but this has yet to be tested.
4. M2 Macrophages and Wound Closure
Wounds contain macrophages with phenotypes associated with both classical and alternative
activation, the ratio of which alters as the wound matures [29]. During the early stages of inflammation,
around 85% of macrophages have an M1 phenotype and avidly secrete pro-inflammatory mediators,
while 15% have an M2 phenotype that secrete anti-inflammatory cytokines and growth factors [29].
This ratio switches as the wound matures so that 5–7 days post injury only 15–20% of macrophages
have an M1 phenotype and the wound is primarily populated by cells with an M2 phenotype [29,30].
At 5 days post injury, M2 macrophages dominating the acute wound express CD301b, along with high
levels of the anti-inflammatory cytokine IL-10 and growth factors such as platelet-derived growth
factor (PDGFβ), and TGF-β1 [30]. By using mice expressing a diphtheria toxin receptor/GFP fusion
protein under the endogenous CD301b promoter to deplete these CD301b expressing population
of M2 cells in mice wounds 3 days post injury, it has been shown that these cells are necessary for
timely re-epithelisation, revascularization and fibroblast regeneration [30]. This mirrors the results
seen when both M1 and M2 phenotypes are depleted [24–26]. To further tease out the role of the
M1 and M2 phenotypes, the cFMS kinase inhibitor GW2580 has been used to selectively inhibit the
transition from M1 to M2 macrophages in an acute wound [31]. Blocking this transition prolongs
the inflammatory phase; mice treated with this inhibitor prior to and during wound healing have
higher number of neutrophils and macrophages at 14 days post injury compared to untreated mice [31].
M2 macrophages secrete factors, such as TGF-β1, that induce the proliferation of fibroblasts and their
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Consequently, the GW2580 treated mice have significantly reduced levels of total collagen suggesting
that M2 macrophages regulate scar formation.
Since M2 cells have been found to promote repair, it has been proposed that increasing M2
macrophage numbers in the wound might accelerate wound closure. Transplantation of the CD301b
M2 population from a day 5 wound into a day 3 wound increases fibroblast proliferation and vascular
regeneration, confirming that these CD301b positive M2 macrophages are key cells regulating the
reparative phases during wound healing [30]. They do not, however, alter wound closure rates [30].
Similarly, injection of anti-inflammatory M2a or M2c macrophages, that have been stimulated in vitro
with IL-4 or IL-10 respectively, into excisional wounds of mice had no effect on wound closure [32].
However, data from chronic diabetic wounds suggest that it may well be how the M2 macrophage
is activated that is crucial for timely wound healing, and that IL-4 or IL-10 are not key drivers of
the reparative M2 phenotype in wounds. Collectively, these results suggest that in an acute wound
the extended and/or increased presence of M1 macrophages, reduced numbers of M2 macrophages
and/or increased M2 activation potentially dictate repair and the level of scar formation in part
through their secretion of TGF-β1. High levels of TGF-β1 lead to an expansion of fibroblast population
and increased differentiation into myofibroblasts, which then secrete more collagen, strengthening
the wound. However, excess collagen increases fibrosis. Collectively, these results suggest that M2
macrophages regulate re-vascularisation, fibroblast regeneration and myofibroblast differentiation and
collagen production.
5. Macrophage Phenotype and Dysregulated Inflammation in Chronic Wounds
5.1. Chronic Wound Macrophages Are Predominantly M1 Pro-Inflammatory Cells
Chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, do not
heal in a timely manner. The pathophysiology of these chronic wounds is complex and can include
diverse factors such diabetic status, venous insufficiency, arterial perfusion or persistent pressure [33].
What these wounds all have in common is an increased and prolonged inflammatory stage with
a distinct wound cell composition, showing changes in both in cell number and the predominant
macrophage phenotype, compared to acute wounds [34–36]. The typical shift in M1 to M2 macrophages
seen in acute wounds is dysregulated in chronic wounds (Figure 2) [34–37]. At the chronic wound
margin, approximately 80% of cells are pro-inflammatory M1 macrophages with these cells playing
a major role in the pathogenesis and the on-going chronicity of wounds [35]. Mouse models of
diabetic wounds show that reduced M2 macrophage levels lead to a reduction in growth factor
levels that regulate the proliferative stage of repair, such as TGFβ1, insulin-like growth factor-1
(IGF-1) and vascular endothelial growth factor (VEGF) [37,38]. These wounds contain high levels of
pro-inflammatory cytokines and mediators, such as TNF, IL-1β, IL-17 and iNOS, which contribute
to the non-healing phenotype [5,35,37–39]. Patients with chronic wounds present with high levels
of pro-inflammatory cytokines in their wound fluid [35,40,41]. At a cellular level, high levels of
pro-inflammatory mediators, such as TNF in the wound extracellular milieu, lead to alterations in the
secretion of MMP-1, MMP-3 and TIMP-1 from dermal fibroblasts [42]. This changes the fine balance
between MMPs and TIMPs, leading to the detrimental excessive ECM proteolysis seen in the wound
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Figure 2. The M1 to M2 switch is dysregulated in chronic wounds and, unlike in acute wounds,
macrophages are unable to phagocytose neutrophils. (A) In the early inflammatory stage of an acute
wound, macrophages phagocytose spent neutrophils. In the later stages, having performed this role,
macrophages switch phenotype and are predominantly M2 macrophages; (B) In a chronic wound,
macrophages are predominantly M1 that are unable phagocytosis spent neutrophils. This leads to the
recruitment of more macrophages and an increase in inflammation.
5.2. Hyperglycaemia Alters Efferocytosis and the Macrophage Phenotypic Switch in Diabetes
Alternative activation and macrophage phenotype can be driven by factors in the extracellular
environment. In vitro M2 alternate activation is driven by stimulation with IL-4/IL-13, but in an acute
wound extracellular IL-4 and IL-13 is lacking [29]. This, along with the fact that transplantation of
in vitro IL-4 or IL-10 differentiated M2 macrophages has no effect on wound closure, suggest that
there may be some other driver of differentiation and perhaps a different phenotype involved [32].
Other than factors in the local environment, macrophage phenotype is also altered after the
phagocytosis of neutrophils, in a process known as efferocytosis (‘to carry to the grave’) [43–45].
In vitro, macrophages that engulf apoptosed neutrophils switch to an M2b phenotype that expresses
low levels of IL-12 and produces high levels of IL-10 and TGF-β [46]. During the initial stages of
wound healing, neutrophils enter the wound and apoptose once they have performed their roles in
clearing pathogens and debris. These spent neutrophils are removed by macrophages, which in turn is
proposed to lead to their switching to an anti-inflammatory M2 phenotype that dampens inflammation
and so aids the resolution of wounds. In acute wounds, neutrophil efferocytosis drives the resolution
of inflammation through the induction of micro-RNA-21, which silences the pro-inflammatory activity
of the programmed cell death 4 (PDCD4) gene and favours cJun-AP1 activity leading to an increased
production of IL-10, a major suppressor of inflammation [47]. Thus, the efferocytosis of neutrophils,
and possibly the local environment, can determine whether macrophages differentiate and effectively
resolve inflammation in a timely manner [43]. Alterations in external cues and in efferocytosis could
prevent these macrophages from differentiating, leaving a pro-inflammatory phenotype that amplifies
inflammation and contributes to the impaired wound resolution phenotype.
Monocytes can be preprogramed prior to entering the wound environment, particularly in
diseases that induce a chronic state of inflammation. In diabetes, the diabetic environment
triggers changes in haematopoietic cells generating monocytes that are pre-programmed towards
a pro-inflammatory phenotype. Hyperglycemia and the associated advanced glycated end
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neutrophils [48–51]. This results in high levels of neutrophils in diabetic wounds. In mice diabetic
models, the increase in apoptotic cells leads to increases in pro-inflammatory cytokines TNF and IL-6
in tissue and wound fluid, with a concomitant decrease in the anti-inflammatory cytokine IL-10 that
would normally act to turn off the inflammatory response [48,49]. TNF is one of the key cytokines that
can impair wound healing [52]. Increased apoptotic cell load leads to increased inflammation as seen
in chronic wounds. Increased apoptosis in an acute wound model leads to an increased inflammatory
response with reduced anti-inflammatory cytokines [48]. This, along with the lack of IL-4 and IL-13
in acute wounds suggests that engulfment of apoptotic cells is a major trigger pushing macrophages
from an M1 pro-inflammatory phenotype towards the M2 anti-inflammatory phenotype to resolve
inflammation (Figure 2).
5.3. Iron Regulates the Macrophage Phenotype in Chronic Venous Ulcers (CVU)
Like diabetes, chronic venous disease is a chronic inflammatory disease. These patients have
persistently raised venous pressure (venous hypertension) in lower limb deep and superficial veins.
Increased pressure and shear stress leads to changes in the endothelium and the activation of
leukocytes including monocytes, macrophages and neutrophils which become “trapped” in the
limbs. These activated leukocytes in turn cause injury to the endothelium, leading to a chronic
inflammatory state. So, like the diabetic monocytes/macrophages, these cells also have an altered
phenotype prior to entering a wound. Within a human chronic venous ulcer (CVU), approximately
80% of the cells at wound margin are macrophages, similar to what is seen in diabetic wounds [35].
These cells differ from those in other wound types in that they contain high amounts of iron from their
engulfment of erythrocytes that have leaked into tissue [35]. In iron-dextran–treated mice, iron laden
macrophages isolated from wound margins at day 5 post injury are dominantly pro-inflammatory M1
with an intermediate anti-inflammatory M2 phenotype (TNF-αhi, IL-12hi, CCR2hi, Ly6Chi, Dectin-1med,
IL-4Rαmed, and CD204med) compared with control mice [35]. Treatment of iron loaded mice with the
iron chelator desferrioxamine improved wound healing, suggesting that the removal of iron might
improve these wounds [35]. Thus, like hypoglycaemia in diabetes, high levels of iron in patients with
chronic venous disease leads to an alteration in the macrophage phenotype. Whether these altered
macrophages have a defect in efferocytosis, as is seen in diabetes, is yet to be tested. Impaired wound
healing is often accompanied by low grade inflammation which can alter cell phenotype, pushing
macrophages towards a premature pro-inflammatory phenotype. The high levels of M1 macrophages
seen in CVUs results an increased production of TNF which correlates with delayed healing in patients.
Addition of recombinant TNF to the margins of an acute wound delays healing [35], while the TNF
inhibitors to chronic wounds rescues delayed healing [35,39]. This suggests one of the key factors in
wound chronicity is TNF with its increased secretion leading to a delayed phenotype and making TNF
a good target to improve wound healing [35].
6. Summary
Collectively, these studies suggest that the extended and/or increased presence of M1
macrophages, reduced numbers of M2 macrophages and/or increased M2 activation can all alter the
delicate balance of inflammation in the wound and so drastically affect the repair process. Any failure
to switch from an M1 phenotype to an M2 phenotype leads to increased inflammation and the secretion
of copious amounts of TNF, which inhibits wound closure in chronic wounds. A driver of this M2
switch in wounds is efferocytosis, a process that is dysregulated in diabetic wounds and potentially in
CVU, possibly through the chronic inflammation seen in these patients. The anti-inflammatory M2 cells
regulate both the repair process and regulate the final scar outcome. These cells secrete growth factors
that stimulate proliferation, angiogenesis and fibroblast differentiation to myofibroblasts in the wound.
The latter cells secrete collagen, which strengthens the wound but excess collagen leads to increased
fibrosis. Great progress has been made in recent years in our understanding of cell types within the
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present in the wound, what are the key phenotype regulating scar formation and can we improve
efferocytosis and the M2 switch in cells from diabetic patients? While macrophage targeted therapies
have not been developed, the progress made in the last decade has provided key data that will help
inform future research and take us one step further toward perfect healing.
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Abbreviations
AGEs advanced glycated end products
CVU chronic venous ulcers
DAMPs damage associated pattern molecules
ECM extracellular matrix
IGF-1 insulin-like growth factor-1
PDGFβ platelet-derived growth factor
TGF-1 transforming growth factor-1
VEGF vascular endothelial growth factor
cJun-AP1 cJun activator protein 1
IFN-γ interferon gamma
iNOS inducible nitric oxide synthase
MMP matrix metalloproteinase
TIMP tissue inhibitor of matrix metalloproteinase
TNF tumour necrosis factor
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Abstract: Extracellular vesicles (EVs) are membrane-enclosed vesicles that are released into the
extracellular environment by various cell types, which can be classified as apoptotic bodies,
microvesicles and exosomes. EVs have been shown to carry DNA, small RNAs, proteins and
membrane lipids which are derived from the parental cells. Recently, several studies have
demonstrated that EVs can regulate many biological processes, such as cancer progression, the immune
response, cell proliferation, cell migration and blood vessel tube formation. This regulation is achieved
through the release and transport of EVs and the transfer of their parental cell-derived molecular
cargo to recipient cells. This thereby influences various physiological and sometimes pathological
functions within the target cells. While intensive investigation of EVs has focused on pathological
processes, the involvement of EVs in normal wound healing is less clear; however, recent preliminarily
investigations have produced some initial insights. This review will provide an overview of EVs and
discuss the current literature regarding the role of EVs in wound healing, especially, their influence
on coagulation, cell proliferation, migration, angiogenesis, collagen production and extracellular
matrix remodelling.
Keywords: wound healing; proliferation; migration; angiogenesis; extracellular membrane vesicles;
microvesicles; apoptotic bodies; exosomes; endothelial cells; keratinocytes
1. Introduction
Membrane-enclosed extracellular vesicles (EVs) include apoptotic bodies, microvesicles and
exosomes which are released by various cell types, and have been found in cell culture media, as
well as body fluids such as breast milk, urine, amniotic fluids, saliva and blood [1–11]. During EV
biogenesis, a number of biological molecules are encapsulated into the EV, including DNA, small
RNAs, proteins and lipids which are derived from parental cells [6,11]. However, the real significance
of EVs lies in their ability to deliver their contents to recipient cells, thereby altering biological and
cellular processes. Furthermore, aberrant delivery of EV cargo to recipient cells has been implicated in
several pathologies such as some autoimmune disorders and cancers [12–15].
Wound healing is a complicated process which involves an overlapping cascade of events
characterised into four distinct phases (Figure 1). These include:
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• Haemostasis, where blood loss ceases;
• The inflammatory phase, characterised by infiltration of immune cells to combat infection and
remove cellular debris;
• The proliferative phase, where fibroblasts and keratinocytes at the wound margins migrate into
the wound and increase in cell number to re-establish the barrier function of the skin; and
• The remodelling phase, during which reorganisation of the dermis occurs and the preliminary
extracellular matrix (ECM), laid down during the earlier phases of the healing response,
is remodelled to strengthen the wound area through the reduction of scar tissue [16].
Preliminary studies have shown that EVs may be involved in wound healing through the control
of a number of cellular processes [17–21]. Therefore, this review will summarise the role of EVs derived
from predominant cells involved in the wound healing process. An overview of EV classification,
biogenesis, components, and cell-to-cell communication via EVs is also described.
Figure 1. Wound healing process. The normal tissue repair process is comprised of continuous and
overlapping phases. These four phases include: (i) Haemostasis; (ii) inflammation; (iii) proliferation;
and (iv) remodelling. Each phase consists of different cellular events which requires the interplay of
multiple cell populations [22].
2. Extracellular Membrane Vesicles (EVs)
EVs have a phospholipid bilayer similar to the cell membrane, with diameters ranging from
40 nm to 5 μm. In general, EVs can be classified into three subtypes: apoptotic bodies (also known as
apoptotic vesicles); microvesicles (also known as shedding vesicles); and exosomes.
2.1. Apoptotic Bodies
Apoptotic bodies are the largest vesicle population, with a diameter ranging from 1 to 5 μm and
have a heterogeneous morphology. Apoptotic bodies are released when cells undergo apoptosis and
therefore they contain various components from their parental cells often including organelles and
DNA fragments [23].
Apoptosis and necrosis are major mechanisms of cell death, which produce cell debris but are
activated by diverse biological stimuli [23–25]. In contrast to apoptosis which is programed cell
death, necrosis is passive and activated by mechanical damage or disease [25]. Interestingly, apoptotic
bodies are released into the extracellular environment through several stages. During the early and
intermediate stages, the cell membrane is contracted, the cytoplasm is condensed, and the cells become
smaller in size [23]. Simultaneously, nuclear chromatin is also condensed and undergoes alteration,
and the plasma membrane deteriorates such that its permeability increases in the late stage. As a result,
the plasma membrane undergoes a process that is commonly known as blebbing [24]; and the cellular
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Therefore, apoptotic bodies contain the cytoplasm, but does not necessarily include tightly packed
organelles or nuclear fragments. However, if organelles are encapsulated within apoptotic bodies,
these organelles have been shown to have their integrity maintained [23]. During the formation process
of apoptotic bodies, phosphatidylserine (PS) residues that are normally located on the internal surface
of the plasma membrane, subsequently translocate to the external surface. This process presents
extracellular signals that attract macrophages to clear the apoptotic bodies via phagocytosis (Figure 2).
 
Figure 2. Formation of apoptotic bodies and clearance by phagocytosis. Formation of apoptotic
bodies includes the condensation and segregation of the nucleus, and the deterioration and blebbing
of the plasma membrane. The result of these processes is a separation of the cellular contents into
membrane-enclosed vesicles which can be cleared by phagocytic cells.
2.2. Microvesicles
Microvesicles, also known as “ectosomes”, are the second largest vesicle type between 100
and 1000 nm in diameter, which are formed by the outward budding and fission of the plasma
membrane [26,27]. However, there is limited understanding about the formation and shedding
mechanism of microvesicles at the cell surface, although it is hypothesised that the formation of
membrane microvesicles may be a result of the dynamic interplay between phospholipid redistribution
and cytoskeletal protein contraction [28,29]. This process is regulated by several enzymes such as
calpain, flippase, floppase, scramblase and gelsolin [30]. Flippases transfer phospholipids from the
outer leaflet to the inner leaflet while floppases transfer phospholipids from the inner leaflet to the
outer leaflet [31]. The translocation of PS to the outer-membrane leaflet is a signal that induces
the membrane budding/vesicle formation (Figure 3) [28]. In addition, microvesicle formation was
associated with ADP-ribosylation factor 6 (ARF6), a small GTPase protein, which regulating the
activation of myosin light chain kinase (MLCK) and subsequent phosphorylation of MLCK lead to
a promotion of contraction of actin-based cytoskeleton [32]. Thereby, the budding process is completed
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Figure 3. Phospholipid translocase activity via floppase and flippase which translocates
phosphatidylserine and other phospholipids from the inner leaflet to the outer leaflet, and outer
leaflet to inner leaflet, respectively, during microvesicle formation. These processes are adenosine
triphosphate (ATP)-dependant [28,30,32,33].
2.3. Exosomes
Exosomes are the smallest class of EVs with diameters between 40 and 100 nm and a cup shape
morphology according to previous studies using electron microscopy [34]. Although the mechanism
of exosome biogenesis is not fully understood, it is commonly accepted that exosomes are formed and
developed via the endocytic pathway, and are subsequently released to the extracellular environment
by exocytosis [35,36]. The formation and release process begins when fluids, solutes, macromolecules,
plasma components and particles are internalized by various endocytic trafficking pathways into
transport vesicles [37,38]. The transport vesicles then fuse with one another or with an existing sorting
endosome to form early endosomes. During the next developmental stage, early endosomes may collect
proteins and other components and develop into late endosomes, and that late endosome may recycle
its components back to the plasma membrane or be subjected to degradation by lysosomes [37,39].
Alternatively, that late endosomes may develop to become multi-vesicular bodies (MVBs) carrying
and releasing exosomes when MVBs fuse with the cellular membrane (Figure 4) [39,40]. Thus while
complex and much remains unknown about exosome biogenesis, it is clear that their formation and
release are tightly regulated by multiple signalling mechanisms. For instance, some evidence suggests
that Endosomal Sorting Complexes Required for Transport (ESCRT) pathway is needed for exosome
biogenesis [39,41] as is Rab27a/b which is involved in endosome development and docking of MVBs
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Figure 4. Exosome biogenesis. Beginning from internalization of membrane proteins and lipid
complexes by endocytosis, endocytotic vesicles are delivered to early endosomes, which fuse with
each other resulting in formation of late endosomes/multivesicular bodies (MVB). MVBs either release
exosomes by fusion with the cellular membrane, or their contents are degraded if they fuse with
lysosomes [40,42,43]. The key steps of the exosomal formation and development process are highlighted
in red.
3. Cell-to-Cell Communication
Cell-to-cell communication is a pivotal mechanism that enables the differentiation of cells and
the development of multicellular organisms. The mechanisms of cell-to-cell communication are very
complex and involve intercellular and intracellular signals, which includes cell junctions, adhesion
contacts and soluble factors [44,45]. Cells can form bridges (cytonemes) to connect and exchange
surface-associated cargo to neighbouring cells based on the mechanism of adhesion [46], or tunnelling
nanotubes to contact and transfer both cell surface molecules and cytoplasmic components to other
cells [46,47]. Recently, EVs were found to be a new means of communication because they carry
functional molecules and can horizontally transfer these to neighbouring cells [19].
Cell-to-cell communication by EVs is described as a way for cells to interact with neighbouring
cells or one another over long distances, when EVs were detected in the circulation and other body
fluids [44]. The binding of EVs to target cells is specific with examples including: platelet-derived EVs
binding to neutrophils [48]; neutrophil-derived EVs binding to dendritic cells [49] or to monocytes and
endothelial cells [50]; and leukocyte-derived EVs binding to platelets [51]. The interaction between
EVs and target cells are thought to require the coordinated action of the cytoskeleton and vesicle fusion
machinery [28]. Despite the limited understanding about EVs transport, different mechanisms of
interaction between EVs and recipient cells include ligand–receptor interaction, internalisation and
direct membrane fusion have been studied [52] (Figure 5).
Examples of ligand–receptor interaction mechanisms include studies of EVs released from
dendritic cells and platelets [53,54]. Dendritic cell-derived exosomes contain MHC class II and CD9 on
their membrane and were found to bind to the surface of activated T cells [53]. This binding could
be an interaction between MHC II molecules on exosome membranes and T cell receptors on T cell
membranes [53]. Interestingly, exosomes only bound to the surface of the plasma membrane without
fusing and internalisation into T cells [53]. Similarly, platelet-derived microvesicles containing the
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then stimulated the adhesion of these cells to the endothelium as well as directed them from peripheral
blood back into the bone marrow [54].
Regarding the mechanism of direct membrane fusion, some evidences suggested that
microvesicles fused directly with the plasma membrane and transferred their contents to the
intracellular milieu of the recipient cells [55–58]. In the case of microvesicles enriched selectively with
P-selectin glycoprotein ligand-1 (PSGL-1), the fusion may be controlled by Annexin V or antibody to
PSGL-1 [55]. Additionally, it seems that the fusion of EVs to the plasma membrane is also dependant on
SNARE proteins, which regulate the fusion and target specificity in intracellular vesicle trafficking [58].
When EVs fuse with and transfer membrane components such as receptors and ligands to their targets,
these can increase the resistance to apoptosis in the case of macrophages receiving chemokine receptors;
or induce an increased frequency of apoptosis in the case of T lymphocytes receiving the Fas ligand
(a death-receptor ligand) [56,57].
Morelli et al. found evidence of the internalisation of circulating EVs into dendritic cells,
phagocytes of spleen, and Kupffer cells in the liver via clathrin-dependent endocytosis [59].
This internalisation of EVs by dendritic cells requires participation of the dendritic cell cytoskeleton as
well as surface molecules such as externalised PS, CD11a, CD54, CD9 and CD81 [59]. Additionally,
cellular maturity also influences the internalisation of EVs by dendritic cells, since immature dendritic
cells exhibit a higher internalisation capability than mature dendritic cells [59]. This internalisation of
EVs into target cells could induce peripheral T-cell tolerance in the absence of danger signals [59] or




Figure 5. Interaction of EVs with target cells: (A) intracellular signalling due to EV membrane ligand
cell surface receptor interactions [53,54]; (B) direct membrane fusion which induces cell function
through release of EV cargo into target cells [55–58]; and (C) internalisation of EVs into target cells,
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4. Functional Components of EVs
4.1. Proteins
In general, all three populations of mammalian EVs share some common characteristics such as
structure (lipid bi-layer), and tend to have common types of cargo such as protein, lipid or genetic
material. However, these characteristics may be distinct depending on the manner of formation as
well as the nature of their parental cells. Specific molecules that are unique to each vesicle population
can be used to distinguish between them. For example, PS is only transferred to the external plasma
membrane surface when cells undergo apoptosis and where microvesicles are formed and shed [28,60].
In another example, the tetraspanin family (e.g., CD9, CD63, and CD81) form a complex network
of interacting molecules which play a role in trafficking of transmembrane proteins [61]. Thus CD9,
CD63, and CD81 are enriched and often detected in exosomes since they are often involved in exosome
biogenesis pathways [8,52,62], however these components are also detected in other vesicles [63].
Interestingly, CD24 could be considered as a marker of exosomes isolated from urine and amniotic
fluids [8]. Additionally, the CD24 has been found to be over-expressed in various cancer cell lines such as
ovarian, breast, non-small cell lung, prostate and pancreatic carcinomas [64]. In terms of other functional
proteins, Dujarin et al. reported that Tau, a microtubule-associated protein, and matrix metalloproteinase
1 (MMP-1) protein, were enriched in microvesicles compared to exosomes [17,65]. However, no studies
have reported whether or not Tau and MMP-1 proteins are enriched in apoptotic bodies.
Importantly, specific EV biomolecular cargo has previously been linked to cancer and tumour
development [50,66,67]. For example, apoptotic bodies, which contained DNA encoding the oncogenes
H-rasV12 and c-myc, were found to induce tumour formation and growth in severe combined
immunodeficient (SCID) mice [66]. Interestingly, the authors also found that these H-rasV12 and
c-myc genes were replicated and incorporated into the recipient genome in newly formed tumour
cells in vivo (SCID mice model) [66]. Furthermore, microvesicles carrying MMP-9 released from breast
carcinoma cells, fibrosarcoma cells and polymorphonuclear leucocytes functioned in the digestion of
the extracellular matrix, which is necessary for the progress of cancer growth and inflammation [50,67].
EVs have also been found to carry components associated with angiogenesis and coagulation
processes [55,68,69]. For instance, endothelial cell-derived microvesicles, which were enriched with
MMPs, could stimulate the invasion and formation of capillary-like structures of human umbilical
vein endothelial cells (HUVECs) [69]. Indeed, MMPs have been identified as important mediators
of angiogenesis [70,71], but exactly how the EV MMPs contribute to the angiogenic process has not
yet been revealed. Interestingly, the accumulation of MMPs within microvesicles was shown to be
stimulated by angiogenic factors including, fibroblast growth factor (FGF)-2 and vascular endothelial
growth factor (VEGF) [69]. Moreover, EVs were also associated with coagulation since microvesicles
contained tissue factor (TF) derived from platelets and monocytes [55,68].
EVs also have a function in the regulation of immune responses, since exosomes have been
found to contain major histocompatibility complex (MHC) class I and II molecules and may transfer
these molecules to dendritic cells [5,72,73]. The transferral of MHC I molecules from melanoma cell
line-derived exosomes to dendritic cells, triggered the production of Interferon γ in these cells [73].
Furthermore, MHC I molecules carried by dendritic cell derived exosomes could activate CD8+ T
cell responses [5,73]. These studies indicate that exosomes can potentially act as extracellular antigen
sources, which could help to develop immune interventions.
Finally, cytoplasmic proteins, such as tubulin, actin, actin-binding proteins, annexins and Rab
proteins, which are involved in intracellular membrane fusion and transport, and ESCRT machinery
complex proteins are also found in exosomes [39,41,74,75]. In addition, molecules responsible for
signal transduction, such as protein kinases, 14-3-3 and heterotrimeric G proteins, are enveloped
during exosome formation and release [39,74,76,77]. While there is evidence to support the conclusion
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cells, unequivocal evidence is still required [19]. Taken together, these studies indicate that EVs and
their cargo are functional and could influence recipient cell behaviour.
4.2. Lipids
Interestingly, EV lipid composition, which includes cholesterol, sphingomyelin, ceramide,
phospholipids and glucans can provide an additional means of identification for exosomes [78–81]. Indeed,
exosomes have been found to be enriched with higher amounts of cholesterol and sphingolipids, including
sphingomyelin and hexosylceramide, but contain lower amounts of accumulated phosphatidylcholine,
compared to parent cell membranes [81]. Importantly, Trajkovic et al. showed that high concentrations
of ceramide exist in the micro-domains where multi-vesicular endosomes are formed. This led to the
hypothesis that ceramide could be useful for enlarging micro-domains and facilitating the inducement
of domain budding [81]. These studies indicate that lipids can partially regulate the formation and
release of vesicles [78,81].
4.3. Genetic Materials (Messenger RNAs and miRNAs)
Regarding genetic biomolecules, RNAs including messenger RNAs (mRNAs) and microRNAs
(miRNAs) have also been found in EVs which have been increasingly found to elicit various functions
in recipient cells [11,82–90]. In particular, large amounts of mRNAs and miRNAs were found in
all three EV types released from both cell cultures and body fluids [14,82–84,87–90]. Importantly,
these EV-derived genetic molecules were selectively sorted into EVs and as such could be used for
diagnostics, such as cancer markers, or as potential treatment targets [90–94]. In addition to carrying
the information from secreting cells, EV mRNAs and miRNAs can also function to promote biological
processes, including proliferation, angiogenesis and apoptosis [86,92,95,96]. Interestingly, there is
evidence showing that EV mRNAs were horizontally transferred to recipient cells and are able to be
translated into proteins [3,95,96]. Additionally, the proteins translated from transferred EV mRNAs
have been shown to activate PI3K/AKT signalling pathways in recipient endothelial cells [96] and
accelerate morphological and functional recovery in rat liver [95]. While these studies provide some
evidence for the role of EV mRNAs and miRNAs in the regulation of biological processes, it is clear that
further studies are required to more fully understand the functional consequences of EV genetic cargo.
5. The Role of EVs in Cutaneous Wound Healing
Wound healing is an essential process that enables the restoration of the structure and function
of damaged or injured tissues. For most tissues, the process requires multiple cell types from
several distinct lineages where each responds to and generates a range of signals at different
times [97]. The wound healing process involves a series of overlapping phases including: haemostasis;
inflammation; migration; and tissue remodelling [16]. During these phases, a series of precise biological
events occur including: rapid vascular spasms, platelet plug formation and coagulation (collectively
known as haemostasis); inflammation; cell migration into the wound site; cell proliferation and
differentiation to form granulation tissue; angiogenesis; and extracellular-matrix reorganisation [97].
Evidence for the involvement of EVs in wound healing has been described for coagulation, cell
proliferation, cell migration and angiogenesis and summarised in Table 1 [17–19,21].
5.1. Coagulation
The blood coagulation cascade is complex and regulated by a range of factors such as calcium ions,
PS and TF in addition to many others. TF is an initiator of coagulation activation that was found to be
present on the plasma membrane of EVs, including microvesicles and exosomes, which were derived
from various cell types such as human monocytes/macrophages [55] human platelets [98]; and EVs
isolated from human saliva [99]. Indeed, monocyte-derived microvesicles enriched with TF and PSDL-1
were found to bind, fuse and transfer their content to collagen-activated platelets [55]. The result of this
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initiate the extrinsic coagulation cascade leading to conversion of prothrombin to thrombin and fibrin
clot formation [55]. Furthermore, in an in vitro study, salivary EVs that contain TF in association with
coagulation factor VII significantly reduced the clotting time of human wound blood (Figure 6) [99].
Similarly, EVs carrying TF from pericardial blood of cardiac surgery patients induced coagulation
in vitro and stimulated thrombogenicity in rats [98]. Conversely, EVs from the venous blood of healthy
individuals also carrying TF did not reduce clotting time [98]. This may be due to soluble inhibitors
including Tissue Factor Pathway Inhibitor (TFPI) or conformational regulation of TF in plasma that
impedes the binding of coagulation factor VII and inhibits its activity [55].
5.2. Cell Proliferation
Cell proliferation, a pivotal cellular process underpinning wound healing, has been shown to
be regulated by EVs derived from a plethora of cell types, such as human mesenchymal stem cells
(MSCs) [21,100,101], fibroblasts [18], murine embryonic stem cells [102], and human endothelial
progenitor cells [103]. The regulation of cell proliferation by EVs occurred through the binding to
or internalisation of EVs into recipient cells and delivery of EV content such as RNAs [104,105].
For instance, the internalisation of EVs into fibroblasts greatly enhanced the cell proliferation due
to the activation of the Akt and Erk1/2 effector pathway by EVs [18,21,100,106,107]. Additionally,
embryonic stem cell-derived EVs may facilitate fibroblast proliferation, possibly through the activation
of the mitogen-activated protein kinase (MAPK) pathway [102]. Importantly, these aforementioned
activated pathways induce the expression of a number of genes involved in cell cycle progression
such as c-myc, cyclin A1 and cyclin D2 which then support cell proliferation [21,106]. Furthermore,
activation of these pathways also promoted the production of growth factors, including insulin-like
growth factor-1 (IGF-1), stromal-derived growth factor-1 (SDF-1) and cytokine interleukin-6 (IL-6),
VEGF-α and transforming growth factor beta (TGF-β) [18,21,101,102]. Thus, it seems clear that EVs can
promote cell proliferation by activation of signalling pathways not only directly involved in stimulation
of cell cycle but also involved in the regulation of growth factor expression. Additionally, this growth
factor expression can act in a paracrine or autocrine fashion to further stimulate cell growth responses.
5.3. Migration
Following clotting, immune cells including neutrophils and macrophages are recruited to remove
necrotic tissues, debris, and bacteria from the wound site. Within hours after injury, other cells
including epithelial cells and fibroblasts migrate into the wound site to perform specific tasks, such as
induction of growth factor secretion, the synthesis of extracellular matrix, angiogenesis and stimulation
of wound closure [97]. Preliminary studies have been conducted investigating the involvement of EVs
in the migration of various cells associated with cutaneous repair, such as human and murine epithelial
cells [108], bovine endothelial cells [109], human MSCs [100], human keratinocytes and fibroblasts
in vitro [110].
Evidently, keratinocyte migration has been shown to be influenced by EVs released from various
cell types; however, different results were observed depending on the specific biomolecules carried
by the EVs [110,111]. For example, CoCl2-treated tumour cell-derived exosomes which contained
C4.4A (Ly6/PLAUR domain-containing protein 3), α6β4 integrin and MMP-14 inhibited keratinocyte
migration through degradation of laminin 332 resulting in delayed wound closure [111]. Conversely,
keratinocyte derived exosomes with heat-shock protein (HSP) 90α cargo significantly enhanced the
migration of primary human keratinocytes in a wound scratch model [110]. Additionally, the migration
of endothelial cells, which are crucial for vascular repair and regeneration, has also been shown to
be influenced by EVs released from cells such as human keratinocytes [108], human MSCs [112,113];
and bovine endothelial cells [109]. However, the mechanisms that facilitate EV mediated endothelial
migration are unclear.
In a wound healing context, fibroblasts are known to release growth factors which induce other
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wound [16,114]. Interestingly, EVs have been shown to regulate the migration of fibroblasts towards
wound sites [104,105,110]. Cheng et al. showed that TGFα stimulates HSP90α secretion from human
keratinocytes via the exosome pathway [110]. Most exosomes contain some member of the heat-shock
protein (HSP) family, such as HSP70 and HSP90 [39,76,115]. This protein family supports the folding
of nascent peptides; prevents the aggregation of proteins; assists with the transportation of other
proteins across cell membranes [116], and can induce cell motility [115,117]. Interestingly, human
keratinocyte conditioned media containing exosomes with HSP90α cargo was found to stimulate
the rapid migration of dermal fibroblasts [110]. HSP90α is comprised of four domains, including an
N-terminal domain, a charged sequence connected to the N-terminal domain, a middle domain and
a C-terminal domain [118]. It is thought that HSP90α may promote cell migration through binding
interactions with the cell surface receptor LRP-1/CD91 [110,117]. Furthermore, in corroboration with
cell migration enhancement, EVs released from mesenchymal stem cells and keratinocytes were also
shown to promote the expression of important genes such as TGF-β, transforming growth factor beta
receptor II, COL I, COL III, N-cadherin, cyclin-1, MMP-1, MMP-3 and IL-6 in fibroblasts [104,105].
These genes are involved in the Erk1/2 signalling pathway, which has roles in both cell proliferation
and migration.
5.4. Angiogenesis
New blood vessel formation is critical for wound healing in order to supply nutrients and oxygen
to newly formed tissues. The formation of new blood vessels requires the proliferation of endothelial
cells, as well as the interaction between endothelial cells, angiogenic factors (such as VEGF and
fibroblast growth factor) and surrounding ECM proteins [119]. Under chemotaxis, endothelial cells
penetrate the underlying vascular basement membrane, invade ECM stroma and form tube-like
structures that continue to extend, branch, and create networks [119,120]. Interestingly, all three
populations of EVs (apoptotic bodies, microvesicles and exosomes) contribute to the regulation of vessel
formation by enhancing the expression of pro-angiogenic factors [21,92,102,103,106,107,109,112,120,121].
For example, exosomes released from human embryonic MSCs [92,113] and human endothelial
cells [103,106] enhanced angiogenesis by promoting endothelial cell proliferation and migration
towards the wound site. Furthermore, a large number of blood vessels were observed in
exosome-treated sites compared to control treatment [106,107,112].
Interestingly, various critical pro-angiogenic genes, including IL-6, IL-8, angiopoietin-1, E-selectin,
and fibroblast growth factor 2, which activate the Erk1/2 signalling pathway, were up-regulated
after platelet-rich plasma and endothelial progenitor cell-derived exosome stimulation [106,122].
Additionally, the downstream target of the Erk1/2 signalling pathway such as inhibitor of DNA binding
1, cyclooxygenase 1, VEGFA, VEGFR-2, c-Myc and cyclin-D1, were also increased after treatment
with exosomes [106,122,123]. This provides further evidence that exosomes enhance endothelial cell
function through activation of the Erk1/2 signalling pathway (Figure 7) [106]. In contrast, microvesicles
from multiple cellular sources inhibited tube-like structure formation of microvascular endothelial
cells via CD36 on the treated cell membrane, while exosome derived from the same cell source
as the microvesicles did not have the same inhibitory activity [124]. Taken together, the previous
studies imply that EVs could potentially be used in vascular regenerative medicine. Moreover, the EV
bioactivities may depend on EV types and the physiological conditions of administered cells However,
further research is required to investigate which specific EV derived biomolecules are responsible for
the stimulation of angiogenesis.
5.5. Collagen Production and ECM Remodelling
Successful wound healing requires the contribution of many cellular events and biological
processes in addition to coagulation, cell proliferation, cell migration and angiogenesis. Besides the
involvement of EVs in the above events, EVs have also been shown to regulate ECM remodelling
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in elastin secretion, which is a structural protein of the ECM [102,112]. Furthermore, when wound sites
are treated with MSC-derived exosomes, an increase of COL I and III were observed in the early stage
of wound healing [105,112,125]. However, in the late stage of wound healing, exosomes may inhibit
collagen expression [105]. Interestingly, EVs catalyse the crosslinking of collagen in the ECM via lysyl
oxidase-like 2 (LOXL2), which is located on the exterior of the exosome membrane [126]. In addition,
a study by Huleihel et al. (2016) observed that EVs present within the ECM were closely associated
with the collagen network of the matrix, but these EVs could be separated from the fibre network [127].
This may indicate that EVs attend to the ECM formation and function. Furthermore, EVs have also
been demonstrated to significantly increase the healing rate and reduce scar widths by interaction with
Annexin A1 and formyl peptide receptors in a rat model [107,108,125]. Taken together, these studies
indicate that EVs play a pivotal role in the ECM remodelling phase of wound healing.
Table 1. Summary of research investigating EVs involvement in wound healing.






Mv, Ex Saliva/granulocytes,EPC Blood TF
Trigger coagulation by initiating
TF/factor VII [99]





Blood TF Promote thrombus formation [98]
Proliferation
Ex MSC FB, EC
Increase expression levels of HGF,
IGF1, NGF, SDF1; increase
re-epithelialisation; reduce scar widths;
promote collagen maturity and the
creation of newly formed vessels;
accelerate maturation of wound sites;
activate Akt, Erk and Stat3 signalling
[21,112]
Ex/nanoparticles * ESC FB
Enhance the expression levels of
mRNA, EVGFα, TGFβ, collagen I,
Ki-67
[102]
Mv, Ex MyoFB FB, EC [18]
Ex KC FB HSP90 Could not promote cell proliferation [110]
Ex Platelet-rich plasma EC VEGF, bFGF,PDGFBB
Activating Pi3K/Akt and Erk
signalling pathway [107]
Ex EC, EPC EC Activating Erk1/2 signalling pathway [103,106]
Mv Platelet-rich plasmaafter exercise HUVEC [128]
Migration
Ex MSC FB, EC
Induction the expression of HGF, IGF1,
NGF, SDF1; activate Akt, Erk and Stat3
signalling
[21,112]
Ex KC KC,HDMECs HSP90
Hsp90-Ex increased cell migration
without the need to bind any cofactor
or ATP; CD91 is receptor of
extracellular Hsp90; TGFβ could not
inhibit cell migration
[110]
Ex/Ev EC Murinewound Annexin-I [108]
Ex/nanop-articles * ESC FB Higher expression of mRNA, EVGFα,TGFβ, collagen I, Ki-67 [102]
Ex Platelet-rich plasma EC VEGF, bFGF,PDGFBB
Activating Pi3K/Akt and Erk
signalling pathway [107]
Ex EC, EPC EC Activating Erk1/2 signalling pathway [103,106]
Ex hUSC HUVEC [121]
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Table 1. Cont.
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Enhance the expression levels of
mRNA, EVGFα, TGFβ, collagen I,
Ki-67
[102]
Mv, Ex MyoFB Fb, EC VEGF, FGF2 Increase angiogenesis [18]
Ex Platelet-rich plasma EC VEGF, bFGF,PDGFBB
Activating Pi3K/Akt and Erk
signalling pathway [107]
Ex EC EC Activating Erk1/2 signalling pathway [103,106]
Ex MSC EC EMMPRIN, VEGF,MMP9 ERK/Akt pathway [123]
Ex MSC EC miR-125a Direct target DLL4 [92]
Ex hUSC HUVEC [121]
Ex Epithelium cells EC VEGFR [129]
Ev Multiple cellularsources EC CD63 [124]





Ex MSC FB TF Increase reepithelialisation, reduce scar
widths, promote collagen maturity and
maturation of wound sites
[112]
Ex MSCs, FB FB Increase collagen production [105,125]
Ex Hypoxic EC ECM LOXL2 ECM remodelling [126]
FB: Fibroblasts, KC: Keratinocytes, MSCs: Mesenchymal stem cells, EC: Endothelial cells, ESC: Embryonic stem cells,
EPC: Epithelial cells, hUSC: Human urine derived stem cells, HUVUEC: Human umbilical vein endothelial cells,
Mv: Microvesicle(s), Ex: Exosome(s), EMMPRIN: Extracellular matrix metalloproteinase inducer, (*) nanoparticles
mimicking. Exosome were extracted from living cells.
 
Figure 6. Promotion of coagulation by TF-barring microvesicle treatment. Rapid coagulation is
triggered by the initiating TF/Factor VII and promotion of fibrin strand formation [98,99].
 
Figure 7. Promotion of angiogenesis by MSC-derived exosomes. Exosomes released from human MSCs
can induce expression of genes and activate PI3K/Akt and Erk1/2 signalling pathways in endothelial
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6. Conclusions
In the past, EVs were disregarded simply as cellular debris. However, current research has
demonstrated that EVs contain bioactive molecules and are able to deliver these to recipient cells
via newly described cell-to-cell communication mechanisms. In wound healing, EVs were initially
shown to regulate inflammation, proliferation, migration, angiogenesis, collagen production and
ECM remodelling. Such regulation could be mediated through the enhancement of gene expression,
suppression of gene translation, and/or activation of signalling pathways important for wound healing
processes. However, the current level of knowledge regarding how the EV molecular cargo regulates
the process of wound healing remains unclear. Therefore, more research is required to clarify the
regulation of EVs during the wound healing process, and to translate these results to the clinic.
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EMMPRIN Extracellular matrix metalloproteinase inducer
EPC(s) Epithelial cell(s)
ESC(s) Embryonic stem cell(s)
ESCRT Endosomal sorting complex required for transport
EV(s) Extracellular membrane vesicle(s)/extracellular vesicle(s)
Ex Exosome(s)
FB Fibroblast
FGF Fibroblast growth factor
HSP Heat-shock protein
HUVEC(s) Human umbilical vein endothelial cell(s)
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TF Tissue factor
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Abstract: Wound healing is a crucial process which protects our body against permanent damage and
invasive infectious agents. Upon tissue damage, inflammation is an early event which is orchestrated
by a multitude of innate and adaptive immune cell subsets including TH17 cells. TH17 cells and TH17
cell associated cytokines can impact wound healing positively by clearing pathogens and modulating
mucosal surfaces and epithelial cells. Injury of the gut mucosa can cause fast expansion of TH17 cells
and their induction from naïve T cells through Interleukin (IL)-6, TGF-β, and IL-1β signaling. TH17
cells produce various cytokines, such as tumor necrosis factor (TNF)-α, IL-17, and IL-22, which can
promote cell survival and proliferation and thus tissue regeneration in several organs including the
skin, the intestine, and the liver. However, TH17 cells are also potentially pathogenic if not tightly
controlled. Failure of these control mechanisms can result in chronic inflammatory conditions, such as
Inflammatory Bowel Disease (IBD), and can ultimately promote carcinogenesis. Therefore, there are
several mechanisms which control TH17 cells. One control mechanism is the regulation of TH17 cells
via regulatory T cells and IL-10. This mechanism is especially important in the intestine to terminate
immune responses and maintain homeostasis. Furthermore, TH17 cells have the potential to convert
from a pro-inflammatory phenotype to an anti-inflammatory phenotype by changing their cytokine
profile and acquiring IL-10 production, thereby limiting their own pathological potential. Finally,
IL-22, a signature cytokine of TH17 cells, can be controlled by an endogenous soluble inhibitory
receptor, Interleukin 22 binding protein (IL-22BP). During tissue injury, the production of IL-22 by
TH17 cells is upregulated in order to promote tissue regeneration. To limit the regenerative program,
which could promote carcinogenesis, IL-22BP is upregulated during the later phase of regeneration
in order to terminate the effects of IL-22. This delicate balance secures the beneficial effects of IL-22
and prevents its potential pathogenicity. An important future goal is to understand the precise
mechanisms underlying the regulation of TH17 cells during inflammation, wound healing, and
carcinogenesis in order to design targeted therapies for a variety of diseases including infections,
cancer, and immune mediated inflammatory disease.
Keywords: TH17 cells; cytokines; wound healing; tissue regeneration; carcinogenesis;
immune regulation
1. Inflammation in Wound Healing and Carcinogenesis
In 1986, Dvorak published an essay with the vivid title: “Tumors: Wounds that do not heal”,
summarizing in this one statement the relation between wound healing and carcinogenesis [1]. Wound
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healing normally follows sequential but overlapping steps. The immediate reaction is hemostasis
to provisionally close the wound. A fibrin clot is formed and platelets aggregate. This is followed
by the inflammatory phase which is characterized by the presence of neutrophils, macrophages, and
lymphocytes in the wound. These cells are attracted by chemokines, which are, for example, released
by platelet cells [2]. The inflammatory phase is important for tissue regeneration due to the release of
pro-inflammatory cytokines and growth factors from immune cells [3–5]. Additionally, phagocytes can
ingest cell debris and invading pathogens. Therefore, the inflammatory phase is essential to prevent
spreading of infections. The proliferative phase follows several days later leading to re-epithelialization,
formation of new blood vessels, and fibrogenesis. During the last phase, the resolution phase, vessel
regression and collagen remodeling occur [6]. Thus, occurrence of a wound has a dramatic impact on
the body. Multiple cell types are necessary to secure a prompt healing process. Research elucidating
this process mainly focuses on innate immunity contributing to tissue regeneration. However, adaptive
immunity also plays its part during this process, even though its contribution and regulation is much
less understood.
Tissue damage, especially at barrier organs such as the intestine, the lung, and the skin, is a
potential gateway for invading pathogens, therefore inflammation is an essential part of wound
healing. In this regard, the involvement of T cells during wound repair has been under investigation
for a long time. In 1987, the hypothesis that T lymphocytes represent the most frequent leucocyte
population in skin wounds was published [7]. Several studies indicate that delayed infiltration of
T cells and a lower concentration of these cells at the site of the wound are associated with impaired
wound healing. Furthermore, CD4+ T cells seem to play a beneficial role during the process of wound
healing and regeneration [8–10]. However, very little is known about the contribution of different T cell
subsets. Furthermore, these mechanisms, which are designed to promote wound healing, also have the
potential to promote chronic inflammation and carcinogenesis. Two important predisposing factors
for colorectal carcinogenesis are chronic intestinal inflammation and tissue injury. This association is
based on the fact that wound healing and carcinogenesis are driven by several common factors and
signaling pathways. Upon tissue injury, factors promoting healing are stimulated and their action
must be tightly controlled in order to avoid carcinogenesis [11]. A chronically inflamed and wounded
tissue is associated with a long-lasting healing response which may lead to fibrosis, tissue dysfunction,
and ultimately the development of cancer. Thus, carcinogenesis could be considered as a consequence
of failing regulatory mechanisms allowing abnormal excessive healing [11].
2. CD4+ T Helper Cells
Conventional αβ CD4+ T cells are one of the main players during an adaptive immune response.
Due to their great variety, CD4+ T cells can orchestrate the immune response and react to the whole
spectrum of immune challenges. Two major CD4+ T helper cell subsets, TH1 and TH2, were discovered
in 1989 [12]. However, the TH1/TH2 paradigm was challenged in 2005 by the description of TH17 cells,
which are primarily needed for the defense against extracellular bacteria and fungi [13]. Additionally,
TH17 cell associated cytokines can promote epithelial proliferation and tissue regeneration [14].
The gastrointestinal tract, like skin and lung, is constantly in contact with hundreds of different
species of commensal bacteria and fungi [15]. How the commensal microbiota modulate the immune
system of the host and vice versa has been an area of intensive research and is still not completely
understood. Nonetheless, it is known that the induction of TH17 cells is dependent on the presence
of microbiota, especially segmented filamentous bacteria (SFB) in the terminal ileum of the small
intestine in mice. Hence, under physiological conditions, TH17 cells are mainly located in the small
intestine [16]. Upon tissue damage, TH17 cells rapidly expand at mucosal surfaces to guarantee a
quick clearance of the invading microorganisms such as commensal bacteria. To this end, TH17 cells
release several chemokines and cytokines, such as IL-17A, IL-17F, and IL-22 which are the signature
cytokines of TH17 cells. One major defense mechanism of TH17 cells is the attraction of inflammatory
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Additionally, TH17 cells contribute to the crosstalk of immune cells and epithelial cells or other innate
immune cells by inducing the release of anti-microbial peptides [19–22]. The signature cytokines,
IL-17A and IL-17F, both binding to IL-17RA [23], and IL-22, binding to IL-22R1, mediate this effect of
TH17 cells. IL-22 does not only promotes the secretion of anti-microbial peptides from the epithelium,
but also exhibits tissue protective properties. An important effect of IL-22 signaling on epithelial cells
is the induction of proliferation, survival, and tissue repair via induction of STAT3 [14,24,25]. Thus,
TH17 cells act at different front lines during the defense of the body: (a) TH17 cells activate and attract
other immune cells, mainly neutrophils, which can phagocyte pathogens. Therefore, tissue resident
TH17 cells could contribute to the inflammatory phase of wound healing. (b) TH17 cells induce the
release of anti-microbial peptides from non-immune cells. (c) Finally, TH17 cell associated cytokines,
such as IL-22, can promote wound healing and tissue regeneration, leading to a faster closing of
potential entryways of microorganisms. In the next sections, we will give an overview of how TH17
cell associated cytokines affect wound healing and carcinogenesis.
3. Effects of TH17 Cell Associated Cytokines on Wound Healing and Carcinogenesis
3.1. Effects of IL-17 on Wound Healing
Interleukin-17 (IL-17), also known as IL-17A, is the main member of the IL-17 family, which
consists of six members: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also named IL-25), and IL-17F. This
mediator is not only secreted by TH17 cells alone, but also by other immune cell types such as natural
killer (NK), natural killer T (NKT), lymphoid tissue inducer (LTi), and LTi-like cells. Apart from immune
cells, IL-17A can also be produced by Paneth cells which are epithelial cells located in the small intestine.
To conduct its biological functions, IL-17 binds to a heteromeric receptor complex consisting of IL-17RA
and IL-17RC. Along with three additional variants, namely IL-17RB, IL-17RD and IL-17RE, IL-17RA
and IL-17RC, they comprise the IL-17 receptor family [26]. IL-17 is a pro-inflammatory cytokine, which
is commonly found at high levels in inflamed sites. Recent studies have identified a link between the
IL-23 induced expansion of TH17 cells followed by IL-17 secretion and the pathogenesis of IBD [27].
TH17 cells are mainly responsible for IL-17 production, which is elevated in IBD. Controversially, a
role of IL-17 in IBD-related mucosal healing was recently found. Song et al. showed that following
epithelial barrier damage, FGF2 is highly expressed and cooperates with IL-17 in order to enhance
tissue repair. Specifically, upon barrier destruction, dysregulated microbiota cause an upregulation of
TGF-β which subsequently stimulates FGF2 production by regulatory T cells. Then, FGF2 together with
IL-17 upregulates genes associated with epithelial healing and boosts epithelial cell proliferation [28].
Recent studies focusing on skin wound healing have concluded that IL-17 plays a role in the early
inflammatory stage of the wound and could act as an inhibitor to normal wound repair. As seen in
psoriasis, IL-17 has several functions in the skin. The expression of IL-17 receptor on keratinocytes,
fibroblasts, and inflammatory cells reveals that IL-17 can affect numerous cell types in the skin. In skin
lesions, it is macrophages and not T cells which are the main cellular source of IL-17. To elucidate the
role of IL-17 in skin wound healing, Rodero et al. used Il17−/− mice and showed that absence of IL-17
enhances and accelerates skin tissue repair. Blocking IL-17 with specific antibodies during the early
steps of healing also resulted in wound closure promotion [29]. On the other hand, a beneficial role of
IL-17 in sensory nerve regeneration has been recently revealed. In a mouse model of corneal abrasion,
an IL-17 dependent signaling pathway involving IL-17, neutrophils, platelets, and vascular endothelial
growth factor (VEGF)-A was found to promote corneal repair and nerve regeneration [30].
In conclusion, IL-17 seems to have dual functions during wound healing. It may have beneficial
functions in the intestine and for nerve regeneration [31]. However, in the skin, especially in psoriasis,
it seems to be mainly pathogenic. Environmental factors may play a crucial role determining the part
IL-17 has in wound healing, but further studies are needed to clarify this point.
Likewise, the role of IL-17 during carcinogenesis is still not completely understood. TH17-related
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to enhance angiogenesis [32]. However, other studies identified a protective role in tumor immune
surveillance together with an inhibition of cancer cell proliferation and metastasis [33–35]. Using
spontaneous intestinal carcinogenesis models, the role of IL-17A in colorectal cancer development
was further elucidated. Recent studies showed that blocked or genetically-induced absence
of IL-17A resulted in significantly attenuated tumor burden in ApcMin/+ mice infected with
enterotoxigenic Bacteroides fragilis and in the standard ApcMin/+ model [36,37]. In the dextran
sulfate sodium/azoxymethane (DSS/AOM) carcinogenesis model, Il17a−/− mice displayed reduced
tumorigenesis, which could be attributed to lower levels of intestinal TNF-α, interferon (IFN)-γ, IL-6
,and STAT3 activity [38]. Interestingly, a highly expressed TH17 cell related mRNA pattern correlates
with poor prognosis in human colorectal cancer [39,40]. This observation is likely associated with the
fact that TH17 cells are the main IL-17A producers in the tumor. However, other immune cell subsets
such as CD8+ CTLs (Tc17 cells), γδ T cells (γδT17 cells), and innate lymphoid cells (ILCs) also produce
IL-17A [41–43]. Notably, upon dendritic cell (DC)-mediated stimulation, γδT17 cells produce IL-17 and
enhance the recruitment and expansion of myeloid-derived suppressor cells. This finding suggests that
IL-17A is likely to be associated with immune silencing in colorectal cancer. Due to the well-described
implication of IL-17A in colorectal cancer, targeting of IL-17A may serve as a promising therapeutic
approach. Interestingly, a recent study showed that blocking of IL-17A in an adenomatous polyposis
coli (APC)-mediated colon carcinogenesis model enhanced tumor sensitivity to the anticancer agent
5-fluorouracil [44]. Similarly, antiangiogenic therapies might fail due to the IL-17A-driven emergence
of resistant tumor stromal cells [45].
Apart from IL-17A, another member of the IL-17 superfamily and ligand of IL-17RE, IL-17C, was
shown to be expressed in intestinal epithelial cells during early stages of colon carcinogenesis. In both
the ApcMin/+ and the DSS/AOM-induced carcinogenesis models, mice lacking IL-17RE displayed a
decreased tumor burden together with a lower expression of the anti-apoptotic proteins BCL-2 and
BCLXL. Interestingly, IL-17C can be associated with the human condition, since it is overexpressed in
human colon cancers [46]. IL-17F, which also belongs to the IL-17 family, resembles IL-17A and acts
via the same receptor, and may play an opposite role in colon carcinogenesis. In contrast to IL-17A and
C, IL-17F is significantly downregulated in human colorectal cancer. Notably, it reduces carcinogenesis
in the DSS/AOM carcinogenesis model by inhibiting angiogenesis [47].
3.2. Effects of IL-22 on Wound Healing
Interleukin-22 (IL-22), a member of the IL-10 cytokine family, participates in the signaling between
the immune system and the peripheral tissues. IL-22 can be produced by several other cell types
such as TH22, T cell receptor (TCR)-γδ, NK, NKT, ILCs, and LTi cells, with the notable exception
of TH17 cells. IL-22 acts via binding to the heterodimer IL-10R2/IL-22R1 complex [48]. IL-22R1 is
expressed on non-hematopoietic cells, such as intestinal epithelial cells, hepatocytes, and fibroblasts
in the skin. After binding of IL-22 to the receptor complex, STAT3, STAT1, and STAT5, as well as
the Janus kinase (JNK) and mitogen-activated protein kinases are activated. The translocation of
activated STAT dimers into the nucleus leads to the activation of several genes linked to proliferation
and cell survival. IL-22 is known to play a key role in tissue regeneration and wound healing [3].
In a mouse model of acute skin injury, an upregulation of Il22 mRNA expression was observed
during the inflammatory stage and IL-22 was identified as a critical mediator for normal fibroblast
function, extracellular matrix protein production, and myofibroblast differentiation during skin wound
healing [49]. IL-22 was found to facilitate the crosstalk between immune cells and fibroblasts during
skin wound healing. It has also been shown to promote keratinocyte proliferation and migration
while acting as an inhibitor for keratinocyte differentiation [3,50–52]. IL-22 is unlikely to play a major
role in the early stages of skin wound healing such as immune cell accumulation and angiogenesis.
Similarly, loss of IL-22 does not affect keratinocyte function during skin wound healing. However,
upon wound healing, fibroblast function was shown to be IL-22-dependent. Specifically, absence of
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(ECM), and wound contraction. Primary dermal fibroblasts are directly affected by IL-22, since they
express IL-22R1, whose IL-22-triggered activation can lead to STAT3 phosphorylation. IL-22 stimulates
ECM production by inducing ECM gene expression in fibroblasts and by promoting myofibroblast
differentiation. A decreased number of myofibroblasts in the wound may lead to defective wound
contraction and impaired ECM formation, as seen in Il22−/− mice. IL-22 may induce the expression of
ECM genes, mainly via STAT3 activation. IL-22-mediated STAT3 phosphorylation leads to activation
of the promoters of fibronectin and collagen.
Interestingly, IL-22 is also essential for intestinal healing and the maintenance of the mucosal
barrier. In studies using the DSS-induced acute intestinal injury in Il22−/− mice, IL-22 was shown to
enhance intestinal wound healing, specifically via STAT3 activation, which in turn regulates signaling
pathways commonly associated with tissue repair and gut homeostasis. Mice lacking IL-22 exhibited an
impaired and delayed recovery from DSS-caused intestinal injury [14]. Similarly, targeting of IL-22 with
specific neutralizing antibodies led to impaired wound healing in wildtype mice. On the other hand,
increase of intestinal IL-22 expression via a gene delivery system boosted the recovery of the injured
intestine [24]. Interestingly, another study showed that IL-22 deficiency leads to altered intestinal
microbiota and therefore increases the severity of the disease in a mouse model of experimental
colitis. This IL-22-mediated changed microbiota can be transferred to co-housed wild type mice, which
subsequently become more susceptible to experimental colitis, suggesting that IL-22 is essential for
maintaining the balance between immunity and intestinal microbiota [52].
Although the beneficial role of IL-22 in wound healing is well documented, in some cases the
delicate balance between protection and harm shifts in favor of the pathogenic direction leading to
carcinogenesis. A tumor-promoting function of IL-22 via STAT3 stimulation has already been identified
in cancers such as hepatocellular carcinoma and lung cancer [53,54]. Recent studies suggest that in the
absence of close regulation, IL-22 also promotes colon carcinogenesis via STAT3 activation [55]. To this
end, Huber et al. recently reported that IL-22 is involved in colitis associated colon cancer in a dual
manner. On the one hand, IL-22 deficiency can delay tissue repair, thereby sustaining inflammation
and leading to tumor development. On the other hand, high levels of IL-22 in Il22bp−/− mice may
prolong the regenerative program and promote colon carcinogenesis [56]. Clinical data show an
association between high serum IL-22 levels and resistance to chemotherapy in patients with colorectal
cancer, an observation which was further confirmed in vitro [57,58]. Recently, Kryczek et al. suggested
that IL-22 can enhance colon cancer stemness. Specifically, IL-22 was found to activate STAT3 in
human colon cancer cells, resulting in the expression of the H3K9-specific N-methyltransferase DOT1L,
which subsequently induced the expression of core stem cell genes such as SOX2, NANOG, and
POU5F1. This pathway promoted colon carcinogenesis and the expression of the implicated genes
was associated with poor patient prognosis [59]. IL-22 is known to promote and sustain the survival
of normal intestinal stem cells in mice [60]. Therefore, a similar function resulting in maintaining the
cancer stem cell niche is likely to be one of the main contributions of IL-22 to colorectal carcinogenesis.
Other studies showed that high expression of RORγt, which is essential for IL-22 production, and
IL-17A, which is commonly found in association with IL-22, indicates poor prognosis in patients with
colorectal cancer [39].
3.3. Effects of TNF-α on Wound Healing
Upon inflammation-induced disruption of the intestinal mucosal barrier, intestinal epithelial cells
(IECs) need to orchestrate the process of tissue restitution and regeneration. To this end, a crosstalk
between epithelial and immune cells needs to take place. TNF-α, an important pro-inflammatory
cytokine, is one of the implicated molecules, playing a key role during inflammation and subsequent
wound healing [61]. Two forms of TNF-α, the soluble and its precursor, transmembrane one,
participate in the inflammatory process. Transmembrane TNF-α acts via cell-to-cell contact, whereas
soluble TNF-α performs its biological effects at distant sites from the TNF-α-secreting cells [62].
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that receives and transfers signals back into the same transmembrane TNF-α-expressing cells [63].
During intestinal inflammation, TNF-α is produced by immune cells such as TH17 cells, stromal cells,
and IECs and subsequently interacts with the latter via two receptors: TNF-R1 (TNFRSF1A) and
TNF-R2 (TNFRSF1B). TNF-α signaling mediates the production of inflammatory molecules, regulates
cell survival, proliferation, and death, and affects epithelial wound healing. Wound healing is a
complicated process involving cellular migration, re-differentiation, and proliferation. TNF-α/TNF-R2
signaling mediates epithelial migration and enhances the survival and proliferation of IECs [64].
Furthermore, TNF-α promotes intestinal wound healing by protecting against epithelial apoptosis
via ErbB pathway activation. TNF-α also enhances re-epithelialization and thus wound healing by
promoting the FGF-7 production. TNF-α induced effects depend on concentration and duration of
exposure. Specifically, low levels of TNF-α promote inflammation and stimulate the production of
macrophage-derived growth factors facilitating wound healing. However, long exposure to high levels
of TNF-α can have a negative impact on healing, as TNF-α can lead to reduced production of ECM
components while promoting the synthesis of metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-9,
MMP-13, and MT1-MMP). In line with this, TNF-α levels are increased in chronic wounds. Infection
can further promote TNF-α accumulation by prolonging inflammation.
A frequent consequence of IBD and especially ulcerative colitis is colon cancer. Although
initially, TNF-α was considered to serve as a tumor-suppressive factor, due to its conditional
pro-apoptotic function, it was recently found to promote colitis-associated tumor development by
linking inflammation and cancer [65–67]. TNF-α can interact strongly with intestinal epithelial cells,
which express high levels of TNFR1, leading to the activation of NF-κB-dependent oncogenic pathways.
Recently, Popivanova et al. identified TNF-α as a key factor for the development of colitis-related
colon cancer. Specifically, upon DSS/AOM-induced colon carcinogenesis, the expression of TNF-α
and the intestinal recruitment of leukocytes expressing the main TNF receptor, namely TNF-Rp55,
were boosted, resulting in the formation of several intestinal tumors. Absence of TNF-Rp55 or specific
blocking of TNF-α led to reduced mucosal injury and inflammation followed by decreased tumor
formation [67]. In other studies, TNF-α deficiency was associated with severe colitis and cancer along
with increased blood levels of IL-6, IFN-γ, and IL-17A. Similarly, recent studies showed that TNF-α
mRNA expression was increased in colorectal tumors compared to surrounding healthy intestinal
tissue. Interestingly, TNF-α was overexpressed in Stage III and IV tumors, suggesting that high TNF-α
expression in tumor cells can be associated with advanced stages of carcinogenesis [68]. Additionally,
a genetic link between TNF-α and colorectal cancer has been identified recently. Furthermore, TNF
was found to play a key role in the colon cancer promoting effect of obesity [69]. Finally, TNF may also
enhance metastasis by promoting epithelial to mesenchymal transition (EMT) in colorectal cancer [70].
4. Control of TH17 Cells
TH17 cells were originally discovered in an autoimmune setting. In a mouse model of multiple
sclerosis, experimental autoimmune encephalomyelitis (EAE), and a mouse model of arthritis, both
formerly linked to an uncontrolled TH1 response, it was discovered that not IL-12, the cytokine
driving TH1 differentiation, but IL-23 was essential for disease development [71,72]. From in vitro
studies, it has been shown that IL-23 can induce the production of IL-17 from effector and memory
T cells [73]. Finally, in 2005, Langrish et al. demonstrated that IL-23 induced IL-17 producing T cells
displayed stronger pathogenic properties in EAE than TH1 cells, and that these TH17 cells have a
distinct gene-expression profile [74]. Besides the described protective properties of TH17 cells, this cell
type is apparently also associated with autoimmune diseases, chronic inflammatory conditions, and
carcinogenesis. Multiple sclerosis, rheumatoid arthritis, IBD, and psoriasis are amongst the diseases
with a strong TH17 cell involvement [75–78]. Additionally, as discussed above, uncontrolled IL-22,
IL-17, and TNF-α level can promote carcinogenesis. Therefore, the immune system needs control
mechanisms to keep TH17 cells in check. There are several layers to control TH17 cells, which are
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4.1. TH17 Cell Differentiation
The first level of control already occurs under physiological conditions by regulating TH17 cell
differentiation. In the past decade, intensive studies have further elucidated the signaling pathways
leading to the differentiation of TH17 cells. Noteworthy, IL-23 signaling is not essential for the induction
of TH17 cells from naïve T cells, since naïve T cells only express very low amounts of IL-23R [79].
Nonetheless, IL-23 signaling is crucial for the terminal differentiation, expansion, and maintenance
of TH17 cells. IL23R-deficient TH17 cells fail to maintain IL-17 expression in vivo and cannot induce
EAE [80]. IL-6 signaling can induce the expression of IL-23R, a crucial step in the early priming phase
of TH17 cells. This leads to the activation of STAT3. Translocation of phosphorylated STAT3 dimers to
the nucleus results in induction of TH17-related genes such as Rorc, Il17, and also Il23r. The induction
of Rorc (encoding RORγt) is indispensable for TH17 cell development [81–83]. RORγt is the master
transcriptional regulator of TH17 cells, demonstrated by the absence of IL-17 producing T cells in
RORγt-deficient mice [17].
TGF-β is another cytokine contributing to the development of TH17 cells, even though its part in
this process is still controversial. In low concentrations, TGF-β can inhibit TH1 and TH2 differentiation
by inhibiting IL-2 dependent STAT5 activation and expression of T-bet and GATA3, the master
regulators of TH1 and TH2, respectively [84]. Nonetheless, higher concentrations of TGF-β result
in downregulation of IL-23R and consequently counter regulate TH17 cell expansion [79]. Additionally,
in 2010, it was demonstrated that TH17 cells can occur in the absence of TGF-β signaling in the gut
mucosa in vivo [85]. On the contrary, TGF-β signaling can induce the differentiation of inducible
regulatory T cells (pTreg). TGF-β is dispensable for TH17 cell differentiation but non-redundant for
the induction of pTregs [85]. TGF-β signaling induces both FOXP3, the master transcription factor
of Treg cells, and RORγt expression. However, in the absence of IL-6 signaling, FOXP3 abrogates
the effects of RORγt [79,86,87]. Additionally, IL-2 signaling can both enhance FOXP3 expression and
induce STAT5, which leads to impaired binding of STAT3 to IL-17 related genes and inhibits TH17 cell
differentiation [88–90]. In the absence of pro-inflammatory cytokines, such as IL-6 or IL-1β, TGF-β
favors the development of regulatory T cells to maintain immune homeostasis. TH17 cells and Treg cells
are cell subsets with opposite functions for the immune system, however, they share common pathways
for their differentiation. This close relationship demonstrates the important and delicate balance the
immune system has to maintain to guarantee immune homeostasis in the presence of foreign antigens
from commensal microorganisms and food and to guarantee effective protection against pathogens.
Besides TGF-β, the cytokine IL-27 is known to negatively regulate TH17 cell induction. IL-27 signaling
inhibits the expression of RORγt and therefore suppresses TH17 cell differentiation [91]. On the other
hand, IL-27 can induce the differentiation of another regulatory T cell subset, type one regulatory
T cells (TR1). These cells are characterized by high expression levels of IL-10, they, however, lack
FOXP3 expression [92,93]. In summary, the differentiation of the two major regulatory T cell subsets is
inversely related with TH17 cell induction, a phenomenon not known for other effector T cell subsets,
such as TH1 and TH2.
Furthermore, IL-1β is important for the differentiation of TH17 cells, which was already
established in human T cells in 2007 [94,95]. Unlike TGF-β signaling, it was demonstrated by using
mice that IL-1β signaling was crucial for TH17 cell induction in all tissues in vivo [96]. IL-1β signaling
has multiple effects on the differentiation of TH17 cells. However, one essential consequence is
the induction of the transcription factor IRF4, which is strictly needed for RORγt expression [97].
Interestingly, TH17 cells, which differentiated in the absence of TGF-β signaling, seem to have an
altered phenotype. Since TGF-β is required for the suppression of T-bet expression in TH17 cells, IL-1β
induced TH17 cells are also T-bet positive and co-express IFN-γ, the signature cytokine of TH1 cells [85].
These IFN-γ producing TH17 cells are frequently linked with the occurrence of autoimmune disease
such as multiple sclerosis [98].
Finally, the microbiota plays an important role in TH17 cell differentiation. Under physiological
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presence of intestinal microbiota. Studies demonstrated that germ free mice have dramatically reduced
levels of TH17 cells, which can be induced by colonialization with conventional microbiota [99]. SFB
were identified as contributing to the expansion of TH17 cells in the small intestine due to the induction
of serum amyloid A (SAA), which can stimulate DCs to release IL-6 and IL-23 and finally promote TH17
cell differentiation [16]. Another effect of the microbiota is the induction of IL-1β, further contributing
to TH17 cell development [100].
Last, but not least, ligands for the aryl hydrocarbon receptor (AHR) also derive from diet or are
products of the intestinal microbiota. AHR is another transcription factor which plays a non-redundant
role for TH17 cell biology. It has been reported that AHR can promote TH17 cell differentiation and is
already highly expressed during the early TH17 cell polarization [101,102]. However, contradicting
studies reported an increase in TH17 cells in AHR-deficient mice, especially in the small intestine,
demonstrating that AHR is not essential for TH17 cell development [103]. Nonetheless, AHR expression
is crucial for IL-22 secretion by TH17 cells and therefore important for some tissue regenerative
functions of TH17 cells [101,104,105].
In conclusion, TH17 cell differentiation is strongly influenced by the cytokine environment in
different tissues of the body and the presence or absence of environmental factors such as microbiota.
In the last decade, immense efforts have been made to understand the regulation of TH17 cell induction.
Environmental factors, such as microbiota or diet, can directly or indirectly via DCs influence the
development and phenotype of TH17 cells. Various cytokines are involved in the differentiation of
TH17 cells and a complex transcriptional network orchestrates this process. Understanding the whole
picture could facilitate the design of new therapeutic strategies targeting TH17 cells.
4.2. Regulation of TH17 Cells Expansion
A second mechanism is to control the expansion of TH17 cells via regulatory T cells. Upon tissue
damage and infections with extracellular bacteria or fungi, TH17 cell immunity is strictly required.
A pro-inflammatory environment favors the differentiation of TH17 cells over regulatory T cells.
Nonetheless, this immune response must be regulated to prevent the onset of chronic inflammatory
conditions. Likewise, during wound healing the inflammatory phase needs to be ended. Very little is
known about the direct role of TH17 cells in the inflammatory phase. However, it was demonstrated
that the absence of regulatory T cells results in decreased inflammation resolution after myocardial
infarct injury and delayed wound healing in skin, further underlining the non-redundant role of CD4+
T cells in regulation of wound repair and regeneration [106,107]. Regulatory T cells, both Treg cells and
TR1 cells, are key to terminate TH17 cell associated immune responses by suppressing the expansion of
TH17 cells. Both regulatory T cell subsets can suppress TH17 cell expansion in vivo [108,109]. A major
suppressive mechanism of regulatory T cells is the release of anti-inflammatory factors, such as TGF-β
and IL-10. IL-10 signaling is a key factor to dampen inflammatory responses. IL-10 deficiency leads to
severe inflammatory diseases in humans [110]. TH17 cells express IL-10 receptor and can be directly
controlled via IL-10 released by regulatory T cells [111]. Another effect of IL-10 signaling is the
reinforcing of regulatory T cell stability [112,113]. An environment high in IL-10 will therefore directly
inhibit or terminate a TH17 cell immune response and amplify anti-inflammatory T cell subsets.
4.3. TH17 Cell Plasticity
A third mechanism to regulate TH17 cell immune responses lies within the TH17 cells themselves.
TH17 cells display a great plasticity depending on their cytokine environment. The acquisition of
IFN-γ production occurs frequently during inflammation and is linked to disease progression in
multiple human diseases [114–116]. TH17 cells can also acquire the production of the TH2 signature
cytokine, IL-4 [117]. These cells are present in patients suffering from allergic asthma, and in mice it
has been demonstrated that these IL-4 producing TH17 cells have greater potential to induce asthma
than conventional TH2 cells [117,118]. However, TH17 cells can also acquire a regulatory phenotype.
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TH17 cells can suppress other effector T cells in vitro and display a non-inflammatory gene expression
profile [119]. Finally, due to the usage of IL-17A fate-mapping mice, it was possible to prove that
TH17 cells can completely transdifferentiate into TR1 cells and therefore contribute to the resolution
of inflammation [120]. The key for new therapeutic approaches for inflammatory diseases may lie
especially within this TH17 cell plasticity.
4.4. Regulation of IL-22 via IL-22BP
Finally, there are ways to control the activity of TH17 cell associated cytokines, such as IL-22.
Apart from its protective characteristics, IL-22 is known to play a pathogenic role in autoimmune
diseases, several cancers, and chronic liver damage. In order to successfully maintain the balance
between protection and harm, endogenous mechanisms controlling the activity of IL-22 are required.
IL-22 binding protein (IL-22BP, IL-22Ra2) is a soluble IL-22 receptor and inhibitor. It has been shown
that IL-22BP binds to IL-22 and blocks its interaction with the membrane bound IL-22R1 in vitro
using human and mouse cells. In vivo studies using mouse models have concluded that the effect of
IL-22BP is dependent on the presence of IL-22, revealing a specific in vivo binding of IL-22BP to IL-22
with higher affinity than to the membrane-bound IL-22R1 [121–124]. IL-22BP is present in lymphatic
organs, the gastrointestinal system, the lung, the skin, the liver, and in the female reproductive system.
Normally, cellular sources of IL-22BP detected in lymphoid organs and the intestine are conventional
dendritic cells (DCs), T cells, and eosinophils. It has been shown previously that endogenous IL-22BP
is responsible for controlling IL-22-induced effects in the intestine. Recently, Pelczar et al. identified
the role of IL-22BP in the development of IBD [125]. It was shown that T cell derived IL-22BP promotes
IBD development. CD4+ T cells from patients with IBD were found to produce high levels of IL-22BP.
Interestingly, reduced IL-22BP expression was found in intestinal CD4+ T cells derived from IBD
patients treated with anti-TNF-α antibodies. Therefore, these studies suggest that the regulation of
IL-22 by IL-22BP is crucial and may serve as a therapeutic target in diseases like IBD.
5. Concluding Remarks and Future Perspective
Adaptive immunity plays a non-redundant role not only for defense against infections, but also
for wound healing, tissue regeneration, or carcinogenesis. However, adaptive immunity has both
beneficial and potential pathogenic characteristics. The immune system performs a constant balancing
act to maintain beneficial properties over pathogenic ones. TH17 cells have been a main focus of
immunological research since their discovery in 2005. As described above, TH17 cells and TH17 cell
related cytokines can act in a beneficial fashion during wound repair and regeneration, but they
can also cause chronic inflammation and carcinogenesis. Therefore, the immune system developed
several control mechanisms to regulate TH17 cell mediated immunity. However, failure of these control
mechanisms results in chronic inflammatory diseases and cancer. Thus, new therapeutic strategies
targeting TH17 cells have been a main focus of clinical research in recent years. Nonetheless, there
are many remaining open questions regarding the involvement and regulation of TH17 cells during
tissue regeneration and wound healing. It has long been known that αβ CD4+ T cells infiltrate the
wound bed, however, recent research lacks detailed analysis of these cells during wound healing. TH17
cells are especially of great interest in this matter, since they can attract neutrophils and other innate
immune cells and induce anti-microbial peptides from epithelial cells. Therefore, TH17 cells could help
to prevent spreading infections in a wound. Additionally, TH17 cell associated cytokines such as IL-22
can promote epithelial cell proliferation. However, the basic question if the inflammatory phase during
wound healing is altered in the absence of TH17 cells has not been fully addressed yet. A detailed
characterization of TH17 cell immune responses during wound healing in different tissues is needed.
TH17 cells are most abundant in the intestine and other barrier organs such as lung and skin, therefore
it can be assumed that TH17 cells are most important during wound healing in these organs. Besides
the beneficial properties of TH17 cells, these cells are strongly associated with chronic inflammatory
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increasing health threat and a therapeutic challenge. Whether or not an uncontrolled TH17 cell immune
response plays an important part during this process is unknown so far. However, if this is the case,
it is crucial to understand control mechanisms of TH17 cells that could allow the reprogramming of
the immune system so that this chronic inflammatory stage can be resolved. Establishing a better
understanding of this process and the underlying mechanisms could potentially facilitate the design
of new therapeutic approaches for a wide variety of diseases including infections, cancer, and immune
mediated inflammatory diseases.
Acknowledgments: This work was supported by the ERC (ERC Stg 337251 to SH).
Author Contributions: Leonie Brockmann and Anastasios D. Giannou wrote the manuscript, Nicola Gagliani
and Samuel Huber supervised and revised the manuscript.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound
healing. N. Engl. J. Med. 1986, 315, 1650–1659. [PubMed]
2. Minutti, C.M.; Knipper, J.A.; Allen, J.E.; Zaiss, D.M. Tissue-specific contribution of macrophages to wound
healing. Semin. Cell Dev. Biol. 2017, 61, 3–11. [CrossRef] [PubMed]
3. Avitabile, S.; Odorisio, T.; Madonna, S.; Eyerich, S.; Guerra, L.; Eyerich, K.; Zambruno, G.; Cavani, A.;
Cianfarani, F. Interleukin-22 promotes wound repair in diabetes by improving keratinocyte pro-healing
functions. J. Investig. Dermatol. 2015, 135, 2862–2870. [CrossRef] [PubMed]
4. Xiao, W.A.; Hu, Z.Y.; Li, T.W.; Li, J.J. Bone fracture healing is delayed in splenectomic rats. Life Sci. 2017, 173,
55–61. [CrossRef] [PubMed]
5. Broekman, W.; Amatngalim, G.D.; de Mooij-Eijk, Y.; Oostendorp, J.; Roelofs, H.; Taube, C.; Stolk, J.;
Hiemstra, P.S. TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial
wound healing in vitro via activation of the epidermal growth factor receptor. Respir. Res. 2016, 17, 3.
[CrossRef] [PubMed]
6. Gosain, A.; DiPietro, L.A. Aging and wound healing. World J. Surg. 2004, 28, 321–326. [CrossRef] [PubMed]
7. Fishel, R.S.; Barbul, A.; Beschorner, W.E.; Wasserkrug, H.L.; Efron, G. Lymphocyte participation in wound
healing. Morphologic assessment using monoclonal antibodies. Ann. Surg. 1987, 206, 25–29. [CrossRef]
[PubMed]
8. Hofmann, U.; Beyersdorf, N.; Weirather, J.; Podolskaya, A.; Bauersachs, J.; Ertl, G.; Kerkau, T.; Frantz, S.
Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial
infarction in mice. Circulation 2012, 125, 1652–1663. [CrossRef] [PubMed]
9. Park, J.E.; Barbul, A. Understanding the role of immune regulation in wound healing. Am. J. Surg. 2004, 187,
11S–16S. [CrossRef]
10. Swift, M.E.; Burns, A.L.; Gray, K.L.; DiPietro, L.A. Age-related alterations in the inflammatory response to
dermal injury. J. Investig. Dermatol. 2001, 117, 1027–1035. [CrossRef] [PubMed]
11. Antonio, N.; Bonnelykke-Behrndtz, M.L.; Ward, L.C.; Collin, J.; Christensen, I.J.; Steiniche, T.; Schmidt, H.;
Feng, Y.; Martin, P. The wound inflammatory response exacerbates growth of pre-neoplastic cells and
progression to cancer. EMBO J. 2015, 34, 2219–2236. [CrossRef] [PubMed]
12. Mosmann, T.R.; Coffman, R.L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different
functional properties. Annu. Rev. Immunol. 1989, 7, 145–173. [CrossRef] [PubMed]
13. Khader, S.A.; Gaffen, S.L.; Kolls, J.K. TH17 cells at the crossroads of innate and adaptive immunity against
infectious diseases at the mucosa. Mucosal Immunol. 2009, 2, 403–411. [CrossRef] [PubMed]
14. Pickert, G.; Neufert, C.; Leppkes, M.; Zheng, Y.; Wittkopf, N.; Warntjen, M.; Lehr, H.A.; Hirth, S.;
Weigmann, B.; Wirtz, S.; et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound
healing. J. Exp. Med. 2009, 206, 1465–1472. [CrossRef] [PubMed]









Int. J. Mol. Sci. 2017, 18, 1033
16. Ivanov, I.I.; Atarashi, K.; Manel, N.; Brodie, E.L.; Shima, T.; Karaoz, U.; Wei, D.; Goldfarb, K.C.; Santee, C.A.;
Lynch, S.V.; et al. Induction of intestinal TH17 cells by segmented filamentous bacteria. Cell 2009, 139,
485–498. [CrossRef] [PubMed]
17. Ivanov, I.I.; McKenzie, B.S.; Zhou, L.; Tadokoro, C.E.; Lepelley, A.; Lafaille, J.J.; Cua, D.J.; Littman, D.R.
The orphan nuclear receptor rorgammat directs the differentiation program of proinflammatory IL-17+ T
helper cells. Cell 2006, 126, 1121–1133. [CrossRef] [PubMed]
18. Moseley, T.A.; Haudenschild, D.R.; Rose, L.; Reddi, A.H. Interleukin-17 family and IL-17 receptors.
Cytokine Growth Factor Rev. 2003, 14, 155–174. [CrossRef]
19. Ouyang, W.; Kolls, J.K.; Zheng, Y. The biological functions of T helper 17 cell effector cytokines in
inflammation. Immunity 2008, 28, 454–467. [CrossRef] [PubMed]
20. Liang, S.C.; Tan, X.Y.; Luxenberg, D.P.; Karim, R.; Dunussi-Joannopoulos, K.; Collins, M.; Fouser, L.A.
Interleukin (IL)-22 and IL-17 are coexpressed by TH17 cells and cooperatively enhance expression of
antimicrobial peptides. J. Exp. Med. 2006, 203, 2271–2279. [CrossRef] [PubMed]
21. Archer, N.K.; Adappa, N.D.; Palmer, J.N.; Cohen, N.A.; Harro, J.M.; Lee, S.K.; Miller, L.S.; Shirtliff, M.E.
Interleukin-17A (IL-17A) and IL-17F are critical for antimicrobial peptide production and clearance of
staphylococcus aureus nasal colonization. Infect. Immun. 2016, 84, 3575–3583. [CrossRef] [PubMed]
22. Meller, S.; Di Domizio, J.; Voo, K.S.; Friedrich, H.C.; Chamilos, G.; Ganguly, D.; Conrad, C.; Gregorio, J.;
Le Roy, D.; Roger, T.; et al. TH17 cells promote microbial killing and innate immune sensing of DNA via
interleukin 26. Nat. Immunol. 2015, 16, 970–979. [CrossRef] [PubMed]
23. Hymowitz, S.G.; Filvaroff, E.H.; Yin, J.P.; Lee, J.; Cai, L.; Risser, P.; Maruoka, M.; Mao, W.; Foster, J.;
Kelley, R.F.; et al. IL-17s adopt a cystine knot fold: Structure and activity of a novel cytokine, IL-17f, and
implications for receptor binding. EMBO J. 2001, 20, 5332–5341. [CrossRef] [PubMed]
24. Sugimoto, K.; Ogawa, A.; Mizoguchi, E.; Shimomura, Y.; Andoh, A.; Bhan, A.K.; Blumberg, R.S.;
Xavier, R.J.; Mizoguchi, A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.
J. Clin. Investig. 2008, 118, 534–544. [CrossRef] [PubMed]
25. Zenewicz, L.A.; Yancopoulos, G.D.; Valenzuela, D.M.; Murphy, A.J.; Stevens, S.; Flavell, R.A. Innate and
adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29, 947–957.
[CrossRef] [PubMed]
26. Quesniaux, V.R.; Ryffel, B.; Di Padova, F. IL-17, IL-22 and Their Producing Cells: Role in Inflammation and
Autoimmunity, 2nd ed.; Springer: Basel, Switzerland, 2013.
27. Catana, C.S.; Berindan Neagoe, I.; Cozma, V.; Magdas, C.; Tabaran, F.; Dumitrascu, D.L. Contribution of
the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2015, 21,
5823–5830. [PubMed]
28. Song, X.; Dai, D.; He, X.; Zhu, S.; Yao, Y.; Gao, H.; Wang, J.; Qu, F.; Qiu, J.; Wang, H.; et al. Growth factor FGF2
cooperates with interleukin-17 to repair intestinal epithelial damage. Immunity 2015, 43, 488–501. [CrossRef]
[PubMed]
29. Rodero, M.P.; Hodgson, S.S.; Hollier, B.; Combadiere, C.; Khosrotehrani, K. Reduced IL17A expression
distinguishes a Ly6c(lo)MHCII(hi) macrophage population promoting wound healing. J. Investig. Dermatol.
2013, 133, 783–792. [CrossRef] [PubMed]
30. Li, Z.; Burns, A.R.; Han, L.; Rumbaut, R.E.; Smith, C.W. IL-17 and VEGF are necessary for efficient corneal
nerve regeneration. Am. J. Pathol. 2011, 178, 1106–1116. [CrossRef] [PubMed]
31. Ono, T.; Okamoto, K.; Nakashima, T.; Nitta, T.; Hori, S.; Iwakura, Y.; Takayanagi, H. IL-17-producing
gammadelta T cells enhance bone regeneration. Nat. Commun. 2016, 7, 10928. [CrossRef] [PubMed]
32. Numasaki, M.; Fukushi, J.; Ono, M.; Narula, S.K.; Zavodny, P.J.; Kudo, T.; Robbins, P.D.; Tahara, H.;
Lotze, M.T. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101, 2620–2627. [CrossRef]
[PubMed]
33. Muranski, P.; Boni, A.; Antony, P.A.; Cassard, L.; Irvine, K.R.; Kaiser, A.; Paulos, C.M.; Palmer, D.C.;
Touloukian, C.E.; Ptak, K.; et al. Tumor-specific TH17-polarized cells eradicate large established melanoma.
Blood 2008, 112, 362–373. [CrossRef] [PubMed]
34. Kryczek, I.; Wei, S.; Szeliga, W.; Vatan, L.; Zou, W. Endogenous IL-17 contributes to reduced tumor growth








Int. J. Mol. Sci. 2017, 18, 1033
35. Martin-Orozco, N.; Muranski, P.; Chung, Y.; Yang, X.O.; Yamazaki, T.; Lu, S.; Hwu, P.; Restifo, N.P.;
Overwijk, W.W.; Dong, C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity
2009, 31, 787–798. [CrossRef] [PubMed]
36. Wu, S.; Rhee, K.J.; Albesiano, E.; Rabizadeh, S.; Wu, X.; Yen, H.R.; Huso, D.L.; Brancati, F.L.; Wick, E.;
McAllister, F.; et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper
type 17 T cell responses. Nat. Med. 2009, 15, 1016–1022. [CrossRef] [PubMed]
37. Housseau, F.; Wu, S.; Wick, E.C.; Fan, H.; Wu, X.; Llosa, N.J.; Smith, K.N.; Tam, A.; Ganguly, S.;
Wanyiri, J.W.; et al. Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis.
Cancer Res. 2016, 76, 2115–2124. [CrossRef] [PubMed]
38. Hyun, Y.S.; Han, D.S.; Lee, A.R.; Eun, C.S.; Youn, J.; Kim, H.Y. Role of IL-17A in the development of
colitis-associated cancer. Carcinogenesis 2012, 33, 931–936. [CrossRef] [PubMed]
39. Tosolini, M.; Kirilovsky, A.; Mlecnik, B.; Fredriksen, T.; Mauger, S.; Bindea, G.; Berger, A.; Bruneval, P.;
Fridman, W.H.; Pages, F.; et al. Clinical impact of different classes of infiltrating T cytotoxic and helper
cells (TH1, TH2, Treg, TH17) in patients with colorectal cancer. Cancer Res. 2011, 71, 1263–1271. [CrossRef]
[PubMed]
40. Bindea, G.; Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Waldner, M.; Obenauf, A.C.; Angell, H.; Fredriksen, T.;
Lafontaine, L.; Berger, A.; et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune
landscape in human cancer. Immunity 2013, 39, 782–795. [CrossRef] [PubMed]
41. Kirchberger, S.; Royston, D.J.; Boulard, O.; Thornton, E.; Franchini, F.; Szabady, R.L.; Harrison, O.; Powrie, F.
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model.
J. Exp. Med. 2013, 210, 917–931. [CrossRef] [PubMed]
42. Wu, P.; Wu, D.; Ni, C.; Ye, J.; Chen, W.; Hu, G.; Wang, Z.; Wang, C.; Zhang, Z.; Xia, W.; et al. GammadeltaT17
cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal
cancer. Immunity 2014, 40, 785–800. [CrossRef] [PubMed]
43. Zhuang, Y.; Peng, L.S.; Zhao, Y.L.; Shi, Y.; Mao, X.H.; Chen, W.; Pang, K.C.; Liu, X.F.; Liu, T.; Zhang, J.Y.; et al.
CD8+ T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with
survival time of patients with gastric cancer. Gastroenterology 2012, 143, 951–962. [CrossRef] [PubMed]
44. Wang, K.; Kim, M.K.; Di Caro, G.; Wong, J.; Shalapour, S.; Wan, J.; Zhang, W.; Zhong, Z.; Sanchez-Lopez, E.;
Wu, L.W.; et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal
tumorigenesis. Immunity 2014, 41, 1052–1063. [CrossRef] [PubMed]
45. Chung, A.S.; Wu, X.; Zhuang, G.; Ngu, H.; Kasman, I.; Zhang, J.; Vernes, J.M.; Jiang, Z.; Meng, Y.G.;
Peale, F.V.; et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic
therapy. Nat. Med. 2013, 19, 1114–1123. [CrossRef] [PubMed]
46. Song, X.; Gao, H.; Lin, Y.; Yao, Y.; Zhu, S.; Wang, J.; Liu, Y.; Yao, X.; Meng, G.; Shen, N.; et al. Alterations in
the microbiota drive interleukin-17c production from intestinal epithelial cells to promote tumorigenesis.
Immunity 2014, 40, 140–152. [CrossRef] [PubMed]
47. Tong, Z.; Yang, X.O.; Yan, H.; Liu, W.; Niu, X.; Shi, Y.; Fang, W.; Xiong, B.; Wan, Y.; Dong, C. A protective role
by interleukin-17F in colon tumorigenesis. PLoS ONE 2012, 7, e34959. [CrossRef] [PubMed]
48. Khare, V.; Paul, G.; Movadat, O.; Frick, A.; Jambrich, M.; Krnjic, A.; Marian, B.; Wrba, F.; Gasche, C. IL10R2
overexpression promotes IL22/STAT3 signaling in colorectal carcinogenesis. Cancer Immunol. Res. 2015, 3,
1227–1235. [CrossRef] [PubMed]
49. McGee, H.M.; Schmidt, B.A.; Booth, C.J.; Yancopoulos, G.D.; Valenzuela, D.M.; Murphy, A.J.; Stevens, S.;
Flavell, R.A.; Horsley, V. IL-22 promotes fibroblast-mediated wound repair in the skin. J. Investig. Dermatol.
2013, 133, 1321–1329. [CrossRef] [PubMed]
50. Boniface, K.; Bernard, F.X.; Garcia, M.; Gurney, A.L.; Lecron, J.C.; Morel, F. IL-22 inhibits epidermal
differentiation and induces proinflammatory gene expression and migration of human keratinocytes.
J. Immunol. 2005, 174, 3695–3702. [CrossRef] [PubMed]
51. Zheng, Y.; Danilenko, D.M.; Valdez, P.; Kasman, I.; Eastham-Anderson, J.; Wu, J.; Ouyang, W. Interleukin-22,
a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445, 648–651.
[CrossRef] [PubMed]
52. Zenewicz, L.A.; Yin, X.; Wang, G.; Elinav, E.; Hao, L.; Zhao, L.; Flavell, R.A. IL-22 deficiency alters colonic








Int. J. Mol. Sci. 2017, 18, 1033
53. Sun, X.; Zhang, J.; Wang, L.; Tian, Z. Growth inhibition of human hepatocellular carcinoma cells by blocking
STAT3 activation with decoy-odn. Cancer Lett. 2008, 262, 201–213. [CrossRef] [PubMed]
54. Bi, Y.; Cao, J.; Jin, S.; Lv, L.; Qi, L.; Liu, F.; Geng, J.; Yu, Y. Interleukin-22 promotes lung cancer cell proliferation
and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways. Mol. Cell. Biochem. 2016, 415,
1–11. [CrossRef] [PubMed]
55. Sun, D.; Lin, Y.; Hong, J.; Chen, H.; Nagarsheth, N.; Peng, D.; Wei, S.; Huang, E.; Fang, J.; Kryczek, I.; et al.
TH22 cells control colon tumorigenesis through STAT3 and polycomb repression complex 2 signaling.
Oncoimmunology 2016, 5, e1082704. [CrossRef] [PubMed]
56. Huber, S.; Gagliani, N.; Zenewicz, L.A.; Huber, F.J.; Bosurgi, L.; Hu, B.; Hedl, M.; Zhang, W.; O’Connor, W., Jr.;
Murphy, A.J.; et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine.
Nature 2012, 491, 259–263. [CrossRef] [PubMed]
57. Wu, T.; Cui, L.; Liang, Z.; Liu, C.; Liu, Y.; Li, J. Elevated serum IL-22 levels correlate with chemoresistant
condition of colorectal cancer. Clin. Immunol. 2013, 147, 38–39. [CrossRef] [PubMed]
58. Wu, T.; Wang, Z.; Liu, Y.; Mei, Z.; Wang, G.; Liang, Z.; Cui, A.; Hu, X.; Cui, L.; Yang, Y.; et al. Interleukin 22
protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine
expression of interleukin 8. Clin. Immunol. 2014, 154, 116–126. [CrossRef] [PubMed]
59. Kryczek, I.; Lin, Y.; Nagarsheth, N.; Peng, D.; Zhao, L.; Zhao, E.; Vatan, L.; Szeliga, W.; Dou, Y.; Owens, S.; et al.
IL-22+CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and
induction of the methyltransferase DOT1L. Immunity 2014, 40, 772–784. [CrossRef] [PubMed]
60. Hanash, A.M.; Dudakov, J.A.; Hua, G.; O’Connor, M.H.; Young, L.F.; Singer, N.V.; West, M.L.; Jenq, R.R.;
Holland, A.M.; Kappel, L.W.; et al. Interleukin-22 protects intestinal stem cells from immune-mediated
tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012, 37, 339–350. [CrossRef]
[PubMed]
61. Ritsu, M.; Kawakami, K.; Kanno, E.; Tanno, H.; Ishii, K.; Imai, Y.; Maruyama, R.; Tachi, M. Critical role of
tumor necrosis factor-α in the early process of wound healing in skin. J. Dermatol. Dermatol. Surg. 2017, 21,
14–19. [CrossRef]
62. Perez, C.; Albert, I.; DeFay, K.; Zachariades, N.; Gooding, L.; Kriegler, M. A nonsecretable cell surface mutant
of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990, 63, 251–258. [CrossRef]
63. Eissner, G.; Kolch, W.; Scheurich, P. Ligands working as receptors: Reverse signaling by members of the tnf
superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004, 15, 353–366.
[CrossRef] [PubMed]
64. Mizoguchi, E.; Mizoguchi, A.; Takedatsu, H.; Cario, E.; de Jong, Y.P.; Ooi, C.J.; Xavier, R.J.; Terhorst, C.;
Podolsky, D.K.; Bhan, A.K. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia
and chronic intestinal inflammation in mice. Gastroenterology 2002, 122, 134–144. [CrossRef] [PubMed]
65. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9, 361–371. [CrossRef] [PubMed]
66. Wu, Y.; Deng, J.; Rychahou, P.G.; Qiu, S.; Evers, B.M.; Zhou, B.P. Stabilization of snail by NF-kappaB is
required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15, 416–428. [CrossRef]
[PubMed]
67. Popivanova, B.K.; Kitamura, K.; Wu, Y.; Kondo, T.; Kagaya, T.; Kaneko, S.; Oshima, M.; Fujii, C.; Mukaida, N.
Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Investig.
2008, 118, 560–570. [CrossRef] [PubMed]
68. Al Obeed, O.A.; Alkhayal, K.A.; Al Sheikh, A.; Zubaidi, A.M.; Vaali-Mohammed, M.A.; Boushey, R.;
McKerrow, J.H.; Abdulla, M.H. Increased expression of tumor necrosis factor-α is associated with advanced
colorectal cancer stages. World J. Gastroenterol. 2014, 20, 18390–18396. [CrossRef] [PubMed]
69. Flores, M.B.; Rocha, G.Z.; Damas-Souza, D.M.; Osorio-Costa, F.; Dias, M.M.; Ropelle, E.R.; Camargo, J.A.;
de Carvalho, R.B.; Carvalho, H.F.; Saad, M.J.; et al. Obesity-induced increase in tumor necrosis factor-α leads
to development of colon cancer in mice. Gastroenterology 2012, 143, 741–753. [CrossRef] [PubMed]
70. Huang, L.; Wang, X.; Wen, C.; Yang, X.; Song, M.; Chen, J.; Wang, C.; Zhang, B.; Wang, L.;
Iwamoto, A.; et al. Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced
epithelial-to-mesenchymal transition in colorectal cancer. Sci. Rep. 2015, 5, 13350. [CrossRef] [PubMed]
71. Cua, D.J.; Sherlock, J.; Chen, Y.; Murphy, C.A.; Joyce, B.; Seymour, B.; Lucian, L.; To, W.; Kwan, S.;
Churakova, T.; et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune








Int. J. Mol. Sci. 2017, 18, 1033
72. Murphy, C.A.; Langrish, C.L.; Chen, Y.; Blumenschein, W.; McClanahan, T.; Kastelein, R.A.; Sedgwick, J.D.;
Cua, D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
J. Exp. Med. 2003, 198, 1951–1957. [CrossRef] [PubMed]
73. Aggarwal, S.; Ghilardi, N.; Xie, M.H.; de Sauvage, F.J.; Gurney, A.L. Interleukin-23 promotes a distinct CD4
T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278, 1910–1914.
[CrossRef] [PubMed]
74. Langrish, C.L.; Chen, Y.; Blumenschein, W.M.; Mattson, J.; Basham, B.; Sedgwick, J.D.; McClanahan, T.;
Kastelein, R.A.; Cua, D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.
J. Exp. Med. 2005, 201, 233–240. [CrossRef] [PubMed]
75. Fouser, L.A.; Wright, J.F.; Dunussi-Joannopoulos, K.; Collins, M. TH17 cytokines and their emerging roles in
inflammation and autoimmunity. Immunol. Rev. 2008, 226, 87–102. [CrossRef] [PubMed]
76. Harbour, S.N.; Maynard, C.L.; Zindl, C.L.; Schoeb, T.R.; Weaver, C.T. TH17 cells give rise to TH1 cells that are
required for the pathogenesis of colitis. Proc. Natl. Acad. Sci. USA 2015, 112, 7061–7066. [CrossRef] [PubMed]
77. Jimeno, R.; Leceta, J.; Garin, M.; Ortiz, A.M.; Mellado, M.; Rodriguez-Frade, J.M.; Martinez, C.;
Perez-Garcia, S.; Gomariz, R.P.; Juarranz, Y. TH17 polarization of memory Th cells in early arthritis: The
vasoactive intestinal peptide effect. J. Leukoc. Biol. 2015, 98, 257–269. [CrossRef] [PubMed]
78. Babaloo, Z.; Aliparasti, M.R.; Babaiea, F.; Almasi, S.; Baradaran, B.; Farhoudi, M. The role of TH17 cells
in patients with relapsing-remitting multiple sclerosis: Interleukin-17A and interleukin-17F serum levels.
Immunol. Lett. 2015, 164, 76–80. [CrossRef] [PubMed]
79. Zhou, L.; Lopes, J.E.; Chong, M.M.; Ivanov, I.I.; Min, R.; Victora, G.D.; Shen, Y.; Du, J.; Rubtsov, Y.P.;
Rudensky, A.Y.; et al. TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing rorgammat
function. Nature 2008, 453, 236–240. [CrossRef] [PubMed]
80. McGeachy, M.J.; Chen, Y.; Tato, C.M.; Laurence, A.; Joyce-Shaikh, B.; Blumenschein, W.M.; McClanahan, T.K.;
O’Shea, J.J.; Cua, D.J. The interleukin 23 receptor is essential for the terminal differentiation of interleukin
17-producing effector T helper cells in vivo. Nat. Immunol. 2009, 10, 314–324. [CrossRef] [PubMed]
81. Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T.B.; Oukka, M.; Weiner, H.L.; Kuchroo, V.K. Reciprocal
developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006,
441, 235–238. [CrossRef] [PubMed]
82. Mangan, P.R.; Harrington, L.E.; O’Quinn, D.B.; Helms, W.S.; Bullard, D.C.; Elson, C.O.; Hatton, R.D.;
Wahl, S.M.; Schoeb, T.R.; Weaver, C.T. Transforming growth factor-β induces development of the T(H)17
lineage. Nature 2006, 441, 231–234. [CrossRef] [PubMed]
83. Veldhoen, M.; Hocking, R.J.; Atkins, C.J.; Locksley, R.M.; Stockinger, B. TGFβ in the context of an
inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006,
24, 179–189. [CrossRef] [PubMed]
84. Qin, H.; Wang, L.; Feng, T.; Elson, C.O.; Niyongere, S.A.; Lee, S.J.; Reynolds, S.L.; Weaver, C.T.; Roarty, K.;
Serra, R.; et al. TGF-β promotes TH17 cell development through inhibition of SOCS3. J. Immunol. 2009, 183,
97–105. [CrossRef] [PubMed]
85. Ghoreschi, K.; Laurence, A.; Yang, X.P.; Tato, C.M.; McGeachy, M.J.; Konkel, J.E.; Ramos, H.L.; Wei, L.;
Davidson, T.S.; Bouladoux, N.; et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling.
Nature 2010, 467, 967–971. [CrossRef] [PubMed]
86. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor
Foxp3. Science 2003, 299, 1057–1061. [CrossRef] [PubMed]
87. Selvaraj, R.K.; Geiger, T.L. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-β. J. Immunol.
2007, 178, 7667–7677. [CrossRef] [PubMed]
88. Davidson, T.S.; DiPaolo, R.J.; Andersson, J.; Shevach, E.M. Cutting edge: IL-2 is essential for TGF-β-mediated
induction of Foxp3+ T regulatory cells. J. Immunol. 2007, 178, 4022–4026. [CrossRef] [PubMed]
89. Brandenburg, S.; Takahashi, T.; de la Rosa, M.; Janke, M.; Karsten, G.; Muzzulini, T.; Orinska, Z.;
Bulfone-Paus, S.; Scheffold, A. IL-2 induces in vivo suppression by CD4+CD25+Foxp3+ regulatory T cells.
Eur. J. Immunol. 2008, 38, 1643–1653. [CrossRef] [PubMed]
90. Laurence, A.; Tato, C.M.; Davidson, T.S.; Kanno, Y.; Chen, Z.; Yao, Z.; Blank, R.B.; Meylan, F.; Siegel, R.;
Hennighausen, L.; et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity








Int. J. Mol. Sci. 2017, 18, 1033
91. Diveu, C.; McGeachy, M.J.; Boniface, K.; Stumhofer, J.S.; Sathe, M.; Joyce-Shaikh, B.; Chen, Y.; Tato, C.M.;
McClanahan, T.K.; de Waal Malefyt, R.; et al. IL-27 blocks rorc expression to inhibit lineage commitment of
TH17 cells. J. Immunol. 2009, 182, 5748–5756. [CrossRef] [PubMed]
92. Awasthi, A.; Carrier, Y.; Peron, J.P.; Bettelli, E.; Kamanaka, M.; Flavell, R.A.; Kuchroo, V.K.;
Oukka, M.; Weiner, H.L. A dominant function for interleukin 27 in generating interleukin 10-producing
anti-inflammatory T cells. Nat. Immunol. 2007, 8, 1380–1389. [CrossRef] [PubMed]
93. Stumhofer, J.S.; Silver, J.S.; Laurence, A.; Porrett, P.M.; Harris, T.H.; Turka, L.A.; Ernst, M.; Saris, C.J.;
O’Shea, J.J.; Hunter, C.A. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10.
Nat. Immunol. 2007, 8, 1363–1371. [CrossRef] [PubMed]
94. Acosta-Rodriguez, E.V.; Napolitani, G.; Lanzavecchia, A.; Sallusto, F. Interleukins 1β and 6 but not
transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T
helper cells. Nat. Immunol. 2007, 8, 942–949. [CrossRef] [PubMed]
95. Wilson, N.J.; Boniface, K.; Chan, J.R.; McKenzie, B.S.; Blumenschein, W.M.; Mattson, J.D.; Basham, B.;
Smith, K.; Chen, T.; Morel, F.; et al. Development, cytokine profile and function of human interleukin
17-producing helper T cells. Nat. Immunol. 2007, 8, 950–957. [CrossRef] [PubMed]
96. Hu, W.; Troutman, T.D.; Edukulla, R.; Pasare, C. Priming microenvironments dictate cytokine requirements
for T helper 17 cell lineage commitment. Immunity 2011, 35, 1010–1022. [CrossRef] [PubMed]
97. Chung, Y.; Chang, S.H.; Martinez, G.J.; Yang, X.O.; Nurieva, R.; Kang, H.S.; Ma, L.; Watowich, S.S.;
Jetten, A.M.; Tian, Q.; et al. Critical regulation of early TH17 cell differentiation by interleukin-1 signaling.
Immunity 2009, 30, 576–587. [CrossRef] [PubMed]
98. Kebir, H.; Ifergan, I.; Alvarez, J.I.; Bernard, M.; Poirier, J.; Arbour, N.; Duquette, P.; Prat, A. Preferential
recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann. Neurol. 2009, 66, 390–402.
[CrossRef] [PubMed]
99. Ivanov, I.I.; Frutos Rde, L.; Manel, N.; Yoshinaga, K.; Rifkin, D.B.; Sartor, R.B.; Finlay, B.B.; Littman, D.R.
Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small
intestine. Cell Host Microbe 2008, 4, 337–349. [CrossRef] [PubMed]
100. Shaw, M.H.; Kamada, N.; Kim, Y.G.; Nunez, G. Microbiota-induced IL-1β, but not IL-6, is critical for the
development of steady-state TH17 cells in the intestine. J. Exp. Med. 2012, 209, 251–258. [CrossRef] [PubMed]
101. Veldhoen, M.; Hirota, K.; Westendorf, A.M.; Buer, J.; Dumoutier, L.; Renauld, J.C.; Stockinger, B. The aryl
hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453,
106–109. [CrossRef] [PubMed]
102. Quintana, F.J.; Basso, A.S.; Iglesias, A.H.; Korn, T.; Farez, M.F.; Bettelli, E.; Caccamo, M.; Oukka, M.;
Weiner, H.L. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453,
65–71. [CrossRef] [PubMed]
103. Li, Y.; Innocentin, S.; Withers, D.R.; Roberts, N.A.; Gallagher, A.R.; Grigorieva, E.F.; Wilhelm, C.; Veldhoen, M.
Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 2011,
147, 629–640. [CrossRef] [PubMed]
104. Yeste, A.; Mascanfroni, I.D.; Nadeau, M.; Burns, E.J.; Tukpah, A.M.; Santiago, A.; Wu, C.; Patel, B.; Kumar, D.;
Quintana, F.J. IL-21 induces IL-22 production in CD4+ T cells. Nat. Commun. 2014, 5, 3753. [CrossRef]
[PubMed]
105. Cochez, P.M.; Michiels, C.; Hendrickx, E.; Van Belle, A.B.; Lemaire, M.M.; Dauguet, N.; Warnier, G.;
de Heusch, M.; Togbe, D.; Ryffel, B.; et al. AhR modulates the IL-22-producing cell proliferation/recruitment
in imiquimod-induced psoriasis mouse model. Eur. J. Immunol. 2016, 46, 1449–1459. [CrossRef] [PubMed]
106. Weirather, J.; Hofmann, U.D.; Beyersdorf, N.; Ramos, G.C.; Vogel, B.; Frey, A.; Ertl, G.; Kerkau, T.; Frantz, S.
Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage
differentiation. Circ. Res. 2014, 115, 55–67. [CrossRef] [PubMed]
107. Nosbaum, A.; Prevel, N.; Truong, H.A.; Mehta, P.; Ettinger, M.; Scharschmidt, T.C.; Ali, N.H.; Pauli, M.L.;
Abbas, A.K.; Rosenblum, M.D. Cutting edge: Regulatory T cells facilitate cutaneous wound healing.
J. Immunol. 2016, 196, 2010–2014. [CrossRef] [PubMed]
108. Littman, D.R.; Rudensky, A.Y. TH17 and regulatory T cells in mediating and restraining inflammation. Cell
2010, 140, 845–858. [CrossRef] [PubMed]
109. Roncarolo, M.G.; Battaglia, M. Regulatory T-cell immunotherapy for tolerance to self antigens and








Int. J. Mol. Sci. 2017, 18, 1033
110. Glocker, E.O.; Frede, N.; Perro, M.; Sebire, N.; Elawad, M.; Shah, N.; Grimbacher, B. Infant colitis—It’s in the
genes. Lancet 2010, 376, 1272. [CrossRef]
111. Huber, S.; Gagliani, N.; Esplugues, E.; O’Connor, W., Jr.; Huber, F.J.; Chaudhry, A.; Kamanaka, M.;
Kobayashi, Y.; Booth, C.J.; Rudensky, A.Y.; et al. TH17 cells express interleukin-10 receptor and are controlled
by Foxp3− and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011, 34,
554–565. [CrossRef] [PubMed]
112. Chaudhry, A.; Samstein, R.M.; Treuting, P.; Liang, Y.; Pils, M.C.; Heinrich, J.M.; Jack, R.S.; Wunderlich, F.T.;
Bruning, J.C.; Muller, W.; et al. Interleukin-10 signaling in regulatory T cells is required for suppression of
TH17 cell-mediated inflammation. Immunity 2011, 34, 566–578. [CrossRef] [PubMed]
113. Brockmann, L.; Gagliani, N.; Steglich, B.; Giannou, A.D.; Kempski, J.; Pelczar, P.; Geffken, M.; Mfarrej, B.;
Huber, F.; Herkel, J.; et al. IL-10 receptor signaling is essential for TR1 cell function in vivo. J. Immunol. 2017,
198, 1130–1141. [CrossRef] [PubMed]
114. Annunziato, F.; Cosmi, L.; Santarlasci, V.; Maggi, L.; Liotta, F.; Mazzinghi, B.; Parente, E.; Fili, L.; Ferri, S.;
Frosali, F.; et al. Phenotypic and functional features of human TH17 cells. J. Exp. Med. 2007, 204, 1849–1861.
[CrossRef] [PubMed]
115. Annunziato, F.; Cosmi, L.; Liotta, F.; Maggi, E.; Romagnani, S. Type 17 T helper cells-origins, features and
possible roles in rheumatic disease. Nat. Rev. Rheumatol. 2009, 5, 325–331. [CrossRef] [PubMed]
116. Cosmi, L.; Cimaz, R.; Maggi, L.; Santarlasci, V.; Capone, M.; Borriello, F.; Frosali, F.; Querci, V.; Simonini, G.;
Barra, G.; et al. Evidence of the transient nature of the TH17 phenotype of CD4+CD161+ T cells in the synovial
fluid of patients with juvenile idiopathic arthritis. Arthritis Rheumatol. 2011, 63, 2504–2515. [CrossRef]
[PubMed]
117. Cosmi, L.; Maggi, L.; Santarlasci, V.; Capone, M.; Cardilicchia, E.; Frosali, F.; Querci, V.; Angeli, R.; Matucci, A.;
Fambrini, M.; et al. Identification of a novel subset of human circulating memory CD4+ T cells that produce
both IL-17A and IL-4. J. Allergy Clin. Immunol. 2010, 125, 222–230. [CrossRef] [PubMed]
118. Wang, Y.H.; Voo, K.S.; Liu, B.; Chen, C.Y.; Uygungil, B.; Spoede, W.; Bernstein, J.A.; Huston, D.P.; Liu, Y.J.
A novel subset of CD4+ TH2 memory/effector cells that produce inflammatory IL-17 cytokine and promote
the exacerbation of chronic allergic asthma. J. Exp. Med. 2010, 207, 2479–2491. [CrossRef] [PubMed]
119. Esplugues, E.; Huber, S.; Gagliani, N.; Hauser, A.E.; Town, T.; Wan, Y.Y.; O’Connor, W., Jr.; Rongvaux, A.;
Van Rooijen, N.; Haberman, A.M.; et al. Control of TH17 cells occurs in the small intestine. Nature 2011, 475,
514–518. [CrossRef] [PubMed]
120. Gagliani, N.; Amezcua Vesely, M.C.; Iseppon, A.; Brockmann, L.; Xu, H.; Palm, N.W.; de Zoete, M.R.;
Licona-Limon, P.; Paiva, R.S.; Ching, T.; et al. TH17 cells transdifferentiate into regulatory T cells during
resolution of inflammation. Nature 2015, 523, 221–225. [CrossRef] [PubMed]
121. Dumoutier, L.; Lejeune, D.; Colau, D.; Renauld, J.C. Cloning and characterization of IL-22 binding protein, a
natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J. Immunol. 2001, 166, 7090–7095.
[CrossRef] [PubMed]
122. Kotenko, S.V.; Izotova, L.S.; Mirochnitchenko, O.V.; Esterova, E.; Dickensheets, H.; Donnelly, R.P.; Pestka, S.
Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its
activity. J. Immunol. 2001, 166, 7096–7103. [CrossRef] [PubMed]
123. Wei, C.C.; Ho, T.W.; Liang, W.G.; Chen, G.Y.; Chang, M.S. Cloning and characterization of mouse IL-22
binding protein. Genes Immun. 2003, 4, 204–211. [CrossRef] [PubMed]
124. Weber, G.F.; Schlautkotter, S.; Kaiser-Moore, S.; Altmayr, F.; Holzmann, B.; Weighardt, H. Inhibition of
interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis. Infect. Immun.
2007, 75, 1690–1697. [CrossRef] [PubMed]
125. Pelczar, P.; Witkowski, M.; Perez, L.G.; Kempski, J.; Hammel, A.G.; Brockmann, L.; Kleinschmidt, D.;
Wende, S.; Haueis, C.; Bedke, T.; et al. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel
disease. Science 2016, 354, 358–362. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution








 International Journal of 
Molecular Sciences
Review
Implications of Extracellular Matrix Production by
Adipose Tissue-Derived Stem Cells for Development
of Wound Healing Therapies
Kathrine Hyldig, Simone Riis, Cristian Pablo Pennisi, Vladimir Zachar and Trine Fink *
Laboratory for Stem Cell Research, Department of Health Science and Technology, Aalborg University,
9220 Aalborg, Denmark; kha12@student.aau.dk (K.H.); sriis@hst.aau.dk (S.R.); cpennisi@hst.aau.dk (C.P.P.);
vlaz@hst.aau.dk (V.Z.)
* Correspondence: trinef@hst.aau.dk; Tel.: +45-9940-7550
Academic Editor: Allison Cowin
Received: 3 April 2017; Accepted: 26 May 2017; Published: 31 May 2017
Abstract: The synthesis and deposition of extracellular matrix (ECM) plays an important role in
the healing of acute and chronic wounds. Consequently, the use of ECM as treatment for chronic
wounds has been of special interest—both in terms of inducing ECM production by resident cells
and applying ex vivo produced ECM. For these purposes, using adipose tissue-derived stem cells
(ASCs) could be of use. ASCs are recognized to promote wound healing of otherwise chronic
wounds, possibly through the reduction of inflammation, induction of angiogenesis, and promotion
of fibroblast and keratinocyte growth. However, little is known regarding the importance of
ASC-produced ECM for wound healing. In this review, we describe the importance of ECM for
wound healing, and how ECM production by ASCs may be exploited in developing new therapies
for the treatment of chronic wounds.
Keywords: adipose stem cells; ASCs; extracellular matrix; wound healing
1. Introduction
Wound healing is a dynamic and well-orchestrated process with both molecular and cellular
events. When for some reason the wound healing process is perturbed, the wounds may
become chronic, with concomitant alterations in the microenvironment leading to prolonged
inflammation, ischemia, dysfunctional extracellular matrix (ECM), and lack of re-epithelialization [1].
Traditional wound healing therapies are often not sufficient, so there is considerable interest in
developing novel more efficient therapies. Among the novel strategies that are being explored, the use
of adipose tissue-derived stem/stromal cells (ASCs) appears to be very promising, judging from
animal studies [2] and early clinical studies [3]. The ASCs are derived from the so-called stromal
vascular fraction of adipose tissue [4,5], which is a rather heterogeneous population. However,
after expansion for just a few passages, the ASCs converge towards a common phenotype comprised
of fewer, perhaps functionally distinct subtypes [6,7].
While it is still not clear how the ASCs mediate their effect, they have been shown to have
immunomodulatory and proangiogenic properties, the ability to promote keratinocyte and fibroblast
growth, as well as ability to reduce tissue scarring [8–13]. However, less is known about the putative
effect of ASCs on the ECM of the chronic wounds. Consequently, in this review we will outline the
role of ECM in wound healing, describe what is known regarding ASCs’ effect on ECM, and speculate
on how ASC-derived ECM may be exploited in novel wound healing therapies.
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2. The ECM of the Skin
In human skin, the ECM contains both fibrous proteins and ground substance. The fibrous
proteins comprise collagens, elastin, and fibronectin, and provide a three-dimensional scaffold upon
which both individual cells and the vascular network are supported or anchored. The most abundant
fibrous protein in the human skin is collagen I, with collagen III and collagen V representing only
minor proportions of the total collagen [14]. During pathological conditions such as scar formation,
the composition and structure of collagen fibers are altered [15]. The ground substance of the ECM
contains proteoglycans and glycosaminoglycans, and surround the fibrous proteins as a jelly-like
substance which provides hydration to the skin due to the strong hydrophilic characteristics.
Initially, ECM was thought to function only as structural support for the cells; however, it has
become clear that the ECM plays a pivotal role in the regulation of cell behavior both under normal
conditions and during wound healing [16,17]. The ECM regulates cell behavior through molecular
signaling primarily mediated by integrins (a family of cell surface receptors), and it has been shown
that these signals are involved in determining whether the cells proliferate, differentiate, or undergo
apoptosis [18]. Among the resident skin cells that express integrins—and thus may be subjected
to modulation by the ECM—are fibroblasts and keratinocytes [19]. In addition, proteins in the
ECM modulate the activity of growth factors and cytokines such as platelet-derived growth factor
(PDGF) and transforming growth factor-β (TGF-β), produced by activated platelets and macrophages,
respectively [20,21]. Thus, the ECM functions as a reservoir by protecting the growth factors from
degradation and controlling their release [22].
ECM homeostasis is partly controlled by the activity of matrix metalloproteinases (MMPs) and
their counterpart, tissue inhibitors of metalloproteinases (TIMPs). The MMPs are mainly secreted by
keratinocytes, fibroblasts, and endothelial cells [23], and TIMPS by—among others—mesenchymal
stem cells (MSCs), keratinocytes, and fibroblasts [24,25]. Thus, the balance between MMPs and TIMPs
is important for ECM remodeling, cell signaling, and cell migration [26], and it has been suggested
that a high MMP/TIMP ratio could be a biomarker of non-healing wounds [27].
3. Role of ECM for Wound Healing
Acute wounds normally heal in four overlapping phases: hemostasis, inflammation, proliferation,
and remodeling (Figure 1) [17,28,29]. Hemostasis occurs immediately after the injury, and is
characterized by the activation and aggregation of platelets into the wounded area followed by
the deposition of fibronectin and fibrin from the blood plasma. The activated platelets help initiate
the inflammatory phase through the secretion of PDGF, which is important for the migration of
macrophages and neutrophils to the wounded area [20], and TGF-β, which plays a major role in the
transformation of monocytes to macrophages [21]. The stimulation of macrophages results in the
development of polarized phenotypes termed classically activated (M1) macrophages that secrete
pro-inflammatory cytokines and predominate during early wound healing and alternatively activated
(M2) macrophages that are associated with a wound healing anti-inflammatory profile and which
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Figure 1. The phases of normal wound healing. Wound healing normally progresses through a tightly
orchestrated process that is usually described as having four overlapping phases. During hemostasis,
a platelet plug is formed and growth factors are secreted. The inflammatory phase has two
stages. The initial stage, where neutrophils and pro-inflammatory M1 macrophages prevail, and a
second stage characterized by the presence of anti-inflammatory M2 macrophages. During the
proliferation phase, fibroblasts proliferate and synthesize extracellular matrix (ECM), new vessels are
formed, and keratinocytes re-epithelialize the surface of the wound. In the final remodeling stage,
the composition of the ECM is altered through degradation and resynthesis. PDGF: platelet-derived
growth factor; TGF-β: transforming growth factor-β.
During the proliferation phase of wound healing, fibroblasts migrate to the wounded area
where they proliferate and initiate ECM synthesis [32]. The temporary matrix of fibrin and
fibronectin is replaced by the collagen matrix, enriched in proteoglycans, glycosaminoglycans,
and glycoproteins, forming a granulation tissue. Subsequently, the abundant extracellular matrix
accumulates, supporting cell migration. In response to the newly-synthesized ECM, endothelial
cells migrate into the wound and initiate the process of angiogenesis to restore the circulation in the
damaged area [33]. The wound environment is characterized by low oxygen supply, regulating the
process of angiogenesis through hypoxia-inducible factor-1 (HIF-1) [34]. Additionally, the secreted
growth factors basic fibroblast growth factor (bFGF), TGF-β, and vascular endothelial growth factor
(VEGF) stimulate the angiogenic activity [35]. Concurrently, keratinocytes migrate from the basement
membrane towards the wound edge and close the wound. The migration of keratinocytes is dependent
on basement membrane degradation, facilitated by MMPs [36].
In the remodeling phase, fibroblasts transform into myofibroblasts and contract the wound
area [37]. Remodeling of the granulation tissue is characterized by the synthesis and breakdown of
collagen, regulated by the MMPs and TIMPs [38].
When the normal progression through the different phases of wound healing is perturbed as
described above, the wounds may become chronic. It appears that non-healing wounds remain in a
transition state between the inflammation and proliferation phases and proliferative and remodeling
phases become impaired [39] (Figure 2, left panel). It is not clear what causes the prolonged
inflammation; however, macrophages in chronic wounds fail to switch from the pro-inflammatory M1
to the anti-inflammatory M2 phenotype [40].
Furthermore, in mouse models of wound healing, there was a correlation between the presence
of M2 macrophages, the resolution of inflammation, and wound healing, suggesting an important
role of the polarization from M1 to M2 macrophages during the process of wound healing [41,42].
Interestingly, a switch in phenotype towards a more anti-inflammatory or pro-healing type has also
been documented for Th1/Th2 cells and MSCs [43,44], which are possibly recruited to the site of injury
from the bone marrow [45].
As wounds become chronic, the ECM homeostasis of the wound area is affected. Indeed,
chronic wound fibroblasts are unresponsive to the stimulatory effect of TGF-β on collagen synthesis
when compared to normal skin fibroblasts [46]. In addition, proteolytic enzymes involved in ECM
degradation are dysregulated in chronic wounds, with increased expression of MMP-1, MMP-2,
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excessive proteolysis of the ECM [48]. As the balance between ECM synthesis and degradation is
impaired, the ECM becomes dysfunctional in terms of supporting cell migration and proliferation as
well as angiogenesis [49].
Figure 2. Characteristics of chronic wounds and the relevant regenerative effects of ASCs on these.
Chronic wounds appear to unable to progress from the inflammatory phase of normal wound healing
and to have impaired proliferation and remodeling phases (left panel). The ASCs have several
regenerative characteristics that may lead to the wound progression from the inflammatory phase
and through the proliferation and remodeling phases (right panel). ASC: adipose tissue-derived
stem/stromal cells; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of metalloproteinase; VEGF:
vascular endothelial growth factor.
4. Using Adipose Stem Cells to Treat Chronic Wounds
The conventional treatment strategy for wound healing is based on wound bed preparation
using tissue debridement, antibiotics, anti-inflammatory drugs, the restoration of moisture balance,
and/or acceleration of epithelization by growth factor therapy [50,51]. Although these treatment
options accelerate the wound healing process in many cases, many wounds are resistant to the current
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Recently, stem cell therapy has emerged as a novel approach for chronic wound healing. So far,
most data is from studies using bone marrow-derived MSCs (BM-MSCs). However, as ASCs and
BM-MSCs share numerous biological properties, much of the knowledge regarding BM-MSCs can
be directly applied to the ASCs [52]. It has also become apparent the vastly higher numbers of ASCs
than BM-MSCs can be obtained in a short time frame [52]. Thus, as procedures for the isolation and
expansion of ASCs for clinical use have been optimized [53], ASCs are emerging as the most promising
candidate for stem cell-based therapies for chronic wounds.
In the chronic wound environment, in vitro and in vivo studies suggest that the ASCs may be able
to discontinue the prolonged inflammation phase and restore the progression through the phases of
proliferation and remodeling (Figure 2, right panel). In terms of effects on the inflammatory processes,
it is well known that ASCs may influence the functional characteristics and cytokine profile of T-, B-,
and dendritic cells [54–56]. Notably, ASCs have also been shown to be able to induce a conversion
of the macrophage phenotype from the pro-inflammatory M1 associated with chronic wounds to the
anti-inflammatory and wound healing M2 phenotype [57,58]. During the proliferation phase, secreted
factors from ASCs enhance several fibroblast characteristics, such as cell proliferation, migration and,
importantly, the synthesis of collagen and other ECM proteins [59–61]. Furthermore, ASCs have been
demonstrated to inhibit ECM degradation through the increased binding of MMPs and secretion of
TIMPs [24]. The ability of ASCs to promote new vessel growth is also relevant to wound healing [62].
Finally, in vitro studies suggest that ASCs may promote re-epithelialization through modulation of
keratinocytes in terms of promoting their proliferation and migration, but more studies are needed to
confirm if this also holds true for chronic wounds [11,63].
To potentiate the wound healing effects of ASCs, the possibility of pre-conditioning the cells during
in vitro expansion prior to clinical use has been suggested. In particular, the use of hypoxic culture
appears interesting, as several of the wound healing properties of ASCs appear to be enhanced [64,65].
Significantly, it was recently found that hypoxic culture of ASCs altered their expression profile of
several proteins related to ECM structure and function [66]. However, more data is needed to determine
if the hypoxic potentiation of the regenerative properties of the ASCs in vitro can be translated into an
enhanced effect in vivo.
5. ECM-Based Scaffolds for Wound Therapy
An alternative approach to using cells for wound therapy is to use acellular ECM. Acellular
ECM-based scaffolds derived from natural tissues have been successfully applied in various preclinical
and clinical settings for the treatment of severe wounds. These natural scaffolds appear to mediate
tissue regeneration through a process known as constructive remodeling, in which the diverse ECM
components orchestrate a process of scarless tissue repair [67]. There are various commercially
available ECM-derived materials that are routinely used for the treatment of burns and chronic
wounds, including materials obtained by the decellularization of animal tissues, such as porcine
or bovine skin [68,69], or from allogeneic human skin [70]. A more detailed review of the variety
of decellularized ECM scaffolds that are currently available for clinical use can be found in the
literature [71]. Despite the relatively high success rates associated with these materials, some issues may
still appear, such as sustained inflammatory responses and incomplete healing due to poor integrity
of the native ECM molecules after decellularization [72]. In addition, xenogeneic ECM components
may cause adverse host immune responses, and there is a risk of pathogen transfer [73]. To avoid
these risks and the limitations associated with the supply of allogeneic human tissues, cell cultures
have recently emerged as viable alternatives for the fabrication of ECM scaffolds. Depending on
the cell type used for ECM synthesis, it is possible to fabricate ECM scaffolds containing specific
proteins and morphogens that appear during early tissue development and which are associated
with enhanced wound healing [74]. In particular, matrices derived from stem cells have shown
promise as scaffolds for various tissue engineering and regenerative medicine applications, including
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properties of BM-MSCs or ASCs in the context of wound healing therapies, little is known regarding
the use of stem cell ECM for wound healing applications. In this context, MSCs may possess a relative
advantage over terminally differentiated skin fibroblasts, as they have shown an increased capacity
to synthesize proteins involved in extracellular matrix, morphogenesis, and development [78,79].
The predominant upregulation of genes such as fibronectin (FN1) and extracellular matrix protein 2
(ECM2) found in MSCs suggests that the ECM derived from these cells may enhance wound healing by
promoting matrix deposition and cell adhesion [78]. Accordingly, comprehensive proteomic analysis
of ECM derived from MSCs has revealed an enrichment of structural proteins, including collagen I,
VI, and XII, which together with an increased presence of MMPs indicates a highly dynamic matrix
turnover [79]. Furthermore, MSC-derived ECM is also enriched in proteoglycans such as perlecan and
hyaluronan, and glycoproteins such as fibronectin, tenascin-C, fibulin-1, and thrombospondin-1 [79].
Overall, these components of the ECM may contribute to the different phases of wound healing by
supporting integrin-mediated cell adhesion and signaling, cell migration, and proliferation. In addition,
decellularized stem cell ECM has demonstrated a significant angiogenic potential, which has been
evidenced through the activation of endothelial cells [80]. An additional advantage of using stem cell
cultures is the possibility of microenvironmental preconditioning of the cells during the fabrication
process to tailor specific biological or biophysical functionalities in the scaffold that may promote
wound healing [81]. In ASCs, in vitro ECM production and assembly has been shown to be controlled
by mechanical and topographical cues from the microenvironment [82,83].
Decellularized ECM-scaffolds may be also used as platforms for cell delivery. It has been
hypothesized that ASCs might have a better survival rate and reduce scar formation when
administrated in combination with ECM-components [84]. Such a co-delivery could be implemented
either using a patch of ECM seeded with ASCs [84] or delivering the ASCs in a fibrin spray glue.
In summary, although fabrication of ECM scaffolds using ASC cultures or co-delivery of ASCs
and ECM represent novel concepts that may offer several comparative advantages for wound healing
applications, the knowledge in this field is still scarce, and more efforts are needed to further develop
these approaches into a clinical reality.
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